US8148089B2	NNP	O
-	:	O
Alpha-synuclein	JJ	O
kinase	NN	O
-	:	O
Google	NN	O
Patents	NNS	O
Info	NNP	O
Links	NNP	O
Images	NNP	O
Classifications	NNP	O
Abstract	NNP	O
Description	NNP	O
RELATED	NNP	O
APPLICATIONS	NNP	O
This	DT	O
application	NN	O
claims	VBZ	O
priority	NN	O
as	IN	O
a	DT	O
divisional	NN	O
of	IN	O
U.S.	NNP	O
patent	NN	O
application	NN	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
12/030,849	CD	O
,	,	O
filed	VBD	O
Feb.	NNP	O
13	CD	O
,	,	O
2008	CD	O
,	,	O
which	WDT	O
is	VBZ	O
a	DT	O
continuation-in-part	NN	O
of	IN	O
U.S.	NNP	O
patent	NN	O
application	NN	O
Ser	NNP	O
.	.	O
No	DT	O
.	.	O
11/669,093	CD	O
,	,	O
filed	VBD	O
Jan.	NNP	O
30	CD	O
,	,	O
2007	CD	O
,	,	O
which	WDT	O
claims	VBZ	O
benefit	NN	O
of	IN	O
U.S.	NNP	O
provisional	JJ	O
application	NN	O
No	NNP	O
.	.	O
60/764,000	CD	O
,	,	O
filed	VBD	O
Jan.	NNP	O
31	CD	O
,	,	O
2006	CD	O
,	,	O
each	DT	O
of	IN	O
which	WDT	O
is	VBZ	O
herein	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
in	IN	O
its	PRP$	O
entirety	NN	O
for	IN	O
all	DT	O
purposes	NNS	O
.	.	O
REFERENCE	NNP	O
TO	NNP	O
A	NNP	O
“	NNP	O
SEQUENCE	NNP	O
LISTING	NNP	O
,	,	O
”	VBZ	O
A	NNP	O
TABLE	NNP	O
,	,	O
OR	NNP	O
A	NNP	O
COMPUTER	NNP	O
PROGRAM	NNP	O
LISTING	NNP	O
SUBMITTED	NNP	O
IN	NNP	O
COMPUTER	NNP	O
READABLE	NNP	O
FORMAT	NNP	O
The	DT	O
Sequence	NNP	O
Listing	NNP	O
written	VBN	O
in	IN	O
file	JJ	O
0-17521US_SEQLST.txt	NN	O
is	VBZ	O
15,436	CD	O
bytes	NNS	O
,	,	O
and	CC	O
was	VBD	O
created	VBN	O
on	IN	O
Feb.	NNP	O
8	CD	O
,	,	O
2010	CD	O
,	,	O
for	IN	O
the	DT	O
application	NN	O
filed	VBN	O
herewith	NN	O
,	,	O
John	NNP	B
P.	NNP	I
Anderson	NNP	I
,	,	I
et	RB	I
al	NN	I
.	.	I
“	JJ	I
Alpha-Synuclein	NNP	I
Kinase.	NNP	I
”	VBZ	I
The	DT	O
information	NN	O
contained	VBN	O
in	IN	O
this	DT	O
file	NN	O
is	VBZ	O
hereby	RB	O
incorporated	VBN	O
by	IN	O
reference	NN	O
.	.	O
BACKGROUND	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
Lewy	NNP	O
body	NN	O
diseases	NNS	O
(	(	O
LBDs	NNP	O
)	)	O
are	VBP	O
characterized	VBN	O
by	IN	O
degeneration	NN	O
of	IN	O
the	DT	O
dopaminergic	NN	O
system	NN	O
,	,	O
motor	NN	O
alterations	NNS	O
,	,	O
cognitive	JJ	O
impairment	NN	O
,	,	O
and	CC	O
formation	NN	O
of	IN	O
Lewy	NNP	O
bodies	NNS	O
(	(	O
LBs	NNP	O
)	)	O
.	.	O
(	(	O
McKeith	NNP	B
et	FW	I
al.	NN	I
,	,	I
Clinical	NNP	I
and	CC	I
pathological	JJ	I
diagnosis	NN	I
of	IN	I
dementia	NN	I
with	IN	I
Lewy	NNP	I
bodies	NNS	I
(	(	I
DLB	NNP	I
)	)	I
:	:	I
Report	NN	I
of	IN	I
the	DT	I
CDLB	NNP	I
International	NNP	I
Workshop	NNP	I
,	,	I
Neurology	NNP	I
(	(	I
1996	CD	I
)	)	I
47:1113-24	NN	I
)	)	O
.	.	O
LBDs	NNP	O
include	VBP	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
,	,	O
Diffuse	NNP	O
Lewy	NNP	O
body	NN	O
disease	NN	O
(	(	O
DLBD	NNP	O
)	)	O
,	,	O
Lewy	NNP	O
body	NN	O
variant	NN	O
of	IN	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
(	(	O
LBV	NNP	O
)	)	O
,	,	O
combined	VBN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
(	(	O
PD	NNP	O
)	)	O
and	CC	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
(	(	O
AD	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
syndromes	NNS	O
identified	VBN	O
as	IN	O
multiple	JJ	O
system	NN	O
atrophy	NN	O
(	(	O
MSA	NNP	O
)	)	O
.	.	O
Dementia	NN	O
with	IN	O
Lewy	NNP	O
bodies	NNS	O
(	(	O
DLB	NNP	O
)	)	O
is	VBZ	O
a	DT	O
term	NN	O
coined	VBN	O
to	TO	O
reconcile	VB	O
differences	NNS	O
in	IN	O
the	DT	O
terminology	NN	O
of	IN	O
LBDs	NNP	O
.	.	O
Disorders	NNS	O
with	IN	O
LBs	NNP	O
continue	VBP	O
to	TO	O
be	VB	O
a	DT	O
common	JJ	O
cause	NN	O
for	IN	O
movement	NN	O
disorders	NNS	O
and	CC	O
cognitive	JJ	O
deterioration	NN	O
in	IN	O
the	DT	O
aging	VBG	O
population	NN	O
(	(	O
Galasko	NNP	B
et	RB	I
al.	RB	I
,	,	I
Clinical-neuropathological	JJ	I
correlations	NNS	I
in	IN	I
Alzheimer	NNP	I
's	POS	I
disease	NN	I
and	CC	I
related	JJ	I
dementias	NN	I
.	.	I
Arch	NNP	I
.	.	I
Neurol	NNP	I
.	.	I
(	(	I
1994	CD	I
)	)	I
51:888-95	NN	I
)	)	O
.	.	O
Although	IN	O
their	PRP$	O
incidence	NN	O
continues	VBZ	O
to	TO	O
increase	VB	O
,	,	O
creating	VBG	O
a	DT	O
serious	JJ	O
public	JJ	O
health	NN	O
problem	NN	O
,	,	O
to	TO	O
date	NN	O
these	DT	O
disorders	NNS	O
lack	VBP	O
approved	JJ	O
treatments	NNS	O
(	(	O
Tanner	NNP	B
et	RB	I
al.	RB	I
,	,	I
Epidemiology	NNP	I
of	IN	I
Parkinson	NNP	I
's	POS	I
disease	NN	I
and	CC	I
akinetic	JJ	I
syndromes	NNS	I
,	,	I
Curr	NNP	I
.	.	I
Opin	NNP	I
.	.	I
Neurol	NNP	I
.	.	I
(	(	I
2000	CD	I
)	)	I
13:427-30	CD	I
)	)	O
.	.	O
The	DT	O
cause	NN	O
for	IN	O
LBDs	NNP	O
is	VBZ	O
controversial	JJ	O
and	CC	O
multiple	JJ	O
factors	NNS	O
have	VBP	O
been	VBN	O
proposed	VBN	O
to	TO	O
play	VB	O
a	DT	O
role	NN	O
,	,	O
including	VBG	O
various	JJ	O
neurotoxins	NNS	O
and	CC	O
genetic	JJ	O
susceptibility	NN	O
factors	NNS	O
.	.	O
In	IN	O
recent	JJ	O
years	NNS	O
,	,	O
new	JJ	O
hope	NN	O
for	IN	O
understanding	VBG	O
the	DT	O
pathogenesis	NN	O
of	IN	O
LBDs	NNP	O
has	VBZ	O
emerged	VBN	O
.	.	O
Specifically	RB	O
,	,	O
several	JJ	O
studies	NNS	O
have	VBP	O
shown	VBN	O
that	IN	O
the	DT	O
synaptic	JJ	O
protein	NN	O
alpha-synuclein	JJ	O
plays	VBZ	O
a	DT	O
central	JJ	O
role	NN	O
in	IN	O
PD	NNP	O
pathogenesis	NN	O
because	IN	O
:	:	O
(	(	O
1	CD	O
)	)	O
this	DT	O
protein	NN	O
accumulates	VBZ	O
in	IN	O
LBs	NNP	O
(	(	O
Spillantini	NNP	B
et	RB	I
al.	RB	I
,	,	I
Nature	NNP	I
(	(	I
1997	CD	I
)	)	I
388:839-40	CD	I
;	:	O
Takeda	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Pathol	NNP	I
.	.	I
(	(	I
1998	CD	I
)	)	I
152:367-72	CD	I
;	:	O
Wakabayashi	NNP	B
et	FW	I
al.	NN	I
,	,	I
Neurosci	NNP	I
.	.	I
Lett	NNP	I
.	.	I
(	(	I
1997	CD	I
)	)	I
239:45-8	CD	I
)	)	O
,	,	O
(	(	O
2	CD	O
)	)	O
mutations	NNS	O
in	IN	O
the	DT	O
alpha-synuclein	JJ	O
gene	NN	O
co-segregate	NN	O
with	IN	O
rare	JJ	O
familial	JJ	O
forms	NNS	O
of	IN	O
parkinsonism	NN	O
(	(	O
Kruger	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
Nature	NNP	I
Gen.	NNP	I
(	(	I
1998	CD	I
)	)	I
18:106-8	CD	I
;	:	O
Polymeropoulos	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Science	NNP	I
(	(	I
1997	CD	I
)	)	I
276:2045-7	CD	I
)	)	O
and	CC	O
,	,	O
(	(	O
3	CD	O
)	)	O
overexpression	NN	O
of	IN	O
alpha-synuclein	NN	O
in	IN	O
transgenic	JJ	O
mice	NN	O
(	(	O
Masliah	NNP	B
et	RB	I
al.	RB	I
,	,	I
Science	NNP	I
(	(	I
2000	CD	I
)	)	I
287:1265-9	CD	I
)	)	O
and	CC	O
Drosophila	NNP	O
(	(	O
Feany	NNP	B
et	RB	I
al.	RB	I
,	,	I
Nature	NNP	I
(	(	I
2000	CD	I
)	)	I
404:394-8	NN	I
)	)	O
mimics	NNS	O
several	JJ	O
pathological	JJ	O
aspects	NNS	O
of	IN	O
PD	NNP	O
.	.	O
Many	JJ	O
scientists	NNS	O
believe	VBP	O
that	IN	O
PD	NNP	O
is	VBZ	O
a	DT	O
relatively	RB	O
late	JJ	O
development	NN	O
in	IN	O
a	DT	O
systemic	JJ	O
synucleinopathy	NN	O
and	CC	O
that	IN	O
“	JJ	O
parkinsonism	NN	O
is	VBZ	O
just	RB	O
the	DT	O
tip	NN	O
of	IN	O
the	DT	O
iceberg	NN	O
”	NNP	O
(	(	O
Langston	NNP	B
,	,	I
Annals	NNP	I
of	IN	I
Neurology	NNP	I
(	(	I
2006	CD	I
)	)	I
59:591-596	NN	I
)	)	O
.	.	O
For	IN	O
example	NN	O
,	,	O
Lewy	NNP	O
bodies	NNS	O
have	VBP	O
been	VBN	O
described	VBN	O
in	IN	O
sympathetic	JJ	O
ganglia	NN	O
and	CC	O
in	IN	O
the	DT	O
myenteric	JJ	O
plexus	NN	O
of	IN	O
the	DT	O
gut	NN	O
(	(	O
Herzog	NNP	B
E.	NNP	I
,	,	I
Dtch	NNP	I
Z	NNP	I
Nervenheilk	NNP	I
(	(	I
1928	CD	I
)	)	I
107	CD	I
:	:	I
75-80	JJ	I
;	:	O
Kupsky	NNP	B
et	FW	I
al.	NN	I
,	,	I
Neurology	NNP	I
(	(	I
1987	CD	I
)	)	I
37:1253-1255	CD	I
)	)	O
.	.	O
Various	JJ	O
disorders	NNS	O
have	VBP	O
been	VBN	O
associated	VBN	O
with	IN	O
the	DT	O
presence	NN	O
of	IN	O
Lewy	NNP	O
bodies	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
Lewy	NNP	O
bodies	NNS	O
have	VBP	O
been	VBN	O
found	VBN	O
in	IN	O
the	DT	O
brain	NN	O
stem	NN	O
of	IN	O
a	DT	O
patient	NN	O
with	IN	O
rapid	JJ	O
eye	NN	O
movement	NN	O
sleep	JJ	O
behavioral	JJ	O
disorder	NN	O
(	(	O
Uchiyama	NNP	B
et	RB	I
al.	RB	I
,	,	I
Neurology	NNP	I
(	(	I
1995	CD	I
)	)	I
45:709-712	NN	I
)	)	O
.	.	O
Olfactory	NNP	O
dysfunction	NN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
in	IN	O
many	JJ	O
PD	NNP	O
patients	NNS	O
long	RB	O
before	IN	O
the	DT	O
development	NN	O
of	IN	O
parkinsonism	NN	O
.	.	O
Examination	NN	O
of	IN	O
cardiac	JJ	O
tissue	NN	O
from	IN	O
patients	NNS	O
with	IN	O
incidental	JJ	O
Lewy	NNP	O
body	NN	O
disease	NN	O
and	CC	O
typical	JJ	O
PD	NNP	O
revealed	VBD	O
synuclein-positive	JJ	O
neuritis	NN	O
in	IN	O
the	DT	O
myocardium	NN	O
(	(	O
Iwanaga	NNP	B
et	RB	I
al.	RB	I
,	,	I
Neurology	NNP	I
(	(	I
1999	CD	I
)	)	I
52:1269-1271	NN	I
)	)	O
.	.	O
There	EX	O
is	VBZ	O
also	RB	O
evidence	NN	O
that	IN	O
esophageal	NN	O
,	,	O
lower	JJR	O
bowel	NN	O
and	CC	O
bladder	NN	O
dysfunction	NN	O
are	VBP	O
early	JJ	O
manifestations	NNS	O
of	IN	O
PD-related	NNP	O
pathology	NN	O
in	IN	O
the	DT	O
peripheral	JJ	O
autonomic	JJ	O
system	NN	O
(	(	O
Qualman	NNP	B
et	VBZ	I
al.	NN	I
,	,	I
Gastroenterology	NNP	I
(	(	I
1984	CD	I
)	)	I
87:848-856	CD	I
;	:	O
Castell	NNP	B
et	FW	I
al.	NN	I
,	,	I
Neurogasdtroenterol	NNP	I
Motil	NNP	I
(	(	I
2001	CD	I
)	)	I
13:361-364	CD	I
;	:	O
Hague	NNP	B
et	FW	I
al.	NN	I
,	,	I
Acta	NNP	I
Neuropathol	NNP	I
(	(	I
Berl	NNP	I
)	)	I
(	(	I
1997	CD	I
)	)	I
94:192-196	CD	I
)	)	O
.	.	O
Thus	RB	O
,	,	O
the	DT	O
fact	NN	O
that	IN	O
accumulation	NN	O
of	IN	O
alpha-synuclein	NN	O
in	IN	O
the	DT	O
brain	NN	O
and	CC	O
other	JJ	O
tissues	NNS	O
is	VBZ	O
associated	VBN	O
with	IN	O
similar	JJ	O
morphological	JJ	O
and	CC	O
neurological	JJ	O
alterations	NNS	O
in	IN	O
species	NNS	O
as	RB	O
diverse	JJ	O
as	IN	O
humans	NNS	O
,	,	O
mice	NN	O
,	,	O
and	CC	O
flies	NNS	O
suggests	VBZ	O
that	IN	O
this	DT	O
molecule	NN	O
contributes	VBZ	O
to	TO	O
the	DT	O
development	NN	O
of	IN	O
PD	NNP	O
.	.	O
BRIEF	NNP	O
SUMMARY	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
In	IN	O
one	CD	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
methods	NNS	O
of	IN	O
screening	VBG	O
an	DT	O
agent	NN	O
for	IN	O
activity	NN	O
for	IN	O
treating	VBG	O
a	DT	O
Lewy	NNP	O
Body	NNP	O
disease	NN	O
(	(	O
LBD	NNP	O
)	)	O
.	.	O
Such	JJ	O
diseases	NNS	O
include	VBP	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
(	(	O
PD	NNP	O
)	)	O
,	,	O
Diffuse	NNP	O
Lewy	NNP	O
body	NN	O
disease	NN	O
(	(	O
DLBD	NNP	O
)	)	O
,	,	O
Lewy	NNP	O
body	NN	O
variant	NN	O
of	IN	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
(	(	O
LBV	NNP	O
)	)	O
,	,	O
combined	VBN	O
PD	NNP	O
and	CC	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
(	(	O
AD	NNP	O
)	)	O
,	,	O
and	CC	O
the	DT	O
syndromes	NNS	O
identified	VBN	O
as	IN	O
multiple	JJ	O
system	NN	O
atrophy	NN	O
(	(	O
MSA	NNP	O
)	)	O
.	.	O
Some	DT	O
methods	NNS	O
entail	VBP	O
identifying	VBG	O
an	DT	O
agent	NN	O
that	WDT	O
modulates	VBZ	O
the	DT	O
activity	NN	O
or	CC	O
expression	NN	O
of	IN	O
a	DT	O
kinase	NN	O
shown	VBN	O
in	IN	O
Table	JJ	O
1A	CD	O
,	,	O
B	NNP	O
;	:	O
C	NNP	O
,	,	O
Table	NNP	O
2	CD	O
,	,	O
Table	JJ	O
11	CD	O
or	CC	O
Table	JJ	O
12	CD	O
,	,	O
and	CC	O
determining	VBG	O
whether	IN	O
the	DT	O
agent	NN	O
shows	VBZ	O
activity	NN	O
useful	JJ	O
in	IN	O
treating	VBG	O
LBD	NNP	O
in	IN	O
an	DT	O
animal	JJ	O
model	NN	O
of	IN	O
the	DT	O
disease	NN	O
.	.	O
In	IN	O
some	DT	O
methods	NNS	O
the	DT	O
modulation	NN	O
is	VBZ	O
inhibition	NN	O
.	.	O
In	IN	O
some	DT	O
methods	NNS	O
,	,	O
step	NN	O
(	(	O
a	DT	O
)	)	O
involves	VBZ	O
identifying	VBG	O
whether	IN	O
the	DT	O
agent	NN	O
inhibits	VBZ	O
the	DT	O
kinase	NN	O
.	.	O
In	IN	O
some	DT	O
methods	NNS	O
,	,	O
step	NN	O
(	(	O
a	DT	O
)	)	O
is	VBZ	O
performed	VBN	O
in	IN	O
a	DT	O
cell	NN	O
transformed	VBN	O
with	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
expressing	VBG	O
the	DT	O
kinase	NN	O
and/or	JJ	O
alpha-synuclein	NN	O
.	.	O
In	IN	O
some	DT	O
methods	NNS	O
,	,	O
step	NN	O
(	(	O
a	DT	O
)	)	O
is	VBZ	O
performed	VBN	O
in	IN	O
vitro	NN	O
.	.	O
In	IN	O
some	DT	O
methods	NNS	O
,	,	O
step	NN	O
(	(	O
b	NN	O
)	)	O
is	VBZ	O
performed	VBN	O
in	IN	O
a	DT	O
transgenic	JJ	O
animal	JJ	O
model	NN	O
of	IN	O
LBD	NNP	O
disease	NN	O
,	,	O
and	CC	O
the	DT	O
transgenic	JJ	O
animal	NN	O
may	MD	O
have	VB	O
a	DT	O
transgene	NN	O
expressing	VBG	O
human	JJ	O
alpha-synuclein	NN	O
.	.	O
Preferably	RB	O
,	,	O
the	DT	O
kinase	NN	O
is	VBZ	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
:	:	O
APEG1	NNP	O
,	,	O
PLK2	NNP	O
,	,	O
CDC7L1	NNP	O
,	,	O
PRKG1	NNP	O
,	,	O
MAPK13	NNP	O
,	,	O
GAK	NNP	O
,	,	O
RHOK	NNP	O
,	,	O
ADRBK1	NNP	O
,	,	O
ADRBK2	NNP	O
,	,	O
GRK2L	NNP	O
,	,	O
GRK5	NNP	O
,	,	O
GRK6	NNP	O
,	,	O
GRK7	NNP	O
,	,	O
IKBKB	NNP	O
,	,	O
CKII	NNP	O
and	CC	O
MET	NNP	O
and	CC	O
the	DT	O
modulation	NN	O
is	VBZ	O
inhibition	NN	O
.	.	O
More	RBR	O
preferably	RB	O
,	,	O
the	DT	O
kinase	NN	O
is	VBZ	O
PLK2	NNP	O
or	CC	O
GRK6	NNP	O
and	CC	O
the	DT	O
modulation	NN	O
is	VBZ	O
inhibition	NN	O
.	.	O
More	RBR	O
preferably	RB	O
,	,	O
the	DT	O
kinase	NN	O
is	VBZ	O
PLK2	NNP	O
.	.	O
Preferably	RB	O
in	IN	O
some	DT	O
methods	NNS	O
,	,	O
the	DT	O
kinase	NN	O
is	VBZ	O
PRKG1	NNP	O
,	,	O
MAPK13	NNP	O
,	,	O
or	CC	O
GAK	NNP	O
and	CC	O
the	DT	O
modulation	NN	O
is	VBZ	O
activation	NN	O
.	.	O
In	IN	O
some	DT	O
aspects	NNS	O
,	,	O
step	NN	O
(	(	O
b	NN	O
)	)	O
involves	VBZ	O
contacting	VBG	O
the	DT	O
transgenic	JJ	O
animal	NN	O
with	IN	O
the	DT	O
agent	NN	O
and	CC	O
determining	VBG	O
whether	IN	O
the	DT	O
agent	NN	O
inhibits	VBZ	O
formation	NN	O
of	IN	O
deposits	NNS	O
of	IN	O
alpha-synuclein	JJ	O
relative	NN	O
to	TO	O
a	DT	O
control	NN	O
transgenic	JJ	O
animal	NN	O
not	RB	O
treated	VBN	O
with	IN	O
the	DT	O
agent	NN	O
.	.	O
In	IN	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
methods	NNS	O
of	IN	O
effecting	VBG	O
treatment	NN	O
or	CC	O
prophylaxis	NN	O
of	IN	O
a	DT	O
LBD	NNP	O
.	.	O
Some	DT	O
examples	NNS	O
of	IN	O
the	DT	O
method	NN	O
involve	VBP	O
administering	VBG	O
to	TO	O
a	DT	O
patient	NN	O
suffering	VBG	O
from	IN	O
or	CC	O
at	IN	O
risk	NN	O
of	IN	O
the	DT	O
disease	NN	O
,	,	O
an	DT	O
effective	JJ	O
regime	NN	O
of	IN	O
an	DT	O
agent	JJ	O
effective	JJ	O
to	TO	O
modulate	VB	O
activity	NN	O
or	CC	O
expression	NN	O
of	IN	O
a	DT	O
kinase	NN	O
.	.	O
The	DT	O
kinase	NN	O
can	MD	O
be	VB	O
one	CD	O
of	IN	O
those	DT	O
shown	VBN	O
in	IN	O
Table	JJ	O
1A	CD	O
,	,	O
B	NNP	O
or	CC	O
C	NNP	O
,	,	O
Table	NNP	O
2	CD	O
,	,	O
Table	JJ	O
11	CD	O
or	CC	O
Table	JJ	O
12	CD	O
.	.	O
Preferably	RB	O
,	,	O
the	DT	O
agent	NN	O
is	VBZ	O
an	DT	O
antibody	NN	O
to	TO	O
the	DT	O
kinase	NN	O
,	,	O
a	DT	O
zinc	NN	O
finger	NN	O
protein	VBP	O
that	IN	O
modulates	VBZ	O
expression	NN	O
of	IN	O
the	DT	O
kinase	NN	O
,	,	O
or	CC	O
an	DT	O
antisense	JJ	O
RNA	NNP	O
,	,	O
siRNA	NN	O
,	,	O
ribozyme	NN	O
or	CC	O
RNA	NNP	O
having	VBG	O
a	DT	O
sequence	NN	O
complementary	NN	O
to	TO	O
a	DT	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
of	IN	O
the	DT	O
kinase	NN	O
.	.	O
In	IN	O
some	DT	O
methods	NNS	O
,	,	O
the	DT	O
modulation	NN	O
is	VBZ	O
inhibition	NN	O
,	,	O
and	CC	O
preferably	RB	O
,	,	O
the	DT	O
kinase	NN	O
is	VBZ	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
following	NN	O
:	:	O
APEG1	NNP	O
,	,	O
PLK2	NNP	O
,	,	O
CDC7L1	NNP	O
,	,	O
RHOK	NNP	O
,	,	O
ADRBK1	NNP	O
,	,	O
ADRBK2	NNP	O
,	,	O
GRK2L	NNP	O
,	,	O
GRK5	NNP	O
,	,	O
GRK6	NNP	O
,	,	O
GRK7	NNP	O
,	,	O
IKBKB	NNP	O
,	,	O
CKII	NNP	O
and	CC	O
MET	NNP	O
.	.	O
More	RBR	O
preferably	RB	O
,	,	O
the	DT	O
kinase	NN	O
is	VBZ	O
PLK2	NNP	O
or	CC	O
GRK6	NNP	O
.	.	O
More	RBR	O
preferably	RB	O
,	,	O
the	DT	O
kinase	NN	O
is	VBZ	O
PLK2	NNP	O
.	.	O
In	IN	O
some	DT	O
of	IN	O
the	DT	O
methods	NNS	O
,	,	O
the	DT	O
kinase	NN	O
is	VBZ	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
PRKG1	NNP	O
,	,	O
MAPK13	NNP	O
,	,	O
and	CC	O
GAK	NNP	O
,	,	O
and	CC	O
the	DT	O
modulation	NN	O
is	VBZ	O
activation	NN	O
.	.	O
In	IN	O
one	CD	O
aspect	NN	O
the	DT	O
invention	NN	O
provides	VBZ	O
method	NN	O
of	IN	O
treating	VBG	O
a	DT	O
patient	NN	O
diagnosed	VBN	O
with	IN	O
Parkinson	NNP	O
's	POS	O
Disease	NNP	O
by	IN	O
administering	VBG	O
a	DT	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
of	IN	O
an	DT	O
agent	NN	O
that	IN	O
inhibits	VBZ	O
PLK2	NNP	O
activity	NN	O
.	.	O
In	IN	O
an	DT	O
embodiment	NN	O
the	DT	O
agent	NN	O
preferentially	RB	O
inhibits	VBZ	O
PLK2	NNP	O
activity	NN	O
relative	NN	O
to	TO	O
inhibition	NN	O
of	IN	O
PLK1	NNP	O
activity	NN	O
and/or	NN	O
PLK3	NNP	O
activity	NN	O
and/or	NN	O
PLK4	NNP	O
activity	NN	O
.	.	O
The	DT	O
agent	NN	O
may	MD	O
be	VB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
an	DT	O
siRNA	NN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
the	DT	O
patient	NN	O
is	VBZ	O
not	RB	O
diagnosed	VBN	O
or	CC	O
under	IN	O
treatment	NN	O
for	IN	O
cancer	NN	O
and/or	NN	O
is	VBZ	O
not	RB	O
diagnosed	VBN	O
or	CC	O
under	IN	O
treatment	NN	O
for	IN	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
.	.	O
In	IN	O
related	JJ	O
aspects	NNS	O
,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
method	NN	O
for	IN	O
inhibiting	VBG	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	NN	O
in	IN	O
a	DT	O
mammalian	JJ	O
cell	NN	O
by	IN	O
reducing	VBG	O
polo-like	JJ	O
kinase	NN	O
2	CD	O
(	(	O
PLK2	NNP	O
)	)	O
activity	NN	O
in	IN	O
the	DT	O
cell	NN	O
such	JJ	O
that	IN	O
phosphorylation	NN	O
of	IN	O
synuclein	NN	O
is	VBZ	O
reduced	VBN	O
.	.	O
In	IN	O
a	DT	O
related	JJ	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
method	NN	O
for	IN	O
inhibiting	VBG	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	NN	O
in	IN	O
a	DT	O
mammalian	JJ	O
cell	NN	O
(	(	O
e.g.	NN	O
,	,	O
a	DT	O
neuronal	JJ	O
cell	NN	O
)	)	O
by	IN	O
contacting	VBG	O
the	DT	O
cell	NN	O
with	IN	O
a	DT	O
compound	NN	O
that	WDT	O
reduces	VBZ	O
PLK2	NNP	O
activity	NN	O
in	IN	O
the	DT	O
cell	NN	O
such	JJ	O
that	IN	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	NN	O
is	VBZ	O
reduced	VBN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
agent	NN	O
may	MD	O
reduce	VB	O
expression	NN	O
of	IN	O
a	DT	O
PLK2	NNP	O
gene	NN	O
product	NN	O
.	.	O
In	IN	O
certain	JJ	O
embodiments	NNS	O
the	DT	O
agent	NN	O
preferentially	RB	O
reduces	VBZ	O
PLK2	NNP	O
activity	NN	O
relative	NN	O
to	TO	O
reduction	NN	O
of	IN	O
PLK1	NNP	O
activity	NN	O
,	,	O
PLK2	NNP	O
activity	NN	O
,	,	O
or	CC	O
PLK3	NNP	O
activity	NN	O
.	.	O
In	IN	O
certain	JJ	O
embodiments	NNS	O
the	DT	O
agent	NN	O
has	VBZ	O
a	DT	O
molecular	JJ	O
weight	NN	O
less	JJR	O
than	IN	O
4000	CD	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
the	DT	O
agent	NN	O
is	VBZ	O
a	DT	O
synthetic	JJ	O
compound	NN	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
the	DT	O
agent	NN	O
is	VBZ	O
a	DT	O
polynucleotide	NN	O
that	IN	O
inhibits	VBZ	O
expression	NN	O
or	CC	O
translation	NN	O
of	IN	O
a	DT	O
PLK2	NNP	O
RNA	NNP	O
transcript	NN	O
,	,	O
such	JJ	O
as	IN	O
an	DT	O
siRNA	NN	O
.	.	O
In	IN	O
an	DT	O
embodiment	NN	O
,	,	O
one	CD	O
strand	NN	O
of	IN	O
the	DT	O
double	NN	O
stranded	VBD	O
region	NN	O
of	IN	O
the	DT	O
siRNA	NN	O
is	VBZ	O
perfectly	RB	O
complementary	JJ	O
to	TO	O
a	DT	O
PLK2	NNP	O
transcript	NN	O
but	CC	O
not	RB	O
to	TO	O
a	DT	O
PLK1	NNP	O
transcript	NN	O
or	CC	O
a	DT	O
PLK3	NNP	O
transcript	NN	O
.	.	O
In	IN	O
another	DT	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
methods	NNS	O
of	IN	O
identifying	VBG	O
a	DT	O
kinase	NN	O
that	WDT	O
phosphorylates	VBZ	O
alpha-synuclein	JJ	O
by	IN	O
transfecting	VBG	O
a	DT	O
cell	NN	O
expressing	VBG	O
alpha-synuclein	JJ	O
with	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
having	VBG	O
a	DT	O
sequence	NN	O
complementary	NN	O
to	TO	O
a	DT	O
gene	NN	O
encoding	VBG	O
a	DT	O
kinase	NN	O
or	CC	O
zinc	NN	O
finger	NN	O
protein	VBP	O
that	IN	O
specifically	RB	O
binds	VBZ	O
to	TO	O
the	DT	O
gene	NN	O
.	.	O
The	DT	O
transfected	JJ	O
nucleic	JJ	O
acid	NN	O
or	CC	O
zinc	NN	O
finger	NN	O
protein	VBP	O
inhibits	VBZ	O
expression	NN	O
of	IN	O
the	DT	O
kinase	NN	O
;	:	O
and	CC	O
an	DT	O
amount	NN	O
of	IN	O
phosphorylated	VBN	O
alpha-synuclein	NN	O
the	DT	O
cell	NN	O
can	MD	O
then	RB	O
be	VB	O
measured	VBN	O
relative	JJ	O
to	TO	O
a	DT	O
control	NN	O
cell	NN	O
not	RB	O
transfected	VBN	O
with	IN	O
the	DT	O
siRNA	NN	O
or	CC	O
nucleic	JJ	O
acid	NN	O
encoding	VBG	O
the	DT	O
same	JJ	O
.	.	O
In	IN	O
this	DT	O
case	NN	O
,	,	O
a	DT	O
reduction	NN	O
in	IN	O
phosphorylated	JJ	O
alpha-synuclein	NN	O
will	MD	O
provide	VB	O
an	DT	O
indication	NN	O
that	IN	O
the	DT	O
kinase	NN	O
phosphorylates	VBZ	O
alpha-synuclein	RB	O
.	.	O
Some	DT	O
methods	NNS	O
also	RB	O
include	VBP	O
measuring	VBG	O
an	DT	O
amount	NN	O
of	IN	O
alpha-synuclein	NN	O
produced	VBN	O
by	IN	O
the	DT	O
cell	NN	O
relative	NN	O
to	TO	O
a	DT	O
control	NN	O
cell	NN	O
not	RB	O
transfected	VBN	O
with	IN	O
the	DT	O
nucleic	JJ	O
acid	NN	O
.	.	O
In	IN	O
some	DT	O
methods	NNS	O
,	,	O
the	DT	O
nucleic	JJ	O
acid	NN	O
is	VBZ	O
an	DT	O
siRNA	NN	O
or	CC	O
a	DT	O
DNA	NN	O
molecule	NN	O
encoding	VBG	O
the	DT	O
same	JJ	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
identifying	VBG	O
an	DT	O
agent	JJ	O
reduces	NNS	O
alpha-synuclein	JJ	O
phosphorylation	NN	O
in	IN	O
a	DT	O
mammalian	JJ	O
cell	NN	O
expressing	VBG	O
alpha-synuclein	NN	O
.	.	O
The	DT	O
method	NN	O
includes	VBZ	O
selecting	VBG	O
an	DT	O
agent	NN	O
that	IN	O
a	DT	O
)	)	O
reduces	VBZ	O
activity	NN	O
of	IN	O
PLK2	NNP	O
in	IN	O
a	DT	O
cell	NN	O
expressing	VBG	O
PLK2	NNP	O
(	(	O
and	CC	O
optionally	RB	O
expressing	VBG	O
synuclein	NN	O
)	)	O
,	,	O
and	CC	O
b	NN	O
)	)	O
does	VBZ	O
not	RB	O
reduce	VB	O
activity	NN	O
of	IN	O
PLK1	NNP	O
in	IN	O
a	DT	O
cell	NN	O
expressing	VBG	O
PLK1	NNP	O
,	,	O
or	CC	O
reduces	VBZ	O
activity	NN	O
of	IN	O
PLK1	NNP	O
at	IN	O
a	DT	O
higher	JJR	O
EC50	NN	O
than	IN	O
for	IN	O
PLK2	NNP	O
;	:	O
and/or	CC	O
c	NNS	O
)	)	O
does	VBZ	O
not	RB	O
reduce	VB	O
activity	NN	O
of	IN	O
PLK3	NNP	O
in	IN	O
a	DT	O
cell	NN	O
expressing	VBG	O
PLK3	NNP	O
,	,	O
or	CC	O
reduces	VBZ	O
activity	NN	O
of	IN	O
PLK3	NNP	O
at	IN	O
a	DT	O
higher	JJR	O
EC50	NN	O
than	IN	O
for	IN	O
PLK2	NNP	O
;	:	O
and/or	CC	O
d	NN	O
)	)	O
does	VBZ	O
not	RB	O
reduce	VB	O
activity	NN	O
of	IN	O
PLK4	NNP	O
in	IN	O
a	DT	O
cell	NN	O
expressing	VBG	O
PLK4	NNP	O
,	,	O
or	CC	O
reduces	VBZ	O
activity	NN	O
of	IN	O
PLK4	NNP	O
at	IN	O
a	DT	O
higher	JJR	O
EC50	NN	O
than	IN	O
for	IN	O
PLK2	NNP	O
.	.	O
The	DT	O
cell	NN	O
can	MD	O
be	VB	O
a	DT	O
mammalian	JJ	O
cell	NN	O
overexpressing	VBG	O
alpha-synuclein	NN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
the	DT	O
agent	NN	O
a	DT	O
)	)	O
reduces	VBZ	O
activity	NN	O
of	IN	O
PLK2	NNP	O
in	IN	O
a	DT	O
cell	NN	O
expressing	VBG	O
PLK2	NNP	O
;	:	O
b	NN	O
)	)	O
does	VBZ	O
not	RB	O
reduce	VB	O
activity	NN	O
of	IN	O
PLK1	NNP	O
in	IN	O
a	DT	O
cell	NN	O
expressing	VBG	O
PLK1	NNP	O
,	,	O
or	CC	O
reduces	VBZ	O
activity	NN	O
of	IN	O
PLK1	NNP	O
at	IN	O
a	DT	O
higher	JJR	O
EC50	NN	O
than	IN	O
for	IN	O
PLK2	NNP	O
;	:	O
c	NNS	O
)	)	O
does	VBZ	O
not	RB	O
reduce	VB	O
activity	NN	O
of	IN	O
PLK3	NNP	O
in	IN	O
a	DT	O
cell	NN	O
expressing	VBG	O
PLK3	NNP	O
,	,	O
or	CC	O
reduces	VBZ	O
activity	NN	O
of	IN	O
PLK3	NNP	O
at	IN	O
a	DT	O
higher	JJR	O
EC50	NN	O
than	IN	O
for	IN	O
PLK2	NNP	O
;	:	O
and	CC	O
d	VB	O
)	)	O
does	VBZ	O
not	RB	O
reduce	VB	O
activity	NN	O
of	IN	O
PLK4	NNP	O
in	IN	O
a	DT	O
cell	NN	O
expressing	VBG	O
PLK4	NNP	O
,	,	O
or	CC	O
reduces	VBZ	O
activity	NN	O
of	IN	O
PLK4	NNP	O
at	IN	O
a	DT	O
higher	JJR	O
EC50	NN	O
than	IN	O
for	IN	O
PLK2	NNP	O
.	.	O
In	IN	O
a	DT	O
further	JJ	O
step	NN	O
,	,	O
the	DT	O
method	NN	O
involves	VBZ	O
determining	VBG	O
whether	IN	O
the	DT	O
selected	VBN	O
agent	NN	O
shows	VBZ	O
activity	NN	O
useful	JJ	O
in	IN	O
treating	VBG	O
Lewy	NNP	O
Body	NNP	O
Disease	NNP	O
in	IN	O
an	DT	O
animal	JJ	O
model	NN	O
of	IN	O
the	DT	O
disease	NN	O
or	CC	O
a	DT	O
cellular	JJ	O
model	NN	O
of	IN	O
the	DT	O
disease	NN	O
.	.	O
Animal	JJ	O
models	NNS	O
include	VBP	O
transgenic	JJ	O
animals	NNS	O
.	.	O
Cellular	JJ	O
models	NNS	O
include	VBP	O
neuronally-derived	JJ	O
cell	NN	O
cultures	NNS	O
and	CC	O
mammalian	JJ	O
cells	NNS	O
over-expressing	JJ	O
alpha-synuclein	JJ	O
.	.	O
Activities	NNS	O
that	WDT	O
can	MD	O
be	VB	O
assayed	VBN	O
include	VBP	O
reduction	NN	O
of	IN	O
the	DT	O
proportion	NN	O
of	IN	O
total	JJ	O
alpha-synuclein	JJ	O
that	WDT	O
is	VBZ	O
phosphorylated	VBN	O
at	IN	O
serine-129	NN	O
or	CC	O
a	DT	O
reduction	NN	O
in	IN	O
aggregation	NN	O
of	IN	O
alpha-synuclein	NN	O
in	IN	O
the	DT	O
cell	NN	O
.	.	O
In	IN	O
other	JJ	O
aspects	NNS	O
,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
methods	NNS	O
of	IN	O
method	NN	O
of	IN	O
screening	VBG	O
an	DT	O
agent	NN	O
for	IN	O
activity	NN	O
for	IN	O
treating	VBG	O
a	DT	O
Lewy	NNP	O
Body	NNP	O
disease	NN	O
(	(	O
LBD	NNP	O
)	)	O
,	,	O
by	IN	O
identifying	VBG	O
an	DT	O
agent	NN	O
that	WDT	O
modulates	VBZ	O
the	DT	O
activity	NN	O
or	CC	O
expression	NN	O
of	IN	O
synphilin	NN	O
,	,	O
and	CC	O
determining	VBG	O
whether	IN	O
the	DT	O
agent	NN	O
shows	VBZ	O
activity	NN	O
useful	JJ	O
in	IN	O
treating	VBG	O
LBD	NNP	O
in	IN	O
an	DT	O
animal	JJ	O
model	NN	O
of	IN	O
the	DT	O
disease	NN	O
.	.	O
In	IN	O
other	JJ	O
aspects	NNS	O
,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
methods	NNS	O
for	IN	O
producing	VBG	O
Ser-129	JJ	O
phosphorylated-alpha	JJ	O
synuclein	NN	O
,	,	O
by	IN	O
providing	VBG	O
a	DT	O
plasmid	JJ	O
encoding	VBG	O
alpha-synuclein	NN	O
and	CC	O
a	DT	O
plasmid	NN	O
encoding	VBG	O
PLK2	NNP	O
in	IN	O
a	DT	O
bacterial	JJ	O
cell	NN	O
,	,	O
culturing	VBG	O
the	DT	O
cell	NN	O
so	RB	O
that	IN	O
the	DT	O
plasmids	NNS	O
are	VBP	O
co-expressing	VBG	O
to	TO	O
produce	VB	O
alpha	JJ	O
synuclein	NN	O
and	CC	O
PLK2	NNP	O
so	IN	O
that	IN	O
the	DT	O
PLK2	NNP	O
phosphorylates	VBZ	O
the	DT	O
alpha-synuclein	NN	O
in	IN	O
a	DT	O
bacterial	JJ	O
cell	NN	O
,	,	O
and	CC	O
isolating	VBG	O
phosphorylated	VBN	O
alpha-synuclein	NN	O
from	IN	O
the	DT	O
cell	NN	O
.	.	O
BRIEF	JJ	O
DESCRIPTION	NNP	O
OF	IN	O
THE	NNP	O
DRAWINGS	NNP	O
FIGS	NNP	O
.	.	O
1A-C	JJ	O
show	NN	O
the	DT	O
results	NNS	O
of	IN	O
the	DT	O
in	IN	O
vitro	JJ	O
phosphorylation	NN	O
assay	NN	O
for	IN	O
alpha-synuclein	JJ	O
phosphorylation	NN	O
by	IN	O
a	DT	O
variety	NN	O
of	IN	O
recombinant	JJ	O
kinases	NNS	O
.	.	O
FIG	NNP	O
.	.	O
1A	CD	O
shows	NNS	O
total	JJ	O
alpha-synuclein	JJ	O
,	,	O
FIG	NNP	O
.	.	O
1B	CD	O
shows	NNS	O
phosphorylation	NN	O
of	IN	O
the	DT	O
pser-129	JJ	O
(	(	O
phospho-serine-129	JJ	O
)	)	O
of	IN	O
alpha-synuclein	NN	O
and	CC	O
FIG	NNP	O
.	.	O
1C	CD	O
shows	NNS	O
phosphorylation	NN	O
of	IN	O
the	DT	O
pser-87	JJ	O
(	(	O
phospho-serine-87	JJ	O
)	)	O
of	IN	O
alpha-synuclein	NN	O
.	.	O
FIGS	NNP	O
.	.	O
1D-F	JJ	O
show	NN	O
a	DT	O
study	NN	O
with	IN	O
recombinant	JJ	O
kinases	NNS	O
,	,	O
including	VBG	O
kinases	NNS	O
from	IN	O
the	DT	O
GPCR-receptor	NNP	O
kinase	NN	O
(	(	O
GRK	NNP	O
)	)	O
family	NN	O
and	CC	O
PLK2	NNP	O
.	.	O
FIG	NNP	O
.	.	O
1D	CD	O
shows	NNS	O
total	JJ	O
alpha-synuclein	JJ	O
,	,	O
FIG	NNP	O
.	.	O
1E	CD	O
shows	NNS	O
phosphorylation	NN	O
of	IN	O
the	DT	O
pser-129	NN	O
of	IN	O
alpha-synuclein	JJ	O
and	CC	O
FIG	NNP	O
.	.	O
1F	CD	O
shows	NNS	O
phosphorylation	NN	O
of	IN	O
the	DT	O
pser-87	NN	O
of	IN	O
alpha-synuclein	NN	O
.	.	O
FIGS	NNP	O
.	.	O
2A	CD	O
and	CC	O
B	NNP	O
show	VBP	O
the	DT	O
results	NNS	O
of	IN	O
kinase	NN	O
activity	NN	O
in	IN	O
vitro	NN	O
for	IN	O
various	JJ	O
kinases	NNS	O
.	.	O
FIG	NNP	O
.	.	O
2A	CD	O
shows	VBZ	O
the	DT	O
total	JJ	O
(	(	O
AS	IN	O
)	)	O
.	.	O
FIG	NNP	O
.	.	O
2B	CD	O
shows	VBZ	O
phosphor-serine	NN	O
129	CD	O
.	.	O
FIGS	NNP	O
.	.	O
3A-C	JJ	O
show	NN	O
the	DT	O
results	NNS	O
of	IN	O
kinase	NN	O
activity	NN	O
in	IN	O
vitro	NN	O
for	IN	O
various	JJ	O
kinases	NNS	O
.	.	O
FIG	NNP	O
.	.	O
2A	CD	O
shows	VBZ	O
the	DT	O
total	JJ	O
AS	NNP	O
.	.	O
FIG	NNP	O
.	.	O
3B	CD	O
shows	NNS	O
Serine	NNP	O
129	CD	O
.	.	O
FIG	NNP	O
.	.	O
3C	CD	O
shows	VBZ	O
phospho-serine	NN	O
87	CD	O
.	.	O
FIGS	NNP	O
.	.	O
4A	CD	O
and	CC	O
B	NNP	O
show	VBP	O
the	DT	O
effect	NN	O
of	IN	O
phospholipid	NN	O
on	IN	O
the	DT	O
assay	NN	O
results	NNS	O
in	IN	O
FIGS	NNP	O
.	.	O
3A	CD	O
and	CC	O
3B	CD	O
.	.	O
FIG	NNP	O
.	.	O
4A	CD	O
shows	VBZ	O
the	DT	O
total	JJ	O
AS	NNP	O
.	.	O
FIG	NNP	O
.	.	O
4B	CD	O
shows	NNS	O
Serine	NNP	O
129	CD	O
.	.	O
FIG	NNP	O
.	.	O
5	CD	O
shows	VBZ	O
the	DT	O
results	NNS	O
of	IN	O
transfection	NN	O
of	IN	O
cDNA	NN	O
to	TO	O
PLK2	NNP	O
into	IN	O
293-synuclein	JJ	O
cells	NNS	O
.	.	O
Cells	NNS	O
were	VBD	O
analyzed	VBN	O
by	IN	O
ELISA	NNP	O
for	IN	O
total	JJ	O
and	CC	O
phospho-synuclein	JJ	O
levels	NNS	O
.	.	O
FIG	NNP	O
.	.	O
6	CD	O
shows	VBZ	O
the	DT	O
results	NNS	O
of	IN	O
transfection	NN	O
of	IN	O
cDNA	NN	O
to	TO	O
GPRK6	NNP	O
and	CC	O
PLK2	NNP	O
into	IN	O
HEK-Synuclein	NNP	O
cells	NNS	O
.	.	O
FIG	NNP	O
.	.	O
7	CD	O
shows	NNS	O
that	IN	O
knockdown	NN	O
of	IN	O
the	DT	O
PLK2	NNP	O
using	VBG	O
siRNA	NN	O
from	IN	O
a	DT	O
second	JJ	O
source	NN	O
causes	VBZ	O
a	DT	O
reduction	NN	O
in	IN	O
the	DT	O
proportion	NN	O
of	IN	O
alpha-synuclein	NN	O
that	WDT	O
is	VBZ	O
phosphorylated	VBN	O
.	.	O
FIGS	NNP	O
.	.	O
8A	CD	O
and	CC	O
8B	CD	O
show	VBP	O
the	DT	O
in	IN	O
vitro	JJ	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	JJ	O
by	IN	O
putative	JJ	O
kinase	NN	O
targets	NNS	O
in	IN	O
alpha-synuclein	JJ	O
KO	NNP	O
mouse	NN	O
brain	NN	O
.	.	O
FIGS	NNP	O
.	.	O
9A	CD	O
and	CC	O
9B	CD	O
show	VBP	O
the	DT	O
in	IN	O
vitro	JJ	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	JJ	O
by	IN	O
putative	JJ	O
kinase	NN	O
targets	NNS	O
in	IN	O
alpha-synuclein	JJ	O
KO	NNP	O
mouse	NN	O
brain	NN	O
.	.	O
FIG	NNP	O
.	.	O
10	CD	O
shows	NNS	O
that	IN	O
siRNA	VBP	O
knockdown	VBN	O
of	IN	O
PLK2	NNP	O
,	,	O
but	CC	O
not	RB	O
PLK3	NNP	O
or	CC	O
PLK4	NNP	O
,	,	O
reduced	VBD	O
alpha-synuclein	JJ	O
phosphorylation	NN	O
.	.	O
DETAILED	JJ	O
DESCRIPTION	NNP	O
OF	IN	O
THE	NNP	O
INVENTION	NNP	O
I.	NNP	O
Definitions	NNP	O
The	DT	O
term	NN	O
“	NNP	O
agent	NN	O
”	NNP	O
is	VBZ	O
used	VBN	O
to	TO	O
describe	VB	O
a	DT	O
compound	NN	O
that	WDT	O
has	VBZ	O
or	CC	O
may	MD	O
have	VB	O
a	DT	O
pharmacological	JJ	O
activity	NN	O
.	.	O
Agents	NNS	O
include	VBP	O
compounds	NNS	O
that	WDT	O
are	VBP	O
known	VBN	O
drugs	NNS	O
,	,	O
compounds	NNS	O
for	IN	O
which	WDT	O
pharmacological	JJ	O
activity	NN	O
has	VBZ	O
been	VBN	O
identified	VBN	O
but	CC	O
which	WDT	O
are	VBP	O
undergoing	VBG	O
further	RBR	O
therapeutic	JJ	O
evaluation	NN	O
,	,	O
and	CC	O
compounds	NNS	O
that	WDT	O
are	VBP	O
members	NNS	O
of	IN	O
collections	NNS	O
and	CC	O
libraries	NNS	O
that	WDT	O
are	VBP	O
to	TO	O
be	VB	O
screened	VBN	O
for	IN	O
a	DT	O
pharmacological	JJ	O
activity	NN	O
.	.	O
A	DT	O
“	JJ	O
pharmacological	JJ	O
”	NN	O
activity	NN	O
means	VBZ	O
that	IN	O
an	DT	O
agent	NN	O
exhibits	VBZ	O
an	DT	O
activity	NN	O
in	IN	O
a	DT	O
screening	NN	O
system	NN	O
that	WDT	O
indicates	VBZ	O
that	IN	O
the	DT	O
agent	NN	O
is	VBZ	O
or	CC	O
may	MD	O
be	VB	O
useful	JJ	O
in	IN	O
the	DT	O
prophylaxis	NN	O
or	CC	O
treatment	NN	O
of	IN	O
a	DT	O
disease	NN	O
.	.	O
The	DT	O
screening	NN	O
system	NN	O
can	MD	O
be	VB	O
in	IN	O
vitro	NN	O
,	,	O
cellular	JJ	O
,	,	O
animal	JJ	O
or	CC	O
human	JJ	O
.	.	O
Agents	NNS	O
can	MD	O
be	VB	O
described	VBN	O
as	IN	O
having	VBG	O
pharmacological	JJ	O
activity	NN	O
notwithstanding	VBG	O
that	IN	O
further	JJ	O
testing	NN	O
may	MD	O
be	VB	O
required	VBN	O
to	TO	O
establish	VB	O
actual	JJ	O
prophylactic	JJ	O
or	CC	O
therapeutic	JJ	O
utility	NN	O
in	IN	O
treatment	NN	O
of	IN	O
a	DT	O
disease	NN	O
.	.	O
A	DT	O
Lewy-like	JJ	O
body	NN	O
is	VBZ	O
a	DT	O
deposit	NN	O
of	IN	O
alpha-synuclein	JJ	O
found	VBN	O
in	IN	O
a	DT	O
transgenic	JJ	O
animal	NN	O
that	WDT	O
resembles	VBZ	O
some	DT	O
or	CC	O
all	DT	O
of	IN	O
the	DT	O
characteristics	NNS	O
of	IN	O
a	DT	O
Lewy	NNP	O
body	NN	O
found	VBD	O
in	IN	O
human	JJ	O
patients	NNS	O
.	.	O
The	DT	O
preferred	JJ	O
characteristics	NNS	O
are	VBP	O
a	DT	O
compact	JJ	O
alpha-synuclein	JJ	O
positive	JJ	O
inclusion	NN	O
.	.	O
These	DT	O
inclusions	NNS	O
preferably	RB	O
form	VBP	O
in	IN	O
an	DT	O
age-dependent	JJ	O
manner	NN	O
.	.	O
The	DT	O
formation	NN	O
of	IN	O
alpha-synuclein	JJ	O
positive	JJ	O
inclusions	NNS	O
preferably	RB	O
results	NNS	O
in	IN	O
observable	JJ	O
cellular	JJ	O
pathology	NN	O
,	,	O
leading	VBG	O
to	TO	O
loss	NN	O
of	IN	O
functionality	NN	O
of	IN	O
affected	JJ	O
neurons	NNS	O
.	.	O
Loss	NNP	O
of	IN	O
function	NN	O
of	IN	O
affected	JJ	O
neurons	NNS	O
can	MD	O
be	VB	O
determined	VBN	O
through	IN	O
behavioral	JJ	O
tests	NNS	O
,	,	O
neuropharmacological	JJ	O
response	NN	O
evaluation	NN	O
and	CC	O
electrophysiology	NN	O
.	.	O
The	DT	O
phrase	NN	O
“	NNP	O
specifically	RB	O
binds	VBZ	O
”	JJ	O
refers	NNS	O
to	TO	O
a	DT	O
binding	NN	O
reaction	NN	O
which	WDT	O
is	VBZ	O
determinative	JJ	O
of	IN	O
the	DT	O
presence	NN	O
of	IN	O
the	DT	O
protein	NN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
a	DT	O
heterogeneous	JJ	O
population	NN	O
of	IN	O
proteins	NNS	O
and	CC	O
other	JJ	O
biologics	NNS	O
.	.	O
Thus	RB	O
,	,	O
under	IN	O
designated	VBN	O
conditions	NNS	O
,	,	O
a	DT	O
specified	JJ	O
ligand	NN	O
binds	VBZ	O
preferentially	RB	O
to	TO	O
a	DT	O
particular	JJ	O
protein	NN	O
and	CC	O
does	VBZ	O
not	RB	O
bind	VB	O
in	IN	O
a	DT	O
significant	JJ	O
amount	NN	O
to	TO	O
other	JJ	O
proteins	NNS	O
present	JJ	O
in	IN	O
the	DT	O
sample	NN	O
.	.	O
A	DT	O
molecule	NN	O
such	JJ	O
as	IN	O
an	DT	O
antibody	NN	O
that	WDT	O
specifically	RB	O
binds	VBZ	O
to	TO	O
a	DT	O
protein	NN	O
often	RB	O
has	VBZ	O
an	DT	O
association	NN	O
constant	NN	O
of	IN	O
at	IN	O
least	JJS	O
106M−1	CD	O
or	CC	O
107	CD	O
M−1	NNP	O
,	,	O
preferably	RB	O
108M−1	CD	O
to	TO	O
109	CD	O
M−1	NNP	O
,	,	O
and	CC	O
more	JJR	O
preferably	RB	O
,	,	O
about	IN	O
1010	CD	O
M−1	NNP	O
to	TO	O
1011	CD	O
M−1	NNP	O
or	CC	O
higher	JJR	O
.	.	O
A	DT	O
variety	NN	O
of	IN	O
immunoassay	JJ	O
formats	NNS	O
may	MD	O
be	VB	O
used	VBN	O
to	TO	O
select	VB	O
antibodies	NNS	O
specifically	RB	O
immunoreactive	VBP	O
with	IN	O
a	DT	O
particular	JJ	O
protein	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
solid-phase	JJ	O
ELISA	NNP	O
immunoassays	NNS	O
are	VBP	O
routinely	RB	O
used	VBN	O
to	TO	O
select	VB	O
monoclonal	JJ	O
antibodies	NNS	O
specifically	RB	O
immunoreactive	VBP	O
with	IN	O
a	DT	O
protein	NN	O
.	.	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
Harlow	NNP	B
and	CC	I
Lane	NNP	I
(	(	I
1988	CD	I
)	)	I
Antibodies	NNPS	I
,	,	I
A	NNP	I
Laboratory	NNP	I
Manual	NNP	I
,	,	I
Cold	NNP	I
Spring	NNP	I
Harbor	NNP	I
Publications	NNP	I
,	,	I
New	NNP	I
York	NNP	I
,	,	O
for	IN	O
examples	NNS	O
of	IN	O
immunoassay	NN	O
formats	NNS	O
and	CC	O
conditions	NNS	O
that	WDT	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
determine	VB	O
specific	JJ	O
immunoreactivity	NN	O
.	.	O
For	IN	O
sequence	NN	O
comparison	NN	O
,	,	O
typically	RB	O
one	CD	O
sequence	NN	O
acts	VBZ	O
as	IN	O
a	DT	O
reference	NN	O
sequence	NN	O
,	,	O
to	TO	O
which	WDT	O
test	NN	O
sequences	NNS	O
are	VBP	O
compared	VBN	O
.	.	O
When	WRB	O
using	VBG	O
a	DT	O
sequence	NN	O
comparison	NN	O
algorithm	NN	O
,	,	O
test	NN	O
and	CC	O
reference	NN	O
sequences	NNS	O
are	VBP	O
input	VBN	O
into	IN	O
a	DT	O
computer	NN	O
,	,	O
subsequent	JJ	O
coordinates	NNS	O
are	VBP	O
designated	VBN	O
,	,	O
if	IN	O
necessary	JJ	O
,	,	O
and	CC	O
sequence	NN	O
algorithm	NN	O
program	NN	O
parameters	NNS	O
are	VBP	O
designated	VBN	O
.	.	O
The	DT	O
sequence	NN	O
comparison	NN	O
algorithm	NN	O
then	RB	O
calculates	VBZ	O
the	DT	O
percent	NN	O
sequence	NN	O
identity	NN	O
for	IN	O
the	DT	O
test	NN	O
sequence	NN	O
(	(	O
s	PRP	O
)	)	O
relative	VBP	O
to	TO	O
the	DT	O
reference	NN	O
sequence	NN	O
,	,	O
based	VBN	O
on	IN	O
the	DT	O
designated	VBN	O
program	NN	O
parameters	NNS	O
.	.	O
Optimal	JJ	O
alignment	NN	O
of	IN	O
sequences	NNS	O
for	IN	O
comparison	NN	O
can	MD	O
be	VB	O
conducted	VBN	O
,	,	O
e.g.	NN	O
,	,	O
by	IN	O
the	DT	O
local	JJ	O
homology	NN	O
algorithm	NN	O
of	IN	O
Smith	NNP	B
&	CC	I
Waterman	NNP	I
,	,	I
Adv	NNP	I
.	.	I
Appl	NNP	I
.	.	I
Math	NN	I
.	.	I
2:482	CD	I
(	(	I
1981	CD	I
)	)	I
,	,	O
by	IN	O
the	DT	O
homology	NN	O
alignment	JJ	O
algorithm	NN	O
of	IN	O
Needleman	NNP	B
&	CC	I
Wunsch	NNP	I
,	,	I
J.	NNP	I
Mol	NNP	I
.	.	I
Biol	NNP	I
.	.	I
48:443	CD	I
(	(	I
1970	CD	I
)	)	I
,	,	O
by	IN	O
the	DT	O
search	NN	O
for	IN	O
similarity	NN	O
method	NN	O
of	IN	O
Pearson	NNP	B
&	CC	I
Lipman	NNP	I
,	,	I
Proc	NNP	I
.	.	I
Nat	NNP	I
'	POS	I
l	NN	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
85:2444	CD	I
(	(	I
1988	CD	I
)	)	I
,	,	O
by	IN	O
computerized	JJ	O
implementations	NNS	O
of	IN	O
these	DT	O
algorithms	NNS	O
(	(	O
GAP	NNP	O
,	,	O
BESTFIT	NNP	O
,	,	O
FASTA	NNP	O
,	,	O
and	CC	O
TFASTA	NNP	O
in	IN	O
the	DT	O
Wisconsin	NNP	O
Genetics	NNP	O
Software	NNP	O
Package	NNP	O
,	,	O
Genetics	NNP	O
Computer	NNP	O
Group	NNP	O
,	,	O
575	CD	O
Science	NNP	O
Dr.	NNP	O
,	,	O
Madison	NNP	O
,	,	O
Wis.	NNP	O
)	)	O
,	,	O
or	CC	O
by	IN	O
visual	JJ	O
inspection	NN	O
(	(	O
see	VB	O
generally	RB	O
Ausubel	NNP	O
et	CC	O
al.	NN	O
,	,	O
supra	NN	O
)	)	O
.	.	O
Another	DT	O
example	NN	O
of	IN	O
algorithm	NN	O
that	WDT	O
is	VBZ	O
suitable	JJ	O
for	IN	O
determining	VBG	O
percent	NN	O
sequence	NN	O
identity	NN	O
and	CC	O
sequence	NN	O
similarity	NN	O
is	VBZ	O
the	DT	O
BLAST	NNP	O
algorithm	NN	O
,	,	O
which	WDT	O
is	VBZ	O
described	VBN	O
in	IN	O
Altschul	NNP	B
et	CC	I
al.	NN	I
,	,	I
J.	NNP	I
Mol	NNP	I
.	.	I
Biol	NNP	I
.	.	I
215:403-410	CD	I
(	(	I
1990	CD	I
)	)	I
.	.	O
Software	NNP	O
for	IN	O
performing	VBG	O
BLAST	NNP	O
analyses	NNS	O
is	VBZ	O
publicly	RB	O
available	JJ	O
through	IN	O
the	DT	O
National	NNP	O
Center	NNP	O
for	IN	O
Biotechnology	NNP	O
Information	NNP	O
(	(	O
http	NN	O
:	:	O
//www.ncbi.nlm.nih.gov/	NN	O
)	)	O
.	.	O
This	DT	O
algorithm	NN	O
involves	VBZ	O
first	RB	O
identifying	JJ	O
high	JJ	O
scoring	VBG	O
sequence	NN	O
pairs	NNS	O
(	(	O
HSPs	NNP	O
)	)	O
by	IN	O
identifying	VBG	O
short	JJ	O
words	NNS	O
of	IN	O
length	NN	O
W	NNP	O
in	IN	O
the	DT	O
query	NN	O
sequence	NN	O
,	,	O
which	WDT	O
either	CC	O
match	NN	O
or	CC	O
satisfy	VB	O
some	DT	O
positive-valued	JJ	O
threshold	NN	O
score	NN	O
T	NNP	O
when	WRB	O
aligned	VBN	O
with	IN	O
a	DT	O
word	NN	O
of	IN	O
the	DT	O
same	JJ	O
length	NN	O
in	IN	O
a	DT	O
database	NN	O
sequence	NN	O
.	.	O
T	NNP	O
is	VBZ	O
referred	VBN	O
to	TO	O
as	IN	O
the	DT	O
neighborhood	NN	O
word	NN	O
score	NN	O
threshold	NN	O
(	(	O
Altschul	NNP	O
et	RB	O
al.	RB	O
,	,	O
supra	NN	O
.	.	O
)	)	O
.	.	O
These	DT	O
initial	JJ	O
neighborhood	NN	O
word	NN	O
hits	VBZ	O
act	NN	O
as	IN	O
seeds	NNS	O
for	IN	O
initiating	VBG	O
searches	NNS	O
to	TO	O
find	VB	O
longer	JJR	O
HSPs	NNP	O
containing	VBG	O
them	PRP	O
.	.	O
The	DT	O
word	NN	O
hits	NNS	O
are	VBP	O
then	RB	O
extended	VBN	O
in	IN	O
both	DT	O
directions	NNS	O
along	IN	O
each	DT	O
sequence	NN	O
for	IN	O
as	RB	O
far	RB	O
as	IN	O
the	DT	O
cumulative	JJ	O
alignment	NN	O
score	NN	O
can	MD	O
be	VB	O
increased	VBN	O
.	.	O
Cumulative	JJ	O
scores	NNS	O
are	VBP	O
calculated	VBN	O
using	VBG	O
,	,	O
for	IN	O
nucleotide	JJ	O
sequences	NNS	O
,	,	O
the	DT	O
parameters	NNS	O
M	NNP	O
(	(	O
reward	NN	O
score	NN	O
for	IN	O
a	DT	O
pair	NN	O
of	IN	O
matching	VBG	O
residues	NNS	O
;	:	O
always	RB	O
>	VBP	O
0	CD	O
)	)	O
and	CC	O
N	NNP	O
(	(	O
penalty	NN	O
score	NN	O
for	IN	O
mismatching	VBG	O
residues	NNS	O
;	:	O
always	RB	O
<	VBP	O
0	CD	O
)	)	O
.	.	O
For	IN	O
amino	NN	O
acid	NN	O
sequences	NNS	O
,	,	O
a	DT	O
scoring	NN	O
matrix	NN	O
is	VBZ	O
used	VBN	O
to	TO	O
calculate	VB	O
the	DT	O
cumulative	JJ	O
score	NN	O
.	.	O
Extension	NN	O
of	IN	O
the	DT	O
word	NN	O
hits	VBZ	O
in	IN	O
each	DT	O
direction	NN	O
are	VBP	O
halted	VBN	O
when	WRB	O
:	:	O
the	DT	O
cumulative	JJ	O
alignment	NN	O
score	NN	O
falls	VBZ	O
off	RP	O
by	IN	O
the	DT	O
quantity	NN	O
X	NNP	O
from	IN	O
its	PRP$	O
maximum	NN	O
achieved	VBN	O
value	NN	O
;	:	O
the	DT	O
cumulative	JJ	O
score	NN	O
goes	VBZ	O
to	TO	O
zero	CD	O
or	CC	O
below	IN	O
,	,	O
due	JJ	O
to	TO	O
the	DT	O
accumulation	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
negative-scoring	JJ	O
residue	JJ	O
alignments	NNS	O
;	:	O
or	CC	O
the	DT	O
end	NN	O
of	IN	O
either	DT	O
sequence	NN	O
is	VBZ	O
reached	VBN	O
.	.	O
For	IN	O
identifying	VBG	O
whether	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
or	CC	O
polypeptide	NN	O
is	VBZ	O
within	IN	O
the	DT	O
scope	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
the	DT	O
default	NN	O
parameters	NNS	O
of	IN	O
the	DT	O
BLAST	NNP	O
programs	NNS	O
are	VBP	O
suitable	JJ	O
.	.	O
The	DT	O
BLASTN	NNP	O
program	NN	O
(	(	O
for	IN	O
nucleotide	RB	O
sequences	NNS	O
)	)	O
uses	VBZ	O
as	IN	O
defaults	NNS	O
a	DT	O
word	NN	O
length	NN	O
(	(	O
W	NNP	O
)	)	O
of	IN	O
11	CD	O
,	,	O
an	DT	O
expectation	NN	O
(	(	O
E	NNP	O
)	)	O
of	IN	O
10	CD	O
,	,	O
M=5	NNP	O
,	,	O
N=−4	NNP	O
,	,	O
and	CC	O
a	DT	O
comparison	NN	O
of	IN	O
both	DT	O
strands	NNS	O
.	.	O
For	IN	O
amino	NN	O
acid	NN	O
sequences	NNS	O
,	,	O
the	DT	O
BLASTP	NNP	O
program	NN	O
uses	VBZ	O
as	IN	O
defaults	NNS	O
a	DT	O
word	NN	O
length	NN	O
(	(	O
W	NNP	O
)	)	O
of	IN	O
3	CD	O
,	,	O
an	DT	O
expectation	NN	O
(	(	O
E	NNP	O
)	)	O
of	IN	O
10	CD	O
,	,	O
and	CC	O
the	DT	O
BLOSUM62	NNP	O
scoring	NN	O
matrix	NN	O
.	.	O
The	DT	O
TBLATN	NNP	O
program	NN	O
(	(	O
using	VBG	O
protein	NN	O
sequence	NN	O
for	IN	O
nucleotide	JJ	O
sequence	NN	O
)	)	O
uses	VBZ	O
as	IN	O
defaults	NNS	O
a	DT	O
word	NN	O
length	NN	O
(	(	O
W	NNP	O
)	)	O
of	IN	O
3	CD	O
,	,	O
an	DT	O
expectation	NN	O
(	(	O
E	NNP	O
)	)	O
of	IN	O
10	CD	O
,	,	O
and	CC	O
a	DT	O
BLOSUM	NNP	O
62	CD	O
scoring	VBG	O
matrix	NN	O
.	.	O
(	(	O
see	VB	O
Henikoff	NNP	B
&	CC	I
Henikoff	NNP	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
89:10915	CD	I
(	(	I
1989	CD	I
)	)	I
)	)	O
.	.	O
In	IN	O
addition	NN	O
to	TO	O
calculating	VBG	O
percent	NN	O
sequence	NN	O
identity	NN	O
,	,	O
the	DT	O
BLAST	NNP	O
algorithm	NN	O
also	RB	O
performs	VBZ	O
a	DT	O
statistical	JJ	O
analysis	NN	O
of	IN	O
the	DT	O
similarity	NN	O
between	IN	O
two	CD	O
sequences	NNS	O
(	(	O
see	VB	O
,	,	O
e.g.	VB	O
,	,	O
Karlin	NNP	B
&	CC	I
Altschul	NNP	I
,	,	I
Proc	NNP	I
.	.	I
Nat	NNP	I
'	POS	I
l	NN	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
90:5873-5787	CD	I
(	(	I
1993	CD	I
)	)	I
)	)	O
.	.	O
One	CD	O
measure	NN	O
of	IN	O
similarity	NN	O
provided	VBN	O
by	IN	O
the	DT	O
BLAST	NNP	O
algorithm	NN	O
is	VBZ	O
the	DT	O
smallest	JJS	O
sum	JJ	O
probability	NN	O
(	(	O
P	NNP	O
(	(	O
N	NNP	O
)	)	O
)	)	O
,	,	O
which	WDT	O
provides	VBZ	O
an	DT	O
indication	NN	O
of	IN	O
the	DT	O
probability	NN	O
by	IN	O
which	WDT	O
a	DT	O
match	NN	O
between	IN	O
two	CD	O
nucleotide	NN	O
or	CC	O
amino	NN	O
acid	JJ	O
sequences	NNS	O
would	MD	O
occur	VB	O
by	IN	O
chance	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
a	DT	O
nucleic	JJ	O
acid	NN	O
is	VBZ	O
considered	VBN	O
similar	JJ	O
to	TO	O
a	DT	O
reference	NN	O
sequence	NN	O
if	IN	O
the	DT	O
smallest	JJS	O
sum	JJ	O
probability	NN	O
in	IN	O
a	DT	O
comparison	NN	O
of	IN	O
the	DT	O
test	NN	O
nucleic	NN	O
acid	NN	O
to	TO	O
the	DT	O
reference	NN	O
nucleic	JJ	O
acid	NN	O
is	VBZ	O
less	JJR	O
than	IN	O
about	RB	O
0.1	CD	O
,	,	O
more	JJR	O
preferably	RB	O
less	RBR	O
than	IN	O
about	RB	O
0.01	CD	O
,	,	O
and	CC	O
most	JJS	O
preferably	RB	O
less	JJR	O
than	IN	O
about	RB	O
0.001	CD	O
.	.	O
For	IN	O
purposes	NNS	O
of	IN	O
classifying	VBG	O
amino	JJ	O
acids	NNS	O
substitutions	NNS	O
as	IN	O
conservative	JJ	O
or	CC	O
non-conservative	JJ	O
,	,	O
amino	JJ	O
acids	NNS	O
are	VBP	O
grouped	VBN	O
as	IN	O
follows	VBZ	O
:	:	O
Group	NNP	O
I	PRP	O
(	(	O
hydrophobic	JJ	O
side	NN	O
chains	NNS	O
)	)	O
:	:	O
norleucine	NN	O
,	,	O
met	VBD	O
,	,	O
ala	NN	O
,	,	O
val	NN	O
,	,	O
leu	NN	O
,	,	O
ile	NN	O
;	:	O
Group	NNP	O
II	NNP	O
(	(	O
neutral	JJ	O
hydrophilic	JJ	O
side	NN	O
chains	NNS	O
)	)	O
:	:	O
cys	NN	O
,	,	O
ser	NN	O
,	,	O
thr	NN	O
;	:	O
Group	NNP	O
III	NNP	O
(	(	O
acidic	JJ	O
side	NN	O
chains	NNS	O
)	)	O
:	:	O
asp	NN	O
,	,	O
glu	NN	O
;	:	O
Group	NNP	O
IV	NNP	O
(	(	O
basic	JJ	O
side	NN	O
chains	NNS	O
)	)	O
:	:	O
asn	NN	O
,	,	O
gln	NN	O
,	,	O
his	PRP$	O
,	,	O
lys	NN	O
,	,	O
arg	RB	O
;	:	O
Group	NNP	O
V	NNP	O
(	(	O
residues	NNS	O
influencing	VBG	O
chain	NN	O
orientation	NN	O
)	)	O
:	:	O
gly	RB	O
,	,	O
pro	FW	O
;	:	O
and	CC	O
Group	NNP	O
VI	NNP	O
(	(	O
aromatic	JJ	O
side	NN	O
chains	NNS	O
)	)	O
:	:	O
trp	NN	O
,	,	O
tyr	NN	O
,	,	O
phe	NN	O
.	.	O
Conservative	JJ	O
substitutions	NNS	O
involve	VBP	O
substitutions	NNS	O
between	IN	O
amino	JJ	O
acids	NNS	O
in	IN	O
the	DT	O
same	JJ	O
class	NN	O
.	.	O
Non-conservative	JJ	O
substitutions	NNS	O
constitute	VBP	O
exchanging	VBG	O
a	DT	O
member	NN	O
of	IN	O
one	CD	O
of	IN	O
these	DT	O
classes	NNS	O
for	IN	O
a	DT	O
member	NN	O
of	IN	O
another	DT	O
.	.	O
Therapeutic	JJ	O
agents	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
typically	RB	O
substantially	RB	O
pure	VBP	O
from	IN	O
undesired	JJ	O
contaminant	NN	O
.	.	O
This	DT	O
means	VBZ	O
that	IN	O
an	DT	O
agent	NN	O
is	VBZ	O
typically	RB	O
at	IN	O
least	JJS	O
about	IN	O
50	CD	O
%	NN	O
w/w	NN	O
(	(	O
weight/weight	NN	O
)	)	O
purity	NN	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
being	VBG	O
substantially	RB	O
free	JJ	O
from	IN	O
interfering	VBG	O
proteins	NNS	O
and	CC	O
contaminants	NNS	O
.	.	O
Sometimes	RB	O
the	DT	O
agents	NNS	O
are	VBP	O
at	IN	O
least	JJS	O
about	IN	O
80	CD	O
%	NN	O
w/w	NN	O
and	CC	O
,	,	O
more	JJR	O
preferably	RB	O
at	IN	O
least	JJS	O
about	IN	O
90	CD	O
%	NN	O
,	,	O
at	IN	O
least	JJS	O
about	IN	O
95	CD	O
%	NN	O
,	,	O
or	CC	O
at	IN	O
least	JJS	O
about	IN	O
99	CD	O
%	NN	O
w/w	JJ	O
purity	NN	O
.	.	O
However	RB	O
,	,	O
using	VBG	O
conventional	JJ	O
protein	JJ	O
purification	NN	O
techniques	NNS	O
,	,	O
homogeneous	JJ	O
peptides	NNS	O
of	IN	O
at	IN	O
least	JJS	O
99	CD	O
%	NN	O
w/w	NN	O
can	MD	O
be	VB	O
obtained	VBN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
antibody	NN	O
”	NNP	O
or	CC	O
“	NNP	O
immunoglobulin	NN	O
”	NN	O
is	VBZ	O
used	VBN	O
to	TO	O
include	VB	O
intact	JJ	O
antibodies	NNS	O
and	CC	O
binding	VBG	O
fragments	NNS	O
thereof	NN	O
.	.	O
Typically	RB	O
,	,	O
fragments	NNS	O
compete	VBP	O
with	IN	O
the	DT	O
intact	JJ	O
antibody	NN	O
from	IN	O
which	WDT	O
they	PRP	O
were	VBD	O
derived	VBN	O
for	IN	O
specific	JJ	O
binding	VBG	O
to	TO	O
an	DT	O
antigen	NN	O
fragment	NN	O
including	VBG	O
separate	JJ	O
heavy	JJ	O
chains	NNS	O
,	,	O
light	NN	O
chains	NNS	O
Fab	NNP	O
,	,	O
Fab′	NNP	O
F	NNP	O
(	(	O
ab′	NN	O
)	)	O
2	CD	O
,	,	O
Fabc	NNP	O
,	,	O
and	CC	O
Fv	NNP	O
.	.	O
Fragments	NNS	O
are	VBP	O
produced	VBN	O
by	IN	O
recombinant	JJ	O
DNA	NNP	O
techniques	NNS	O
,	,	O
or	CC	O
by	IN	O
enzymatic	JJ	O
or	CC	O
chemical	JJ	O
separation	NN	O
of	IN	O
intact	JJ	O
immunoglobulins	NNS	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
antibody	NN	O
”	NNP	O
also	RB	O
includes	VBZ	O
one	CD	O
or	CC	O
more	JJR	O
immunoglobulin	NN	O
chains	NNS	O
that	WDT	O
are	VBP	O
chemically	RB	O
conjugated	VBN	O
to	TO	O
,	,	O
or	CC	O
expressed	VBN	O
as	IN	O
,	,	O
fusion	NN	O
proteins	NNS	O
with	IN	O
other	JJ	O
proteins	NNS	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
antibody	NN	O
”	NNP	O
also	RB	O
includes	VBZ	O
bispecific	JJ	O
antibody	NN	O
.	.	O
A	DT	O
bispecific	NN	O
or	CC	O
bifunctional	JJ	O
antibody	NN	O
is	VBZ	O
an	DT	O
artificial	JJ	O
hybrid	NN	O
antibody	NN	O
having	VBG	O
two	CD	O
different	JJ	O
heavy/light	NN	O
chain	NN	O
pairs	NNS	O
and	CC	O
two	CD	O
different	JJ	O
binding	VBG	O
sites	NNS	O
.	.	O
Bispecific	NNP	O
antibodies	NNS	O
can	MD	O
be	VB	O
produced	VBN	O
by	IN	O
a	DT	O
variety	NN	O
of	IN	O
methods	NNS	O
including	VBG	O
fusion	NN	O
of	IN	O
hybridomas	NN	O
or	CC	O
linking	NN	O
of	IN	O
Fab′	NNP	O
fragments	NNS	O
.	.	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
Songsivilai	NNP	B
&	CC	I
Lachmann	NNP	I
,	,	I
Clin	NNP	I
.	.	I
Exp	NNP	I
.	.	I
Immunol	NNP	I
.	.	I
79:315-321	CD	I
(	(	I
1990	CD	I
)	)	I
;	:	O
Kostelny	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Immunol	NNP	I
.	.	I
148	CD	I
,	,	I
1547-1553	CD	I
(	(	I
1992	CD	I
)	)	I
.	.	O
A	DT	O
symptom	NN	O
of	IN	O
a	DT	O
disorder	NN	O
means	VBZ	O
a	DT	O
phenomenon	NN	O
experienced	VBN	O
by	IN	O
an	DT	O
individual	JJ	O
having	VBG	O
the	DT	O
disorder	NN	O
indicating	VBG	O
a	DT	O
departure	NN	O
from	IN	O
normal	JJ	O
function	NN	O
,	,	O
sensation	NN	O
or	CC	O
appearance	NN	O
.	.	O
A	DT	O
sign	NN	O
of	IN	O
a	DT	O
disorder	NN	O
is	VBZ	O
any	DT	O
bodily	JJ	O
manifestation	NN	O
that	WDT	O
serves	VBZ	O
to	TO	O
indicate	VB	O
presence	NN	O
or	CC	O
risk	NN	O
of	IN	O
a	DT	O
disorder	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
patient	NN	O
”	NNP	O
includes	VBZ	O
human	JJ	O
and	CC	O
other	JJ	O
mammalian	JJ	O
subjects	NNS	O
that	WDT	O
receive	VBP	O
either	DT	O
prophylactic	JJ	O
or	CC	O
therapeutic	JJ	O
treatment	NN	O
.	.	O
As	IN	O
used	VBN	O
herein	NN	O
,	,	O
“	NNP	O
treating	VBG	O
”	RP	O
a	DT	O
condition	NN	O
(	(	O
e.g.	JJ	O
,	,	O
Parkinson	NNP	O
's	POS	O
Disease	NNP	O
)	)	O
or	CC	O
patient	JJ	O
refers	NNS	O
to	TO	O
taking	VBG	O
steps	NNS	O
to	TO	O
obtain	VB	O
beneficial	JJ	O
or	CC	O
desired	JJ	O
result	NN	O
.	.	O
For	IN	O
purposes	NNS	O
of	IN	O
this	DT	O
invention	NN	O
,	,	O
beneficial	JJ	O
or	CC	O
desired	JJ	O
results	NNS	O
include	VBP	O
,	,	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
,	,	O
alleviation	NN	O
or	CC	O
amelioration	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
symptoms	NNS	O
of	IN	O
Parkinson	NNP	O
's	POS	O
Disease	NNP	O
,	,	O
diminishment	NN	O
of	IN	O
extent	NN	O
of	IN	O
disease	NN	O
,	,	O
delay	NN	O
or	CC	O
slowing	NN	O
of	IN	O
disease	NN	O
progression	NN	O
,	,	O
amelioration	NN	O
,	,	O
palliation	NN	O
or	CC	O
stabilization	NN	O
of	IN	O
the	DT	O
disease	NN	O
state	NN	O
.	.	O
As	IN	O
used	VBN	O
herein	NN	O
,	,	O
a	DT	O
“	NNP	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
”	NNP	O
of	IN	O
a	DT	O
drug	NN	O
is	VBZ	O
an	DT	O
amount	NN	O
of	IN	O
a	DT	O
drug	NN	O
that	IN	O
,	,	O
when	WRB	O
administered	VBN	O
to	TO	O
a	DT	O
subject	NN	O
diagnosed	VBN	O
with	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
,	,	O
or	CC	O
diagnosed	VBD	O
as	IN	O
being	VBG	O
at	IN	O
high	JJ	O
risk	NN	O
for	IN	O
developing	VBG	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
will	MD	O
have	VB	O
the	DT	O
intended	VBN	O
therapeutic	JJ	O
effect	NN	O
,	,	O
e.g.	NN	O
,	,	O
alleviation	NN	O
,	,	O
amelioration	NN	O
,	,	O
palliation	NN	O
or	CC	O
elimination	NN	O
of	IN	O
one	CD	O
or	CC	O
more	JJR	O
manifestations	NNS	O
of	IN	O
the	DT	O
disease	NN	O
in	IN	O
the	DT	O
subject	NN	O
.	.	O
The	DT	O
full	JJ	O
therapeutic	JJ	O
effect	NN	O
does	VBZ	O
not	RB	O
necessarily	RB	O
occur	VBN	O
by	IN	O
administration	NN	O
of	IN	O
one	CD	O
dose	NN	O
,	,	O
and	CC	O
may	MD	O
occur	VB	O
only	RB	O
after	IN	O
administration	NN	O
of	IN	O
a	DT	O
series	NN	O
of	IN	O
doses	NNS	O
.	.	O
Thus	RB	O
,	,	O
a	DT	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
may	MD	O
be	VB	O
administered	VBN	O
in	IN	O
one	CD	O
or	CC	O
more	JJR	O
administrations	NNS	O
.	.	O
Compositions	NNS	O
or	CC	O
methods	NNS	O
“	VBP	O
comprising	VBG	O
”	RP	O
one	CD	O
or	CC	O
more	JJR	O
recited	JJ	O
elements	NNS	O
may	MD	O
include	VB	O
other	JJ	O
elements	NNS	O
not	RB	O
specifically	RB	O
recited	VBN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
a	DT	O
composition	NN	O
that	WDT	O
comprises	VBZ	O
alpha-synuclein	JJ	O
peptide	NN	O
encompasses	VBZ	O
both	DT	O
an	DT	O
isolated	JJ	O
alpha-synuclein	JJ	O
peptide	NN	O
and	CC	O
alpha-synuclein	JJ	O
peptide	NN	O
as	IN	O
a	DT	O
component	NN	O
of	IN	O
a	DT	O
larger	JJR	O
polypeptide	JJ	O
sequence	NN	O
.	.	O
Unless	IN	O
otherwise	RB	O
apparent	NN	O
from	IN	O
the	DT	O
context	NN	O
,	,	O
each	DT	O
embodiment	NN	O
,	,	O
element	NN	O
,	,	O
step	NN	O
or	CC	O
feature	NN	O
of	IN	O
the	DT	O
invention	NN	O
can	MD	O
be	VB	O
used	VBN	O
in	IN	O
combination	NN	O
with	IN	O
any	DT	O
other	JJ	O
.	.	O
II	NNP	O
.	.	O
General	NNP	O
The	DT	O
invention	NN	O
is	VBZ	O
premised	VBN	O
in	IN	O
part	NN	O
on	IN	O
the	DT	O
insight	NN	O
that	WDT	O
Lewy	NNP	O
Body	NNP	O
diseases	VBZ	O
(	(	O
LBDs	NNP	O
)	)	O
can	MD	O
be	VB	O
inhibited	VBN	O
by	IN	O
inhibiting	VBG	O
one	CD	O
or	CC	O
more	JJR	O
kinases	NNS	O
that	WDT	O
phosphorylate	VBP	O
alpha-synuclein	JJ	O
and/or	JJ	O
inhibit	NN	O
its	PRP$	O
production	NN	O
.	.	O
Although	IN	O
practice	NN	O
of	IN	O
the	DT	O
invention	NN	O
is	VBZ	O
not	RB	O
dependent	JJ	O
on	IN	O
an	DT	O
understanding	NN	O
of	IN	O
mechanism	NN	O
,	,	O
it	PRP	O
is	VBZ	O
believed	VBN	O
that	IN	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	NN	O
at	IN	O
serine-129	NN	O
is	VBZ	O
one	CD	O
of	IN	O
a	DT	O
series	NN	O
of	IN	O
molecular	JJ	O
events	NNS	O
leading	VBG	O
to	TO	O
formation	NN	O
of	IN	O
intracellular	JJ	O
deposits	NNS	O
of	IN	O
alpha-synuclein	NN	O
.	.	O
Alpha-synuclein	NNP	O
phosphorylated	VBD	O
at	IN	O
ser-129	NN	O
is	VBZ	O
highly	RB	O
enriched	VBN	O
in	IN	O
Lewy	NNP	O
bodies	NNS	O
(	(	O
LBs	NNP	O
)	)	O
in	IN	O
Diffuse	NNP	O
Lewy	NNP	O
body	NN	O
disease	NN	O
(	(	O
DLBD	NNP	O
)	)	O
,	,	O
multiple	JJ	O
system	NN	O
atrophy	NN	O
(	(	O
MSA	NNP	O
)	)	O
and	CC	O
familial	JJ	O
forms	NNS	O
of	IN	O
Parkinson	NNP	O
's	POS	O
Disease	NNP	O
(	(	O
PD	NNP	O
)	)	O
.	.	O
The	DT	O
abnormal	JJ	O
accumulation	NN	O
of	IN	O
phospho-alpha-synuclein	NN	O
in	IN	O
LBs	NNP	O
indicates	VBZ	O
that	IN	O
phospho-synuclein	NN	O
may	MD	O
be	VB	O
a	DT	O
pathogenic	JJ	O
species	NNS	O
that	WDT	O
drives	VBZ	O
LB	NNP	O
formation	NN	O
,	,	O
and	CC	O
that	IN	O
the	DT	O
kinase	NN	O
(	(	O
s	PRP	O
)	)	O
responsible	JJ	O
for	IN	O
its	PRP$	O
phosphorylation	NN	O
or	CC	O
which	WDT	O
regulates	VBZ	O
production	NN	O
of	IN	O
alpha-synuclein	JJ	O
itself	PRP	O
are	VBP	O
therapeutic	JJ	O
target	NN	O
(	(	O
s	JJ	O
)	)	O
for	IN	O
treatment	NN	O
of	IN	O
multiple	JJ	O
synucleinopathies	NNS	O
.	.	O
Other	JJ	O
events	NNS	O
in	IN	O
this	DT	O
series	NN	O
likely	RB	O
include	VBP	O
proteolytic	JJ	O
cleavages	NNS	O
following	VBG	O
phosphorylation	NN	O
(	(	O
see	VB	O
WO	NNP	O
2005/013889	CD	O
,	,	O
filed	VBD	O
May	NNP	O
19	CD	O
,	,	O
2004	CD	O
)	)	O
.	.	O
Identification	NN	O
of	IN	O
the	DT	O
kinase	NN	O
(	(	O
s	PRP	O
)	)	O
primarily	RB	O
responsible	JJ	O
for	IN	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	JJ	O
allows	NNS	O
compounds	VBZ	O
that	IN	O
reduce	VB	O
activity	NN	O
of	IN	O
the	DT	O
relevant	JJ	O
kinase	NN	O
(	(	O
s	PRP	O
)	)	O
to	TO	O
be	VB	O
identified	VBN	O
.	.	O
For	IN	O
convenience	NN	O
,	,	O
reference	NN	O
herein	NN	O
to	TO	O
“	VB	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	JJ	O
”	NN	O
refers	NNS	O
to	TO	O
phosphorylation	NN	O
at	IN	O
Serine-129	NNP	O
(	(	O
but	CC	O
does	VBZ	O
not	RB	O
exclude	VB	O
additional	JJ	O
phosphorylation	NN	O
elsewhere	RB	O
,	,	O
e.g.	NN	O
,	,	O
Serine-87	NNP	O
)	)	O
.	.	O
The	DT	O
present	JJ	O
application	NN	O
reports	NNS	O
identification	NN	O
of	IN	O
several	JJ	O
kinases	NNS	O
where	WRB	O
reduction	NN	O
in	IN	O
kinase	NN	O
activity	NN	O
is	VBZ	O
accompanied	VBN	O
by	IN	O
a	DT	O
reduction	NN	O
of	IN	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	JJ	O
and/or	NN	O
a	DT	O
reduction	NN	O
in	IN	O
total	JJ	O
alpha-synuclein	JJ	O
level	NN	O
.	.	O
In	IN	O
particular	JJ	O
,	,	O
the	DT	O
kinase	NN	O
PLK2	NNP	O
can	MD	O
be	VB	O
inhibited	VBN	O
to	TO	O
reduce	VB	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	NN	O
.	.	O
The	DT	O
invention	NN	O
provides	VBZ	O
methods	NNS	O
of	IN	O
(	(	O
i	NN	O
)	)	O
identifying	VBG	O
modulators	NNS	O
of	IN	O
the	DT	O
activity	NN	O
and	CC	O
expression	NN	O
of	IN	O
these	DT	O
kinases	NNS	O
,	,	O
(	(	O
ii	NN	O
)	)	O
methods	NNS	O
of	IN	O
treating	VBG	O
Lewy	NNP	O
body	NN	O
diseases	VBZ	O
using	VBG	O
kinase	NN	O
inhibitors	NNS	O
,	,	O
and	CC	O
(	(	O
iii	NN	O
)	)	O
exemplary	JJ	O
kinase	NN	O
inhibitors	NNS	O
for	IN	O
use	NN	O
in	IN	O
treating	VBG	O
Lewy	NNP	O
body	NN	O
diseases	NNS	O
.	.	O
As	IN	O
discussed	VBN	O
in	IN	O
the	DT	O
Examples	NNP	O
,	,	O
infra	NN	O
,	,	O
we	PRP	O
have	VBP	O
carried	VBN	O
out	RP	O
a	DT	O
variety	NN	O
of	IN	O
experiments	NNS	O
to	TO	O
identify	VB	O
kinases	NNS	O
important	JJ	O
in	IN	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	NN	O
.	.	O
Section	NN	O
III	NNP	O
outlines	VBZ	O
a	DT	O
strategy	NN	O
for	IN	O
identifying	VBG	O
alpha-synuclein	JJ	O
kinases	NNS	O
.	.	O
Section	NN	O
IV	NNP	O
summarizes	VBZ	O
results	NNS	O
of	IN	O
screening	VBG	O
assays	NNS	O
used	VBN	O
to	TO	O
identify	VB	O
likely	JJ	O
alpha-synuclein	JJ	O
kinases	NNS	O
.	.	O
Section	NN	O
V	NNP	O
describes	VBZ	O
agents	NNS	O
that	IN	O
reduce	VB	O
synuclein	JJ	O
kinase	NN	O
activity	NN	O
or	CC	O
expression	NN	O
and	CC	O
may	MD	O
be	VB	O
used	VBN	O
therapeutically	RB	O
.	.	O
Section	NN	O
VI	NNP	O
describes	VBZ	O
methods	NNS	O
for	IN	O
treating	VBG	O
Parkinson	NNP	O
's	POS	O
Disease	NNP	O
and	CC	O
other	JJ	O
Lewy	NNP	O
Body	NNP	O
Diseases	NNP	O
.	.	O
Section	NN	O
VII	NNP	O
describes	VBZ	O
Lewy	NNP	O
Body	NNP	O
Diseases	NNP	O
.	.	O
Section	NN	O
VIII	NNP	O
describes	VBZ	O
transgenic	JJ	O
animal	NN	O
and	CC	O
cellular	JJ	O
models	NNS	O
of	IN	O
Lewy	NNP	O
Body	NNP	O
Disease	NNP	O
.	.	O
Section	NN	O
IX	NNP	O
describes	VBZ	O
method	NN	O
for	IN	O
identification	NN	O
of	IN	O
modulators	NNS	O
of	IN	O
PLK2	NNP	O
and	CC	O
other	JJ	O
kinases	NNS	O
.	.	O
Section	NN	O
X	NNP	O
describes	VBZ	O
methods	NNS	O
for	IN	O
alpha-synuclein	JJ	O
isolation	NN	O
.	.	O
Section	NN	O
XI	NNP	O
provides	VBZ	O
experimental	JJ	O
results	NNS	O
including	VBG	O
the	DT	O
aforementioned	JJ	O
screening	NN	O
assays	NNS	O
.	.	O
III	NNP	O
.	.	O
Identification	NN	O
of	IN	O
Target	NNP	O
Kinases	NNP	O
Kinases	VBZ	O
that	WDT	O
directly	RB	O
or	CC	O
indirectly	RB	O
modulate	JJ	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	NN	O
can	MD	O
be	VB	O
identified	VBN	O
as	IN	O
shown	VBN	O
in	IN	O
the	DT	O
Examples	NNP	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
a	DT	O
library	NN	O
of	IN	O
potential	JJ	O
inhibitors	NNS	O
is	VBZ	O
designed	VBN	O
based	VBN	O
on	IN	O
the	DT	O
known	JJ	O
sequences	NNS	O
of	IN	O
a	DT	O
collection	NN	O
of	IN	O
kinase	NN	O
genes	NNS	O
.	.	O
The	DT	O
members	NNS	O
of	IN	O
the	DT	O
library	NN	O
can	MD	O
be	VB	O
any	DT	O
of	IN	O
the	DT	O
types	NNS	O
of	IN	O
molecule	NN	O
described	VBN	O
above	IN	O
.	.	O
Members	NNS	O
of	IN	O
the	DT	O
library	NN	O
are	VBP	O
then	RB	O
introduced	VBN	O
into	IN	O
cells	NNS	O
expressing	VBG	O
alpha-synuclein	NN	O
.	.	O
Preferably	RB	O
both	DT	O
the	DT	O
cells	NNS	O
and	CC	O
the	DT	O
alpha-synuclein	NN	O
are	VBP	O
human	JJ	O
.	.	O
Usually	RB	O
,	,	O
such	JJ	O
cells	NNS	O
are	VBP	O
transfected	VBN	O
with	IN	O
both	DT	O
DNA	NNP	O
encoding	VBG	O
human	JJ	O
alpha-synuclein	JJ	O
and	CC	O
DNA	NNP	O
encoding	VBG	O
the	DT	O
library	JJ	O
member	NN	O
to	TO	O
be	VB	O
tested	VBN	O
.	.	O
Library	JJ	O
members	NNS	O
can	MD	O
be	VB	O
screened	VBN	O
individually	RB	O
or	CC	O
en	FW	O
masse	FW	O
.	.	O
After	IN	O
introduction	NN	O
of	IN	O
a	DT	O
library	JJ	O
member	NN	O
,	,	O
and	CC	O
culturing	VBG	O
for	IN	O
a	DT	O
period	NN	O
sufficient	NN	O
for	IN	O
the	DT	O
library	JJ	O
member	NN	O
to	TO	O
be	VB	O
expressed	VBN	O
and	CC	O
effect	NN	O
repression	NN	O
of	IN	O
its	PRP$	O
kinase	NN	O
,	,	O
the	DT	O
levels	NNS	O
of	IN	O
total	JJ	O
alpha-synuclein	JJ	O
and	CC	O
phosphorylated	JJ	O
alpha-synuclein	NNS	O
are	VBP	O
measured	VBN	O
and	CC	O
compared	VBN	O
with	IN	O
corresponding	NN	O
levels	NNS	O
in	IN	O
an	DT	O
otherwise	RB	O
similar	JJ	O
control	NN	O
cell	NN	O
not	RB	O
treated	VBN	O
with	IN	O
a	DT	O
library	JJ	O
member	NN	O
to	TO	O
suppress	VB	O
expression	NN	O
of	IN	O
a	DT	O
kinase	NN	O
.	.	O
Measurements	NNS	O
can	MD	O
be	VB	O
made	VBN	O
by	IN	O
immunoassay	NN	O
using	VBG	O
an	DT	O
antibody	NN	O
specific	JJ	O
for	IN	O
alpha-synuclein	JJ	O
(	(	O
preferably	JJ	O
human	JJ	O
alpha-synuclein	NN	O
)	)	O
to	TO	O
measure	VB	O
total	JJ	O
levels	NNS	O
of	IN	O
alpha-synuclein	NN	O
,	,	O
and	CC	O
an	DT	O
antibody	NN	O
specific	NN	O
for	IN	O
phosphorylated	JJ	O
alpha-synuclein	NN	O
to	TO	O
measure	VB	O
the	DT	O
level	NN	O
of	IN	O
phosphorylated	JJ	O
alpha-synuclein	NN	O
.	.	O
Exemplary	JJ	O
antibodies	NNS	O
are	VBP	O
described	VBN	O
in	IN	O
WO05047860	NNP	O
,	,	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
.	.	O
A	DT	O
reduction	NN	O
in	IN	O
level	NN	O
of	IN	O
phosphorylated	JJ	O
alpha-synuclein	NN	O
between	IN	O
the	DT	O
treated	JJ	O
and	CC	O
control	NN	O
cell	NN	O
that	WDT	O
is	VBZ	O
significant	JJ	O
in	IN	O
the	DT	O
sense	NN	O
of	IN	O
being	VBG	O
outside	IN	O
the	DT	O
typical	JJ	O
margin	NN	O
of	IN	O
error	NN	O
for	IN	O
measurements	NNS	O
,	,	O
indicates	VBZ	O
that	IN	O
the	DT	O
inhibitor	NN	O
introduced	VBD	O
into	IN	O
the	DT	O
cell	NN	O
inhibited	VBD	O
a	DT	O
kinase	NN	O
,	,	O
which	WDT	O
directly	RB	O
or	CC	O
indirectly	RB	O
affected	JJ	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	NN	O
.	.	O
The	DT	O
identity	NN	O
of	IN	O
the	DT	O
kinase	NN	O
can	MD	O
be	VB	O
determined	VBN	O
from	IN	O
the	DT	O
identity	NN	O
of	IN	O
inhibitor	NN	O
,	,	O
either	RB	O
by	IN	O
screening	VBG	O
inhibitors	NNS	O
individually	RB	O
,	,	O
or	CC	O
if	IN	O
inhibitors	NNS	O
are	VBP	O
screened	VBN	O
en	IN	O
masse	NN	O
,	,	O
by	IN	O
sequencing	VBG	O
the	DT	O
nucleic	JJ	O
acid	NN	O
encoding	VBG	O
the	DT	O
inhibitor	NN	O
.	.	O
Likewise	VB	O
a	DT	O
reduction	NN	O
in	IN	O
the	DT	O
total	JJ	O
level	NN	O
of	IN	O
alpha-synuclein	NN	O
between	IN	O
treated	VBN	O
and	CC	O
control	VB	O
cells	NNS	O
that	WDT	O
is	VBZ	O
outside	IN	O
the	DT	O
margin	NN	O
of	IN	O
typical	JJ	O
experimental	JJ	O
error	NN	O
in	IN	O
measuring	VBG	O
such	JJ	O
levels	NNS	O
provides	VBZ	O
an	DT	O
indication	NN	O
that	IN	O
the	DT	O
inhibitor	NN	O
inhibits	VBZ	O
a	DT	O
kinase	NN	O
that	WDT	O
indirectly	RB	O
affects	VBZ	O
the	DT	O
expression	NN	O
level	NN	O
of	IN	O
alpha-synuclein	NN	O
.	.	O
Kinases	NNS	O
identified	VBN	O
by	IN	O
the	DT	O
initial	JJ	O
screen	NN	O
,	,	O
particularly	RB	O
,	,	O
kinases	NNS	O
known	VBN	O
to	TO	O
be	VB	O
serine	JJ	O
kinases	NNS	O
,	,	O
can	MD	O
then	RB	O
be	VB	O
tested	VBN	O
for	IN	O
their	PRP$	O
capacity	NN	O
to	TO	O
phosphorylate	VB	O
alpha-synuclein	NNS	O
in	IN	O
vitro	NN	O
,	,	O
in	IN	O
cells	NNS	O
or	CC	O
in	IN	O
transgenic	JJ	O
animal	NN	O
models	NNS	O
.	.	O
An	DT	O
in	IN	O
vitro	NN	O
assay	NN	O
is	VBZ	O
an	DT	O
indication	NN	O
of	IN	O
whether	IN	O
a	DT	O
kinase	NN	O
directly	RB	O
phosphorylates	VBZ	O
alpha-synuclein	NN	O
and	CC	O
is	VBZ	O
therefore	RB	O
only	RB	O
useful	JJ	O
for	IN	O
the	DT	O
kinases	NNS	O
identified	VBN	O
in	IN	O
the	DT	O
initial	JJ	O
screen	NN	O
which	WDT	O
are	VBP	O
thought	VBN	O
to	TO	O
be	VB	O
capable	JJ	O
of	IN	O
directly	RB	O
phosphorylating	VBG	O
alpha-synuclein	NN	O
.	.	O
Cellular	JJ	O
and	CC	O
transgenic	JJ	O
assays	NNS	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
screen	VB	O
kinases	NNS	O
that	WDT	O
affect	VBP	O
phosphorylation	NN	O
either	DT	O
directly	RB	O
or	CC	O
indirectly	RB	O
.	.	O
In	IN	O
vitro	JJ	O
assays	NNS	O
may	MD	O
be	VB	O
performed	VBN	O
by	IN	O
contacting	VBG	O
alpha-synuclein	JJ	O
with	IN	O
the	DT	O
kinase	NN	O
under	IN	O
test	NN	O
and	CC	O
ATP	NNP	O
in	IN	O
a	DT	O
suitable	JJ	O
buffer	NN	O
.	.	O
Preferably	RB	O
,	,	O
the	DT	O
ATP	NNP	O
is	VBZ	O
γ-32P	JJ	O
ATP	NNP	O
,	,	O
in	IN	O
which	WDT	O
case	NN	O
phosphorylated	VBD	O
alpha-synuclein	NN	O
is	VBZ	O
radiolabeled	VBN	O
and	CC	O
can	MD	O
be	VB	O
detected	VBN	O
on	IN	O
a	DT	O
gel	NN	O
.	.	O
Phosphorylation	NN	O
can	MD	O
also	RB	O
be	VB	O
measured	VBN	O
using	VBG	O
an	DT	O
antibody	NN	O
specific	JJ	O
to	TO	O
phosphorylated	JJ	O
alpha-synuclein	JJ	O
as	IN	O
described	VBN	O
before	IN	O
.	.	O
Alternatively	RB	O
,	,	O
phosphorylation	NN	O
can	MD	O
be	VB	O
measured	VBN	O
indirectly	RB	O
by	IN	O
measuring	VBG	O
ATP	NNP	O
consumption	NN	O
using	VBG	O
a	DT	O
coupled	JJ	O
assay	NN	O
,	,	O
in	IN	O
which	WDT	O
ADP	NNP	O
is	VBZ	O
detected	VBN	O
as	IN	O
described	NN	O
for	IN	O
example	NN	O
by	IN	O
Nature	NNP	B
78	CD	I
,	,	I
632	CD	I
(	(	I
1956	CD	I
)	)	I
;	:	I
Mol	NNP	I
.	.	I
Pharmacol	NNP	I
.	.	I
6	CD	I
,	,	I
31-40	CD	I
(	(	I
1970	CD	I
)	)	I
.	.	O
The	DT	O
extent	NN	O
of	IN	O
phosphorylation	NN	O
can	MD	O
be	VB	O
compared	VBN	O
with	IN	O
a	DT	O
control	NN	O
in	IN	O
which	WDT	O
the	DT	O
kinase	NN	O
or	CC	O
ATP	NNP	O
or	CC	O
both	DT	O
is/are	JJ	O
omitted	VBN	O
.	.	O
An	DT	O
increase	NN	O
in	IN	O
phosphorylation	NN	O
is	VBZ	O
an	DT	O
indication	NN	O
that	IN	O
the	DT	O
kinase	NN	O
directly	RB	O
phosphorylates	VBZ	O
alpha-synuclein	NN	O
.	.	O
Cellular	JJ	O
assays	NNS	O
are	VBP	O
performed	VBN	O
on	IN	O
cells	NNS	O
expressing	VBG	O
alpha-synuclein	NN	O
,	,	O
preferably	RB	O
human	JJ	O
alpha-synuclein	NN	O
transfected	VBD	O
into	IN	O
the	DT	O
cells	NNS	O
.	.	O
A	DT	O
nucleic	JJ	O
acid	NN	O
capable	JJ	O
of	IN	O
expressing	VBG	O
the	DT	O
kinase	NN	O
is	VBZ	O
also	RB	O
transfected	VBN	O
into	IN	O
the	DT	O
cells	NNS	O
.	.	O
The	DT	O
level	NN	O
of	IN	O
phosphorylated	JJ	O
alpha-synuclein	NN	O
in	IN	O
the	DT	O
cells	NNS	O
is	VBZ	O
measured	VBN	O
relative	JJ	O
to	TO	O
that	DT	O
in	IN	O
similar	JJ	O
control	NN	O
cells	NNS	O
lacking	VBG	O
the	DT	O
transfected	JJ	O
kinase	NN	O
.	.	O
An	DT	O
increase	NN	O
in	IN	O
phosphorylation	NN	O
is	VBZ	O
an	DT	O
indication	NN	O
that	IN	O
the	DT	O
kinase	NN	O
directly	RB	O
or	CC	O
indirectly	RB	O
phosphorylates	VBZ	O
alpha-synuclein	NN	O
.	.	O
Transgenic	NNP	O
assays	NNS	O
can	MD	O
be	VB	O
performed	VBN	O
by	IN	O
comparing	VBG	O
a	DT	O
transgenic	JJ	O
animal	NN	O
expressing	VBG	O
human	JJ	O
alpha-synuclein	NNS	O
disposed	VBD	O
to	TO	O
develop	VB	O
Lewy	NNP	O
body-like	JJ	O
deposits	NNS	O
with	IN	O
a	DT	O
similar	JJ	O
animal	NN	O
also	RB	O
expressing	VBG	O
a	DT	O
kinase	NN	O
transgene	NN	O
.	.	O
A	DT	O
reduction	NN	O
in	IN	O
phosphorylated	JJ	O
alpha-synuclein	JJ	O
and/or	NN	O
in	IN	O
Lewy	NNP	O
body-like	NN	O
deposits	NNS	O
in	IN	O
the	DT	O
transgenic	JJ	O
animal	NN	O
with	IN	O
the	DT	O
additional	JJ	O
kinase	NN	O
transgene	NN	O
relative	NN	O
to	TO	O
the	DT	O
transgenic	JJ	O
animal	NN	O
with	IN	O
just	RB	O
the	DT	O
alpha-synuclein	JJ	O
transgene	NN	O
is	VBZ	O
an	DT	O
indication	NN	O
that	IN	O
the	DT	O
kinase	NN	O
is	VBZ	O
directly	RB	O
or	CC	O
indirectly	RB	O
involved	VBN	O
in	IN	O
phosphorylating	VBG	O
alpha-synuclein	NN	O
.	.	O
IV	NNP	O
.	.	O
Target	NN	O
Kinases	VBZ	O
Tables	NNP	O
1A	CD	O
,	,	O
1B	CD	O
and	CC	O
1C	CD	O
show	NN	O
proteins	NNS	O
whose	WP$	O
inhibition	NN	O
modulates	VBZ	O
the	DT	O
phosphorylation	NN	O
at	IN	O
position	NN	O
ser-129	NN	O
.	.	O
Table	JJ	O
1A	CD	O
shows	NNS	O
kinases	NNS	O
that	WDT	O
can	MD	O
phosphorylate	VB	O
serine	JJ	O
and/or	JJ	O
threonine	NN	O
residues	NNS	O
and	CC	O
sometimes	RB	O
tyrosine	VB	O
.	.	O
Table	JJ	O
1B	CD	O
shows	NNS	O
tyrosine	VBP	O
kinases	NNS	O
that	WDT	O
can	MD	O
not	RB	O
(	(	O
so	RB	O
far	RB	O
as	IN	O
is	VBZ	O
known	VBN	O
)	)	O
modify	FW	O
serine	NN	O
residues	NNS	O
.	.	O
Table	JJ	O
1C	CD	O
shows	NNS	O
kinases	NNS	O
that	WDT	O
phosphorylate	VBP	O
non-protein	JJ	O
targets	NNS	O
but	CC	O
are	VBP	O
not	RB	O
known	VBN	O
to	TO	O
phosphorylate	VB	O
proteins	NNS	O
.	.	O
Kinases	NNS	O
from	IN	O
the	DT	O
upper	JJ	O
portion	NN	O
of	IN	O
Table	JJ	O
1A	CD	O
are	VBP	O
candidates	NNS	O
for	IN	O
direct	JJ	O
phosphorylation	NN	O
of	IN	O
ser-129	NN	O
of	IN	O
alpha-synuclein	NN	O
.	.	O
Kinases	NNS	O
from	IN	O
the	DT	O
upper	JJ	O
part	NN	O
of	IN	O
Table	JJ	O
1B	CD	O
are	VBP	O
also	RB	O
useful	JJ	O
therapeutic	JJ	O
targets	NNS	O
via	IN	O
roles	NNS	O
indirectly	RB	O
phosphorylating	VBG	O
alpha-synuclein	NN	O
.	.	O
Proteins	NNS	O
in	IN	O
the	DT	O
upper	JJ	O
part	NN	O
of	IN	O
Table	JJ	O
1C	CD	O
are	VBP	O
also	RB	O
useful	JJ	O
therapeutic	JJ	O
targets	NNS	O
for	IN	O
the	DT	O
same	JJ	O
reason	NN	O
.	.	O
Cols	NNP	O
.	.	O
1	CD	O
,	,	O
2	CD	O
and	CC	O
3	CD	O
of	IN	O
each	DT	O
table	NN	O
indicate	VBP	O
the	DT	O
gene	NN	O
name	NN	O
,	,	O
kinase	NN	O
name	NN	O
and	CC	O
Genbank	NNP	O
accession	NN	O
number	NN	O
of	IN	O
kinases	NNS	O
.	.	O
The	DT	O
next	JJ	O
column	NN	O
indicates	VBZ	O
whether	IN	O
treatment	NN	O
of	IN	O
cells	NNS	O
with	IN	O
siRNA	NN	O
to	TO	O
that	DT	O
kinase	NN	O
decreased	VBD	O
(	(	O
“	VB	O
down	RP	O
”	NNP	O
)	)	O
or	CC	O
increased	VBN	O
(	(	O
“	VB	O
up	RP	O
”	NNP	O
)	)	O
phosphorylation	NN	O
of	IN	O
ser-129	NN	O
.	.	O
The	DT	O
next	JJ	O
three	CD	O
columns	NN	O
indicate	VBP	O
the	DT	O
number	NN	O
of	IN	O
standard	JJ	O
deviations	NNS	O
the	DT	O
measured	JJ	O
level	NN	O
of	IN	O
phosphorylation	NN	O
departs	NNS	O
from	IN	O
the	DT	O
mean	NN	O
in	IN	O
three	CD	O
independent	JJ	O
experiments	NNS	O
.	.	O
The	DT	O
final	JJ	O
two	CD	O
columns	NN	O
indicate	VBP	O
the	DT	O
kinase	NN	O
family	NN	O
(	(	O
i.e.	FW	O
,	,	O
amino	JJ	O
acid	VBP	O
specificity	NN	O
)	)	O
and	CC	O
group	NN	O
.	.	O
Table	JJ	O
2	CD	O
shows	NNS	O
kinases	NNS	O
whose	WP$	O
inhibition	NN	O
modulates	VBZ	O
the	DT	O
overall	JJ	O
levels	NNS	O
of	IN	O
human	JJ	O
alpha-synuclein	NN	O
without	IN	O
changing	VBG	O
the	DT	O
percentage	NN	O
of	IN	O
phosphorylation	NN	O
.	.	O
Table	JJ	O
2	CD	O
shows	VBZ	O
all	DT	O
of	IN	O
the	DT	O
kinases	NNS	O
with	IN	O
the	DT	O
strongest	JJS	O
reduction	NN	O
in	IN	O
levels	NNS	O
of	IN	O
human	JJ	O
alpha-synuclein	NN	O
.	.	O
The	DT	O
columns	NN	O
are	VBP	O
labeled	VBN	O
similarly	RB	O
to	TO	O
Tables	NNP	O
1A	CD	O
,	,	O
1B	CD	O
and	CC	O
1C	CD	O
.	.	O
Tables	NNS	O
3	CD	O
and	CC	O
4	CD	O
show	NN	O
kinases	NNS	O
from	IN	O
Tables	NNP	O
1	CD	O
and	CC	O
2	CD	O
that	WDT	O
were	VBD	O
confirmed	VBN	O
in	IN	O
the	DT	O
Examples	NNP	O
to	TO	O
modulate	VB	O
overall	JJ	O
levels	NNS	O
of	IN	O
human	JJ	O
alpha-synuclein	NN	O
.	.	O
The	DT	O
kinases	NNS	O
that	WDT	O
were	VBD	O
verified	VBN	O
include	VBP	O
PLK2	NNP	O
,	,	O
APEG1	NNP	O
,	,	O
CDC7L1	NNP	O
,	,	O
MET	NNP	O
,	,	O
GRK1	NNP	O
,	,	O
2	CD	O
,	,	O
6	CD	O
,	,	O
and	CC	O
7	CD	O
as	IN	O
kinases	NNS	O
that	WDT	O
phosphorylate	VBP	O
alpha-synuclein	JJ	O
directly	RB	O
or	CC	O
indirectly	RB	O
.	.	O
The	DT	O
kinases	NNS	O
that	WDT	O
were	VBD	O
found	VBN	O
to	TO	O
increase	VB	O
alpha-synuclein	JJ	O
phosphorylation	NN	O
when	WRB	O
inhibited	VBN	O
,	,	O
PRKG1	NNP	O
,	,	O
MAPK13	NNP	O
,	,	O
and	CC	O
GAK	NNP	O
,	,	O
are	VBP	O
likely	JJ	O
to	TO	O
function	VB	O
as	IN	O
negative	JJ	O
regulators	NNS	O
of	IN	O
alpha-synuclein	JJ	O
phosphorylation	NN	O
.	.	O
Further	RB	O
data	NNS	O
from	IN	O
phosphorylation	NN	O
studies	NNS	O
in	IN	O
vitro	NN	O
identified	VBN	O
PKL2	NNP	O
,	,	O
GRK2	NNP	O
,	,	O
5	CD	O
,	,	O
6	CD	O
,	,	O
and	CC	O
7	CD	O
as	IN	O
capable	JJ	O
of	IN	O
phosphorylating	VBG	O
alpha-synuclein	NN	O
in	IN	O
vitro	NN	O
and	CC	O
also	RB	O
identified	VBN	O
CKII	NNP	O
and	CC	O
IKBKB	NNP	O
.	.	O
Further	JJ	O
studies	NNS	O
in	IN	O
cell	NN	O
culture	NN	O
showed	VBD	O
that	IN	O
PLK2	NNP	O
and	CC	O
GPRK6	NNP	O
could	MD	O
directly	RB	O
phosphorylate	VB	O
alpha-synuclein	NN	O
in	IN	O
cell	NN	O
culture	NN	O
.	.	O
These	DT	O
data	NNS	O
were	VBD	O
substantiated	VBN	O
with	IN	O
immunohistochemistry	NN	O
.	.	O
In	IN	O
summary	JJ	O
,	,	O
PLK2	NNP	O
and	CC	O
,	,	O
to	TO	O
a	DT	O
lesser	JJR	O
extent	NN	O
,	,	O
GRK6	NNP	O
are	VBP	O
particularly	RB	O
preferred	JJ	O
targets	NNS	O
for	IN	O
therapeutic	JJ	O
intervention	NN	O
in	IN	O
Lewy	NNP	O
body	NN	O
diseases	NNS	O
because	IN	O
they	PRP	O
can	MD	O
directly	RB	O
phosphorylate	VB	O
alpha-synuclein	NN	O
.	.	O
Agents	NNS	O
that	WDT	O
inhibit	VBP	O
PLK2	NNP	O
and	CC	O
GRK6	NNP	O
also	RB	O
inhibit	VBP	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	JJ	O
and	CC	O
thus	RB	O
can	MD	O
be	VB	O
used	VBN	O
in	IN	O
treatment	NN	O
or	CC	O
prophylaxis	NN	O
of	IN	O
Lewy	NNP	O
body	NN	O
disease	NN	O
.	.	O
In	IN	O
the	DT	O
Examples	NNP	O
,	,	O
below	IN	O
,	,	O
transfection	NN	O
of	IN	O
cells	NNS	O
with	IN	O
siRNA	NN	O
and	CC	O
knockdown	NN	O
of	IN	O
specific	JJ	O
kinase	NNP	O
targets	NNS	O
was	VBD	O
employed	VBN	O
to	TO	O
identify	VB	O
kinases	NNS	O
that	WDT	O
modulated	VBD	O
alpha-synuclein	JJ	O
phosphorylation	NN	O
directly	RB	O
or	CC	O
indirectly	RB	O
.	.	O
Subsequent	JJ	O
experiments	NNS	O
in	IN	O
vitro	NN	O
and	CC	O
in	IN	O
cell	NN	O
culture	NN	O
showed	VBD	O
that	IN	O
two	CD	O
of	IN	O
these	DT	O
kinases	NNS	O
,	,	O
PLK2	NNP	O
directly	RB	O
and	CC	O
specifically	RB	O
phosphorylated	VBD	O
the	DT	O
serine	JJ	O
129	CD	O
of	IN	O
alpha-synuclein	NN	O
.	.	O
Further	JJ	O
experiments	NNS	O
showed	VBD	O
that	IN	O
PLK2	NNP	O
phosphorylated	VBD	O
the	DT	O
serine	JJ	O
129	CD	O
of	IN	O
alpha-synuclein	NN	O
to	TO	O
a	DT	O
much	RB	O
greater	JJR	O
extent	NN	O
than	IN	O
GRK6	NNP	O
and	CC	O
other	JJ	O
kinases	NNS	O
described	VBN	O
herein	JJ	O
under	IN	O
the	DT	O
experimental	JJ	O
conditions	NNS	O
used	VBN	O
.	.	O
Thus	RB	O
,	,	O
PLK2	NNP	O
is	VBZ	O
very	RB	O
likely	JJ	O
a	DT	O
synuclein	JJ	O
kinase	NN	O
.	.	O
Additional	JJ	O
evidence	NN	O
that	IN	O
PLK2	NNP	O
is	VBZ	O
a	DT	O
synuclein	JJ	O
kinase	NN	O
is	VBZ	O
provided	VBN	O
in	IN	O
Examples	NNP	O
11-16	CD	O
.	.	O
Synuclein	NNP	O
phosphorylation	NN	O
is	VBZ	O
reduced	VBN	O
in	IN	O
cells	NNS	O
treated	VBN	O
with	IN	O
siRNA	NN	O
directed	VBN	O
to	TO	O
PLK2	NNP	O
,	,	O
inhibitors	NNS	O
of	IN	O
PLK2	NNP	O
activity	NN	O
reduce	VB	O
synuclein	NN	O
phosphorylation	NN	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
cell	NN	O
types	NNS	O
including	VBG	O
primary	JJ	O
neuronal	JJ	O
cultures	NNS	O
and	CC	O
cells	NNS	O
over	IN	O
expressing	VBG	O
PLK2	NNP	O
,	,	O
inhibitors	NNS	O
affect	VBP	O
endogenous	JJ	O
kinase	NN	O
in	IN	O
with	IN	O
an	DT	O
EC50	NNP	O
consistent	NN	O
with	IN	O
the	DT	O
EC50	NNP	O
observed	VBD	O
for	IN	O
their	PRP$	O
effect	NN	O
on	IN	O
PLK2	NNP	O
.	.	O
PLK2	NNP	O
is	VBZ	O
a	DT	O
Polo	NNP	O
like	IN	O
kinase	NN	O
that	WDT	O
is	VBZ	O
a	DT	O
G1	NNP	O
cell	NN	O
cycle	NN	O
protein	NN	O
,	,	O
has	VBZ	O
a	DT	O
rapid	JJ	O
turnover	NN	O
in	IN	O
cells	NNS	O
,	,	O
and	CC	O
is	VBZ	O
expressed	VBN	O
in	IN	O
brain	NN	O
where	WRB	O
it	PRP	O
is	VBZ	O
involved	VBN	O
in	IN	O
synaptic	JJ	O
plasticity	NN	O
.	.	O
The	DT	O
PLK	NNP	O
family	NN	O
members	NNS	O
are	VBP	O
serine/threonine	JJ	O
kinases	NNS	O
,	,	O
and	CC	O
contains	VBZ	O
four	CD	O
members	NNS	O
that	WDT	O
have	VBP	O
an	DT	O
N-terminal	JJ	O
kinase	NN	O
domain	NN	O
and	CC	O
a	DT	O
C-terminal	JJ	O
regulatory	JJ	O
domain	NN	O
consisting	VBG	O
of	IN	O
two	CD	O
(	(	O
PLKs	NNP	O
1-3	CD	O
)	)	O
or	CC	O
one	CD	O
(	(	O
PLK4	NNP	O
)	)	O
polo-box	NN	O
domains	NNS	O
.	.	O
The	DT	O
polo-box	JJ	O
domain	NN	O
serves	NNS	O
to	TO	O
bind	VB	O
to	TO	O
scaffolding	VBG	O
proteins	NNS	O
that	IN	O
then	RB	O
target	VB	O
the	DT	O
PLKs	NNP	O
to	TO	O
specific	VB	O
sub-cellular	JJ	O
locations	NNS	O
and	CC	O
to	TO	O
phosphorylate	VB	O
their	PRP$	O
target	NN	O
proteins	NNS	O
(	(	O
Seeburg	NNP	B
,	,	I
D.	NNP	I
P.	NNP	I
et	FW	I
al	NN	I
,	,	I
Oncogene	NNP	I
,	,	I
2005	CD	I
)	)	O
.	.	O
The	DT	O
polo-box	NN	O
also	RB	O
serves	VBZ	O
to	TO	O
negatively	RB	O
regulate	VB	O
the	DT	O
kinase	NN	O
domain	NN	O
by	IN	O
adopting	VBG	O
a	DT	O
conformation	NN	O
that	WDT	O
prevents	VBZ	O
kinase	NN	O
activity	NN	O
.	.	O
Upon	IN	O
binding	NN	O
of	IN	O
the	DT	O
polo-box	NN	O
to	TO	O
a	DT	O
scaffolding	NN	O
protein	NN	O
,	,	O
the	DT	O
polo-box	NN	O
is	VBZ	O
removed	VBN	O
from	IN	O
the	DT	O
kinase	NN	O
domain	NN	O
,	,	O
whereupon	IN	O
the	DT	O
kinase	NN	O
becomes	VBZ	O
active	JJ	O
and	CC	O
is	VBZ	O
able	JJ	O
to	TO	O
phosphorylate	VB	O
its	PRP$	O
substrate/s	NN	O
.	.	O
Polo-like	JJ	O
kinases	NNS	O
are	VBP	O
described	VBN	O
in	IN	O
Seeburg	NNP	B
et	CC	I
al.	NN	I
,	,	I
2005	CD	I
,	,	I
“	VBD	I
Polo-like	JJ	I
kinases	NNS	I
in	IN	I
the	DT	I
nervous	JJ	I
system	NN	I
”	JJ	I
Oncogene	NNP	I
24:292-8	CD	I
;	:	O
Lowery	NNP	B
et	FW	I
al.	NN	I
,	,	I
2005	CD	I
,	,	I
“	JJ	I
Structure	NNP	I
and	CC	I
function	NN	I
of	IN	I
Polo-like	NNP	I
kinases	NNS	I
”	NNP	I
Oncogene	NNP	I
24:248-59	JJ	I
;	:	O
and	CC	O
Winkles	NNP	B
et	VBP	I
al.	NN	I
,	,	I
2005	CD	I
,	,	I
“	NNP	I
Differential	NNP	I
regulation	NN	I
of	IN	I
polo-like	JJ	I
kinase	NN	I
1	CD	I
,	,	I
2	CD	I
,	,	I
3	CD	I
,	,	I
and	CC	I
4	CD	I
gene	NN	I
expression	NN	I
in	IN	I
mammalian	JJ	I
cells	NNS	I
and	CC	I
tissues	NNS	I
”	VBP	I
Oncogene	NNP	I
24:260-6	CD	I
.	.	O
DNA	NN	O
and	CC	O
protein	NN	O
sequences	NNS	O
can	MD	O
be	VB	O
found	VBN	O
at	IN	O
the	DT	O
accession	NN	O
numbers	NNS	O
below	IN	O
:	:	O
When	WRB	O
PLK2	NNP	O
is	VBZ	O
activated	VBN	O
,	,	O
it	PRP	O
is	VBZ	O
targeted	VBN	O
to	TO	O
dendrites	NNS	O
of	IN	O
activated	JJ	O
neurons	NNS	O
,	,	O
where	WRB	O
it	PRP	O
is	VBZ	O
believed	VBN	O
to	TO	O
phosphorylate	VB	O
proteins	NNS	O
in	IN	O
the	DT	O
synaptic	JJ	O
terminals	NNS	O
.	.	O
An	DT	O
exemplary	JJ	O
accession	NN	O
number	NN	O
for	IN	O
PLK2	NNP	O
is	VBZ	O
provided	VBN	O
Table	JJ	O
1A	CD	O
.	.	O
The	DT	O
sequence	NN	O
for	IN	O
PLK2	NNP	O
can	MD	O
also	RB	O
be	VB	O
found	VBN	O
in	IN	O
any	DT	O
one	CD	O
of	IN	O
Ma	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
Mol	NNP	I
.	.	I
Cell	NNP	I
.	.	I
Biol	NNP	I
.	.	I
23	CD	I
(	(	I
19	CD	I
)	)	I
,	,	I
6936-6943	JJ	I
(	(	I
2003	CD	I
)	)	I
,	,	O
Burns	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
Mol	NNP	I
.	.	I
Cell	NNP	I
.	.	I
Biol	NNP	I
.	.	I
23	CD	I
(	(	I
16	CD	I
)	)	I
,	,	I
5556-5571	JJ	I
(	(	I
2003	CD	I
)	)	I
,	,	O
Matsuda	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
Oncogene	NNP	I
22	CD	I
(	(	I
21	CD	I
)	)	I
,	,	I
3307-3318	JJ	I
(	(	I
2003	CD	I
)	)	I
,	,	O
Shimizu-Yoshida	NNP	B
et	FW	I
al	NN	I
.	.	I
Biochem	NNP	I
.	.	I
Biophys	NNP	I
.	.	I
Res	NNP	I
.	.	I
Commun	NNP	I
.	.	I
289	CD	I
(	(	I
2	CD	I
)	)	I
,	,	I
491-498	JJ	I
(	(	I
2001	CD	I
)	)	I
,	,	O
Liby	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
DNA	NN	I
seq	NN	I
.	.	I
11	CD	I
(	(	I
6	CD	I
)	)	I
,	,	I
527-533	JJ	I
(	(	I
2001	CD	I
)	)	I
,	,	O
Holtrich	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
Oncogene	NNP	I
19	CD	I
(	(	I
42	CD	I
)	)	I
,	,	I
4832-4839	JJ	I
,	,	O
Ouyang	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
Oncogene	NNP	I
18	CD	I
(	(	I
44	CD	I
)	)	I
,	,	I
6029-6036	JJ	I
(	(	I
1999	CD	I
)	)	I
,	,	O
and	CC	O
Kauselmann	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
EMBO	NNP	I
J	NNP	I
.	.	I
18	CD	I
(	(	I
20	CD	I
)	)	I
,	,	I
5528-5539	JJ	I
;	:	O
reference	NN	O
to	TO	O
an	DT	O
amino	NN	O
acid	NN	O
or	CC	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
of	IN	O
PLK2	NNP	O
includes	VBZ	O
the	DT	O
sequences	NNS	O
of	IN	O
any	DT	O
of	IN	O
these	DT	O
references	NNS	O
or	CC	O
allelic	JJ	O
variants	NNS	O
thereof	NN	O
.	.	O
PLK2	NNP	O
is	VBZ	O
also	RB	O
called	VBN	O
SNK	NNP	O
;	:	O
for	IN	O
consistency	NN	O
,	,	O
the	DT	O
name	NN	O
PLK2	NNP	O
is	VBZ	O
used	VBN	O
throughout	IN	O
the	DT	O
present	JJ	O
patent	NN	O
application	NN	O
.	.	O
APEG1	NNP	O
,	,	O
CDC7L1	NNP	O
,	,	O
MET	NNP	O
,	,	O
IKBKB	NNP	O
,	,	O
CKII	NNP	O
,	,	O
GRK1	NNP	O
,	,	O
GRK2	NNP	O
,	,	O
GRK6	NNP	O
and	CC	O
GRK7	NNP	O
are	VBP	O
also	RB	O
targets	NNS	O
for	IN	O
therapeutic	JJ	O
intervention	NN	O
in	IN	O
Lewy	NNP	O
body	NN	O
diseases	NNS	O
because	IN	O
they	PRP	O
are	VBP	O
likely	JJ	O
to	TO	O
be	VB	O
indirect	JJ	O
activators	NNS	O
of	IN	O
the	DT	O
direct	JJ	O
kinase	NN	O
(	(	O
s	NN	O
)	)	O
.	.	O
Thus	RB	O
,	,	O
agents	NNS	O
that	IN	O
inhibit	NN	O
APEG1	NNP	O
,	,	O
CDC7L1	NNP	O
,	,	O
MET	NNP	O
,	,	O
IKBKB	NNP	O
,	,	O
CKII	NNP	O
,	,	O
GRK1	NNP	O
,	,	O
GRK2	NNP	O
,	,	O
GRK6	NNP	O
and	CC	O
GRK7	NNP	O
also	RB	O
inhibit	VBP	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	JJ	O
and	CC	O
can	MD	O
be	VB	O
used	VBN	O
for	IN	O
treatment	NN	O
or	CC	O
prophylaxis	NN	O
of	IN	O
Lewy	NNP	O
body	NN	O
disease	NN	O
.	.	O
PRKG1	NNP	O
,	,	O
MAPK13	NNP	O
,	,	O
and	CC	O
GAK	NNP	O
are	VBP	O
negative	JJ	O
regulators	NNS	O
of	IN	O
the	DT	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	NN	O
.	.	O
Thus	RB	O
,	,	O
agents	NNS	O
that	WDT	O
activate	VBP	O
these	DT	O
kinases	NNS	O
decrease	VBP	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	JJ	O
and	CC	O
can	MD	O
be	VB	O
used	VBN	O
in	IN	O
treatment	NN	O
or	CC	O
prophylaxis	NN	O
of	IN	O
Lewy	NNP	O
body	NN	O
disease	NN	O
.	.	O
GRK6	NNP	O
,	,	O
also	RB	O
called	VBD	O
GPRK6	NNP	O
,	,	O
is	VBZ	O
a	DT	O
G	NNP	O
protein-coupled	JJ	O
receptor	NN	O
kinase	NN	O
and	CC	O
is	VBZ	O
involved	VBN	O
in	IN	O
signal	JJ	O
transduction	NN	O
.	.	O
G	NNP	O
protein-coupled	JJ	O
receptor	NN	O
kinases	NNS	O
phosphorylate	VBP	O
and	CC	O
desensitize	VB	O
ligand-activated	JJ	O
G	NNP	O
protein-coupled	JJ	O
receptors	NNS	O
.	.	O
GRK6	NNP	O
expression	NN	O
has	VBZ	O
previously	RB	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
significantly	RB	O
elevated	VBN	O
in	IN	O
the	DT	O
MPTP-lesioned	JJ	O
group	NN	O
in	IN	O
most	JJS	O
brain	NN	O
regions	NNS	O
.	.	O
For	IN	O
the	DT	O
purposes	NNS	O
of	IN	O
consistency	NN	O
,	,	O
the	DT	O
name	NN	O
GRK6	NNP	O
will	MD	O
be	VB	O
used	VBN	O
throughout	IN	O
the	DT	O
present	JJ	O
patent	NN	O
application	NN	O
.	.	O
An	DT	O
exemplary	JJ	O
accession	NN	O
number	NN	O
is	VBZ	O
provided	VBN	O
in	IN	O
Table	JJ	O
1A	CD	O
.	.	O
The	DT	O
sequence	NN	O
for	IN	O
GRK6	NNP	O
can	MD	O
be	VB	O
found	VBN	O
in	IN	O
any	DT	O
one	CD	O
of	IN	O
Teli	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Anesthesiology	NNP	I
98	CD	I
(	(	I
2	CD	I
)	)	I
,	,	I
343-348	JJ	I
(	(	I
2003	CD	I
)	)	I
;	:	O
Miyagawa	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Biophys	NNP	I
.	.	I
Res	NNP	I
.	.	I
Commun	NNP	I
.	.	I
300	CD	I
(	(	I
3	CD	I
)	)	I
,	,	I
669-673	JJ	I
(	(	I
2003	CD	I
)	)	I
;	:	O
Gaudreau	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
277	CD	I
(	(	I
35	CD	I
)	)	I
,	,	I
31567-31576	JJ	I
(	(	I
2002	CD	I
)	)	I
;	:	O
Grange-Midroit	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Brain	NNP	I
Res	NNP	I
.	.	I
Mol	NNP	I
.	.	I
Brain	NNP	I
Res	NNP	I
.	.	I
101	CD	I
(	(	I
1-2	JJ	I
)	)	I
,	,	I
39-51	JJ	I
(	(	I
2002	CD	I
)	)	I
;	:	O
Willets	NNS	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
277	CD	I
(	(	I
18	CD	I
)	)	I
,	,	I
15523-15529	JJ	I
(	(	I
2002	CD	I
)	)	I
;	:	O
Blaukat	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
276	CD	I
(	(	I
44	CD	I
)	)	I
,	,	I
40431-40440	JJ	I
(	(	I
2001	CD	I
)	)	I
;	:	O
Zhou	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Pharmacol	NNP	I
.	.	I
Exp	NNP	I
.	.	I
Ther	DT	I
.	.	I
298	CD	I
(	(	I
3	CD	I
)	)	I
,	,	I
1243-1251	JJ	I
(	(	I
2001	CD	I
)	)	I
;	:	O
Pronin	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
275	CD	I
(	(	I
34	CD	I
)	)	I
,	,	I
26515-26522	JJ	I
(	(	I
2000	CD	I
)	)	I
;	:	O
Tiruppathi	NNP	B
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
U.S.A.	NNP	I
,	,	I
97	CD	I
(	(	I
13	CD	I
)	)	I
,	,	I
7440-7445	JJ	I
(	(	I
2000	CD	I
)	)	I
;	:	O
Premont	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem.	NNP	I
,	,	I
274	CD	I
(	(	I
41	CD	I
)	)	I
,	,	I
29381-29389	JJ	I
(	(	I
1999	CD	I
)	)	I
;	:	O
Brenninkmeijer	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Endocrinol	NNP	I
.	.	I
162	CD	I
(	(	I
3	CD	I
)	)	I
,	,	I
401-408	JJ	I
(	(	I
1999	CD	I
)	)	I
;	:	O
Hall	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
274	CD	I
(	(	I
34	CD	I
)	)	I
,	,	I
24328-24334	JJ	I
(	(	I
1999	CD	I
)	)	I
;	:	O
Lazari	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Mol	NNP	I
.	.	I
Endocrinol	NNP	I
.	.	I
13	CD	I
(	(	I
6	CD	I
)	)	I
,	,	I
866-878	JJ	I
(	(	I
1999	CD	I
)	)	I
;	:	O
Milcent	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Biochem	NNP	I
.	.	I
Biophys	NNP	I
.	.	I
Res	NNP	I
.	.	I
Commun	NNP	I
.	.	I
259	CD	I
(	(	I
1	CD	I
)	)	I
,	,	I
224-229	JJ	I
(	(	I
1999	CD	I
)	)	I
;	:	O
Premont	NNP	B
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
U.S.A.	NNP	I
95	CD	I
(	(	I
24	CD	I
)	)	I
,	,	I
14082-14087	JJ	I
(	(	I
1998	CD	I
)	)	I
;	:	O
Stoffel	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Biochemistry	NNP	I
37	CD	I
(	(	I
46	CD	I
)	)	I
,	,	I
16053-16059	JJ	I
(	(	I
1998	CD	I
)	)	I
;	:	O
Loudon	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
272	CD	I
(	(	I
43	CD	I
)	)	I
,	,	I
27422-27427	JJ	I
(	(	I
1997	CD	I
)	)	I
;	:	O
Freedman	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
272	CD	I
(	(	I
28	CD	I
)	)	I
,	,	I
17734-17743	JJ	I
(	(	I
1997	CD	I
)	)	I
;	:	O
Bullrich	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
Cytogenet	NNP	I
.	.	I
Cell	NNP	I
Genet	NNP	I
.	.	I
70	CD	I
(	(	I
3-4	CD	I
)	)	I
,	,	I
250-254	JJ	I
(	(	I
1995	CD	I
)	)	I
;	:	O
Stoffel	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
;	:	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
269	CD	I
(	(	I
45	CD	I
)	)	I
,	,	I
27791-27794	JJ	I
(	(	I
1994	CD	I
)	)	I
;	:	O
Loudon	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
269	CD	I
(	(	I
36	CD	I
)	)	I
,	,	I
22691-22697	JJ	I
(	(	I
1994	CD	I
)	)	I
;	:	O
Haribabu	NNP	B
and	CC	I
Snyderman	NNP	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
U.S.A.	NNP	I
90	CD	I
(	(	I
20	CD	I
)	)	I
,	,	I
9398-9402	CD	I
(	(	I
1993	CD	I
)	)	I
;	:	O
and	CC	O
Benovic	NNP	B
and	CC	I
Gomez	NNP	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
268	CD	I
(	(	I
26	CD	I
)	)	I
,	,	I
19521-19527	JJ	I
(	(	I
1993	CD	I
)	)	I
;	:	O
reference	NN	O
to	TO	O
the	DT	O
amino	NN	O
acid	NN	O
or	CC	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
of	IN	O
GRK6	NNP	O
includes	VBZ	O
the	DT	O
amino	NN	O
acid	NN	O
or	CC	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
of	IN	O
any	DT	O
of	IN	O
these	DT	O
references	NNS	O
and	CC	O
allelic	JJ	O
variants	NNS	O
thereof	NN	O
.	.	O
Casein	NNP	O
kinase	VBD	O
2	CD	O
(	(	O
also	RB	O
called	VBN	O
Casein	NNP	O
kinase	NN	O
II	NNP	O
,	,	O
CKII	NNP	O
,	,	O
CSNK2	NNP	O
and	CC	O
CSNKII	NNP	O
)	)	O
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
phosphorylate	VB	O
alpha-synuclein	NN	O
.	.	O
For	IN	O
consistency	NN	O
,	,	O
the	DT	O
name	NN	O
CKII	NNP	O
will	MD	O
be	VB	O
used	VBN	O
herein	NN	O
.	.	O
The	DT	O
sequence	NN	O
for	IN	O
CKII	NNP	O
has	VBZ	O
been	VBN	O
provided	VBN	O
in	IN	O
Genbank	NNP	O
under	IN	O
the	DT	O
following	JJ	O
accession	NN	O
numbers	NNS	O
:	:	O
NM—001896	NNP	O
,	,	O
NM—001320	NNP	O
and/or	NN	O
can	MD	O
be	VB	O
found	VBN	O
in	IN	O
any	DT	O
one	CD	O
of	IN	O
Panasyu	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
281	CD	I
(	(	I
42	CD	I
)	)	I
,	,	I
31188-31201	JJ	I
(	(	I
2006	CD	I
)	)	I
;	:	O
Salvi	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
FEBS	NNP	I
Lett	NNP	I
.	.	I
580	CD	I
(	(	I
16	CD	I
)	)	I
,	,	I
3948-3952	JJ	I
(	(	I
2006	CD	I
)	)	I
;	:	O
Lim	NNP	B
et	FW	I
al	NN	I
.	.	I
Cell	NNP	I
125	CD	I
(	(	I
4	CD	I
)	)	I
,	,	I
801-814	JJ	I
(	(	I
2006	CD	I
)	)	I
;	:	O
Llorens	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
Biochem	NNP	I
.	.	I
J	NNP	I
.	.	I
394	CD	I
(	(	I
Pt	NNP	I
.	.	I
1	CD	I
)	)	I
,	,	I
227-236	JJ	I
,	,	I
(	(	I
2006	CD	I
)	)	I
;	:	O
Bjorling-Poulsen	NNP	B
,	,	I
et	VBZ	I
al	NN	I
.	.	I
Oncogene	NNP	I
24	CD	I
(	(	I
40	CD	I
)	)	I
,	,	I
6194-6200	JJ	I
(	(	I
2005	CD	I
)	)	I
;	:	O
Schubert	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
Eur	NNP	I
.	.	I
J.	NNP	I
Biochem	NNP	I
.	.	I
204	CD	I
(	(	I
2	CD	I
)	)	I
,	,	I
875-883	JJ	I
(	(	I
1991	CD	I
)	)	I
;	:	O
Voss	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
266	CD	I
(	(	I
21	CD	I
)	)	I
,	,	I
13706-13711	JJ	I
(	(	I
1991	CD	I
)	)	I
;	:	O
Yang-Feng	NNP	B
,	,	I
et	VBZ	I
al	NN	I
.	.	I
Genomics	NNS	I
8	CD	I
(	(	I
4	CD	I
)	)	I
,	,	I
741-742	JJ	I
(	(	I
1990	CD	I
)	)	I
;	:	O
Heller-Harrison	NNP	B
,	,	I
et	VBZ	I
al	NN	I
.	.	I
Biochemistry	NN	I
28	CD	I
(	(	I
23	CD	I
)	)	I
,	,	I
9053-9058	CD	I
(	(	I
1989	CD	I
)	)	I
;	:	O
Ackermann	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
Mol	NNP	I
.	.	I
Cell	NNP	I
.	.	I
Biochem	NNP	I
.	.	I
274	CD	I
(	(	I
1-2	JJ	I
)	)	I
,	,	I
91-101	CD	I
(	(	I
2005	CD	I
)	)	I
;	:	O
Barrios-Rodiles	NNP	B
,	,	I
et	VBZ	I
al	NN	I
.	.	I
Science	NN	I
307	CD	I
(	(	I
5715	CD	I
)	)	I
,	,	I
1621-1625	JJ	I
(	(	I
2005	CD	I
)	)	I
;	:	O
Andersen	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
Nature	NN	I
433	CD	I
(	(	I
7021	CD	I
)	)	I
,	,	I
77-83	JJ	I
(	(	I
2005	CD	I
)	)	I
;	:	O
Ballif	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
Mol	NNP	I
.	.	I
Cell	NNP	I
.	.	I
Proteomics	NNS	I
,	,	I
3	CD	I
(	(	I
11	CD	I
)	)	I
,	,	I
1093-1101	JJ	I
(	(	I
2004	CD	I
)	)	I
;	:	O
Beausoleil	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
PNAS	NNP	I
,	,	I
USA	NNP	I
101	CD	I
(	(	I
33	CD	I
)	)	I
,	,	I
12130-12135	JJ	I
(	(	I
2004	CD	I
)	)	I
;	:	O
Marais	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
EMBO	NNP	I
J	NNP	I
.	.	I
11	CD	I
(	(	I
1	CD	I
)	)	I
,	,	I
97-105	CD	I
(	(	I
1992	CD	I
)	)	I
.	.	O
Reference	NN	O
to	TO	O
the	DT	O
amino	NN	O
acid	NN	O
or	CC	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
of	IN	O
CKII	NNP	O
includes	VBZ	O
the	DT	O
amino	NN	O
acid	NN	O
or	CC	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
of	IN	O
any	DT	O
of	IN	O
these	DT	O
references	NNS	O
and	CC	O
allelic	JJ	O
variants	NNS	O
thereof	NN	O
.	.	O
IKBKB	NNP	O
and	CC	O
the	DT	O
related	JJ	O
IKBKA	NNP	O
are	VBP	O
positive	JJ	O
regulators	NNS	O
of	IN	O
the	DT	O
NFkB	NNP	O
inflammatory	JJ	O
pathway	NN	O
.	.	O
The	DT	O
sequence	NN	O
for	IN	O
IKBKB	NNP	O
has	VBZ	O
been	VBN	O
provided	VBN	O
in	IN	O
Genbank	NNP	O
under	IN	O
the	DT	O
following	JJ	O
accession	NN	O
number	NN	O
:	:	O
NM—001556	NNP	O
and/or	NN	O
can	MD	O
be	VB	O
found	VBN	O
in	IN	O
any	DT	O
one	CD	O
of	IN	O
:	:	O
Caterino	NN	B
,	,	I
et	CC	I
al	NN	I
.	.	I
FEBS	NNP	I
Lett	NNP	I
.	.	I
580	CD	I
(	(	I
28-29	JJ	I
)	)	I
,	,	I
6527-6532	JJ	I
(	(	I
2006	CD	I
)	)	I
;	:	O
Castle	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
Genome	NNP	I
Biol	NNP	I
.	.	I
4	CD	I
(	(	I
10	CD	I
)	)	I
,	,	I
R66	NNP	I
(	(	I
2003	CD	I
)	)	I
;	:	O
Satoh	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
Biochim	NNP	I
,	,	I
Biophys	NNP	I
.	.	I
Acta	NN	I
1600	CD	I
(	(	I
103	CD	I
)	)	I
,	,	I
61-67	JJ	I
(	(	I
2002	CD	I
)	)	I
,	,	O
Caohuy	NNP	B
,	,	I
and	CC	I
Pollard	NNP	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
277	CD	I
(	(	I
28	CD	I
)	)	I
,	,	I
25217-25225	JJ	I
(	(	I
2002	CD	I
)	)	I
;	:	O
Yu	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
277	CD	I
(	(	I
18	CD	I
)	)	I
,	,	I
15819-15827	JJ	I
(	(	I
2002	CD	I
)	)	I
;	:	O
Selbert	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
J	NNP	I
.	.	I
Cell	NNP	I
.	.	I
Sci	NNP	I
.	.	I
108	CD	I
(	(	I
Pt	NNP	I
.	.	I
1	CD	I
)	)	I
,	,	I
85095	CD	I
(	(	I
1995	CD	I
)	)	I
;	:	O
Shirvan	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
Biochemistry	NN	I
33	CD	I
(	(	I
22	CD	I
)	)	I
,	,	I
6888-6901	JJ	I
(	(	I
1994	CD	I
)	)	I
;	:	O
Creutz	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
Biochem	NNP	I
.	.	I
Biophys	NNP	I
.	.	I
Res	NNP	I
.	.	I
Commun	NNP	I
.	.	I
184	CD	I
(	(	I
1	CD	I
)	)	I
,	,	I
347-352	CD	I
(	(	I
1992	CD	I
)	)	I
;	:	O
Megendzo	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
266	CD	I
(	(	I
5	CD	I
)	)	I
,	,	I
3228-3232	JJ	I
(	(	I
1991	CD	I
)	)	I
;	:	O
Burns	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
PNAS	NNP	I
,	,	I
USA	NNP	I
86	CD	I
(	(	I
10	CD	I
)	)	I
,	,	I
3798-3802	JJ	I
(	(	I
1989	CD	I
)	)	I
.	.	O
Reference	NN	O
to	TO	O
the	DT	O
amino	NN	O
acid	NN	O
or	CC	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
of	IN	O
IKBKB	NNP	O
includes	VBZ	O
the	DT	O
amino	NN	O
acid	NN	O
or	CC	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
of	IN	O
any	DT	O
of	IN	O
these	DT	O
references	NNS	O
and	CC	O
allelic	JJ	O
variants	NNS	O
thereof	NN	O
.	.	O
Synphilin	NNP	O
is	VBZ	O
a	DT	O
synuclein-associated	JJ	O
protein	NN	O
that	WDT	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
bind	VB	O
alpha-synuclein	JJ	O
.	.	O
Although	IN	O
not	RB	O
a	DT	O
kinase	NN	O
itself	PRP	O
,	,	O
Synphilin	NNP	O
was	VBD	O
found	VBN	O
herein	RB	O
to	TO	O
promote	VB	O
phosphorylation	NN	O
of	IN	O
synuclein	JJ	O
particularly	RB	O
in	IN	O
combination	NN	O
with	IN	O
PLK2	NNP	O
.	.	O
The	DT	O
synphilin	NN	O
appeared	VBD	O
to	TO	O
promote	VB	O
phosphorylation	NN	O
of	IN	O
synuclein	NN	O
in	IN	O
a	DT	O
PLK2-dependent	JJ	O
manner	NN	O
.	.	O
The	DT	O
sequence	NN	O
for	IN	O
synphilin	NN	O
has	VBZ	O
been	VBN	O
provided	VBN	O
in	IN	O
Genbank	NNP	O
under	IN	O
the	DT	O
following	JJ	O
accession	NN	O
number	NN	O
:	:	O
NM—005460	NNP	O
and/or	NN	O
can	MD	O
be	VB	O
found	VBN	O
in	IN	O
any	DT	O
one	CD	O
of	IN	O
:	:	O
Tanji	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
Am	NNP	I
.	.	I
J.	NNP	I
Pathol	NNP	I
.	.	I
169	CD	I
(	(	I
2	CD	I
)	)	I
,	,	I
553-565	JJ	I
(	(	I
2006	CD	I
)	)	I
;	:	O
Eyal	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
PNAS	NNP	I
,	,	I
USA	NNP	I
103	CD	I
(	(	I
15	CD	I
)	)	I
,	,	I
5917-5922	JJ	I
(	(	I
2006	CD	I
)	)	I
;	:	O
Avraham	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
280	CD	I
(	(	I
52	CD	I
)	)	I
,	,	I
42877-42886	JJ	I
(	(	I
2005	CD	I
)	)	I
;	:	O
Bandopadhyay	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
Neurobiol	NNP	I
.	.	I
Dis	NNP	I
.	.	I
20	CD	I
(	(	I
2	CD	I
)	)	I
,	,	I
401-411	JJ	I
(	(	I
2005	CD	I
)	)	I
;	:	O
Lim	NNP	B
et	FW	I
al	NN	I
.	.	I
J.	NNP	I
Neurosci	NNP	I
.	.	I
25	CD	I
(	(	I
8	CD	I
)	)	I
,	,	I
2002-2009	CD	I
(	(	I
2005	CD	I
)	)	I
;	:	O
Ribeiro	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
277	CD	I
(	(	I
26	CD	I
)	)	I
,	,	I
23927-23933	JJ	I
(	(	I
2002	CD	I
)	)	I
;	:	O
Chung	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
Nat	NNP	I
.	.	I
Med	NNP	I
.	.	I
7	CD	I
(	(	I
10	CD	I
)	)	I
,	,	I
1144-1150	JJ	I
(	(	I
2001	CD	I
)	)	I
;	:	O
Engelender	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
Mamm	NNP	I
.	.	I
Genome	NNP	I
11	CD	I
(	(	I
9	CD	I
)	)	I
,	,	I
763-766	JJ	I
(	(	I
2000	CD	I
)	)	I
;	:	O
Engelender	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
Nat	NNP	I
.	.	I
Genet	NNP	I
.	.	I
22	CD	I
(	(	I
1	CD	I
)	)	I
,	,	I
110-114	JJ	I
(	(	I
1999	CD	I
)	)	I
.	.	O
Reference	NN	O
to	TO	O
the	DT	O
amino	NN	O
acid	NN	O
or	CC	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
of	IN	O
synphilin	NN	O
includes	VBZ	O
the	DT	O
amino	NN	O
acid	NN	O
or	CC	O
nucleic	JJ	O
acid	JJ	O
sequence	NN	O
of	IN	O
any	DT	O
of	IN	O
these	DT	O
references	NNS	O
and	CC	O
allelic	JJ	O
variants	NNS	O
thereof	NN	O
.	.	O
V.	NNP	O
Agents	NNS	O
to	TO	O
Modulate	NNP	O
Synuclein	NNP	O
Kinase	NNP	O
Activity	NNP	O
or	CC	O
Expression	NNP	O
In	IN	O
one	CD	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
methods	NNS	O
of	IN	O
effecting	VBG	O
treatment	NN	O
or	CC	O
prophylaxis	NN	O
of	IN	O
an	DT	O
LBD	NNP	O
by	IN	O
administering	VBG	O
an	DT	O
agent	NN	O
that	WDT	O
modulates	VBZ	O
activity	NN	O
or	CC	O
expression	NN	O
of	IN	O
a	DT	O
kinase	NN	O
described	VBN	O
herein	NN	O
.	.	O
A	DT	O
number	NN	O
of	IN	O
agents	NNS	O
of	IN	O
well-characterized	JJ	O
general	JJ	O
classes	NNS	O
can	MD	O
be	VB	O
used	VBN	O
.	.	O
Without	IN	O
limitation	NN	O
these	DT	O
include	VBP	O
inhibitory	NN	O
nucleic	JJ	O
acids	NNS	O
(	(	O
e.g.	NN	O
,	,	O
siRNA	NN	O
,	,	O
antisense	JJ	O
RNA	NNP	O
,	,	O
ribozymes	RB	O
)	)	O
,	,	O
inhibitory	JJ	O
proteins	NNS	O
(	(	O
e.g.	NN	O
,	,	O
zinc	NN	O
finger	NN	O
proteins	NNS	O
)	)	O
,	,	O
antibodies	NNS	O
,	,	O
and	CC	O
small	JJ	O
molecule	NN	O
inhibitors	NNS	O
.	.	O
Preferably	RB	O
the	DT	O
gene	NN	O
to	TO	O
be	VB	O
inhibited	VBN	O
is	VBZ	O
PLK2	NNP	O
or	CC	O
GRK6	NNP	O
because	IN	O
the	DT	O
kinases	NNS	O
encoded	VBN	O
by	IN	O
these	DT	O
genes	NNS	O
directly	RB	O
phosphorylate	VBP	O
alpha-synuclein	NNS	O
,	,	O
and	CC	O
particularly	RB	O
PLK2	NNP	O
.	.	O
APEG1	NNP	O
,	,	O
CDC7L1	NNP	O
,	,	O
MET	NNP	O
GRK1	NNP	O
,	,	O
GRK2	NNP	O
,	,	O
GRK6	NNP	O
,	,	O
IKBKB	NNP	O
,	,	O
CKII	NNP	O
and	CC	O
GRK7	NNP	O
genes	NNS	O
are	VBP	O
also	RB	O
preferred	JJ	O
targets	NNS	O
for	IN	O
inhibition	NN	O
because	IN	O
they	PRP	O
are	VBP	O
likely	JJ	O
to	TO	O
encode	VB	O
indirect	JJ	O
activators	NNS	O
of	IN	O
the	DT	O
direct	JJ	O
kinase	NN	O
(	(	O
s	NN	O
)	)	O
.	.	O
PRKG1	NNP	O
,	,	O
MAPK13	NNP	O
,	,	O
and	CC	O
GAK	NNP	O
are	VBP	O
preferred	VBN	O
candidates	NNS	O
for	IN	O
activation	NN	O
in	IN	O
Lewy	NNP	O
body	NN	O
diseases	NNS	O
because	IN	O
they	PRP	O
encode	VBP	O
negative	JJ	O
regulators	NNS	O
of	IN	O
the	DT	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	NN	O
.	.	O
The	DT	O
synphilin	NN	O
gene	NN	O
is	VBZ	O
a	DT	O
preferred	JJ	O
target	NN	O
for	IN	O
inhibition	NN	O
because	IN	O
,	,	O
although	IN	O
synphilin	NN	O
is	VBZ	O
not	RB	O
a	DT	O
kinase	NN	O
,	,	O
it	PRP	O
is	VBZ	O
associated	VBN	O
with	IN	O
increased	JJ	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	NN	O
(	(	O
typically	RB	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
a	DT	O
kinase	NN	O
such	JJ	O
as	IN	O
PLK2	NNP	O
)	)	O
.	.	O
Inhibitors	NNS	O
that	WDT	O
show	VBP	O
specificity	NN	O
for	IN	O
PLK2	NNP	O
over	IN	O
one	CD	O
or	CC	O
more	JJR	O
other	JJ	O
polo-like	JJ	O
kinase	NN	O
family	NN	O
members	NNS	O
(	(	O
i.e.	FW	O
,	,	O
PLK1	NNP	O
,	,	O
PLK3	NNP	O
,	,	O
and	CC	O
PLK4	NNP	O
)	)	O
are	VBP	O
preferred	VBN	O
.	.	O
Inhibitors	NNS	O
especially	RB	O
suited	VBN	O
for	IN	O
therapeutic	JJ	O
use	NN	O
may	MD	O
be	VB	O
identified	VBN	O
by	IN	O
selecting	VBG	O
for	IN	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
the	DT	O
following	JJ	O
properties	NNS	O
:	:	O
As	IN	O
used	VBN	O
in	IN	O
this	DT	O
context	NN	O
,	,	O
“	VBZ	O
no	DT	O
effect	NN	O
”	NN	O
means	VBZ	O
administration	NN	O
of	IN	O
the	DT	O
agent	NN	O
does	VBZ	O
not	RB	O
reduce	VB	O
expression	NN	O
,	,	O
or	CC	O
reduces	NNS	O
expression	NN	O
by	IN	O
a	DT	O
physiologically	RB	O
insignificant	JJ	O
degree	NN	O
.	.	O
“	NN	O
Reduced	NNP	O
effect	NN	O
”	NN	O
means	VBZ	O
that	IN	O
the	DT	O
EC50	NNP	O
or	CC	O
Ki	NNP	O
values	NNS	O
for	IN	O
inhibiting	VBG	O
PLK2	NNP	O
is	VBZ	O
lower	JJR	O
than	IN	O
the	DT	O
EC50	NNP	O
for	IN	O
the	DT	O
reference	NN	O
PLK	NNP	O
(	(	O
s	NN	O
)	)	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
the	DT	O
EC50	NNP	O
may	MD	O
be	VB	O
at	IN	O
least	JJS	O
2-fold	JJ	O
lower	JJR	O
,	,	O
and	CC	O
is	VBZ	O
sometimes	RB	O
at	IN	O
least	JJS	O
10-fold	JJ	O
lower	JJR	O
,	,	O
and	CC	O
may	MD	O
be	VB	O
at	IN	O
least	JJS	O
100-fold	JJ	O
,	,	O
or	CC	O
even	RB	O
at	IN	O
least	JJS	O
1000-fold	JJ	O
lower	JJR	O
.	.	O
As	IN	O
used	VBN	O
in	IN	O
this	DT	O
context	NN	O
,	,	O
inhibition	NN	O
of	IN	O
PLK2	NNP	O
“	NNP	O
activity	NN	O
”	NN	O
can	MD	O
result	VB	O
from	IN	O
reducing	VBG	O
protein	JJ	O
expression	NN	O
(	(	O
e.g.	JJ	O
,	,	O
reducing	VBG	O
expression	NN	O
of	IN	O
the	DT	O
PLK2	NNP	O
gene	NN	O
,	,	O
interfering	VBG	O
with	IN	O
processing	NN	O
of	IN	O
PLK2	NNP	O
RNA	NNP	O
,	,	O
reducing	VBG	O
the	DT	O
half-life	NN	O
of	IN	O
PLK2	NNP	O
mRNA	NN	O
or	CC	O
protein	NN	O
)	)	O
or	CC	O
by	IN	O
competitive	JJ	O
or	CC	O
noncompetitive	JJ	O
inhibition	NN	O
of	IN	O
the	DT	O
PLK2	NNP	O
kinase	NN	O
activity	NN	O
.	.	O
Inhibitors	NNS	O
that	WDT	O
show	VBP	O
specificity	NN	O
for	IN	O
PLK2	NNP	O
over	IN	O
non-polo	JJ	O
kinases	NNS	O
,	,	O
especially	RB	O
other	JJ	O
kinases	NNS	O
expressed	VBN	O
in	IN	O
the	DT	O
tissues	NNS	O
to	TO	O
which	WDT	O
the	DT	O
agent	NN	O
is	VBZ	O
delivered	VBN	O
are	VBP	O
especially	RB	O
preferred	VBN	O
.	.	O
In	IN	O
preferred	JJ	O
embodiments	NNS	O
the	DT	O
agent	NN	O
does	VBZ	O
not	RB	O
inhibit	VB	O
non-polo	JJ	O
kinases	NNS	O
(	(	O
or	CC	O
has	VBZ	O
a	DT	O
EC50	NNP	O
greater	JJR	O
than	IN	O
10-times	CD	O
higher	JJR	O
,	,	O
sometimes	RB	O
100-times	JJ	O
greater	JJR	O
,	,	O
and	CC	O
sometimes	RB	O
greater	JJR	O
than	IN	O
1000-times	CD	O
higher	JJR	O
)	)	O
for	IN	O
non-polo	JJ	O
kinases	NNS	O
compared	VBN	O
to	TO	O
PLK2	NNP	O
.	.	O
However	RB	O
,	,	O
inhibition	NN	O
of	IN	O
other	JJ	O
kinases	NNS	O
may	MD	O
be	VB	O
tolerated	VBN	O
depending	VBG	O
on	IN	O
the	DT	O
role	NN	O
and	CC	O
expression	NN	O
of	IN	O
the	DT	O
kinase	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
a	DT	O
kinase	NN	O
that	WDT	O
functions	NNS	O
in	IN	O
the	DT	O
gut	NN	O
may	MD	O
not	RB	O
be	VB	O
affected	VBN	O
by	IN	O
an	DT	O
inhibitor	NN	O
delivered	VBD	O
to	TO	O
the	DT	O
brain	NN	O
.	.	O
To	TO	O
further	RBR	O
guide	VB	O
the	DT	O
reader	NN	O
,	,	O
inhibitory	JJ	O
nucleic	JJ	O
acids	NNS	O
(	(	O
e.g.	NN	O
,	,	O
siRNA	NN	O
,	,	O
antisense	JJ	O
RNA	NNP	O
,	,	O
ribozymes	RB	O
)	)	O
,	,	O
inhibitory	JJ	O
proteins	NNS	O
(	(	O
e.g.	NN	O
,	,	O
zinc	NN	O
finger	NN	O
proteins	NNS	O
)	)	O
,	,	O
antibodies	NNS	O
,	,	O
and	CC	O
small	JJ	O
molecule	NN	O
inhibitors	NNS	O
are	VBP	O
discussed	VBN	O
below	IN	O
.	.	O
A.	NN	O
Inhibitory	NNP	O
Polynucleotides	NNP	O
Several	NNP	O
examples	NNS	O
of	IN	O
inhibitors	NNS	O
of	IN	O
target	NN	O
kinases	NNS	O
,	,	O
including	VBG	O
PLK2	NNP	O
,	,	O
are	VBP	O
described	VBN	O
below	IN	O
.	.	O
Polynucleotide	JJ	O
inhibitors	NNS	O
are	VBP	O
designed	VBN	O
to	TO	O
bind	VB	O
specific	JJ	O
target	NN	O
sequences	NNS	O
within	IN	O
a	DT	O
target	NN	O
transcript	NN	O
.	.	O
Preferably	RB	O
the	DT	O
inhibitors	NNS	O
bind	VBP	O
to	TO	O
a	DT	O
target	NN	O
site	NN	O
in	IN	O
a	DT	O
PLK2	NNP	O
RNA	NNP	O
without	IN	O
binding	VBG	O
a	DT	O
target	NN	O
site	NN	O
in	IN	O
:	:	O
PLK1	NNP	O
and/or	VBZ	O
PLK3	NNP	O
and/or	NN	O
PLK4	NNP	O
.	.	O
Suitable	JJ	O
target	NN	O
sites	NNS	O
are	VBP	O
identified	VBN	O
by	IN	O
selecting	VBG	O
segments	NNS	O
of	IN	O
PLK2	NNP	O
that	WDT	O
have	VBP	O
no	DT	O
exact	JJ	O
corresponding	VBG	O
segment	NN	O
in	IN	O
other	JJ	O
PLKs	NNP	O
.	.	O
Preferably	RB	O
,	,	O
a	DT	O
selected	VBN	O
segment	NN	O
of	IN	O
PLK2	NNP	O
lacks	VBZ	O
a	DT	O
corresponding	JJ	O
segment	NN	O
having	VBG	O
substantial	JJ	O
sequence	NN	O
identity	NN	O
(	(	O
for	IN	O
example	NN	O
,	,	O
a	DT	O
selected	VBN	O
segment	NN	O
from	IN	O
PLK2	NNP	O
should	MD	O
show	VB	O
less	JJR	O
than	IN	O
95	CD	O
,	,	O
90	CD	O
,	,	O
75	CD	O
or	CC	O
50	CD	O
%	NN	O
sequence	NN	O
identity	NN	O
with	IN	O
the	DT	O
closest	JJS	O
corresponding	NN	O
segment	NN	O
in	IN	O
PLK4	NNP	O
)	)	O
.	.	O
A	DT	O
selected	VBN	O
target	NN	O
segment	NN	O
is	VBZ	O
also	RB	O
preferably	RB	O
screened	VBN	O
against	IN	O
a	DT	O
gene	NN	O
database	NN	O
to	TO	O
ensure	VB	O
that	IN	O
it	PRP	O
does	VBZ	O
not	RB	O
show	VB	O
significant	JJ	O
sequence	NN	O
identity	NN	O
with	IN	O
unrelated	JJ	O
genes	NNS	O
by	IN	O
chance	NN	O
.	.	O
Polynucleotide	NNP	O
inhibitors	NNS	O
of	IN	O
PLK2	NNP	O
preferably	RB	O
show	VBP	O
at	IN	O
least	JJS	O
30	CD	O
,	,	O
50	CD	O
,	,	O
75	CD	O
,	,	O
95	CD	O
,	,	O
or	CC	O
99	CD	O
%	NN	O
inhibition	NN	O
of	IN	O
levels	NNS	O
of	IN	O
PLK2	NNP	O
mRNA	NN	O
or	CC	O
protein	NN	O
with	IN	O
little	JJ	O
or	CC	O
no	DT	O
detectable	JJ	O
reduction	NN	O
in	IN	O
levels	NNS	O
of	IN	O
PLK1	NNP	O
and/or	NN	O
PLK3	NNP	O
and/or	NN	O
PLK4	NNP	O
mRNA	NN	O
or	CC	O
protein	NN	O
(	(	O
i.e	JJ	O
,	,	O
less	JJR	O
than	IN	O
10	CD	O
,	,	O
5	CD	O
or	CC	O
1	CD	O
%	NN	O
inhibition	NN	O
)	)	O
.	.	O
Protein	NNP	O
expression	NN	O
can	MD	O
be	VB	O
quantified	VBN	O
by	IN	O
forming	VBG	O
immunological	JJ	O
analyses	NNS	O
using	VBG	O
an	DT	O
antibody	NN	O
that	WDT	O
specifically	RB	O
binds	VBZ	O
to	TO	O
the	DT	O
protein	NN	O
followed	VBN	O
by	IN	O
detection	NN	O
of	IN	O
complex	JJ	O
formed	VBN	O
between	IN	O
the	DT	O
antibody	NN	O
and	CC	O
protein	NN	O
.	.	O
mRNA	NN	O
levels	NNS	O
can	MD	O
be	VB	O
quantified	VBN	O
by	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
dot	NN	O
blot	NN	O
analysis	NN	O
,	,	O
in-situ	JJ	O
hybridization	NN	O
,	,	O
RT-PCR	NNP	O
,	,	O
quantitative	JJ	O
reverse-transcription	NN	O
PCR	NNP	O
(	(	O
i.e.	FW	O
,	,	O
the	DT	O
so-called	JJ	O
“	NNP	O
TaqMan	NNP	O
”	NNP	O
methods	NNS	O
)	)	O
,	,	O
Northern	NNP	O
blots	NNS	O
and	CC	O
nucleic	JJ	O
acid	NN	O
probe	NN	O
array	NN	O
methods	NNS	O
.	.	O
i	NN	O
)	)	O
Short	NNP	O
Inhibitory	NNP	O
RNAs	NNP	O
siRNAs	NN	O
are	VBP	O
relatively	RB	O
short	JJ	O
,	,	O
at	IN	O
least	JJS	O
partly	RB	O
double	RB	O
stranded	VBN	O
,	,	O
RNA	NNP	O
molecules	VBZ	O
that	IN	O
serve	NN	O
to	TO	O
inhibit	VB	O
expression	NN	O
or	CC	O
translation	NN	O
of	IN	O
a	DT	O
complementary	JJ	O
mRNA	NN	O
transcript	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
kinase	NN	O
transcript	NN	O
.	.	O
Although	IN	O
an	DT	O
understanding	NN	O
of	IN	O
mechanism	NN	O
is	VBZ	O
not	RB	O
required	VBN	O
for	IN	O
practice	NN	O
of	IN	O
the	DT	O
invention	NN	O
,	,	O
it	PRP	O
is	VBZ	O
believed	VBN	O
that	IN	O
siRNAs	NN	O
act	NN	O
by	IN	O
inducing	VBG	O
degradation	NN	O
of	IN	O
a	DT	O
complementary	JJ	O
mRNA	NN	O
transcript	NN	O
.	.	O
Principles	NNS	O
for	IN	O
design	NN	O
and	CC	O
use	NN	O
of	IN	O
siRNAs	NN	O
generally	RB	O
are	VBP	O
described	VBN	O
by	IN	O
WO	NNP	O
99/32619	CD	O
,	,	O
Elbashir	NNP	B
,	,	I
EMBO	NNP	I
J	NNP	I
.	.	I
20	CD	I
,	,	I
6877-6888	CD	I
(	(	I
2001	CD	I
)	)	I
and	CC	O
Nykanen	NNP	B
et	VBP	I
al.	NN	I
,	,	I
Cell	NNP	I
107	CD	I
,	,	I
309-321	CD	I
(	(	I
2001	CD	I
)	)	I
;	:	O
WO	$	O
01/29058	CD	O
.	.	O
siRNAs	NNS	O
are	VBP	O
formed	VBN	O
from	IN	O
two	CD	O
strands	NNS	O
of	IN	O
at	IN	O
least	JJS	O
partly	RB	O
complementary	JJ	O
RNA	NNP	O
,	,	O
each	DT	O
strand	NN	O
preferably	RB	O
of	IN	O
10-30	JJ	O
,	,	O
15-25	JJ	O
,	,	O
or	CC	O
17-23	CD	O
or	CC	O
19-21	JJ	O
nucleotides	NNS	O
long	RB	O
.	.	O
The	DT	O
strands	NNS	O
can	MD	O
be	VB	O
perfectly	RB	O
complementary	JJ	O
to	TO	O
each	DT	O
other	JJ	O
throughout	IN	O
their	PRP$	O
length	NN	O
or	CC	O
can	MD	O
have	VB	O
single	JJ	O
stranded	VBN	O
3′-overhangs	NNS	O
at	IN	O
one	CD	O
or	CC	O
both	DT	O
ends	NNS	O
of	IN	O
an	DT	O
otherwise	NN	O
double	NN	O
stranded	VBD	O
molecule	NN	O
.	.	O
Single	NNP	O
stranded	VBD	O
overhangs	NNS	O
,	,	O
if	IN	O
present	JJ	O
,	,	O
are	VBP	O
usually	RB	O
of	IN	O
1-6	JJ	O
bases	NNS	O
with	IN	O
1	CD	O
or	CC	O
2	CD	O
bases	NNS	O
being	VBG	O
preferred	VBN	O
.	.	O
The	DT	O
antisense	JJ	O
strand	NN	O
of	IN	O
an	DT	O
siRNA	NN	O
is	VBZ	O
selected	VBN	O
to	TO	O
be	VB	O
substantially	RB	O
complementary	JJ	O
(	(	O
e.g.	JJ	O
,	,	O
at	IN	O
least	JJS	O
80	CD	O
,	,	O
90	CD	O
,	,	O
95	CD	O
%	NN	O
and	CC	O
preferably	RB	O
100	CD	O
%	NN	O
complementary	NN	O
)	)	O
to	TO	O
a	DT	O
segment	NN	O
of	IN	O
a	DT	O
transcript	NN	O
from	IN	O
a	DT	O
gene	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Any	DT	O
mismatched	JJ	O
bases	NNS	O
preferably	RB	O
occur	VBP	O
at	IN	O
or	CC	O
near	IN	O
the	DT	O
ends	NNS	O
of	IN	O
the	DT	O
strands	NNS	O
of	IN	O
the	DT	O
siRNA	NN	O
.	.	O
Mismatched	VBN	O
bases	NNS	O
at	IN	O
the	DT	O
ends	NNS	O
can	MD	O
be	VB	O
deoxyribonucleotides	NNS	O
.	.	O
The	DT	O
sense	NN	O
strand	NN	O
of	IN	O
an	DT	O
siRNA	NN	O
shows	VBZ	O
an	DT	O
analogous	JJ	O
relationship	NN	O
with	IN	O
the	DT	O
complement	NN	O
of	IN	O
the	DT	O
segment	NN	O
of	IN	O
the	DT	O
gene	NN	O
transcript	NN	O
of	IN	O
interest	NN	O
.	.	O
siRNAs	RB	O
having	VBG	O
two	CD	O
strands	NNS	O
,	,	O
each	DT	O
having	VBG	O
19	CD	O
bases	NNS	O
of	IN	O
perfect	JJ	O
complementarity	NN	O
,	,	O
and	CC	O
having	VBG	O
two	CD	O
unmatched	JJ	O
bases	NNS	O
at	IN	O
the	DT	O
3′	CD	O
end	NN	O
of	IN	O
the	DT	O
sense	NN	O
strand	NN	O
and	CC	O
one	CD	O
at	IN	O
the	DT	O
3′	CD	O
end	NN	O
of	IN	O
the	DT	O
antisense	NN	O
strand	NN	O
are	VBP	O
particularly	RB	O
suitable	JJ	O
.	.	O
If	IN	O
an	DT	O
siRNA	NN	O
is	VBZ	O
to	TO	O
be	VB	O
administered	VBN	O
as	IN	O
such	JJ	O
,	,	O
as	IN	O
distinct	JJ	O
from	IN	O
the	DT	O
form	NN	O
of	IN	O
DNA	NNP	O
encoding	VBG	O
the	DT	O
siRNA	NN	O
,	,	O
then	RB	O
the	DT	O
strands	NNS	O
of	IN	O
an	DT	O
siRNA	NN	O
can	MD	O
contain	VB	O
one	CD	O
or	CC	O
more	JJR	O
nucleotide	JJ	O
analogs	NNS	O
.	.	O
The	DT	O
nucleotide	JJ	O
analogs	NNS	O
are	VBP	O
located	VBN	O
at	IN	O
positions	NNS	O
at	IN	O
which	WDT	O
inhibitor	NN	O
activity	NN	O
is	VBZ	O
not	RB	O
substantially	RB	O
affected	VBN	O
,	,	O
e.g	NN	O
.	.	O
in	IN	O
a	DT	O
region	NN	O
at	IN	O
the	DT	O
5′-end	JJ	O
and/or	NN	O
the	DT	O
3′-end	JJ	O
,	,	O
particularly	RB	O
single	JJ	O
stranded	VBD	O
overhang	JJ	O
regions	NNS	O
.	.	O
Preferred	NNP	O
nucleotide	IN	O
analogues	NNS	O
are	VBP	O
sugar-	JJ	O
or	CC	O
backbone-modified	JJ	O
ribonucleotides	NNS	O
.	.	O
Nucleobase-modified	JJ	O
ribonucleotides	NNS	O
,	,	O
i.e	NN	O
.	.	O
ribonucleotides	NNS	O
,	,	O
containing	VBG	O
a	DT	O
non-naturally	JJ	O
occurring	VBG	O
nucleobase	JJ	O
instead	RB	O
of	IN	O
a	DT	O
naturally	RB	O
occurring	VBG	O
nucleobase	NN	O
such	JJ	O
as	IN	O
uridines	NNS	O
or	CC	O
cytidines	NNS	O
modified	VBN	O
at	IN	O
the	DT	O
5-position	NN	O
,	,	O
e.g	NN	O
.	.	O
5-	JJ	O
(	(	O
2-amino	JJ	O
)	)	O
propyl	NN	O
uridine	JJ	O
,	,	O
5-bromo	JJ	O
uridine	NN	O
;	:	O
adenosines	NNS	O
and	CC	O
guanosines	NNS	O
modified	VBN	O
at	IN	O
the	DT	O
8	CD	O
position	NN	O
,	,	O
e.g	NN	O
.	.	O
8-bromo	JJ	O
guanosine	NN	O
;	:	O
deaza	NN	O
nucleotides	NNS	O
,	,	O
e.g	NN	O
.	.	O
7-deaza-adenosine	JJ	O
;	:	O
O-	JJ	O
and	CC	O
N-alkylated	JJ	O
nucleotides	NNS	O
,	,	O
e.g	NN	O
.	.	O
N6-methyl	JJ	O
adenosine	NN	O
are	VBP	O
also	RB	O
suitable	JJ	O
.	.	O
In	IN	O
preferred	JJ	O
sugar-modified	JJ	O
ribonucleotides	NNS	O
,	,	O
the	DT	O
2′	CD	O
OH-group	NN	O
is	VBZ	O
replaced	VBN	O
by	IN	O
a	DT	O
group	NN	O
selected	VBN	O
from	IN	O
H	NNP	O
,	,	O
OR	NNP	O
,	,	O
R	NNP	O
,	,	O
halo	NN	O
,	,	O
SH	NNP	O
,	,	O
SR	NNP	O
,	,	O
NH2	NNP	O
,	,	O
NHR	NNP	O
,	,	O
NR2	NNP	O
or	CC	O
CN	NNP	O
,	,	O
wherein	NN	O
R	NNP	O
is	VBZ	O
C1-C6	NNP	O
alkyl	NN	O
,	,	O
alkenyl	NN	O
or	CC	O
alkynyl	NN	O
and	CC	O
halo	NN	O
is	VBZ	O
F	NNP	O
,	,	O
CI	NNP	O
,	,	O
Br	NNP	O
or	CC	O
I	PRP	O
.	.	O
In	IN	O
preferred	JJ	O
backbone-modified	JJ	O
ribonucleotides	NNS	O
the	DT	O
phosphoester	NN	O
group	NN	O
connecting	VBG	O
to	TO	O
adjacent	JJ	O
ribonucleotides	NNS	O
is	VBZ	O
replaced	VBN	O
by	IN	O
a	DT	O
modified	JJ	O
group	NN	O
,	,	O
e.g	NN	O
.	.	O
of	IN	O
phosphothioate	NN	O
group	NN	O
.	.	O
A	DT	O
further	JJ	O
preferred	JJ	O
modification	NN	O
is	VBZ	O
to	TO	O
introduce	VB	O
a	DT	O
phosphate	NN	O
group	NN	O
on	IN	O
the	DT	O
5′	CD	O
hydroxide	NN	O
residue	NN	O
of	IN	O
an	DT	O
siRNA	NN	O
.	.	O
Such	JJ	O
a	DT	O
group	NN	O
can	MD	O
be	VB	O
introduced	VBN	O
by	IN	O
treatment	NN	O
of	IN	O
an	DT	O
siRNA	NN	O
with	IN	O
ATP	NNP	O
and	CC	O
T4	NNP	O
kinase	NN	O
.	.	O
The	DT	O
phosphodiester	NN	O
linkages	NNS	O
of	IN	O
natural	JJ	O
RNA	NNP	O
can	MD	O
also	RB	O
be	VB	O
modified	VBN	O
to	TO	O
include	VB	O
at	IN	O
least	JJS	O
one	CD	O
of	IN	O
a	DT	O
nitrogen	NN	O
or	CC	O
sulfur	JJ	O
heteroatom	NN	O
.	.	O
Modifications	NNS	O
in	IN	O
RNA	NNP	O
structure	NN	O
can	MD	O
be	VB	O
tailored	VBN	O
to	TO	O
allow	VB	O
specific	JJ	O
genetic	JJ	O
inhibition	NN	O
while	IN	O
avoiding	VBG	O
a	DT	O
general	JJ	O
panic	NN	O
response	NN	O
in	IN	O
some	DT	O
organisms	NNS	O
which	WDT	O
is	VBZ	O
generated	VBN	O
by	IN	O
dsRNA	NN	O
.	.	O
Likewise	RB	O
,	,	O
bases	NNS	O
can	MD	O
be	VB	O
modified	VBN	O
to	TO	O
block	VB	O
the	DT	O
activity	NN	O
of	IN	O
adenosine	JJ	O
deaminase	NN	O
.	.	O
One	CD	O
example	NN	O
of	IN	O
such	PDT	O
an	DT	O
agent	NN	O
is	VBZ	O
siRNA	JJ	O
specific	JJ	O
for	IN	O
PLK2	NNP	O
.	.	O
siRNAs	NN	O
to	TO	O
the	DT	O
gene	NN	O
encoding	VBG	O
PLK2	NNP	O
can	MD	O
be	VB	O
specifically	RB	O
designed	VBN	O
using	VBG	O
methods	NNS	O
described	VBN	O
below	IN	O
.	.	O
An	DT	O
exemplary	JJ	O
accession	NN	O
number	NN	O
for	IN	O
PLK2	NNP	O
is	VBZ	O
[	JJ	O
NM—006622	NNP	O
]	NNP	O
as	IN	O
provided	VBN	O
in	IN	O
Table	JJ	O
1A	CD	O
.	.	O
The	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
of	IN	O
human	JJ	O
PLK2	NNP	O
is	VBZ	O
also	RB	O
set	VBN	O
forth	NN	O
as	IN	O
SEQ	NNP	O
ID	NNP	O
NO:2	NNP	O
and	CC	O
SEQ	NNP	O
ID	NNP	O
NO:1	NNP	O
is	VBZ	O
the	DT	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
encoding	VBG	O
the	DT	O
amino	NN	O
acid	JJ	O
sequence	NN	O
.	.	O
For	IN	O
convenience	NN	O
exemplary	JJ	O
sequences	NNS	O
are	VBP	O
provided	VBN	O
below	IN	O
.	.	O
ii	NN	O
)	)	O
Design	NN	O
and	CC	O
Production	NN	O
of	IN	O
siRNA	NN	O
An	DT	O
advantage	NN	O
of	IN	O
inhibitory	NN	O
polynucleotides	NNS	O
is	VBZ	O
that	IN	O
they	PRP	O
can	MD	O
be	VB	O
designed	VBN	O
to	TO	O
be	VB	O
highly	RB	O
target	NN	O
specific	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
siRNAs	NN	O
specific	NN	O
for	IN	O
PLK2	NNP	O
can	MD	O
be	VB	O
designed	VBN	O
using	VBG	O
target	NN	O
sequences	NNS	O
that	WDT	O
distinguish	VBP	O
PLK2	NNP	O
from	IN	O
other	JJ	O
PLKs	NNP	O
.	.	O
The	DT	O
program	NN	O
“	NNP	O
siDESIGN	NN	O
”	NNP	O
(	(	O
Dharmacon	NNP	O
,	,	O
Inc.	NNP	O
,	,	O
Lafayette	NNP	O
,	,	O
Colo.	NNP	O
)	)	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
predict	VB	O
siRNA	JJ	O
sequences	NNS	O
for	IN	O
any	DT	O
nucleic	JJ	O
acid	NN	O
sequence	NN	O
,	,	O
and	CC	O
is	VBZ	O
available	JJ	O
on	IN	O
the	DT	O
World	NNP	O
Wide	NNP	O
Web	NNP	O
at	IN	O
dharmacon.com	NN	O
.	.	O
A	DT	O
number	NN	O
of	IN	O
other	JJ	O
programs	NNS	O
for	IN	O
designing	VBG	O
siRNAs	NN	O
are	VBP	O
available	JJ	O
from	IN	O
others	NNS	O
,	,	O
including	VBG	O
Genscript	NNP	O
(	(	O
available	JJ	O
on	IN	O
the	DT	O
Web	NNP	O
at	IN	O
genscript.com/ss1-bin/app/rnai	NN	O
)	)	O
and	CC	O
from	IN	O
the	DT	O
Whitehead	NNP	O
Institute	NNP	O
for	IN	O
Biomedical	NNP	O
Research	NNP	O
jura.wi.mit.edu/pubint/http	NN	O
:	:	O
//iona.wi.mit.edu/siRNAext/	NN	O
.	.	O
Guidelines	NNS	O
for	IN	O
designing	VBG	O
siRNA	NN	O
are	VBP	O
available	JJ	O
in	IN	O
the	DT	O
scientific	JJ	O
literature	NN	O
(	(	O
see	VB	O
,	,	O
e.g.	VB	O
,	,	O
Elbashir	NNP	B
et	FW	I
al.	NN	I
,	,	I
2001	CD	I
,	,	I
“	NNP	I
Duplexes	NNP	I
of	IN	I
21-nucleotide	JJ	I
RNAs	NNP	I
mediate	NN	I
RNA	NNP	I
interference	NN	I
in	IN	I
cultured	JJ	I
mammalian	JJ	I
cells	NNS	I
”	JJ	I
Nature	NNP	I
.	.	I
411:494-8.	JJ	I
;	:	O
and	CC	O
Elbashir	NNP	B
et	VBP	I
al.	NN	I
,	,	I
2001	CD	I
,	,	I
“	FW	I
RNA	NNP	I
interference	NN	I
is	VBZ	I
mediated	VBN	I
by	IN	I
21-	JJ	I
and	CC	I
22-nucleotide	JJ	I
RNAs	NNP	I
”	NNP	I
Genes	NNP	I
Dev	NNP	I
.	.	I
15:188-200	JJ	I
)	)	O
and	CC	O
published	VBN	O
on	IN	O
the	DT	O
Web	NNP	O
(	(	O
see	VB	O
,	,	O
e.g.	VB	O
,	,	O
“	NNP	O
rnaiweb.com/RNAi/siRNA_Design/	VBZ	O
”	NNP	O
and	CC	O
“	NNP	O
protocol-online.org/prot/Protocols/Rules-of-siRNA-design-for-RNA-interference—RNAi—3210.html	JJ	O
”	NN	O
)	)	O
.	.	O
There	EX	O
are	VBP	O
a	DT	O
variety	NN	O
of	IN	O
ways	NNS	O
to	TO	O
produce	VB	O
siRNAs	NN	O
.	.	O
siRNAs	NN	O
can	MD	O
be	VB	O
generated	VBN	O
using	VBG	O
kits	NNS	O
which	WDT	O
generate	VBP	O
siRNA	NN	O
from	IN	O
the	DT	O
kinase	NN	O
(	(	O
e.g.	JJ	O
,	,	O
PLK2	NNP	O
)	)	O
gene	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
“	JJ	O
Dicer	NNP	O
siRNA	NN	O
Generation	NNP	O
”	NNP	O
kit	NNP	O
(	(	O
catalog	NN	O
number	NN	O
T510001	NNP	O
,	,	O
Gene	NNP	O
Therapy	NNP	O
Systems	NNP	O
,	,	O
Inc.	NNP	O
,	,	O
San	NNP	O
Diego	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
uses	VBZ	O
the	DT	O
recombinant	JJ	O
human	JJ	O
enzyme	NN	O
“	NNP	O
dicer	NN	O
”	NN	O
in	IN	O
vitro	NN	O
to	TO	O
cleave	VB	O
long	RB	O
double	RB	O
stranded	VBN	O
RNA	NNP	O
into	IN	O
22	CD	O
bp	NN	O
siRNAs	NN	O
.	.	O
By	IN	O
producing	VBG	O
a	DT	O
mixture	NN	O
of	IN	O
siRNAs	NN	O
,	,	O
the	DT	O
kit	NN	O
permits	VBZ	O
a	DT	O
high	JJ	O
degree	NN	O
of	IN	O
success	NN	O
in	IN	O
generating	VBG	O
siRNAs	NN	O
that	WDT	O
will	MD	O
reduce	VB	O
expression	NN	O
of	IN	O
the	DT	O
target	NN	O
gene	NN	O
.	.	O
Similarly	RB	O
,	,	O
the	DT	O
Silencer™	NNP	O
siRNA	NN	O
Cocktail	NNP	O
Kit	NNP	O
(	(	O
RNase	NNP	O
III	NNP	O
)	)	O
(	(	O
catalog	NN	O
no	DT	O
.	.	O
1625	CD	O
,	,	O
Ambion	NNP	O
,	,	O
Inc.	NNP	O
,	,	O
Austin	NNP	O
,	,	O
Tex	NNP	O
.	.	O
)	)	O
generates	VBZ	O
a	DT	O
mixture	NN	O
of	IN	O
siRNAs	NN	O
from	IN	O
dsRNA	NN	O
using	VBG	O
RNase	NNP	O
III	NNP	O
instead	RB	O
of	IN	O
dicer	NN	O
.	.	O
Like	IN	O
dicer	NN	O
,	,	O
RNase	NNP	O
III	NNP	O
cleaves	VBZ	O
dsRNA	VB	O
into	IN	O
12-30	JJ	O
bp	NN	O
dsRNA	NN	O
fragments	NNS	O
with	IN	O
2	CD	O
to	TO	O
3	CD	O
nucleotide	RB	O
3′	CD	O
overhangs	NNS	O
,	,	O
and	CC	O
5′-phosphate	JJ	O
and	CC	O
3′-hydroxyl	JJ	O
termini	NN	O
.	.	O
According	VBG	O
to	TO	O
the	DT	O
manufacturer	NN	O
,	,	O
dsRNA	NN	O
is	VBZ	O
produced	VBN	O
using	VBG	O
T7	NNP	O
RNA	NNP	O
polymerase	NN	O
,	,	O
and	CC	O
reaction	NN	O
and	CC	O
purification	NN	O
components	NNS	O
included	VBD	O
in	IN	O
the	DT	O
kit	NN	O
.	.	O
The	DT	O
dsRNA	NN	O
is	VBZ	O
then	RB	O
digested	VBN	O
by	IN	O
RNase	NNP	O
III	NNP	O
to	TO	O
create	VB	O
a	DT	O
population	NN	O
of	IN	O
siRNAs	NN	O
.	.	O
The	DT	O
kit	NN	O
includes	VBZ	O
reagents	NNS	O
to	TO	O
synthesize	VB	O
long	JJ	O
dsRNAs	NN	O
by	IN	O
in	IN	O
vitro	JJ	O
transcription	NN	O
and	CC	O
to	TO	O
digest	VB	O
those	DT	O
dsRNAs	NNS	O
into	IN	O
siRNA-like	JJ	O
molecules	NNS	O
using	VBG	O
RNase	NNP	O
III	NNP	O
.	.	O
The	DT	O
manufacturer	NN	O
indicates	VBZ	O
that	IN	O
the	DT	O
user	NN	O
need	MD	O
only	RB	O
supply	VB	O
a	DT	O
DNA	NN	O
template	NN	O
with	IN	O
opposing	VBG	O
T7	NNP	O
phage	NN	O
polymerase	NN	O
promoters	NNS	O
or	CC	O
two	CD	O
separate	JJ	O
templates	NNS	O
with	IN	O
promoters	NNS	O
on	IN	O
opposite	JJ	O
ends	NNS	O
of	IN	O
the	DT	O
region	NN	O
to	TO	O
be	VB	O
transcribed	VBN	O
.	.	O
The	DT	O
siRNAs	NN	O
of	IN	O
the	DT	O
invention	NN	O
can	MD	O
also	RB	O
be	VB	O
expressed	VBN	O
from	IN	O
vectors	NNS	O
.	.	O
Typically	RB	O
,	,	O
such	JJ	O
vectors	NNS	O
are	VBP	O
administered	VBN	O
in	IN	O
conjunction	NN	O
with	IN	O
a	DT	O
second	JJ	O
vector	NN	O
encoding	VBG	O
the	DT	O
corresponding	JJ	O
complementary	JJ	O
strand	NN	O
.	.	O
Once	RB	O
expressed	VBN	O
,	,	O
the	DT	O
two	CD	O
strands	NNS	O
anneal	VBP	O
to	TO	O
each	DT	O
other	JJ	O
and	CC	O
form	VB	O
the	DT	O
functional	JJ	O
double	NN	O
stranded	VBD	O
siRNA	NN	O
.	.	O
One	CD	O
exemplar	JJ	O
vector	NN	O
suitable	NN	O
for	IN	O
use	NN	O
in	IN	O
the	DT	O
invention	NN	O
is	VBZ	O
pSuper	JJ	O
,	,	O
available	JJ	O
from	IN	O
OligoEngine	NNP	O
,	,	O
Inc.	NNP	O
(	(	O
Seattle	NNP	O
,	,	O
Wash.	NNP	O
)	)	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
,	,	O
the	DT	O
vector	NN	O
contains	VBZ	O
two	CD	O
promoters	NNS	O
,	,	O
one	CD	O
positioned	VBD	O
downstream	NN	O
of	IN	O
the	DT	O
first	JJ	O
and	CC	O
in	IN	O
antiparallel	JJ	O
orientation	NN	O
.	.	O
The	DT	O
first	JJ	O
promoter	NN	O
is	VBZ	O
transcribed	VBN	O
in	IN	O
one	CD	O
direction	NN	O
,	,	O
and	CC	O
the	DT	O
second	JJ	O
in	IN	O
the	DT	O
direction	NN	O
antiparallel	NN	O
to	TO	O
the	DT	O
first	JJ	O
,	,	O
resulting	VBG	O
in	IN	O
expression	NN	O
of	IN	O
the	DT	O
complementary	JJ	O
strands	NNS	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
set	NN	O
of	IN	O
embodiments	NNS	O
,	,	O
the	DT	O
promoter	NN	O
is	VBZ	O
followed	VBN	O
by	IN	O
a	DT	O
first	JJ	O
segment	NN	O
encoding	VBG	O
the	DT	O
first	JJ	O
strand	NN	O
,	,	O
and	CC	O
a	DT	O
second	JJ	O
segment	NN	O
encoding	VBG	O
the	DT	O
second	JJ	O
strand	NN	O
.	.	O
The	DT	O
second	JJ	O
strand	NN	O
is	VBZ	O
complementary	JJ	O
to	TO	O
the	DT	O
palindrome	NN	O
of	IN	O
the	DT	O
first	JJ	O
strand	NN	O
.	.	O
Between	IN	O
the	DT	O
first	JJ	O
and	CC	O
the	DT	O
second	JJ	O
strands	NNS	O
is	VBZ	O
a	DT	O
section	NN	O
of	IN	O
RNA	NNP	O
serving	VBG	O
as	IN	O
a	DT	O
linker	NN	O
(	(	O
sometimes	RB	O
called	VBD	O
a	DT	O
“	JJ	O
spacer	NN	O
”	NN	O
)	)	O
to	TO	O
permit	VB	O
the	DT	O
second	JJ	O
strand	NN	O
to	TO	O
bend	VB	O
around	RB	O
and	CC	O
anneal	VB	O
to	TO	O
the	DT	O
first	JJ	O
strand	NN	O
,	,	O
in	IN	O
a	DT	O
configuration	NN	O
known	VBN	O
as	IN	O
a	DT	O
“	JJ	O
hairpin.	NN	O
”	VBD	O
The	DT	O
formation	NN	O
of	IN	O
hairpin	NN	O
RNAs	NNP	O
,	,	O
including	VBG	O
use	NN	O
of	IN	O
linker	NN	O
sections	NNS	O
,	,	O
is	VBZ	O
well	RB	O
known	VBN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
Typically	RB	O
,	,	O
an	DT	O
siRNA	JJ	O
expression	NN	O
cassette	NN	O
is	VBZ	O
employed	VBN	O
,	,	O
using	VBG	O
a	DT	O
Polymerase	NNP	O
III	NNP	O
promoter	NN	O
such	JJ	O
as	IN	O
human	JJ	O
U6	NNP	O
,	,	O
mouse	NN	O
U6	NNP	O
,	,	O
or	CC	O
human	JJ	O
H1	NNP	O
.	.	O
The	DT	O
coding	NN	O
sequence	NN	O
is	VBZ	O
typically	RB	O
a	DT	O
19-nucleotide	JJ	O
sense	NN	O
siRNA	NN	O
sequence	NN	O
linked	VBD	O
to	TO	O
its	PRP$	O
reverse	NN	O
complementary	JJ	O
antisense	NN	O
siRNA	NN	O
sequence	NN	O
by	IN	O
a	DT	O
short	JJ	O
spacer	NN	O
.	.	O
Nine-nucleotide	JJ	O
spacers	NNS	O
are	VBP	O
typical	JJ	O
,	,	O
although	IN	O
other	JJ	O
spacers	NNS	O
can	MD	O
be	VB	O
designed	VBN	O
.	.	O
Further	RB	O
,	,	O
5-6	JJ	O
T	NNP	O
's	POS	O
are	VBP	O
often	RB	O
added	VBN	O
to	TO	O
the	DT	O
3′	CD	O
end	NN	O
of	IN	O
the	DT	O
oligonucleotide	NN	O
to	TO	O
serve	VB	O
as	IN	O
a	DT	O
termination	NN	O
site	NN	O
for	IN	O
Polymerase	NNP	O
III	NNP	O
.	.	O
See	NNP	O
also	RB	O
,	,	O
Yu	NNP	B
et	FW	I
al.	NN	I
,	,	I
Mol	NNP	I
Ther	NNP	I
7	CD	I
(	(	I
2	CD	I
)	)	I
:228-36	NN	I
(	(	I
2003	CD	I
)	)	I
;	:	O
Matsukura	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nucleic	NNP	I
Acids	NNP	I
Res	NNP	I
31	CD	I
(	(	I
15	CD	I
)	)	I
:	:	I
e77	NN	I
(	(	I
2003	CD	I
)	)	I
.	.	O
The	DT	O
siRNA	JJ	O
targets	NNS	O
can	MD	O
be	VB	O
targeted	VBN	O
by	IN	O
hairpin	NN	O
siRNA	NN	O
as	IN	O
follows	VBZ	O
.	.	O
To	TO	O
attack	VB	O
the	DT	O
same	JJ	O
targets	NNS	O
by	IN	O
short	JJ	O
hairpin	NN	O
RNAs	NNP	O
,	,	O
produced	VBN	O
by	IN	O
a	DT	O
vector	NN	O
(	(	O
permanent	JJ	O
RNAi	NNP	O
effect	NN	O
)	)	O
,	,	O
sense	NN	O
and	CC	O
antisense	NN	O
strand	NN	O
can	MD	O
be	VB	O
put	VBN	O
in	IN	O
a	DT	O
row	NN	O
with	IN	O
a	DT	O
loop	NN	O
forming	VBG	O
sequence	NN	O
in	IN	O
between	IN	O
and	CC	O
suitable	JJ	O
sequences	NNS	O
for	IN	O
an	DT	O
adequate	JJ	O
expression	NN	O
vector	NN	O
to	TO	O
both	DT	O
ends	NNS	O
of	IN	O
the	DT	O
sequence	NN	O
.	.	O
The	DT	O
siRNA	NN	O
of	IN	O
the	DT	O
invention	NN	O
can	MD	O
be	VB	O
made	VBN	O
using	VBG	O
any	DT	O
suitable	JJ	O
method	NN	O
for	IN	O
producing	VBG	O
a	DT	O
nucleic	JJ	O
acid	NN	O
,	,	O
such	JJ	O
as	IN	O
the	DT	O
chemical	NN	O
synthesis	NN	O
and	CC	O
recombinant	NN	O
methods	NNS	O
disclosed	VBD	O
herein	NN	O
and	CC	O
known	VBN	O
to	TO	O
one	CD	O
of	IN	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
It	PRP	O
will	MD	O
be	VB	O
appreciated	VBN	O
that	IN	O
the	DT	O
oligonucleotides	NNS	O
can	MD	O
be	VB	O
made	VBN	O
using	VBG	O
nonstandard	JJ	O
bases	NNS	O
(	(	O
e.g.	NN	O
,	,	O
other	JJ	O
than	IN	O
adenine	NN	O
,	,	O
cytidine	NN	O
,	,	O
guanine	NN	O
,	,	O
and	CC	O
uridine	JJ	O
)	)	O
or	CC	O
nonstandard	JJ	O
backbone	NN	O
structures	NNS	O
to	TO	O
provide	VB	O
desirable	JJ	O
properties	NNS	O
(	(	O
e.g.	JJ	O
,	,	O
increased	JJ	O
nuclease-resistance	NN	O
,	,	O
tighter-binding	NN	O
,	,	O
stability	NN	O
or	CC	O
a	DT	O
desired	JJ	O
Tm	NNP	O
)	)	O
.	.	O
Techniques	NNS	O
for	IN	O
rendering	VBG	O
oligonucleotides	JJ	O
nuclease-resistant	JJ	O
include	VBP	O
those	DT	O
described	VBN	O
in	IN	O
PCT	NNP	O
Publication	NNP	O
WO	NNP	O
94/12633	CD	O
.	.	O
A	DT	O
wide	JJ	O
variety	NN	O
of	IN	O
useful	JJ	O
modified	VBN	O
oligonucleotides	NNS	O
may	MD	O
be	VB	O
produced	VBN	O
,	,	O
including	VBG	O
oligonucleotides	NNS	O
having	VBG	O
a	DT	O
peptide-nucleic	JJ	O
acid	NN	O
(	(	O
PNA	NNP	O
)	)	O
backbone	NN	O
(	(	O
Nielsen	NNP	B
et	RB	I
al.	RB	I
,	,	I
1991	CD	I
,	,	I
Science	NNP	I
254:1497	CD	I
)	)	O
or	CC	O
incorporating	VBG	O
2′-O-methyl	JJ	O
ribonucleotides	NNS	O
,	,	O
phosphorothioate	NN	O
nucleotides	NNS	O
,	,	O
methyl	NN	O
phosphonate	NN	O
nucleotides	NNS	O
,	,	O
phosphotriester	NN	O
nucleotides	NNS	O
,	,	O
phosphorothioate	NN	O
nucleotides	NNS	O
,	,	O
phosphoramidates	NNS	O
.	.	O
For	IN	O
example	NN	O
and	CC	O
not	RB	O
limitation	NN	O
,	,	O
the	DT	O
following	VBG	O
are	VBP	O
examples	NNS	O
of	IN	O
siRNA	NN	O
sequences	NNS	O
that	WDT	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
inhibit	VB	O
PLK2	NNP	O
.	.	O
“	JJ	O
Start	NNP	O
position	NN	O
”	NN	O
refers	NNS	O
to	TO	O
the	DT	O
sequence	NN	O
at	IN	O
accession	NN	O
number	NN	O
NM—006622	NNP	O
.	.	O
The	DT	O
siRNAs	NN	O
above	IN	O
were	VBD	O
designed	VBN	O
using	VBG	O
the	DT	O
siDESIGN®	NN	O
center	NN	O
at	IN	O
www	NN	O
followed	VBN	O
by	IN	O
dharmacon.com/DesignCenter/DesignCenterPage.aspx	NN	O
.	.	O
Each	DT	O
will	MD	O
be	VB	O
double	JJ	O
stranded	VBN	O
and	CC	O
have	VBP	O
a	DT	O
“	JJ	O
TT	NNP	O
”	NNP	O
overhang	NN	O
.	.	O
As	IN	O
additional	JJ	O
examples	NNS	O
,	,	O
siRNAs	NN	O
from	IN	O
the	DT	O
Ambion	NNP	O
Kinase	NNP	O
siRNA	VBD	O
Library	NNP	O
(	(	O
Ambion	NNP	O
,	,	O
Austin	NNP	O
,	,	O
Tex	NNP	O
.	.	O
)	)	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
inhibit	VB	O
PLK2	NNP	O
.	.	O
Exemplary	JJ	O
sequences	NNS	O
are	VBP	O
provided	VBN	O
below	IN	O
.	.	O
Each	DT	O
siRNA	NN	O
is	VBZ	O
double-stranded	JJ	O
with	IN	O
the	DT	O
final	JJ	O
TT	NNP	O
's	POS	O
(	(	O
present	JJ	O
on	IN	O
both	DT	O
strands	NNS	O
)	)	O
as	IN	O
overhangs	NNS	O
:	:	O
iii	NN	O
)	)	O
Antisense	NNP	O
Polynucleotides	NNP	O
Antisense	NNP	O
polynucleotides	NNS	O
can	MD	O
cause	VB	O
suppression	NN	O
by	IN	O
binding	VBG	O
to	TO	O
,	,	O
and	CC	O
interfering	VBG	O
with	IN	O
the	DT	O
translation	NN	O
of	IN	O
sense	NN	O
mRNA	NN	O
,	,	O
interfering	VBG	O
with	IN	O
transcription	NN	O
,	,	O
interfering	VBG	O
with	IN	O
processing	NN	O
or	CC	O
localization	NN	O
of	IN	O
RNA	NNP	O
precursors	NNS	O
,	,	O
repressing	VBG	O
transcription	NN	O
of	IN	O
mRNA	NN	O
or	CC	O
acting	VBG	O
through	IN	O
some	DT	O
other	JJ	O
mechanism	NN	O
(	(	O
see	VB	O
,	,	O
e.g.	VB	O
,	,	O
Sallenger	NNP	B
et	CC	I
al	NN	I
.	.	I
Nature	NN	I
418	CD	I
,	,	I
252	CD	I
(	(	I
2002	CD	I
)	)	I
.	.	O
The	DT	O
particular	JJ	O
mechanism	NN	O
by	IN	O
which	WDT	O
the	DT	O
antisense	NN	O
molecule	NN	O
reduces	NNS	O
expression	NN	O
is	VBZ	O
not	RB	O
critical	JJ	O
.	.	O
Typically	RB	O
antisense	JJ	O
polynucleotides	NNS	O
comprise	VBP	O
a	DT	O
single-stranded	JJ	O
antisense	NN	O
sequence	NN	O
of	IN	O
at	IN	O
least	JJS	O
7	CD	O
to	TO	O
10	CD	O
to	TO	O
typically	RB	O
20	CD	O
or	CC	O
more	JJR	O
nucleotides	NNS	O
that	IN	O
specifically	RB	O
hybridize	VB	O
to	TO	O
a	DT	O
sequence	NN	O
from	IN	O
mRNA	NN	O
of	IN	O
a	DT	O
kinase	JJ	O
gene	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Some	DT	O
antisense	NN	O
polynucleotides	NNS	O
are	VBP	O
from	IN	O
about	IN	O
10	CD	O
to	TO	O
about	IN	O
50	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
or	CC	O
from	IN	O
about	RB	O
14	CD	O
to	TO	O
about	IN	O
35	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
.	.	O
Some	DT	O
antisense	NN	O
polynucleotides	NNS	O
are	VBP	O
polynucleotides	NNS	O
of	IN	O
less	JJR	O
than	IN	O
about	RB	O
100	CD	O
nucleotides	NNS	O
or	CC	O
less	JJR	O
than	IN	O
about	RB	O
200	CD	O
nucleotides	NNS	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
the	DT	O
antisense	JJ	O
polynucleotide	NN	O
should	MD	O
be	VB	O
long	RB	O
enough	RB	O
to	TO	O
form	VB	O
a	DT	O
stable	JJ	O
duplex	NN	O
but	CC	O
short	JJ	O
enough	RB	O
,	,	O
depending	VBG	O
on	IN	O
the	DT	O
mode	NN	O
of	IN	O
delivery	NN	O
,	,	O
to	TO	O
administer	VB	O
in	IN	O
vivo	NN	O
,	,	O
if	IN	O
desired	VBN	O
.	.	O
The	DT	O
minimum	JJ	O
length	NN	O
of	IN	O
a	DT	O
polynucleotide	NN	O
required	VBN	O
for	IN	O
specific	JJ	O
hybridization	NN	O
to	TO	O
a	DT	O
target	NN	O
sequence	NN	O
depends	VBZ	O
on	IN	O
several	JJ	O
factors	NNS	O
,	,	O
such	JJ	O
as	IN	O
G/C	NNP	O
content	NN	O
,	,	O
positioning	NN	O
of	IN	O
mismatched	VBN	O
bases	NNS	O
(	(	O
if	IN	O
any	DT	O
)	)	O
,	,	O
degree	NN	O
of	IN	O
uniqueness	NN	O
of	IN	O
the	DT	O
sequence	NN	O
as	IN	O
compared	VBN	O
to	TO	O
the	DT	O
population	NN	O
of	IN	O
target	NN	O
polynucleotides	NNS	O
,	,	O
and	CC	O
chemical	JJ	O
nature	NN	O
of	IN	O
the	DT	O
polynucleotide	NN	O
(	(	O
e.g.	JJ	O
,	,	O
methylphosphonate	VB	O
backbone	NN	O
,	,	O
peptide	JJ	O
nucleic	JJ	O
acid	NN	O
,	,	O
phosphorothioate	NN	O
)	)	O
,	,	O
among	IN	O
other	JJ	O
factors	NNS	O
.	.	O
iv	NN	O
)	)	O
Ribozymes	NNPS	O
Ribozymes	NNPS	O
are	VBP	O
RNA	NNP	O
molecules	NNS	O
that	WDT	O
act	VBP	O
as	IN	O
enzymes	NNS	O
and	CC	O
can	MD	O
be	VB	O
engineered	VBN	O
to	TO	O
cleave	VB	O
other	JJ	O
RNA	NNP	O
molecules	NNS	O
at	IN	O
specific	JJ	O
sites	NNS	O
.	.	O
The	DT	O
ribozyme	NN	O
itself	PRP	O
is	VBZ	O
not	RB	O
consumed	VBN	O
in	IN	O
this	DT	O
process	NN	O
,	,	O
and	CC	O
can	MD	O
act	VB	O
catalytically	RB	O
to	TO	O
cleave	VB	O
multiple	JJ	O
copies	NNS	O
of	IN	O
mRNA	NN	O
target	NN	O
molecules	NNS	O
.	.	O
General	NNP	O
rules	NNS	O
for	IN	O
the	DT	O
design	NN	O
of	IN	O
ribozymes	NNS	O
that	WDT	O
cleave	VBP	O
target	NN	O
RNA	NNP	O
in	IN	O
trans	NNS	O
are	VBP	O
described	VBN	O
in	IN	O
Haseloff	NNP	B
&	CC	I
Gerlach	NNP	I
,	,	I
(	(	I
1988	CD	I
)	)	I
Nature	NN	I
334:585-591	JJ	I
and	CC	O
Hollenbeck	NNP	B
,	,	I
(	(	I
1987	CD	I
)	)	I
Nature	NN	I
328:596-603	JJ	I
and	CC	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,496,698	CD	O
.	.	O
Ribozymes	NNP	O
typically	RB	O
include	VBP	O
two	CD	O
flanking	JJ	O
segments	NNS	O
that	WDT	O
show	VBP	O
complementarity	NN	O
to	TO	O
and	CC	O
bind	VB	O
to	TO	O
two	CD	O
sites	NNS	O
on	IN	O
a	DT	O
transcript	NN	O
(	(	O
target	VB	O
subsites	NNS	O
)	)	O
of	IN	O
a	DT	O
gene	NN	O
encoding	VBG	O
a	DT	O
kinase	NN	O
of	IN	O
the	DT	O
invention	NN	O
and	CC	O
a	DT	O
catalytic	JJ	O
region	NN	O
between	IN	O
the	DT	O
flanking	NN	O
segments	NNS	O
.	.	O
The	DT	O
flanking	NN	O
segments	NNS	O
are	VBP	O
typically	RB	O
5-9	JJ	O
nucleotides	NNS	O
long	JJ	O
and	CC	O
optimally	RB	O
6	CD	O
to	TO	O
8	CD	O
nucleotides	NNS	O
long	RB	O
.	.	O
The	DT	O
catalytic	JJ	O
region	NN	O
of	IN	O
the	DT	O
ribozyme	NN	O
is	VBZ	O
generally	RB	O
about	RB	O
22	CD	O
nucleotides	NNS	O
in	IN	O
length	NN	O
.	.	O
The	DT	O
mRNA	NN	O
target	NN	O
contains	VBZ	O
a	DT	O
consensus	NN	O
cleavage	NN	O
site	NN	O
between	IN	O
the	DT	O
target	NN	O
subsites	VBZ	O
having	VBG	O
the	DT	O
general	JJ	O
formula	NN	O
NUN	NNP	O
,	,	O
and	CC	O
preferably	RB	O
GUC	NNP	O
.	.	O
(	(	O
Kashani-Sabet	NNP	B
and	CC	I
Scanlon	NNP	I
,	,	I
(	(	I
1995	CD	I
)	)	I
Cancer	NNP	I
Gene	NNP	I
Therapy	NNP	I
2:213-223	CD	I
;	:	O
Perriman	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
(	(	I
1992	CD	I
)	)	I
Gene	NNP	I
(	(	I
Amst	NNP	I
.	.	I
)	)	I
113:157-163	JJ	I
;	:	O
Ruffner	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
(	(	I
1990	CD	I
)	)	I
Biochemistry	FW	I
29	CD	I
:	:	I
10695-10702	JJ	I
)	)	O
;	:	O
Birikh	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
(	(	I
1997	CD	I
)	)	I
Eur	NNP	I
.	.	I
J.	NNP	I
Biochem	NNP	I
.	.	I
245:1-16	JJ	I
;	:	O
Perrealt	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
(	(	I
1991	CD	I
)	)	I
Biochemistry	NNP	I
30:4020-4025	JJ	I
)	)	O
.	.	O
The	DT	O
specificity	NN	O
of	IN	O
a	DT	O
ribozyme	NN	O
can	MD	O
be	VB	O
controlled	VBN	O
by	IN	O
selection	NN	O
of	IN	O
the	DT	O
target	NN	O
subsites	NNS	O
and	CC	O
thus	RB	O
the	DT	O
flanking	JJ	O
segments	NNS	O
of	IN	O
the	DT	O
ribozyme	NN	O
that	WDT	O
are	VBP	O
complementary	JJ	O
to	TO	O
such	JJ	O
subsites	NNS	O
.	.	O
Ribozymes	NNS	O
can	MD	O
be	VB	O
delivered	VBN	O
either	CC	O
as	IN	O
RNA	NNP	O
molecules	NNS	O
or	CC	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
DNA	NNP	O
encoding	VBG	O
the	DT	O
ribozyme	NN	O
as	IN	O
a	DT	O
component	NN	O
of	IN	O
a	DT	O
replicable	JJ	O
vector	NN	O
or	CC	O
in	IN	O
nonreplicable	JJ	O
form	NN	O
as	IN	O
described	VBN	O
below	IN	O
.	.	O
Expression	NN	O
of	IN	O
a	DT	O
target	NN	O
kinase	NN	O
gene	NN	O
can	MD	O
also	RB	O
be	VB	O
reduced	VBN	O
by	IN	O
delivering	VBG	O
nucleic	JJ	O
acids	NNS	O
having	VBG	O
sequences	NNS	O
complementary	JJ	O
to	TO	O
the	DT	O
regulatory	JJ	O
region	NN	O
of	IN	O
the	DT	O
target	NN	O
gene	NN	O
(	(	O
i.e.	FW	O
,	,	O
the	DT	O
target	NN	O
gene	NN	O
promoter	NN	O
and/or	IN	O
enhancers	NNS	O
)	)	O
to	TO	O
form	VB	O
triple	JJ	O
helical	JJ	O
structures	NNS	O
which	WDT	O
prevent	VBP	O
transcription	NN	O
of	IN	O
the	DT	O
target	NN	O
gene	NN	O
in	IN	O
target	NN	O
cells	NNS	O
in	IN	O
the	DT	O
body	NN	O
.	.	O
See	NNP	O
generally	RB	O
,	,	O
Helene	NNP	B
,	,	I
(	(	I
1991	CD	I
)	)	I
,	,	I
Anticancer	NNP	I
Drug	NNP	I
Des.	NNP	I
,	,	I
6	CD	I
(	(	I
6	CD	I
)	)	I
:569-584	NN	I
;	:	O
Helene	NNP	B
,	,	I
et	FW	I
al.	NN	I
,	,	I
(	(	I
1992	CD	I
)	)	I
,	,	I
Ann	NNP	I
.	.	I
N.Y.	NNP	I
Acad	NNP	I
.	.	I
Sci.	NNP	I
,	,	I
60:27-36	JJ	I
;	:	O
and	CC	O
Maher	NNP	B
,	,	I
(	(	I
1992	CD	I
)	)	I
,	,	I
Bioassays	VBZ	I
14	CD	I
(	(	I
12	CD	I
)	)	I
:807-815.	JJ	I
v	NN	O
)	)	O
Administration	NN	O
of	IN	O
siRNA	NN	O
and	CC	O
Other	JJ	O
Inhibitory	NNP	O
Nucleic	NNP	O
Acids	NNP	O
The	DT	O
brain	NN	O
is	VBZ	O
the	DT	O
therapeutic	JJ	O
target	NN	O
of	IN	O
kinase	JJ	O
inhibitors	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Therapeutic	JJ	O
polynucleotides	NNS	O
such	JJ	O
as	IN	O
siRNAs	NN	O
,	,	O
ribozymes	NNS	O
and	CC	O
antisense	JJ	O
polynucleotides	NNS	O
can	MD	O
be	VB	O
administered	VBN	O
in	IN	O
a	DT	O
number	NN	O
of	IN	O
ways	NNS	O
.	.	O
Methods	NNS	O
of	IN	O
introduction	NN	O
include	VBP	O
but	CC	O
are	VBP	O
not	RB	O
limited	VBN	O
to	TO	O
intradermal	VB	O
,	,	O
intramuscular	JJ	O
,	,	O
intraperitoneal	JJ	O
,	,	O
intravenous	JJ	O
,	,	O
subcutaneous	JJ	O
,	,	O
intranasal	JJ	O
,	,	O
epidural	JJ	O
,	,	O
and	CC	O
oral	JJ	O
routes	NNS	O
.	.	O
The	DT	O
compounds	NNS	O
may	MD	O
be	VB	O
administered	VBN	O
by	IN	O
any	DT	O
convenient	JJ	O
route	NN	O
,	,	O
for	IN	O
example	NN	O
by	IN	O
infusion	NN	O
,	,	O
by	IN	O
bolus	JJ	O
injection	NN	O
,	,	O
by	IN	O
absorption	NN	O
through	IN	O
epithelial	JJ	O
or	CC	O
mucocutaneous	JJ	O
linings	NNS	O
(	(	O
e.g.	NN	O
,	,	O
oral	JJ	O
,	,	O
rectal	JJ	O
and	CC	O
intestinal	JJ	O
mucosa	NN	O
,	,	O
etc	FW	O
.	.	O
)	)	O
,	,	O
and	CC	O
may	MD	O
be	VB	O
administered	VBN	O
together	RB	O
with	IN	O
other	JJ	O
biologically	RB	O
active	JJ	O
agents	NNS	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
therapeutic	JJ	O
polynucleotides	NNS	O
can	MD	O
be	VB	O
administered	VBN	O
remotely	RB	O
(	(	O
e.g.	UH	O
,	,	O
by	IN	O
i.v	NN	O
.	.	O
injection	NN	O
)	)	O
with	IN	O
a	DT	O
carrier	NN	O
that	WDT	O
facilitates	VBZ	O
transfer	NN	O
to	TO	O
the	DT	O
brain	NN	O
or	CC	O
they	PRP	O
can	MD	O
be	VB	O
delivered	VBN	O
directly	RB	O
to	TO	O
the	DT	O
brain	NN	O
.	.	O
For	IN	O
direct	JJ	O
administration	NN	O
to	TO	O
the	DT	O
brain	NN	O
,	,	O
siRNAs	NN	O
(	(	O
i.e.	FW	O
,	,	O
pharmaceutical	JJ	O
compositions	NNS	O
containing	VBG	O
siRNAs	NN	O
)	)	O
can	MD	O
be	VB	O
administered	VBN	O
by	IN	O
any	DT	O
suitable	JJ	O
route	NN	O
,	,	O
including	VBG	O
intraventricular	JJ	O
and	CC	O
intrathecal	JJ	O
injection	NN	O
;	:	O
intraventricular	JJ	O
injection	NN	O
may	MD	O
be	VB	O
facilitated	VBN	O
by	IN	O
an	DT	O
intraventricular	JJ	O
catheter	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
attached	VBN	O
to	TO	O
a	DT	O
reservoir	NN	O
,	,	O
such	JJ	O
as	IN	O
an	DT	O
Ommaya	NNP	O
reservoir	NN	O
,	,	O
direct	JJ	O
injection	NN	O
or	CC	O
perfusion	NN	O
at	IN	O
the	DT	O
lesion	NN	O
site	NN	O
,	,	O
injection	NN	O
into	IN	O
the	DT	O
brain	NN	O
arterial	JJ	O
system	NN	O
,	,	O
or	CC	O
by	IN	O
chemical	NN	O
or	CC	O
osmotic	JJ	O
opening	NN	O
of	IN	O
the	DT	O
blood-brain	JJ	O
barrier	NN	O
.	.	O
In	IN	O
one	CD	O
approach	NN	O
the	DT	O
therapeutic	JJ	O
polynucleotide	NN	O
(	(	O
e.g.	JJ	O
,	,	O
siRNA	NN	O
)	)	O
is	VBZ	O
delivered	VBN	O
as	IN	O
a	DT	O
peptide	NN	O
conjugate	NN	O
.	.	O
Kumar	NNP	O
et	CC	O
al	NN	O
.	.	O
exploited	VBN	O
the	DT	O
fact	NN	O
that	IN	O
neurotropic	NN	O
viruses	NNS	O
,	,	O
such	JJ	O
as	IN	O
rabies	NNS	O
viruses	NNS	O
,	,	O
that	IN	O
preferentially	RB	O
infect	VBP	O
the	DT	O
nervous	JJ	O
system	NN	O
can	MD	O
penetrate	VB	O
the	DT	O
brain	NN	O
.	.	O
The	DT	O
rabies	NNS	O
virus	VBP	O
achieves	VBZ	O
this	DT	O
through	IN	O
glycoprotein	NN	O
on	IN	O
its	PRP$	O
lipid	JJ	O
envelope	NN	O
.	.	O
To	TO	O
transfer	VB	O
siRNA	NN	O
to	TO	O
the	DT	O
neural	JJ	O
cells	NNS	O
in	IN	O
the	DT	O
brain	NN	O
,	,	O
Kumar	NNP	O
et	CC	O
al	NN	O
.	.	O
identified	VBN	O
a	DT	O
29-residue	JJ	O
peptide	NN	O
from	IN	O
the	DT	O
rabies	NNS	O
virus	VBP	O
glycoprotein	NN	O
(	(	O
RVG	NNP	O
)	)	O
envelope	VBP	O
that	IN	O
selectively	RB	O
binds	VBZ	O
to	TO	O
the	DT	O
acetylcholine	NN	O
receptor	NN	O
expressed	VBN	O
by	IN	O
neurons	NNS	O
.	.	O
They	PRP	O
fused	VBD	O
this	DT	O
peptide	NN	O
with	IN	O
a	DT	O
sequence	NN	O
of	IN	O
9	CD	O
arginine	NN	O
residues	NNS	O
that	WDT	O
binds	VBZ	O
to	TO	O
siRNAs	VB	O
.	.	O
After	IN	O
intravenous	JJ	O
injection	NN	O
into	IN	O
mice	NN	O
with	IN	O
this	DT	O
peptide-conjugated	JJ	O
siRNA	NN	O
,	,	O
they	PRP	O
found	VBD	O
that	IN	O
the	DT	O
peptide	NN	O
not	RB	O
only	RB	O
enabled	VBD	O
the	DT	O
transvascular	JJ	O
delivery	NN	O
of	IN	O
siRNA	NN	O
to	TO	O
the	DT	O
brain	NN	O
but	CC	O
also	RB	O
resulted	VBD	O
in	IN	O
efficient	JJ	O
gene	NN	O
silencing	NN	O
(	(	O
Kumar	NNP	B
et	RB	I
al.	RB	I
,	,	I
(	(	I
2007	CD	I
)	)	I
Nature	NNP	I
448:39-43	JJ	I
)	)	O
.	.	O
The	DT	O
therapeutic	JJ	O
polynucleotide	NN	O
(	(	O
e.g.	JJ	O
,	,	O
siRNA	NN	O
)	)	O
can	MD	O
be	VB	O
delivered	VBN	O
using	VBG	O
a	DT	O
liposome	NN	O
and	CC	O
targeted	VBD	O
monoclonal	JJ	O
antibody	NN	O
system	NN	O
.	.	O
Pardridge	NNP	O
reported	VBD	O
that	IN	O
chemically	RB	O
modified	VBN	O
liposomes	RB	O
conjugated	VBN	O
to	TO	O
monoclonal	JJ	O
antibodies	NNS	O
raised	VBN	O
against	IN	O
epidermal	JJ	O
growth	NN	O
factor	NN	O
can	MD	O
penetrate	VB	O
mouse	NN	O
brain	NN	O
.	.	O
Plasmid	NNP	O
DNA	NNP	O
encoding	VBG	O
for	IN	O
short	JJ	O
hairpin	NN	O
RNA	NNP	O
(	(	O
shRNA	NN	O
)	)	O
was	VBD	O
delivered	VBN	O
to	TO	O
the	DT	O
brain	NN	O
following	VBG	O
intravenous	JJ	O
administration	NN	O
with	IN	O
pegylated	JJ	O
immunoliposomes	NNS	O
(	(	O
PILs	NNP	O
)	)	O
.	.	O
The	DT	O
plasmid	NN	O
DNA	NNP	O
is	VBZ	O
encapsulated	VBN	O
in	IN	O
liposome	NN	O
,	,	O
which	WDT	O
is	VBZ	O
pegylated	VBN	O
,	,	O
and	CC	O
conjugated	VBD	O
with	IN	O
receptor	NN	O
specific	JJ	O
targeting	VBG	O
monoclonal	JJ	O
antibodies	NNS	O
.	.	O
Intravenous	JJ	O
RNAi	NNP	O
with	IN	O
PILs	NNP	O
enables	VBZ	O
a	DT	O
90	CD	O
%	NN	O
knockdown	NN	O
of	IN	O
the	DT	O
human	JJ	O
epidermal	JJ	O
growth	NN	O
factor	NN	O
receptor	NN	O
,	,	O
which	WDT	O
results	NNS	O
in	IN	O
a	DT	O
90	CD	O
%	NN	O
increase	NN	O
in	IN	O
survival	JJ	O
time	NN	O
in	IN	O
mice	NN	O
with	IN	O
intra-cranial	JJ	O
brain	NN	O
cancer	NN	O
(	(	O
Pardridge	NNP	B
,	,	I
(	(	I
2007	CD	I
)	)	I
Adv	NNP	I
.	.	I
Drug	NN	I
Deliv	NNP	I
.	.	I
Rev	NNP	I
.	.	I
59:141-152	JJ	I
)	)	O
.	.	O
Similarly	RB	O
,	,	O
Boado	NNP	O
disclosed	VBD	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
“	NNP	O
Trojan	NNP	O
Horse	NNP	O
Liposome	NNP	O
”	NNP	O
(	(	O
THL	NNP	O
)	)	O
technology	NN	O
as	IN	O
an	DT	O
effective	JJ	O
delivery	NN	O
system	NN	O
to	TO	O
deliver	VB	O
shRNA	NN	O
to	TO	O
the	DT	O
brain	NN	O
.	.	O
The	DT	O
tissue	NN	O
target	NN	O
specificity	NN	O
of	IN	O
THL	NNP	O
is	VBZ	O
given	VBN	O
by	IN	O
conjugation	NN	O
of	IN	O
approximately	RB	O
1	CD	O
%	NN	O
of	IN	O
the	DT	O
PEG	NNP	O
residues	NNS	O
in	IN	O
the	DT	O
liposome	NN	O
to	TO	O
peptidomimetic	JJ	O
monoclonal	JJ	O
antibodies	NNS	O
that	WDT	O
bind	VBP	O
to	TO	O
specific	JJ	O
endogenous	JJ	O
receptors	NNS	O
(	(	O
i.e	NN	O
.	.	O
insulin	NN	O
and	CC	O
transferrin	JJ	O
receptors	NNS	O
)	)	O
located	VBN	O
on	IN	O
both	DT	O
the	DT	O
BBB	NNP	O
and	CC	O
the	DT	O
brain	NN	O
cellular	JJ	O
membranes	NNS	O
,	,	O
respectively	RB	O
.	.	O
(	(	O
Boado	NNP	B
(	(	I
2007	CD	I
)	)	I
Pharm	NN	I
.	.	I
Res	NNP	I
.	.	I
24:1772-1787	JJ	I
)	)	O
.	.	O
The	DT	O
therapeutic	JJ	O
polynucleotide	NN	O
(	(	O
e.g.	JJ	O
,	,	O
siRNA	NN	O
)	)	O
can	MD	O
be	VB	O
delivered	VBN	O
by	IN	O
the	DT	O
combined	VBN	O
use	NN	O
of	IN	O
receptor	NN	O
specific	JJ	O
antibody	NN	O
delivery	NN	O
systems	NNS	O
and	CC	O
avidin-biotin	JJ	O
technology	NN	O
.	.	O
The	DT	O
siRNA	NN	O
was	VBD	O
mono-biotinylated	VBN	O
on	IN	O
either	DT	O
terminus	NN	O
of	IN	O
the	DT	O
sense	NN	O
strand	NN	O
,	,	O
in	IN	O
parallel	NN	O
with	IN	O
the	DT	O
production	NN	O
of	IN	O
a	DT	O
conjugate	NN	O
of	IN	O
the	DT	O
targeting	VBG	O
monoclonal	JJ	O
antibody	NN	O
and	CC	O
streptavidin	NN	O
.	.	O
Rat	NNP	O
glial	JJ	O
cells	NNS	O
permanently	RB	O
transfected	VBN	O
with	IN	O
the	DT	O
luciferase	NN	O
gene	NN	O
were	VBD	O
implanted	VBN	O
in	IN	O
the	DT	O
brain	NN	O
of	IN	O
adult	NN	O
rats	NNS	O
.	.	O
Following	VBG	O
the	DT	O
formation	NN	O
of	IN	O
intra-cranial	JJ	O
tumors	NNS	O
,	,	O
the	DT	O
rats	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
a	DT	O
single	JJ	O
intravenous	JJ	O
injection	NN	O
of	IN	O
biotinylated	VBN	O
siRNA	NN	O
attached	VBN	O
to	TO	O
a	DT	O
transferrin	NN	O
receptor	NN	O
antibody	NN	O
via	IN	O
a	DT	O
biotin-streptavidin	JJ	O
linker	NN	O
.	.	O
The	DT	O
intravenous	JJ	O
administration	NN	O
of	IN	O
the	DT	O
siRNA	NN	O
caused	VBD	O
a	DT	O
69-81	JJ	O
%	NN	O
decrease	NN	O
in	IN	O
luciferase	JJ	O
gene	NN	O
expression	NN	O
in	IN	O
the	DT	O
intracranial	JJ	O
brain	NN	O
cancer	NN	O
in	IN	O
vivo	NN	O
(	(	O
Xia	NNP	B
et	RB	I
al.	RB	I
,	,	I
(	(	I
2007	CD	I
)	)	I
Pharm	NN	I
.	.	I
Res	NNP	I
.	.	I
24:2309-2316	JJ	I
)	)	O
.	.	O
The	DT	O
therapeutic	JJ	O
polynucleotide	NN	O
(	(	O
e.g.	JJ	O
,	,	O
siRNA	NN	O
)	)	O
can	MD	O
be	VB	O
delivered	VBN	O
by	IN	O
stereotactic	JJ	O
surgery	NN	O
or	CC	O
injection	NN	O
.	.	O
Davidson	NNP	O
and	CC	O
Boudreau	NNP	O
reviewed	VBD	O
in	IN	O
their	PRP$	O
article	NN	O
that	IN	O
siRNA	NN	O
can	MD	O
be	VB	O
delivered	VBN	O
into	IN	O
the	DT	O
brain	NN	O
using	VBG	O
neurosurgical	JJ	O
method	NN	O
of	IN	O
stereotaxis	NN	O
and	CC	O
showed	VBD	O
that	IN	O
a	DT	O
decrease	NN	O
in	IN	O
the	DT	O
transcription	NN	O
of	IN	O
certain	JJ	O
genes	NNS	O
alleviated	VBD	O
symptoms	NNS	O
of	IN	O
neuronal	JJ	O
diseases	NNS	O
(	(	O
Davidson	NNP	B
and	CC	I
Boudreau	NNP	I
,	,	I
(	(	I
2007	CD	I
)	)	I
Neuron	NNP	I
53:781-788	JJ	I
)	)	O
.	.	O
Xia	NN	O
et	CC	O
al	NN	O
.	.	O
reported	VBD	O
that	DT	O
upon	IN	O
intracerebellar	JJ	O
injection	NN	O
,	,	O
recombinant	JJ	O
adeno-associated	JJ	O
virus	NN	O
vectors	NNS	O
expressing	VBG	O
short	JJ	O
hairpin	NN	O
RNAs	NNP	O
,	,	O
which	WDT	O
once	RB	O
expressed	VBN	O
are	VBP	O
processed	VBN	O
into	IN	O
siRNAs	NN	O
,	,	O
improved	VBN	O
motor	NN	O
coordination	NN	O
,	,	O
restored	VBD	O
cerebellar	JJ	O
morphology	NN	O
and	CC	O
resolved	VBD	O
characteristic	JJ	O
ataxin-1	JJ	O
inclusions	NNS	O
in	IN	O
Purkinje	NNP	O
cells	NNS	O
of	IN	O
spinocerebellar	JJ	O
ataxia	NN	O
type	NN	O
1	CD	O
mice	NN	O
(	(	O
Xia	NNP	B
et	RB	I
al.	RB	I
,	,	I
(	(	I
2004	CD	I
)	)	I
Nature	NN	I
Med	NNP	I
.	.	I
10:816-820	JJ	I
)	)	O
.	.	O
Further	RB	O
,	,	O
DiFiglia	NNP	O
et	CC	O
al	NN	O
.	.	O
reported	VBN	O
injecting	VBG	O
intrastriatally	RB	O
cholesterol-conjugated	JJ	O
siRNA	NN	O
that	WDT	O
targets	VBZ	O
human	JJ	O
huntingtin	NN	O
mRNA	NN	O
.	.	O
The	DT	O
authors	NNS	O
found	VBD	O
that	IN	O
a	DT	O
single	JJ	O
administration	NN	O
into	IN	O
the	DT	O
adult	NN	O
mouse	NN	O
striatum	NN	O
of	IN	O
the	DT	O
siRNA	NN	O
effected	VBD	O
silencing	NN	O
of	IN	O
the	DT	O
gene	NN	O
,	,	O
attenuated	VBD	O
neuronal	JJ	O
pathology	NN	O
,	,	O
and	CC	O
delayed	VBD	O
the	DT	O
abnormal	JJ	O
behavioral	JJ	O
phenotype	NN	O
observed	VBN	O
in	IN	O
a	DT	O
rapid-onset	NN	O
,	,	O
viral	JJ	O
transgenic	NN	O
mouse	NN	O
model	NN	O
of	IN	O
Huntington	NNP	O
's	POS	O
disease	NN	O
(	(	O
DiFiglia	NNP	B
et	RB	I
al	RB	I
.	.	I
(	(	I
2007	CD	I
)	)	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
104:17204-17209	CD	I
)	)	O
.	.	O
It	PRP	O
is	VBZ	O
noted	VBN	O
that	IN	O
such	JJ	O
method	NN	O
results	NNS	O
only	RB	O
in	IN	O
localized	JJ	O
delivery	NN	O
around	IN	O
the	DT	O
injection	NN	O
site	NN	O
,	,	O
with	IN	O
no	DT	O
widespread	JJ	O
effect	NN	O
within	IN	O
the	DT	O
brain	NN	O
.	.	O
Singer	NNP	O
et	CC	O
al	NN	O
.	.	O
disclosed	VBN	O
using	VBG	O
modified	JJ	O
lentiviral	JJ	O
vectors	NNS	O
to	TO	O
deliver	VB	O
siRNAs	NN	O
into	IN	O
the	DT	O
brain	NN	O
cells	NNS	O
of	IN	O
the	DT	O
transgenic	JJ	O
mice	NN	O
that	WDT	O
were	VBD	O
producing	VBG	O
vast	JJ	O
amounts	NNS	O
of	IN	O
human	JJ	O
beta-amyloid	JJ	O
and	CC	O
whose	WP$	O
brains	NNS	O
where	WRB	O
littered	VBN	O
with	IN	O
plaques	NNS	O
.	.	O
They	PRP	O
found	VBD	O
that	IN	O
lentiviral	JJ	O
vector	NN	O
delivery	NN	O
of	IN	O
beta-secretase	NN	O
siRNA	NN	O
specifically	RB	O
reduced	VBD	O
the	DT	O
cleavage	NN	O
of	IN	O
amyloid	NN	O
precursor	NN	O
protein	NN	O
and	CC	O
neurodegeneration	NN	O
in	IN	O
vivo	NN	O
and	CC	O
indicated	VBD	O
that	IN	O
this	DT	O
approach	NN	O
could	MD	O
have	VB	O
potential	JJ	O
therapeutic	JJ	O
value	NN	O
for	IN	O
treatment	NN	O
of	IN	O
Alzheimer	NNP	O
disease	NN	O
(	(	O
Singer	NNP	B
et	VBZ	I
al	NN	I
.	.	I
(	(	I
2005	CD	I
)	)	I
Nature	NN	I
Neurosci	NNP	I
.	.	I
8:1343-1349	JJ	I
;	:	O
reviewed	VBN	O
in	IN	O
Orlacchio	NNP	B
et	CC	I
al	NN	I
.	.	I
(	(	I
2007	CD	I
)	)	I
Mini	NNP	I
.	.	I
Rev	NNP	I
.	.	I
Med	NNP	I
.	.	I
Chem	NNP	I
.	.	I
7:1166-1176	JJ	I
)	)	O
.	.	O
Koutsilieri	NNP	O
et	CC	O
al	NN	O
.	.	O
reviewed	VBN	O
the	DT	O
literature	NN	O
in	IN	O
the	DT	O
field	NN	O
of	IN	O
siRNA	NN	O
,	,	O
disclosed	VBD	O
different	JJ	O
siRNA	JJ	O
target	NN	O
strategies	NNS	O
aiming	VBG	O
for	IN	O
an	DT	O
allele-specific	JJ	O
degradation	NN	O
of	IN	O
disease-inducing	JJ	O
mRNA	NN	O
and	CC	O
its	PRP$	O
application	NN	O
in	IN	O
animal	JJ	O
models	NNS	O
of	IN	O
neurodegenerative	JJ	O
diseases	NNS	O
,	,	O
including	VBG	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
(	(	O
AD	NNP	O
)	)	O
,	,	O
amyotrophic	JJ	O
lateral	JJ	O
sclerosis	NN	O
(	(	O
ALS	NNP	O
)	)	O
,	,	O
Huntington	NNP	O
's	POS	O
disease	NN	O
(	(	O
HD	NNP	O
)	)	O
and	CC	O
spinocerebellar	JJ	O
ataxia	NN	O
(	(	O
SCA1	NNP	O
)	)	O
(	(	O
Koutsilieri	NNP	B
et	RB	I
al	RB	I
.	.	I
(	(	I
2007	CD	I
)	)	I
J.	NNP	I
Neural	NNP	I
Transm	NNP	I
Suppl	NNP	I
.	.	I
(	(	I
72	CD	I
)	)	I
:43-49	NN	I
)	)	O
.	.	O
Hassani	NNP	O
et	CC	O
al	NN	O
.	.	O
demonstrated	VBN	O
that	IN	O
cationic	JJ	O
lipids	NNS	O
and	CC	O
polyethylenimine	NN	O
(	(	O
PEI	NNP	O
)	)	O
based	VBN	O
polyplexes	NNS	O
provided	VBD	O
efficient	JJ	O
delivery	NN	O
of	IN	O
siRNAs	NN	O
into	IN	O
the	DT	O
brains	NNS	O
of	IN	O
new	JJ	O
born	JJ	O
mice	NN	O
,	,	O
producing	VBG	O
>	JJ	O
80	CD	O
%	NN	O
inhibition	NN	O
of	IN	O
an	DT	O
exogenous	JJ	O
gene	NN	O
with	IN	O
only	JJ	O
picomolar	JJ	O
levels	NNS	O
of	IN	O
siRNA	NN	O
(	(	O
Hassani	NNP	B
et	RB	I
al	RB	I
.	.	I
(	(	I
2005	CD	I
)	)	I
J.	NNP	I
Gene	NNP	I
Med	NNP	I
.	.	I
7:198-207	JJ	I
)	)	O
.	.	O
Kateb	NNP	O
et	CC	O
al	NN	O
.	.	O
employed	JJ	O
nanotechnology	NN	O
as	IN	O
a	DT	O
method	NN	O
for	IN	O
delivering	VBG	O
drugs	NNS	O
to	TO	O
the	DT	O
brain	NN	O
for	IN	O
treatment	NN	O
of	IN	O
brain	NN	O
cancers	NNS	O
.	.	O
Specifically	RB	O
,	,	O
the	DT	O
authors	NNS	O
disclosed	VBD	O
the	DT	O
use	NN	O
Multi-Walled	JJ	O
Carbon	NNP	O
Nanotubes	NNP	O
(	(	O
MWCNTs	NNP	O
)	)	O
as	IN	O
nanovectors	NNS	O
for	IN	O
transporting	VBG	O
siRNA	NN	O
(	(	O
Kateb	NNP	B
et	RB	I
al	RB	I
.	.	I
(	(	I
2007	CD	I
)	)	I
Neuroimage	NN	I
37	CD	I
Suppl	NNP	I
1	CD	I
:	:	I
S9-17	NN	I
)	)	O
.	.	O
The	DT	O
therapeutic	JJ	O
polynucleotide	NN	O
(	(	O
e.g.	JJ	O
,	,	O
siRNA	NN	O
)	)	O
can	MD	O
be	VB	O
used	VBN	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
agents	NNS	O
to	TO	O
improve	VB	O
or	CC	O
enhance	VB	O
the	DT	O
therapeutic	JJ	O
effect	NN	O
of	IN	O
either	DT	O
.	.	O
This	DT	O
process	NN	O
can	MD	O
involve	VB	O
administering	VBG	O
both	DT	O
agents	NNS	O
to	TO	O
the	DT	O
patient	NN	O
at	IN	O
the	DT	O
same	JJ	O
time	NN	O
,	,	O
either	RB	O
as	IN	O
a	DT	O
single	JJ	O
composition	NN	O
or	CC	O
pharmacological	JJ	O
formulation	NN	O
that	WDT	O
includes	VBZ	O
both	DT	O
agents	NNS	O
,	,	O
or	CC	O
by	IN	O
administering	VBG	O
two	CD	O
distinct	JJ	O
compositions	NNS	O
or	CC	O
formulations	NNS	O
,	,	O
wherein	VBP	O
one	CD	O
composition	NN	O
includes	VBZ	O
the	DT	O
siRNA	NN	O
of	IN	O
the	DT	O
invention	NN	O
and	CC	O
the	DT	O
other	JJ	O
includes	VBZ	O
the	DT	O
second	JJ	O
agent	NN	O
(	(	O
s	NN	O
)	)	O
.	.	O
The	DT	O
siRNA	NN	O
therapy	NN	O
also	RB	O
can	MD	O
precede	VB	O
or	CC	O
follow	VB	O
the	DT	O
other	JJ	O
agent	NN	O
treatment	NN	O
by	IN	O
intervals	NNS	O
ranging	VBG	O
from	IN	O
minutes	NNS	O
to	TO	O
weeks	NNS	O
.	.	O
Polynucleotides	NNS	O
can	MD	O
be	VB	O
delivered	VBN	O
via	IN	O
a	DT	O
controlled	VBN	O
release	NN	O
system	NN	O
.	.	O
As	IN	O
an	DT	O
example	NN	O
,	,	O
a	DT	O
pump	NN	O
may	MD	O
be	VB	O
used	VBN	O
(	(	O
Langer	NNP	B
,	,	I
supra	NN	I
;	:	O
Sefton	NNP	B
,	,	I
1987	CD	I
,	,	I
CRC	NNP	I
Crit	NNP	I
.	.	I
Ref	NNP	I
.	.	I
Biomed	NNP	I
.	.	I
Eng	NNP	I
.	.	I
14:201-240	JJ	I
;	:	O
Buchwald	NNP	B
et	FW	I
al.	NN	I
,	,	I
1980	CD	I
,	,	I
Surgery	NNP	I
88:507-516	CD	I
;	:	O
Saudek	NNP	B
et	FW	I
al.	NN	I
,	,	I
1989	CD	I
,	,	I
N.	NNP	I
Engl	NNP	I
.	.	I
J.	NNP	I
Med	NNP	I
.	.	I
321:574-579	JJ	I
)	)	O
.	.	O
Alternatively	RB	O
,	,	O
polymeric	JJ	O
materials	NNS	O
can	MD	O
be	VB	O
used	VBN	O
(	(	O
Medical	JJ	B
Applications	NNS	I
of	IN	I
Controlled	NNP	I
Release	NNP	I
,	,	I
Langer	NNP	I
and	CC	I
Wise	NNP	I
,	,	I
eds.	NN	I
,	,	I
CRC	NNP	I
Press	NNP	I
,	,	I
Boca	NNP	I
Raton	NNP	I
,	,	I
Fla.	NNP	I
,	,	I
1974	CD	I
;	:	O
Controlled	VBN	B
Drug	NNP	I
Bioavailability	NNP	I
,	,	I
Drug	NNP	I
Product	NNP	I
Design	NNP	I
and	CC	I
Performance	NNP	I
,	,	I
Smolen	NNP	I
and	CC	I
Ball	NNP	I
,	,	I
eds.	NN	I
,	,	I
Wiley	NNP	I
,	,	I
N.Y.	NNP	I
,	,	I
1984	CD	I
;	:	O
Ranger	NNP	B
and	CC	I
Peppas	NNP	I
,	,	I
1983	CD	I
,	,	I
Macromol	NNP	I
.	.	I
Sci	NNP	I
.	.	I
Rev	NNP	I
.	.	I
Macromol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
23:61	CD	I
;	:	O
Levy	NNP	B
et	FW	I
al.	NN	I
,	,	I
1985	CD	I
,	,	I
Science	NNP	I
228:190-192	CD	I
;	:	O
During	IN	B
et	FW	I
al.	NN	I
,	,	I
1989	CD	I
,	,	I
Ann	NNP	I
.	.	I
Neurol	NNP	I
.	.	I
25:351-356	JJ	I
;	:	O
Howard	NNP	B
et	FW	I
al.	NN	I
,	,	I
1989	CD	I
,	,	I
J.	NNP	I
Neurosurg	NNP	I
.	.	I
71:858-863	JJ	I
)	)	O
.	.	O
In	IN	O
yet	RB	O
another	DT	O
alternative	NN	O
,	,	O
a	DT	O
controlled	VBN	O
release	NN	O
system	NN	O
can	MD	O
be	VB	O
placed	VBN	O
in	IN	O
proximity	NN	O
of	IN	O
the	DT	O
therapeutic	JJ	O
target	NN	O
,	,	O
i.e.	NN	O
,	,	O
the	DT	O
brain	NN	O
,	,	O
thus	RB	O
requiring	VBG	O
only	RB	O
a	DT	O
fraction	NN	O
of	IN	O
the	DT	O
systemic	JJ	O
dose	NN	O
(	(	O
e.g.	JJ	O
,	,	O
Goodson	NNP	B
,	,	I
1984	CD	I
,	,	I
In	IN	I
:	:	I
Medical	JJ	I
Applications	NNS	I
of	IN	I
Controlled	NNP	I
Release	NNP	I
,	,	I
supra	NN	I
,	,	I
Vol	NNP	I
.	.	I
2	CD	I
,	,	I
pp	NN	I
.	.	I
115-138	JJ	I
)	)	O
.	.	O
Other	JJ	O
controlled	VBD	O
release	NN	O
systems	NNS	O
are	VBP	O
discussed	VBN	O
in	IN	O
the	DT	O
review	NN	O
by	IN	O
Langer	NNP	B
(	(	I
1990	CD	I
,	,	I
Science	NNP	I
249:1527-1533	CD	I
)	)	I
.	.	O
Other	JJ	O
approaches	NNS	O
can	MD	O
include	VB	O
the	DT	O
use	NN	O
of	IN	O
various	JJ	O
transport	NN	O
and	CC	O
carrier	NN	O
systems	NNS	O
,	,	O
for	IN	O
example	NN	O
though	IN	O
the	DT	O
use	NN	O
of	IN	O
viral	JJ	O
and/or	JJ	O
non-viral	JJ	O
delivery	NN	O
systems	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
siRNA	NN	O
can	MD	O
be	VB	O
introduced	VBN	O
into	IN	O
the	DT	O
brain	NN	O
in	IN	O
a	DT	O
virus	NN	O
modified	VBN	O
to	TO	O
serve	VB	O
as	IN	O
a	DT	O
vehicle	NN	O
without	IN	O
causing	VBG	O
pathogenicity	NN	O
.	.	O
The	DT	O
virus	NN	O
can	MD	O
be	VB	O
,	,	O
e.g.	FW	O
,	,	O
adenovirus	NN	O
,	,	O
fowlpox	JJ	O
virus	NN	O
,	,	O
vaccinia	NN	O
virus	NN	O
,	,	O
lentivirus	NN	O
,	,	O
or	CC	O
neurotropic	RB	O
virus	NNS	O
such	JJ	O
as	IN	O
HIV	NNP	O
,	,	O
herpes	VBZ	O
simplex	JJ	O
virus	NN	O
,	,	O
flavivirus	NN	O
,	,	O
or	CC	O
rabies	NNS	O
virus	VBP	O
.	.	O
(	(	O
Li	NNP	B
et	RB	I
al.	RB	I
,	,	I
Methods	NNP	I
Mol	NNP	I
.	.	I
Biol	NNP	I
.	.	I
309:261-272	CD	I
(	(	I
2005	CD	I
)	)	I
;	:	O
Davidson	NNP	B
et	FW	I
al.	NN	I
,	,	I
Neuron	NNP	I
53:781-788	CD	I
(	(	I
2007	CD	I
)	)	I
;	:	O
Xia	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nature	NNP	I
Med	NNP	I
10:816-820	CD	I
(	(	I
2004	CD	I
)	)	I
;	:	O
Kumar	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nature	NNP	I
448:39-43	CD	I
(	(	I
2007	CD	I
)	)	I
;	:	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
Nos	NNP	O
.	.	O
6,344,445	CD	O
,	,	O
6,924,144	CD	O
,	,	O
6,521,457	CD	O
)	)	O
.	.	O
Furthermore	RB	O
,	,	O
gene	NN	O
therapy	NN	O
approaches	NNS	O
,	,	O
for	IN	O
example	NN	O
as	IN	O
described	VBN	O
in	IN	O
Kaplitt	NNP	O
et	CC	O
al.	NN	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,180,613	CD	O
and	CC	O
Davidson	NNP	O
,	,	O
WO	NNP	O
04/013280	CD	O
,	,	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
express	VB	O
nucleic	JJ	O
acid	NN	O
molecules	NNS	O
in	IN	O
the	DT	O
brain	NN	O
.	.	O
Various	JJ	O
non-viral	JJ	O
delivery	NN	O
systems	NNS	O
are	VBP	O
known	VBN	O
and	CC	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
administer	VB	O
a	DT	O
therapeutic	JJ	O
polynucleotide	NN	O
(	(	O
e.g.	JJ	O
,	,	O
siRNA	NN	O
)	)	O
to	TO	O
the	DT	O
brain	NN	O
,	,	O
e.g.	NN	O
,	,	O
encapsulation	NN	O
in	IN	O
liposomes	NNS	O
,	,	O
microparticles	NNS	O
,	,	O
microcapsules	NNS	O
,	,	O
by	IN	O
iontophoresis	NN	O
,	,	O
or	CC	O
by	IN	O
incorporation	NN	O
into	IN	O
other	JJ	O
vehicles	NNS	O
,	,	O
such	JJ	O
as	IN	O
biodegradable	JJ	O
polymers	NNS	O
,	,	O
hydrogels	NNS	O
,	,	O
cyclodextrins	NNS	O
(	(	O
see	VB	O
for	IN	O
example	NN	O
Gonzalez	NNP	B
et	CC	I
al.	NN	I
,	,	I
1999	CD	I
,	,	I
Bioconjugate	NNP	I
Chem.	NNP	I
,	,	I
10	CD	I
,	,	I
1068-1074	CD	I
;	:	O
Wang	NNP	B
et	FW	I
al.	NN	I
,	,	I
International	NNP	I
PCT	NNP	I
publication	NN	I
Nos	NNP	I
.	.	I
WO	$	O
03/47518	CD	O
and	CC	O
WO	NNP	O
03/46185	CD	O
)	)	O
,	,	O
poly	JJ	O
(	(	O
lactic-co-glycolic	JJ	O
)	)	O
acid	NN	O
(	(	O
PLGA	NNP	O
)	)	O
and	CC	O
PLCA	NNP	O
microspheres	NNS	O
(	(	O
see	VB	O
for	IN	O
example	NN	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,447,796	CD	O
and	CC	O
US	NNP	O
Patent	NNP	O
Application	NNP	O
Publication	NNP	O
No	NNP	O
.	.	O
US	PRP	O
2002130430	CD	O
)	)	O
,	,	O
biodegradable	JJ	O
nanocapsules	NNS	O
,	,	O
and	CC	O
bioadhesive	JJ	O
microspheres	NNS	O
,	,	O
or	CC	O
by	IN	O
proteinaceous	JJ	O
vectors	NNS	O
(	(	O
O'Hare	NNP	B
and	CC	I
Normand	NNP	I
,	,	I
International	NNP	I
PCT	NNP	I
Publication	NNP	I
No	NNP	O
.	.	O
WO	NNP	O
00/53722	CD	O
)	)	O
or	CC	O
by	IN	O
the	DT	O
use	NN	O
of	IN	O
conjugates	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
chemically	RB	O
modified	VBN	O
liposomes	NNS	O
encapsulating	VBG	O
small	JJ	O
hairpin	NN	O
RNA	NNP	O
can	MD	O
be	VB	O
conjugated	VBN	O
to	TO	O
monoclonal	JJ	O
antibodies	NNS	O
specific	VBP	O
for	IN	O
specific	JJ	O
endogenous	JJ	O
receptors	NNS	O
(	(	O
e.g.	NN	O
,	,	O
such	JJ	O
as	IN	O
insulin	NN	O
and	CC	O
transferrin	NN	O
)	)	O
located	VBN	O
on	IN	O
the	DT	O
blood	NN	O
brain	NN	O
barrier	NN	O
and	CC	O
brain	NN	O
cellular	JJ	O
membranes	NNS	O
(	(	O
see	VB	O
Boado	NNP	B
,	,	I
Pharm	NNP	I
.	.	I
Res	NNP	I
.	.	I
24	CD	I
(	(	I
9	CD	I
)	)	I
:1772-1787	NN	I
(	(	I
2007	CD	I
)	)	I
)	)	O
.	.	O
As	IN	O
a	DT	O
further	JJ	O
example	NN	O
,	,	O
siRNA	NN	O
duplexes	NNS	O
can	MD	O
be	VB	O
delivered	VBN	O
with	IN	O
the	DT	O
combined	VBN	O
use	NN	O
of	IN	O
receptor	NN	O
specific	JJ	O
antibody	NN	O
delivery	NN	O
systems	NNS	O
and	CC	O
avidin-biotin	JJ	O
technology	NN	O
.	.	O
The	DT	O
siRNA	NN	O
can	MD	O
be	VB	O
mono-biotinylated	JJ	O
in	IN	O
parallel	NN	O
with	IN	O
the	DT	O
production	NN	O
of	IN	O
a	DT	O
conjugate	NN	O
of	IN	O
the	DT	O
targeting	VBG	O
monoclonal	JJ	O
antibody	NN	O
and	CC	O
streptavidin	NN	O
(	(	O
see	VB	O
Xia	NNP	B
et	FW	I
al.	NN	I
,	,	I
Pharm	NNP	I
Res	NNP	I
.	.	I
24	CD	I
(	(	I
12	CD	I
)	)	I
:2309-16	NN	I
(	(	I
2007	CD	I
)	)	I
)	)	O
.	.	O
Other	JJ	O
methods	NNS	O
to	TO	O
deliver	VB	O
siRNA	JJ	O
across	IN	O
plasma	JJ	O
membranes	NNS	O
in	IN	O
vivo	JJ	O
include	VBP	O
chemically	RB	O
modified	VBN	O
siRNAs	NN	O
such	JJ	O
as	IN	O
cholesterol-conjugated	JJ	O
siRNAs	NN	O
(	(	O
see	VB	O
DiFiglia	NNP	B
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
Natl	NNP	I
Acad	NNP	I
Sci	NNP	I
USA	NNP	I
.	.	I
104	CD	I
(	(	I
43	CD	I
)	)	I
:17204-9	NN	I
(	(	I
2007	CD	I
)	)	I
;	:	O
Wolfrum	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nature	NNP	I
Biotech	NNP	I
.	.	I
25	CD	I
(	(	I
10	CD	I
)	)	I
:1149-1157	NN	I
(	(	I
2007	CD	I
)	)	I
;	:	O
Soutschek	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nature	NNP	I
432:173-178	CD	I
(	(	I
2003	CD	I
)	)	I
)	)	O
.	.	O
C.	NNP	O
Zinc	NNP	O
Finger	NNP	O
Proteins	NNP	O
Zinc	NNP	O
finger	NN	O
proteins	NNS	O
can	MD	O
be	VB	O
engineered	VBN	O
or	CC	O
selected	VBN	O
to	TO	O
bind	VB	O
to	TO	O
any	DT	O
desired	JJ	O
target	NN	O
site	NN	O
within	IN	O
a	DT	O
kinase	JJ	O
gene	NN	O
of	IN	O
known	VBN	O
sequence	NN	O
including	VBG	O
,	,	O
for	IN	O
example	NN	O
,	,	O
PLK2	NNP	O
.	.	O
An	DT	O
exemplary	JJ	O
motif	NN	O
characterizing	VBG	O
one	CD	O
class	NN	O
of	IN	O
these	DT	O
proteins	NNS	O
(	(	O
C2H2	NNP	O
class	NN	O
)	)	O
is	VBZ	O
-Cys-	JJ	O
(	(	O
X	NNP	O
)	)	O
2-4-Cys-	CD	O
(	(	O
X	NNP	O
)	)	O
12-His-	CD	O
(	(	O
X	NNP	O
)	)	O
3-5-His	CD	O
(	(	O
where	WRB	O
X	NNP	O
is	VBZ	O
any	DT	O
amino	JJ	O
acid	NN	O
)	)	O
.	.	O
A	DT	O
single	JJ	O
finger	NN	O
domain	NN	O
is	VBZ	O
about	IN	O
30	CD	O
amino	JJ	O
acids	NNS	O
in	IN	O
length	NN	O
,	,	O
and	CC	O
several	JJ	O
structural	JJ	O
studies	NNS	O
have	VBP	O
demonstrated	VBN	O
that	IN	O
it	PRP	O
contains	VBZ	O
an	DT	O
alpha	JJ	O
helix	NN	O
containing	VBG	O
the	DT	O
two	CD	O
invariant	JJ	O
histidine	NN	O
residues	NNS	O
and	CC	O
two	CD	O
invariant	JJ	O
cysteine	NN	O
residues	NNS	O
in	IN	O
a	DT	O
beta	NN	O
turn	NN	O
co-ordinated	JJ	O
through	IN	O
zinc	NN	O
.	.	O
In	IN	O
some	DT	O
methods	NNS	O
,	,	O
the	DT	O
target	NN	O
site	NN	O
is	VBZ	O
within	IN	O
a	DT	O
promoter	NN	O
or	CC	O
enhancer	NN	O
.	.	O
In	IN	O
other	JJ	O
methods	NNS	O
,	,	O
the	DT	O
target	NN	O
site	NN	O
is	VBZ	O
within	IN	O
the	DT	O
structural	JJ	O
gene	NN	O
.	.	O
In	IN	O
some	DT	O
methods	NNS	O
,	,	O
the	DT	O
zinc	NN	O
finger	NN	O
protein	NN	O
is	VBZ	O
linked	VBN	O
to	TO	O
a	DT	O
transcriptional	JJ	O
repressor	NN	O
,	,	O
such	JJ	O
as	IN	O
the	DT	O
KRAB	NNP	O
repression	NN	O
domain	NN	O
from	IN	O
the	DT	O
human	JJ	O
KOX-1	NNP	O
protein	NN	O
(	(	O
Thiesen	NNP	B
et	RB	I
al.	RB	I
,	,	I
New	NNP	I
Biologist	NNP	I
2	CD	I
,	,	I
363-374	CD	I
(	(	I
1990	CD	I
)	)	I
;	:	O
Margolin	NNP	B
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
91	CD	I
,	,	I
4509-4513	CD	I
(	(	I
1994	CD	I
)	)	I
;	:	O
Pengue	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nucl	NNP	I
.	.	I
Acids	NNP	I
Res	NNP	I
.	.	I
22:2908-2914	CD	I
(	(	I
1994	CD	I
)	)	I
;	:	O
Witzgall	NNP	B
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
91	CD	I
,	,	I
4514-4518	CD	I
(	(	I
1994	CD	I
)	)	I
)	)	O
.	.	O
In	IN	O
some	DT	O
methods	NNS	O
,	,	O
the	DT	O
zinc	NN	O
finger	NN	O
protein	NN	O
is	VBZ	O
linked	VBN	O
to	TO	O
a	DT	O
transcriptional	JJ	O
activator	NN	O
,	,	O
such	JJ	O
as	IN	O
VIP16	NNP	O
.	.	O
Zinc	NNP	O
finger	NN	O
proteins	NNS	O
can	MD	O
also	RB	O
be	VB	O
used	VBN	O
to	TO	O
activate	VB	O
expression	NN	O
of	IN	O
desired	VBN	O
genes	NNS	O
.	.	O
Methods	NNS	O
for	IN	O
selecting	VBG	O
target	NN	O
sites	NNS	O
suitable	JJ	O
for	IN	O
targeting	VBG	O
by	IN	O
zinc	NN	O
finger	NN	O
proteins	NNS	O
,	,	O
and	CC	O
methods	NNS	O
for	IN	O
designing	VBG	O
zinc	NN	O
finger	NN	O
proteins	VBZ	O
to	TO	O
bind	VB	O
to	TO	O
selected	VBN	O
target	NN	O
sites	NNS	O
are	VBP	O
described	VBN	O
in	IN	O
WO	NNP	O
00/00388	CD	O
.	.	O
Methods	NNS	O
for	IN	O
selecting	VBG	O
zinc	NN	O
finger	NN	O
proteins	VBZ	O
to	TO	O
bind	VB	O
to	TO	O
a	DT	O
target	NN	O
using	VBG	O
phage	NN	O
display	NN	O
are	VBP	O
described	VBN	O
by	IN	O
EP.95908614.1	NNP	O
.	.	O
The	DT	O
target	NN	O
site	NN	O
used	VBN	O
for	IN	O
design	NN	O
of	IN	O
a	DT	O
zinc	NN	O
finger	NN	O
protein	NN	O
is	VBZ	O
typically	RB	O
of	IN	O
the	DT	O
order	NN	O
of	IN	O
9-19	CD	O
nucleotides	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
proteins	NNS	O
have	VBP	O
been	VBN	O
described	VBN	O
that	WDT	O
have	VBP	O
the	DT	O
ability	NN	O
to	TO	O
translocate	VB	O
desired	JJ	O
nucleic	JJ	O
acids	NNS	O
across	IN	O
a	DT	O
cell	NN	O
membrane	NN	O
.	.	O
Typically	RB	O
,	,	O
such	JJ	O
proteins	NNS	O
have	VBP	O
amphiphilic	JJ	O
or	CC	O
hydrophobic	JJ	O
subsequences	NNS	O
that	WDT	O
have	VBP	O
the	DT	O
ability	NN	O
to	TO	O
act	VB	O
as	IN	O
membrane-translocating	JJ	O
carriers	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
homeodomain	NN	O
proteins	NNS	O
have	VBP	O
the	DT	O
ability	NN	O
to	TO	O
translocate	VB	O
across	IN	O
cell	NN	O
membranes	NNS	O
.	.	O
The	DT	O
shortest	JJS	O
internalizable	JJ	O
peptide	NN	O
of	IN	O
a	DT	O
homeodomain	NN	O
protein	NN	O
,	,	O
Antennapedia	NNP	O
,	,	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
the	DT	O
third	JJ	O
helix	NN	O
of	IN	O
the	DT	O
protein	NN	O
,	,	O
from	IN	O
amino	NN	O
acid	JJ	O
position	NN	O
43	CD	O
to	TO	O
58	CD	O
(	(	O
see	VB	O
,	,	O
e.g.	VB	O
,	,	O
Prochiantz	NNP	B
,	,	I
Current	NNP	I
Opinion	NNP	I
in	IN	I
Neurobiology	NNP	I
6:629-634	CD	I
(	(	I
1996	CD	I
)	)	I
.	.	O
Another	DT	O
subsequence	NN	O
,	,	O
the	DT	O
h	NN	O
(	(	O
hydrophobic	JJ	O
)	)	O
domain	NN	O
of	IN	O
signal	JJ	O
peptides	NNS	O
,	,	O
was	VBD	O
found	VBN	O
to	TO	O
have	VB	O
similar	JJ	O
cell	NN	O
membrane	NN	O
translocation	NN	O
characteristics	NNS	O
(	(	O
see	VB	O
,	,	O
e.g.	VB	O
,	,	O
Lin	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
270:14255-14258	CD	I
(	(	I
1995	CD	I
)	)	I
)	)	O
.	.	O
Such	JJ	O
subsequences	NNS	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
translocate	VB	O
oligonucleotides	NNS	O
across	IN	O
a	DT	O
cell	NN	O
membrane	NN	O
.	.	O
Oligonucleotides	NNS	O
can	MD	O
be	VB	O
conveniently	RB	O
derivatized	VBN	O
with	IN	O
such	JJ	O
sequences	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
a	DT	O
linker	NN	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
link	VB	O
the	DT	O
oligonucleotides	NNS	O
and	CC	O
the	DT	O
translocation	NN	O
sequence	NN	O
.	.	O
Any	DT	O
suitable	JJ	O
linker	NN	O
can	MD	O
be	VB	O
used	VBN	O
,	,	O
e.g.	FW	O
,	,	O
a	DT	O
peptide	JJ	O
linker	NN	O
or	CC	O
any	DT	O
other	JJ	O
suitable	JJ	O
chemical	NN	O
linker	NN	O
.	.	O
D.	NNP	O
Antibodies	NNP	O
Kinase	NNP	O
activity	NN	O
can	MD	O
be	VB	O
reduced	VBN	O
by	IN	O
administering	VBG	O
anti-kinase	NN	O
(	(	O
e.g.	JJ	O
,	,	O
anti-PLK2	JJ	O
)	)	O
antibodies	NNS	O
,	,	O
both	DT	O
intact	JJ	O
and	CC	O
binding	VBG	O
fragments	NNS	O
thereof	RB	O
,	,	O
such	JJ	O
as	IN	O
Fabs	NNP	O
,	,	O
Fvs	NNP	O
,	,	O
which	WDT	O
specifically	RB	O
bind	VBP	O
to	TO	O
a	DT	O
kinase	NN	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Usually	RB	O
the	DT	O
antibody	NN	O
is	VBZ	O
a	DT	O
monoclonal	JJ	O
antibody	NN	O
although	IN	O
polyclonal	JJ	O
antibodies	NNS	O
can	MD	O
also	RB	O
be	VB	O
expressed	VBN	O
recombinantly	RB	O
(	(	O
see	VB	O
,	,	O
e.g.	VB	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,555,310	CD	O
)	)	O
.	.	O
Examples	NNS	O
of	IN	O
antibodies	NNS	O
that	WDT	O
can	MD	O
be	VB	O
expressed	VBN	O
include	JJ	O
mouse	NN	O
antibodies	NNS	O
,	,	O
chimeric	JJ	O
antibodies	NNS	O
,	,	O
humanized	JJ	O
antibodies	NNS	O
,	,	O
veneered	JJ	O
antibodies	NNS	O
and	CC	O
human	JJ	O
antibodies	NNS	O
.	.	O
Chimeric	JJ	O
antibodies	NNS	O
are	VBP	O
antibodies	NNS	O
whose	WP$	O
light	NN	O
and	CC	O
heavy	JJ	O
chain	NN	O
genes	NNS	O
have	VBP	O
been	VBN	O
constructed	VBN	O
,	,	O
typically	RB	O
by	IN	O
genetic	JJ	O
engineering	NN	O
,	,	O
from	IN	O
immunoglobulin	JJ	O
gene	NN	O
segments	NNS	O
belonging	VBG	O
to	TO	O
different	JJ	O
species	NNS	O
(	(	O
see	VB	O
,	,	O
e.g.	VB	O
,	,	O
Boyce	NNP	B
et	FW	I
al.	NN	I
,	,	I
Annals	NNP	I
of	IN	I
Oncology	NNP	I
14:520-535	CD	I
(	(	I
2003	CD	I
)	)	I
)	)	O
.	.	O
For	IN	O
example	NN	O
,	,	O
the	DT	O
variable	JJ	O
(	(	O
V	NNP	O
)	)	O
segments	NNS	O
of	IN	O
the	DT	O
genes	NNS	O
from	IN	O
a	DT	O
mouse	NN	O
monoclonal	JJ	O
antibody	NN	O
may	MD	O
be	VB	O
joined	VBN	O
to	TO	O
human	JJ	O
constant	NN	O
(	(	O
C	NNP	O
)	)	O
segments	NNS	O
.	.	O
A	DT	O
typical	JJ	O
chimeric	NN	O
antibody	NN	O
is	VBZ	O
thus	RB	O
a	DT	O
hybrid	JJ	O
protein	NN	O
consisting	VBG	O
of	IN	O
the	DT	O
V	NNP	O
or	CC	O
antigen-binding	JJ	O
domain	NN	O
from	IN	O
a	DT	O
mouse	NN	O
antibody	NN	O
and	CC	O
the	DT	O
C	NNP	O
or	CC	O
effector	NN	O
domain	NN	O
from	IN	O
a	DT	O
human	JJ	O
antibody	NN	O
.	.	O
Humanized	VBN	O
antibodies	NNS	O
have	VBP	O
variable	JJ	O
region	NN	O
framework	NN	O
residues	NNS	O
substantially	RB	O
from	IN	O
a	DT	O
human	JJ	O
antibody	NN	O
(	(	O
termed	VBD	O
an	DT	O
acceptor	NN	O
antibody	NN	O
)	)	O
and	CC	O
complementarity	NN	O
determining	VBG	O
regions	NNS	O
substantially	RB	O
from	IN	O
a	DT	O
mouse-antibody	NN	O
,	,	O
(	(	O
referred	VBN	O
to	TO	O
as	IN	O
the	DT	O
donor	NN	O
immunoglobulin	NN	O
)	)	O
.	.	O
See	VB	O
Queen	JJ	B
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
86:10029-10033	CD	I
(	(	I
1989	CD	I
)	)	I
and	CC	O
WO	$	O
90/07861	CD	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,693,762	CD	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,693,761	CD	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,585,089	CD	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,530,101	CD	O
and	CC	O
Winter	NNP	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,225,539	CD	O
.	.	O
The	DT	O
constant	JJ	O
region	NN	O
(	(	O
s	NN	O
)	)	O
,	,	O
if	IN	O
present	JJ	O
,	,	O
are	VBP	O
also	RB	O
substantially	RB	O
or	CC	O
entirely	RB	O
from	IN	O
a	DT	O
human	JJ	O
immunoglobulin	NN	O
.	.	O
Antibodies	NNS	O
can	MD	O
be	VB	O
obtained	VBN	O
by	IN	O
conventional	JJ	O
hybridoma	NN	O
approaches	NNS	O
,	,	O
phage	NN	O
display	NN	O
(	(	O
see	VB	O
,	,	O
e.g.	VB	O
,	,	O
Dower	NNP	O
et	FW	O
al.	NN	O
,	,	O
WO	NNP	O
91/17271	CD	O
and	CC	O
McCafferty	NNP	O
et	VBP	O
al.	NN	O
,	,	O
WO	NNP	O
92/01047	CD	O
)	)	O
,	,	O
use	NN	O
of	IN	O
transgenic	JJ	O
mice	NN	O
with	IN	O
human	JJ	O
immune	JJ	O
systems	NNS	O
(	(	O
Lonberg	NNP	B
et	RB	I
al.	RB	I
,	,	I
WO93/12227	NNP	I
(	(	I
1993	CD	I
)	)	I
)	)	O
,	,	O
among	IN	O
other	JJ	O
sources	NNS	O
.	.	O
Nucleic	NNP	O
acids	NNS	O
encoding	VBG	O
immunoglobulin	NN	O
chains	NNS	O
can	MD	O
be	VB	O
obtained	VBN	O
from	IN	O
hybridomas	NN	O
or	CC	O
cell	NN	O
lines	NNS	O
producing	VBG	O
antibodies	NNS	O
,	,	O
or	CC	O
based	VBN	O
on	IN	O
immunoglobulin	NN	O
nucleic	JJ	O
acid	NN	O
or	CC	O
amino	NN	O
acid	JJ	O
sequences	NNS	O
in	IN	O
the	DT	O
published	JJ	O
literature	NN	O
.	.	O
Antibodies	NNS	O
can	MD	O
be	VB	O
administered	VBN	O
by	IN	O
intravenous	JJ	O
injection	NN	O
.	.	O
A	DT	O
portion	NN	O
of	IN	O
the	DT	O
injected	JJ	O
antibodies	NNS	O
will	MD	O
cross	VB	O
the	DT	O
blood-brain	JJ	O
barrier	NN	O
.	.	O
Alternatively	RB	O
antibodies	NNS	O
can	MD	O
be	VB	O
administered	VBN	O
directly	RB	O
to	TO	O
the	DT	O
brain	NN	O
(	(	O
e.g.	JJ	O
,	,	O
by	IN	O
intraventricular	JJ	O
or	CC	O
intrathecal	JJ	O
injection	NN	O
)	)	O
.	.	O
Antibodies	NNS	O
may	MD	O
be	VB	O
internalized	VBN	O
by	IN	O
synuclein-expressing	JJ	O
cells	NNS	O
by	IN	O
endocytosis	NN	O
.	.	O
Alternatively	RB	O
,	,	O
antibodies	NNS	O
may	MD	O
be	VB	O
linked	VBN	O
to	TO	O
carrier	NN	O
moiety	NN	O
that	WDT	O
facilitates	VBZ	O
transport	RB	O
across	IN	O
the	DT	O
cell	NN	O
membrane	NN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
an	DT	O
intrabody	NN	O
is	VBZ	O
used	VBN	O
to	TO	O
reduce	VB	O
PLK2	NNP	O
activity	NN	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
intrabody	NN	O
”	NNP	O
or	CC	O
“	NNP	O
intrabodies	NNS	O
”	VBP	O
refers	NNS	O
to	TO	O
intracellularly	VB	O
expressed	VBN	O
antibody	NN	O
constructs	NNS	O
,	,	O
usually	RB	O
single-chain	JJ	O
Fv	NNP	O
antibodies	NNS	O
,	,	O
directed	VBN	O
against	IN	O
a	DT	O
target	NN	O
inside	IN	O
a	DT	O
cell	NN	O
.	.	O
Nam	NNP	B
,	,	I
et	RB	I
al	NN	I
.	.	I
(	(	I
2002	CD	I
)	)	I
Methods	NNP	I
Mol	NNP	I
.	.	I
Biol	NNP	I
.	.	I
193:301	CD	I
;	:	O
der	NN	B
Maurr	NNP	I
et	CC	I
al	NN	I
.	.	I
(	(	I
2002	CD	I
)	)	I
J.	NNP	I
Biol	NNP	I
Chem	NNP	I
Nov	NNP	I
22	CD	I
;	:	I
277	CD	I
(	(	I
47	CD	I
)	)	I
:45075	NN	I
;	:	O
Cohen	NNP	B
(	(	I
2002	CD	I
)	)	I
Methods	NNP	I
Mol	NNP	I
Biol	NNP	I
178:367	CD	I
.	.	O
The	DT	O
scFv	JJ	O
gene	NN	O
can	MD	O
be	VB	O
transferred	VBN	O
into	IN	O
cells	NNS	O
,	,	O
where	WRB	O
scFv	NN	O
protein	IN	O
expression	NN	O
can	MD	O
modulate	VB	O
the	DT	O
properties	NNS	O
of	IN	O
its	PRP$	O
target	NN	O
,	,	O
e.g	NN	O
.	.	O
PLK2	NNP	O
,	,	O
sometimes	RB	O
extinguishing	VBG	O
protein	JJ	O
function	NN	O
and	CC	O
causing	VBG	O
a	DT	O
phenotypic	NN	O
knockout	NN	O
.	.	O
Indeed	RB	O
,	,	O
the	DT	O
scFv	NN	O
intrabody	NN	O
can	MD	O
be	VB	O
expressed	VBN	O
in	IN	O
the	DT	O
cytoplasm	NN	O
and	CC	O
directed	VBD	O
to	TO	O
any	DT	O
cellular	JJ	O
compartment	NN	O
where	WRB	O
it	PRP	O
can	MD	O
target	VB	O
intracellular	JJ	O
proteins	NNS	O
and	CC	O
elicit	JJ	O
specific	JJ	O
biological	JJ	O
effects	NNS	O
.	.	O
Intrabodies	NNS	O
thus	RB	O
provide	VBP	O
effective	JJ	O
means	NNS	O
for	IN	O
blocking	VBG	O
or	CC	O
modulating	VBG	O
the	DT	O
activity	NN	O
of	IN	O
proteins	NNS	O
such	JJ	O
as	IN	O
PLK2	NNP	O
.	.	O
E.	NNP	O
Kinase	NNP	O
Inhibitors	NNP	O
to	TO	O
Modulate	NNP	O
Activity	NNP	O
In	IN	O
addition	NN	O
to	TO	O
the	DT	O
biological	JJ	O
molecules	NNS	O
discussed	VBN	O
above	IN	O
,	,	O
small	JJ	O
molecule	NN	O
compounds	NNS	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
modulate	VB	O
(	(	O
usually	RB	O
inhibit	VBP	O
)	)	O
expression	NN	O
or	CC	O
activity	NN	O
of	IN	O
kinases	NNS	O
.	.	O
As	IN	O
discussed	VBN	O
below	IN	O
,	,	O
known	VBN	O
kinase	NN	O
inhibitors	NNS	O
can	MD	O
be	VB	O
screened	VBN	O
for	IN	O
desired	JJ	O
target	NN	O
specificity	NN	O
and	CC	O
other	JJ	O
properties	NNS	O
,	,	O
and	CC	O
additional	JJ	O
inhibitors	NNS	O
can	MD	O
be	VB	O
identified	VBN	O
based	VBN	O
on	IN	O
target	NN	O
specificity	NN	O
.	.	O
PLK2	NNP	O
or	CC	O
GRK6	NNP	O
are	VBP	O
preferred	JJ	O
kinases	NNS	O
for	IN	O
inhibition	NN	O
because	IN	O
they	PRP	O
are	VBP	O
candidates	NNS	O
for	IN	O
directly	RB	O
phosphorylating	VBG	O
alpha-synuclein	NN	O
.	.	O
PLK2	NNP	O
is	VBZ	O
a	DT	O
particularly	RB	O
preferred	JJ	O
kinase	NN	O
because	IN	O
it	PRP	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
phosphorylate	VB	O
alpha-synuclein	NNS	O
to	TO	O
a	DT	O
much	RB	O
higher	JJR	O
level	NN	O
than	IN	O
GRK6	NNP	O
or	CC	O
other	JJ	O
kinases	NNS	O
tested	VBN	O
herein	NN	O
.	.	O
Other	JJ	O
kinase	JJ	O
targets	NNS	O
include	VBP	O
APEG1	NNP	O
,	,	O
CDC7L1	NNP	O
,	,	O
MET	NNP	O
GRK1	NNP	O
,	,	O
GRK2	NNP	O
,	,	O
GRK6	NNP	O
,	,	O
IKBKB	NNP	O
,	,	O
CKII	NNP	O
and	CC	O
GRK7	NNP	O
are	VBP	O
also	RB	O
preferred	JJ	O
kinases	NNS	O
for	IN	O
inhibition	NN	O
because	IN	O
they	PRP	O
are	VBP	O
likely	JJ	O
to	TO	O
be	VB	O
indirect	JJ	O
activators	NNS	O
of	IN	O
the	DT	O
direct	JJ	O
kinase	NN	O
(	(	O
s	NN	O
)	)	O
.	.	O
PRKG1	NNP	O
,	,	O
MAPK13	NNP	O
,	,	O
and	CC	O
GAK	NNP	O
are	VBP	O
preferred	JJ	O
kinases	NNS	O
for	IN	O
activation	NN	O
in	IN	O
Lewy	NNP	O
body	NN	O
diseases	NNS	O
because	IN	O
they	PRP	O
are	VBP	O
negative	JJ	O
regulators	NNS	O
of	IN	O
the	DT	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	NN	O
.	.	O
Alternatively	RB	O
,	,	O
these	DT	O
kinases	VBZ	O
themselves	PRP	O
or	CC	O
fragments	NNS	O
or	CC	O
mimetics	NNS	O
thereof	IN	O
having	VBG	O
similar	JJ	O
activity	NN	O
can	MD	O
be	VB	O
used	VBN	O
directly	RB	O
as	IN	O
inhibitors	NNS	O
of	IN	O
alpha-synuclein	JJ	O
phosphorylation	NN	O
.	.	O
Synphilin	NNP	O
can	MD	O
be	VB	O
used	VBN	O
as	IN	O
an	DT	O
alternative	JJ	O
therapeutic	JJ	O
target	NN	O
for	IN	O
inhibition	NN	O
of	IN	O
alpha-synuclein	JJ	O
phosphorylation	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
synphilin	NN	O
can	MD	O
be	VB	O
added	VBN	O
to	TO	O
an	DT	O
assay	JJ	O
having	VBG	O
alpha-synuclein	JJ	O
and	CC	O
PLK-2	JJ	O
expression	NN	O
and	CC	O
inhibitors	NNS	O
of	IN	O
synphilin	NN	O
identified	VBN	O
.	.	O
Compounds	NNS	O
to	TO	O
be	VB	O
screened	VBN	O
for	IN	O
capacity	NN	O
to	TO	O
modulate	VB	O
expression	NN	O
or	CC	O
activity	NN	O
of	IN	O
kinases	NNS	O
include	VBP	O
the	DT	O
modulators	NNS	O
of	IN	O
expression	NN	O
described	VBN	O
in	IN	O
Section	NNP	O
IV	NNP	O
.	.	O
These	DT	O
compounds	NNS	O
also	RB	O
include	VBP	O
many	JJ	O
known	JJ	O
examples	NNS	O
of	IN	O
kinase	NN	O
inhibitors	NNS	O
,	,	O
some	DT	O
of	IN	O
which	WDT	O
are	VBP	O
already	RB	O
approved	VBN	O
for	IN	O
therapeutic	JJ	O
uses	NNS	O
or	CC	O
in	IN	O
clinical	JJ	O
trials	NNS	O
,	,	O
usually	RB	O
for	IN	O
treatment	NN	O
of	IN	O
cancer	NN	O
.	.	O
Lead	JJ	O
structures	NNS	O
include	VBP	O
quinazolines	NNS	O
,	,	O
pyrido	NN	O
[	NNP	O
d	NN	O
]	NNP	O
-	:	O
and	CC	O
pyrimidol	VB	O
[	NNP	O
d	NN	O
]	NNP	O
pyrimidines	NNS	O
,	,	O
pyrazolo	NN	O
[	NNP	O
d	NN	O
]	NNP	O
-pyrimidines	NNS	O
,	,	O
pyrrolo	NN	O
[	NNP	O
d	NN	O
]	NNP	O
pyrimidines	NNS	O
,	,	O
pheylamino-pyrimidines	NNS	O
,	,	O
1-oxo-3-aryl-1H-indene-2-carboxylic	JJ	O
acid	NN	O
derivatives	NNS	O
,	,	O
and	CC	O
substituted	VBD	O
indolin-2-ones	NNS	O
and	CC	O
natural	JJ	O
products	NNS	O
such	JJ	O
as	IN	O
strauosporine	NN	O
(	(	O
see	VB	O
Traxler	NNP	B
et	FW	I
al.	NN	I
,	,	I
2001	CD	I
,	,	I
Medicinal	NNP	I
Research	NNP	I
Reviews	NNP	I
21:499-512	JJ	I
)	)	O
.	.	O
Some	DT	O
such	JJ	O
compounds	NNS	O
are	VBP	O
commercially	RB	O
available	JJ	O
from	IN	O
Calbiochem-Novabiochem	NNP	O
Corp.	NNP	O
(	(	O
La	NNP	O
Jolla	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
including	VBG	O
H89	NNP	O
,	,	O
Y27632	NNP	O
,	,	O
AT877	NNP	O
(	(	O
fasudil	JJ	O
hydrochloride	NN	O
)	)	O
,	,	O
rottlerin	NN	O
,	,	O
KN62	NNP	O
,	,	O
U0123	NNP	O
,	,	O
PD184352	NNP	O
,	,	O
PD98059	NNP	O
,	,	O
SB203580	NNP	O
,	,	O
SB202190	NNP	O
,	,	O
wortmannin	NN	O
,	,	O
Li+	NNP	O
,	,	O
Ro	NNP	O
318220	CD	O
,	,	O
chelerythrein	NN	O
and	CC	O
10-	JJ	O
[	JJ	O
3-	JJ	O
(	(	O
1-piperazinyl	JJ	O
)	)	O
propyl	NN	O
]	JJ	O
-2-trifluoromethyl-phenothiazine	NN	O
(	(	O
see	VB	O
Davies	NNPS	B
,	,	I
Biochem	NNP	I
.	.	I
J	NNP	I
.	.	I
351	CD	I
,	,	I
95-105	CD	I
(	(	I
2000	CD	I
)	)	I
)	)	O
.	.	O
Other	JJ	O
compounds	NNS	O
currently	RB	O
in	IN	O
clinical	JJ	O
trials	NNS	O
include	VBP	O
STI571	NNP	O
(	(	O
Glivec™	NNP	O
,	,	O
a	DT	O
phenylamino-pyrimidine	JJ	O
derivative	NN	O
)	)	O
(	(	O
Novartis	NNP	O
)	)	O
,	,	O
ZD1839	NNP	O
(	(	O
Iressa	NNP	O
)	)	O
(	(	O
AstraZeneca	NNP	O
)	)	O
,	,	O
OSI-774	NNP	O
(	(	O
Roche/OSI	NNP	O
)	)	O
,	,	O
PKI166	NNP	O
(	(	O
Novartis	NNP	O
)	)	O
,	,	O
CI1033	NNP	O
(	(	O
Pfizer/Warner-Lambert	NNP	O
)	)	O
,	,	O
EKB-569	NNP	O
(	(	O
Wyeth-Ayerst	NNP	O
)	)	O
,	,	O
SU5416	NNP	O
(	(	O
SUGEN	NNP	O
)	)	O
,	,	O
PTK787/ZK224584	NNP	O
,	,	O
aniline-phthalazine	JJ	O
derivative	NN	O
(	(	O
Novartis/Schering	NNP	O
AG	NNP	O
)	)	O
,	,	O
SU6668	NNP	O
(	(	O
Sugen	NNP	O
)	)	O
,	,	O
ZD6474	NNP	O
(	(	O
AstraZeneca	NNP	O
)	)	O
,	,	O
and	CC	O
CEP2583	NNP	O
(	(	O
Cephalon	NNP	O
)	)	O
.	.	O
Caveolin-1	NNP	O
is	VBZ	O
an	DT	O
example	NN	O
of	IN	O
a	DT	O
compound	NN	O
known	VBN	O
to	TO	O
modulate	VB	O
the	DT	O
activity	NN	O
of	IN	O
the	DT	O
GRK	NNP	O
kinases	NNS	O
.	.	O
Examples	NNS	O
of	IN	O
compounds	NNS	O
known	VBN	O
to	TO	O
modulate	VB	O
the	DT	O
activity	NN	O
of	IN	O
the	DT	O
PLK2/SNK	NNP	O
kinases	NNS	O
include	VBP	O
the	DT	O
RING-H2	NNP	O
domain	NN	O
of	IN	O
hVPS18	NN	O
(	(	O
human	JJ	O
vacuolar	NN	O
protein	NN	O
sorting	VBG	O
18	CD	O
)	)	O
,	,	O
and	CC	O
calcium-	JJ	O
and	CC	O
integrin-binding	JJ	O
protein	NN	O
CIB	NNP	O
.	.	O
In	IN	O
certain	JJ	O
embodiments	NNS	O
the	DT	O
therapeutic	JJ	O
agent	NN	O
is	VBZ	O
a	DT	O
small	JJ	O
molecule	NN	O
that	WDT	O
is	VBZ	O
a	DT	O
thiazolidone	NN	O
,	,	O
a	DT	O
quinazoline	NN	O
,	,	O
a	DT	O
pyrimidine	NN	O
(	(	O
e.g.	NN	O
,	,	O
a	DT	O
pyrido	NN	O
[	NNP	O
d	NN	O
]	NNP	O
-pyrimidine	NNP	O
,	,	O
pyrimidol	NN	O
[	NNP	O
d	NN	O
]	NNP	O
pyrimidine	NN	O
,	,	O
a	DT	O
pyrazolo	NN	O
[	NNP	O
d	NN	O
]	NNP	O
-pyrimidine	NNP	O
,	,	O
a	DT	O
pyrrolo	NN	O
[	NNP	O
d	NN	O
]	NNP	O
pyrimidine	NN	O
,	,	O
a	DT	O
pheylamino-pyrimidines	JJ	O
,	,	O
or	CC	O
a	DT	O
phenylamino-pyrimidine	JJ	O
derivative	NN	O
)	)	O
;	:	O
an	DT	O
indazole-pyridine	JJ	O
derivative	NN	O
,	,	O
a	DT	O
carboxylic	JJ	O
acid	NN	O
derivative	NN	O
(	(	O
e.g.	NN	O
,	,	O
a	DT	O
1-oxo-3-aryl-1H-indene-2-carboxylic	JJ	O
acid	NN	O
derivative	NN	O
)	)	O
,	,	O
a	DT	O
substituted	JJ	O
indolin-2-one	NN	O
,	,	O
an	DT	O
aniline-phthalazine	JJ	O
derivative	NN	O
;	:	O
a	DT	O
quinolinone	NN	O
derivative	NN	O
,	,	O
a	DT	O
benzthiazole-3	JJ	O
oxide	NN	O
compound	NN	O
,	,	O
an	DT	O
azaindazole	JJ	O
compound	NN	O
,	,	O
or	CC	O
a	DT	O
dihydropteridinone	NN	O
.	.	O
In	IN	O
certain	JJ	O
embodiments	NNS	O
the	DT	O
therapeutic	JJ	O
agent	NN	O
is	VBZ	O
a	DT	O
small	JJ	O
molecule	NN	O
protein	NN	O
kinase	VBD	O
inhibitor	NN	O
described	NN	O
in	IN	O
US	NNP	O
20070203143	CD	O
;	:	O
US	PRP	O
2007/0179177	CD	O
;	:	O
US	PRP	O
2007/0135387	CD	O
;	:	O
US	PRP	O
2007/0010565	CD	O
;	:	O
US	PRP	O
2007/0037862	CD	O
;	:	O
US	PRP	O
2007/0010566	CD	O
;	:	O
US	PRP	O
2006/0074119	CD	O
;	:	O
US	PRP	O
2006/0079503	CD	O
;	:	O
US	PRP	O
2006/0223833	CD	O
;	:	O
US	PRP	O
2005/0014761	CD	O
;	:	O
US	PRP	O
2004/0176380	CD	O
;	:	O
US	PRP	O
2006/0040997	CD	O
;	:	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,861,422	CD	O
;	:	O
US	PRP	O
2005/0014760	CD	O
;	:	O
US	PRP	O
2006/0025411	CD	O
;	:	O
US	PRP	O
2004/0176380	CD	O
;	:	O
US	PRP	O
2005/0014761	CD	O
;	:	O
US	PRP	O
2007/0203143	CD	O
;	:	O
US	PRP	O
2007/0072833	CD	O
;	:	O
US	PRP	O
2007/0135387	CD	O
or	CC	O
WO	NNP	O
03087095	CD	O
.	.	O
Each	DT	O
of	IN	O
the	DT	O
aforelisted	JJ	O
publications	NNS	O
is	VBZ	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
.	.	O
Compounds	NNS	O
may	MD	O
be	VB	O
synthetic	JJ	O
or	CC	O
can	MD	O
be	VB	O
obtained	VBN	O
from	IN	O
natural	JJ	O
sources	NNS	O
,	,	O
such	JJ	O
as	IN	O
,	,	O
e.g.	NN	O
,	,	O
marine	JJ	O
microorganisms	NN	O
,	,	O
algae	NN	O
,	,	O
plants	NNS	O
,	,	O
and	CC	O
fungi	NNS	O
.	.	O
Other	JJ	O
compounds	NNS	O
that	WDT	O
can	MD	O
be	VB	O
tested	VBN	O
include	JJ	O
compounds	NNS	O
known	VBN	O
to	TO	O
interact	VB	O
with	IN	O
alpha-synuclein	JJ	O
,	,	O
such	JJ	O
as	IN	O
synphilin	NN	O
.	.	O
Alternatively	RB	O
,	,	O
compounds	NNS	O
can	MD	O
be	VB	O
from	IN	O
combinatorial	JJ	O
libraries	NNS	O
of	IN	O
agents	NNS	O
,	,	O
including	VBG	O
peptides	NNS	O
or	CC	O
small	JJ	O
molecules	NNS	O
,	,	O
or	CC	O
from	IN	O
existing	VBG	O
repertories	NNS	O
of	IN	O
chemical	NN	O
compounds	NNS	O
synthesized	VBN	O
in	IN	O
industry	NN	O
,	,	O
e.g.	NN	O
,	,	O
by	IN	O
the	DT	O
chemical	NN	O
,	,	O
pharmaceutical	JJ	O
,	,	O
environmental	JJ	O
,	,	O
agricultural	JJ	O
,	,	O
marine	JJ	O
,	,	O
cosmeceutical	JJ	O
,	,	O
drug	NN	O
,	,	O
and	CC	O
biotechnological	JJ	O
industries	NNS	O
.	.	O
Combinatorial	JJ	O
libraries	NNS	O
can	MD	O
be	VB	O
produced	VBN	O
for	IN	O
many	JJ	O
types	NNS	O
of	IN	O
compounds	NNS	O
that	WDT	O
can	MD	O
be	VB	O
synthesized	VBN	O
in	IN	O
a	DT	O
step-by-step	JJ	O
fashion	NN	O
.	.	O
Such	JJ	O
compounds	NNS	O
include	VBP	O
polypeptides	NNS	O
,	,	O
proteins	NNS	O
,	,	O
nucleic	JJ	O
acids	NNS	O
,	,	O
beta-turn	JJ	O
mimetics	NNS	O
,	,	O
polysaccharides	NNS	O
,	,	O
phospholipids	NNS	O
,	,	O
hormones	NNS	O
,	,	O
prostaglandins	NNS	O
,	,	O
steroids	NNS	O
,	,	O
aromatic	JJ	O
compounds	NNS	O
,	,	O
heterocyclic	JJ	O
compounds	NNS	O
,	,	O
benzodiazepines	NNS	O
,	,	O
oligomeric	JJ	O
N-substituted	JJ	O
glycines	NNS	O
and	CC	O
oligocarbamates	NNS	O
.	.	O
Large	JJ	O
combinatorial	JJ	O
libraries	NNS	O
of	IN	O
compounds	NNS	O
can	MD	O
be	VB	O
constructed	VBN	O
by	IN	O
the	DT	O
encoded	JJ	O
synthetic	JJ	O
libraries	NNS	O
(	(	O
ESL	NNP	O
)	)	O
method	NN	O
described	VBN	O
in	IN	O
Affymax	NNP	O
WO	NNP	O
95/12608	CD	O
,	,	O
Affymax	NNP	O
WO	NNP	O
93/06121	CD	O
,	,	O
Columbia	NNP	O
University	NNP	O
WO	NNP	O
94/08051	CD	O
,	,	O
Pharmacopeia	NNP	O
WO	NNP	O
95/35503	CD	O
and	CC	O
Scripps	NNP	O
WO	NNP	O
95/30642	CD	O
(	(	O
each	DT	O
of	IN	O
which	WDT	O
is	VBZ	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
in	IN	O
its	PRP$	O
entirety	NN	O
for	IN	O
all	DT	O
purposes	NNS	O
)	)	O
.	.	O
Peptide	NNP	O
libraries	NNS	O
can	MD	O
also	RB	O
be	VB	O
generated	VBN	O
by	IN	O
phage	NN	O
display	NN	O
methods	NNS	O
.	.	O
See	VB	O
,	,	O
e.g.	VB	O
,	,	O
Devlin	NNP	O
,	,	O
WO	NNP	O
91/18980	CD	O
.	.	O
Compounds	NNS	O
to	TO	O
be	VB	O
screened	VBN	O
can	MD	O
also	RB	O
be	VB	O
obtained	VBN	O
from	IN	O
governmental	JJ	O
or	CC	O
private	JJ	O
sources	NNS	O
,	,	O
including	VBG	O
,	,	O
e.g.	NN	O
,	,	O
the	DT	O
National	NNP	O
Cancer	NNP	O
Institute	NNP	O
's	POS	O
(	(	O
NCI	NNP	O
)	)	O
Natural	NNP	O
Product	NNP	O
Repository	NNP	O
,	,	O
Bethesda	NNP	O
,	,	O
Md.	NNP	O
,	,	O
the	DT	O
NCI	NNP	O
Open	NNP	O
Synthetic	NNP	O
Compound	NNP	O
Collection	NNP	O
,	,	O
Bethesda	NNP	O
,	,	O
Md.	NNP	O
,	,	O
NCI	NNP	O
's	POS	O
Developmental	JJ	O
Therapeutics	NNPS	O
Program	NNP	O
,	,	O
or	CC	O
the	DT	O
like	JJ	O
.	.	O
Compounds	NNS	O
can	MD	O
include	VB	O
,	,	O
e.g.	FW	O
,	,	O
pharmaceuticals	NNS	O
,	,	O
therapeutics	NNS	O
,	,	O
environmental	JJ	O
,	,	O
agricultural	JJ	O
,	,	O
or	CC	O
industrial	JJ	O
agents	NNS	O
,	,	O
pollutants	NNS	O
,	,	O
cosmeceuticals	NNS	O
,	,	O
drugs	NNS	O
,	,	O
organic	JJ	O
compounds	NNS	O
,	,	O
lipids	NNS	O
,	,	O
glucocorticoids	NNS	O
,	,	O
antibiotics	NNS	O
,	,	O
peptides	NNS	O
,	,	O
proteins	NNS	O
,	,	O
sugars	NNS	O
,	,	O
carbohydrates	NNS	O
,	,	O
and	CC	O
chimeric	JJ	O
molecules	NNS	O
.	.	O
As	IN	O
discussed	VBN	O
above	IN	O
,	,	O
kinase	VB	O
inhibitors	NNS	O
that	WDT	O
preferentially	RB	O
inhibit	VBP	O
PLK2	NNP	O
are	VBP	O
of	IN	O
particular	JJ	O
value	NN	O
.	.	O
As	IN	O
is	VBZ	O
shown	VBN	O
in	IN	O
Examples	NNP	O
13-16	CD	O
,	,	O
below	IN	O
,	,	O
we	PRP	O
assayed	VBD	O
the	DT	O
effect	NN	O
of	IN	O
several	JJ	O
kinase	NN	O
inhibitors	NNS	O
levels	NNS	O
of	IN	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	NN	O
in	IN	O
rat	JJ	O
ventral	JJ	O
mesencephalon	NN	O
and	CC	O
mouse	VB	O
cortical	JJ	O
cell	NN	O
cultures	NNS	O
,	,	O
and	CC	O
other	JJ	O
cells	NNS	O
.	.	O
An	DT	O
exemplary	JJ	O
compound	NN	O
for	IN	O
use	NN	O
according	VBG	O
to	TO	O
the	DT	O
invention	NN	O
is	VBZ	O
the	DT	O
compound	NN	O
BI2536	NNP	O
having	VBG	O
the	DT	O
structure	NN	O
:	:	O
As	IN	O
demonstrated	VBN	O
in	IN	O
the	DT	O
Examples	NNP	O
below	IN	O
,	,	O
BI	NNP	O
2536	CD	O
(	(	O
4-	JJ	O
[	NN	O
[	NNP	O
(	(	O
7r	CD	O
)	)	O
-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl	NN	O
]	NNP	O
amino	NN	O
]	NNP	O
-3-methoxy-n-	NNP	O
(	(	O
1-methyl-4-piperidinyl	JJ	O
)	)	O
-benzamide	NN	O
;	:	O
also	RB	O
called	VBD	O
ELN-481574-2	NNP	O
;	:	O
)	)	O
reduced	VBD	O
phosphorylation	NN	O
of	IN	O
alpha	JJ	O
synuclein	NN	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
cell	NN	O
types	NNS	O
.	.	O
BI	IN	O
2536	CD	O
inhibits	NNS	O
PLK1	NNP	O
,	,	O
PLK2	NNP	O
and	CC	O
PLK3	NNP	O
(	(	O
see	VB	O
,	,	O
Steegmaier	NNP	B
et	FW	I
al.	NN	I
,	,	I
2007	CD	I
,	,	I
Current	NNP	I
Biology	NNP	I
,	,	I
17:316-322	JJ	I
)	)	O
and	CC	O
does	VBZ	O
not	RB	O
inhibit	VB	O
PLK4	NNP	O
(	(	O
Johnson	NNP	B
et	RB	I
al.	RB	I
,	,	I
2007	CD	I
,	,	I
Biochemistry	NNP	I
46:9551-9563	CD	I
)	)	O
.	.	O
Steegmaier	NNP	O
et	CC	O
al	NN	O
.	.	O
reported	VBD	O
an	DT	O
IC50	NNP	O
of	IN	O
0.83	CD	O
nM	NNS	O
for	IN	O
PLK1	NNP	O
,	,	O
3.5	CD	O
nM	NN	O
for	IN	O
PLK2	NNP	O
and	CC	O
9	CD	O
nM	NN	O
for	IN	O
PLK3	NNP	O
.	.	O
In	IN	O
tests	NNS	O
described	VBN	O
in	IN	O
Example	NNP	O
15	CD	O
,	,	O
below	IN	O
,	,	O
BI2536	NNP	O
was	VBD	O
shown	VBN	O
to	TO	O
have	VB	O
16-fold	JJ	O
selectivity	NN	O
for	IN	O
PLK2	NNP	O
(	(	O
IC50	NNP	O
11	CD	O
nM	NN	O
)	)	O
and	CC	O
13-fold	JJ	O
selectivity	NN	O
for	IN	O
PLK3	NNP	O
(	(	O
IC50	NNP	O
14	CD	O
nM	NN	O
)	)	O
.	.	O
BI	NN	O
2536	CD	O
has	VBZ	O
category	VBN	O
IV	NNP	O
PLK2	NNP	O
specificity	NN	O
(	(	O
Inhibits	NNP	O
PLK2	NNP	O
activity	NN	O
and	CC	O
has	VBZ	O
no	DT	O
,	,	O
or	CC	O
reduced	VBN	O
,	,	O
effect	NN	O
on	IN	O
PLK4	NNP	O
)	)	O
and	CC	O
is	VBZ	O
a	DT	O
candidate	NN	O
for	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
therapeutics	NNS	O
.	.	O
Accordingly	RB	O
,	,	O
in	IN	O
one	CD	O
aspect	NN	O
the	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
method	NN	O
for	IN	O
inhibiting	VBG	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	NN	O
in	IN	O
a	DT	O
mammalian	JJ	O
cell	NN	O
by	IN	O
contacting	VBG	O
the	DT	O
cell	NN	O
with	IN	O
an	DT	O
amount	NN	O
of	IN	O
BI	NNP	O
2536	CD	O
that	IN	O
reduces	VBZ	O
PLK2	NNP	O
activity	NN	O
in	IN	O
the	DT	O
cell	NN	O
such	JJ	O
that	IN	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	NN	O
is	VBZ	O
reduced	VBN	O
.	.	O
In	IN	O
a	DT	O
related	JJ	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
treating	VBG	O
a	DT	O
patient	NN	O
diagnosed	VBN	O
with	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
by	IN	O
administering	VBG	O
a	DT	O
therapeutically	RB	O
effective	JJ	O
amount	NN	O
of	IN	O
BI	NNP	O
2536	CD	O
.	.	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
6,861,422	CD	O
,	,	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
,	,	O
describes	VBZ	O
BI	NNP	O
2536	CD	O
and	CC	O
structurally	RB	O
related	JJ	O
dihydropteridinone	NN	O
kinase	NN	O
inhibitors	NNS	O
.	.	O
Dihydropteridinone	NNP	O
compounds	VBZ	O
that	IN	O
inhibit	NN	O
PLK2	NNP	O
are	VBP	O
useful	JJ	O
for	IN	O
inhibiting	VBG	O
phosphorylation	NN	O
of	IN	O
synuclein	NN	O
.	.	O
Another	DT	O
exemplary	JJ	O
compound	NN	O
for	IN	O
use	NN	O
according	VBG	O
to	TO	O
the	DT	O
invention	NN	O
is	VBZ	O
the	DT	O
compound	NN	O
ELN-481080	NNP	O
having	VBG	O
the	DT	O
structure	NN	O
:	:	O
See	VB	O
,	,	O
McInnes	NNP	B
et	FW	I
al.	NN	I
,	,	I
2006	CD	I
,	,	I
Current	NNP	I
Topics	NNPS	I
in	IN	I
Medicinal	NNP	I
Chemistry	NNP	I
5:181-97	JJ	I
(	(	O
Compound	NNP	O
8	CD	O
)	)	O
.	.	O
Also	RB	O
see	VBP	O
US	PRP	O
2006/0040997	CD	O
,	,	O
“	JJR	O
Benzthiazole-3	NNP	O
oxides	NNS	O
useful	JJ	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
proliferative	JJ	O
disorders	NNS	O
”	VBP	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
.	.	O
See	VB	O
Example	JJ	O
14	CD	O
,	,	O
below	NN	O
.	.	O
Several	JJ	O
inhibitors	NNS	O
of	IN	O
polo-like	JJ	O
kinases	NNS	O
are	VBP	O
described	VBN	O
in	IN	O
Johnson	NNP	B
et	CC	I
al.	NN	I
,	,	I
2007	CD	I
,	,	I
“	NNP	I
Pharmacological	NNP	I
and	CC	I
functional	JJ	I
comparison	NN	I
of	IN	I
the	DT	I
polo-like	JJ	I
kinase	NN	I
family	NN	I
:	:	I
insight	NN	I
into	IN	I
inhibitor	NN	I
and	CC	I
substrate	JJ	I
specificity	NN	I
”	NNP	I
Biochemistry	NNP	I
46:9551-63	CD	I
.	.	O
Of	IN	O
those	DT	O
characterized	VBN	O
in	IN	O
that	DT	O
study	NN	O
,	,	O
several	JJ	O
preferentially	RB	O
inhibit	JJ	O
PLK2	NNP	O
and	CC	O
may	MD	O
be	VB	O
used	VBN	O
as	IN	O
therapeutic	JJ	O
agents	NNS	O
.	.	O
For	IN	O
example	NN	O
,	,	O
CHIR-258	NNP	O
(	(	O
3	CD	O
)	)	O
is	VBZ	O
a	DT	O
multitarget	NN	O
growth	NN	O
factor	NN	O
kinase	NN	O
inhibitor	NN	O
developed	VBD	O
for	IN	O
treatment	NN	O
of	IN	O
t	NN	O
(	(	O
4	CD	O
;	:	O
14	CD	O
)	)	O
multiple	NN	O
myeloma	NN	O
(	(	O
Trudel	NNP	B
et	RB	I
al.	RB	I
,	,	I
2005	CD	I
,	,	I
Blood	NNP	I
.	.	I
105:2941-8	JJ	I
)	)	O
.	.	O
Ki	NNP	O
values	NNS	O
for	IN	O
CHIR-258	NNP	O
for	IN	O
PLK1	NNP	O
,	,	O
PLK2	NNP	O
,	,	O
PLK3	NNP	O
and	CC	O
PLK4	NNP	O
are	VBP	O
>	JJ	O
20	CD	O
,	,	O
0.85	CD	O
,	,	O
>	FW	O
20	CD	O
,	,	O
and	CC	O
1.4	CD	O
uM	JJ	O
respectively	RB	O
meaning	VBG	O
CHR-258	NNP	O
is	VBZ	O
a	DT	O
Type	NNP	O
VI	NNP	O
inhibitor	NN	O
(	(	O
inhibits	JJ	O
PLK2	NNP	O
activity	NN	O
and	CC	O
has	VBZ	O
reduced	VBN	O
effect	NN	O
on	IN	O
PLK1	NNP	O
,	,	O
PLK3	NNP	O
and	CC	O
PLK4	NNP	O
)	)	O
.	.	O
Although	IN	O
CHIR-258	NNP	O
is	VBZ	O
an	DT	O
inhibitor	NN	O
of	IN	O
receptor	NN	O
tyrosine	NN	O
kinases	NNS	O
,	,	O
warranting	VBG	O
study	NN	O
of	IN	O
the	DT	O
side	NN	O
effect	NN	O
profile	NN	O
,	,	O
targeted	VBN	O
delivery	NN	O
to	TO	O
the	DT	O
brain	NN	O
and/or	IN	O
particular	JJ	O
treatment	NN	O
regimens	NNS	O
can	MD	O
be	VB	O
investigated	VBN	O
to	TO	O
determine	VB	O
whether	IN	O
the	DT	O
compound	NN	O
has	VBZ	O
an	DT	O
acceptable	JJ	O
therapeutic	JJ	O
index	NN	O
for	IN	O
treatment	NN	O
and	CC	O
prevention	NN	O
of	IN	O
Parkinson	NNP	O
's	POS	O
Disease	NNP	O
,	,	O
and	CC	O
a	DT	O
clinically	RB	O
acceptable	JJ	O
side	NN	O
effect	NN	O
profile	NN	O
.	.	O
CHIR-258	NNP	O
and	CC	O
related	VBN	O
quinolinone	NN	O
derivatives	NNS	O
are	VBP	O
described	VBN	O
in	IN	O
WO03087095	NNP	O
,	,	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
.	.	O
Sunitinib	NNP	O
(	(	O
SU11248	NNP	O
)	)	O
(	(	O
4	CD	O
)	)	O
is	VBZ	O
an	DT	O
example	NN	O
of	IN	O
a	DT	O
Type	NNP	O
IV	NNP	O
inhibitor	NN	O
,	,	O
based	VBN	O
on	IN	O
the	DT	O
Johnson	NNP	O
et	CC	O
al.	NN	O
,	,	O
2007	CD	O
,	,	O
studies	NNS	O
(	(	O
inhibits	NNS	O
PLK2	NNP	O
activity	NN	O
with	IN	O
reduced	JJ	O
effect	NN	O
on	IN	O
PLK1	NNP	O
or	CC	O
PLK3	NNP	O
)	)	O
.	.	O
Sunitinib	NNP	O
was	VBD	O
identified	VBN	O
as	IN	O
an	DT	O
inhibitor	NN	O
of	IN	O
FLT3	NNP	O
receptor	NN	O
tyrosine	NN	O
kinase	NN	O
(	(	O
RTK	NNP	O
)	)	O
approved	VBD	O
for	IN	O
treatment	NN	O
of	IN	O
advanced	JJ	O
renal	JJ	O
cell	NN	O
carcinoma	NN	O
and	CC	O
gastrointestinal	JJ	O
stromal	NN	O
tumors	NNS	O
that	WDT	O
are	VBP	O
refractory	JJ	O
or	CC	O
intolerant	JJ	O
to	TO	O
imatinib	VB	O
(	(	O
Gleevec	NNP	O
)	)	O
.	.	O
O'Farrell	NNP	B
et	CC	I
al.	NN	I
,	,	I
2003	CD	I
,	,	I
Blood	NNP	I
101:3597-605	CD	I
.	.	O
5-	JJ	O
(	(	O
5,6-dimethoxy-1H-benzimidazol-1-yl	JJ	O
)	)	O
-3-	FW	O
{	(	O
[	JJ	O
2-	JJ	O
(	(	O
trifluoromethyl	NN	O
)	)	O
-benzyl	VBZ	O
]	JJ	O
oxy	JJ	O
}	)	O
thiophene-2-carboxamide	JJ	O
(	(	O
5	CD	O
)	)	O
is	VBZ	O
an	DT	O
example	NN	O
of	IN	O
a	DT	O
Type	NNP	O
III	NNP	O
agent	NN	O
(	(	O
inhibits	JJ	O
PLK2	NNP	O
activity	NN	O
and	CC	O
has	VBZ	O
reduced	VBN	O
effect	NN	O
on	IN	O
PLK4	NNP	O
)	)	O
.	.	O
The	DT	O
compound	NN	O
was	VBD	O
initially	RB	O
identified	VBN	O
as	IN	O
a	DT	O
selective	JJ	O
thiophene	NN	O
benzimidazole	JJ	O
ATP-competitive	JJ	O
inhibitor	NN	O
of	IN	O
PLK1	NNP	O
and	CC	O
PLK3	NNP	O
for	IN	O
treatment	NN	O
of	IN	O
neoplasms	NNS	O
.	.	O
Lansing	VBG	B
et	NN	I
al.	NN	I
,	,	I
2007	CD	I
,	,	I
Mol	NNP	I
Cancer	NNP	I
Ther	NNP	I
.	.	I
6:450-9	JJ	I
.	.	O
Also	RB	O
see	VBP	O
US	PRP	O
20060074119	CD	O
,	,	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
,	,	O
describing	VBG	O
other	JJ	O
inhibitors	NNS	O
of	IN	O
PLKs	NNP	O
.	.	O
Compounds	NNS	O
6	CD	O
and	CC	O
7	CD	O
are	VBP	O
indazole-pyridine	JJ	O
based	VBN	O
inhibitors	NNS	O
of	IN	O
protein	JJ	O
kinase	NN	O
B/Akt	NNP	O
proposed	VBD	O
as	IN	O
antitumor	NN	O
agents	NNS	O
(	(	O
see	VB	O
Woods	NNP	B
et	FW	I
al.	NN	I
,	,	I
2006	CD	I
,	,	I
Bioorg	NNP	I
Med	NNP	I
Chem	NNP	I
.	.	I
14:6832-46	JJ	I
)	)	O
.	.	O
Each	DT	O
has	VBZ	O
a	DT	O
lower	JJR	O
Ki	NNP	O
for	IN	O
PLK2	NNP	O
than	IN	O
for	IN	O
PLK1	NNP	O
or	CC	O
PLK3	NNP	O
(	(	O
Type	NNP	O
IV	NNP	O
inhibitor	NN	O
)	)	O
and	CC	O
may	MD	O
be	VB	O
used	VBN	O
for	IN	O
treatment	NN	O
of	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
the	DT	O
agent	NN	O
is	VBZ	O
a	DT	O
naturally	RB	O
occurring	VBG	O
agent	NN	O
.	.	O
In	IN	O
some	DT	O
embodiments	NNS	O
the	DT	O
agent	NN	O
has	VBZ	O
a	DT	O
molecular	JJ	O
weight	NN	O
less	JJR	O
than	IN	O
4000	CD	O
,	,	O
sometimes	RB	O
less	JJR	O
than	IN	O
3000	CD	O
,	,	O
sometimes	RB	O
less	JJR	O
than	IN	O
2000	CD	O
,	,	O
usually	RB	O
less	JJR	O
than	IN	O
1000	CD	O
,	,	O
and	CC	O
sometimes	RB	O
less	JJR	O
than	IN	O
500	CD	O
.	.	O
In	IN	O
certain	JJ	O
embodiments	NNS	O
the	DT	O
therapeutic	JJ	O
agent	NN	O
is	VBZ	O
a	DT	O
small	JJ	O
molecule	NN	O
other	JJ	O
than	IN	O
a	DT	O
thiazolidone	NN	O
.	.	O
In	IN	O
certain	JJ	O
embodiments	NNS	O
the	DT	O
therapeutic	JJ	O
agent	NN	O
is	VBZ	O
a	DT	O
small	JJ	O
molecule	NN	O
other	JJ	O
than	IN	O
X	NN	O
,	,	O
where	WRB	O
X	NN	O
is	VBZ	O
one	CD	O
of	IN	O
,	,	O
or	CC	O
an	DT	O
independently	RB	O
selected	VBN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
,	,	O
(	(	O
i	NN	O
)	)	O
a	DT	O
thiazolidone	NN	O
,	,	O
(	(	O
ii	NN	O
)	)	O
a	DT	O
quinazoline	NN	O
,	,	O
(	(	O
iii	NN	O
)	)	O
a	DT	O
pyrimidine	NN	O
,	,	O
(	(	O
iv	NN	O
)	)	O
pyrido	NN	O
[	NNP	O
d	NN	O
]	NNP	O
-pyrimidine	NN	O
,	,	O
(	(	O
v	NN	O
)	)	O
a	DT	O
pyrimidol	NN	O
[	NNP	O
d	NN	O
]	NNP	O
pyrimidine	NN	O
,	,	O
(	(	O
vi	NN	O
)	)	O
a	DT	O
pyrazolo	NN	O
[	NNP	O
d	NN	O
]	NNP	O
-pyrimidine	NN	O
,	,	O
(	(	O
vii	NN	O
)	)	O
a	DT	O
pyrrolo	NN	O
[	NNP	O
d	NN	O
]	NNP	O
pyrimidine	NN	O
,	,	O
(	(	O
viii	NN	O
)	)	O
a	DT	O
pheylamino-pyrimidines	JJ	O
,	,	O
(	(	O
ix	NN	O
)	)	O
phenylamino-pyrimidine	NN	O
derivative	JJ	O
,	,	O
(	(	O
x	NN	O
)	)	O
a	DT	O
indazole-pyridine	JJ	O
derivative	NN	O
,	,	O
(	(	O
xi	NN	O
)	)	O
a	DT	O
carboxylic	JJ	O
acid	NN	O
derivative	NN	O
,	,	O
(	(	O
xii	NN	O
)	)	O
a	DT	O
1-oxo-3-aryl-1H-indene-2-carboxylic	JJ	O
acid	NN	O
derivative	NN	O
,	,	O
(	(	O
xiii	NN	O
)	)	O
a	DT	O
substituted	JJ	O
indolin-2-one	NN	O
,	,	O
(	(	O
xiv	NNP	O
)	)	O
an	DT	O
aniline-phthalazine	JJ	O
derivative	NN	O
;	:	O
(	(	O
xv	FW	O
)	)	O
a	DT	O
quinolinone	NN	O
derivative	NN	O
,	,	O
(	(	O
xvi	NN	O
)	)	O
a	DT	O
thiazolidinone	NN	O
compound	NN	O
,	,	O
(	(	O
xvii	NN	O
)	)	O
a	DT	O
benzthiazole-3	JJ	O
oxide	NN	O
(	(	O
xviii	NNP	O
)	)	O
a	DT	O
dihydropteridinone	NN	O
or	CC	O
(	(	O
xix	NN	O
)	)	O
an	DT	O
azaindazole	JJ	O
compound	NN	O
.	.	O
In	IN	O
certain	JJ	O
embodiments	NNS	O
the	DT	O
therapeutic	JJ	O
agent	NN	O
is	VBZ	O
a	DT	O
small	JJ	O
molecule	NN	O
with	IN	O
the	DT	O
proviso	NN	O
it	PRP	O
is	VBZ	O
not	RB	O
a	DT	O
compound	NN	O
described	VBN	O
in	IN	O
US	NNP	O
2007/0179177	CD	O
.	.	O
In	IN	O
certain	JJ	O
embodiments	NNS	O
the	DT	O
therapeutic	JJ	O
agent	NN	O
is	VBZ	O
a	DT	O
small	JJ	O
molecule	NN	O
with	IN	O
the	DT	O
proviso	NN	O
it	PRP	O
is	VBZ	O
not	RB	O
a	DT	O
compound	NN	O
described	VBN	O
in	IN	O
US	NNP	O
2007/0010565	CD	O
.	.	O
In	IN	O
certain	JJ	O
embodiments	NNS	O
the	DT	O
therapeutic	JJ	O
agent	NN	O
is	VBZ	O
a	DT	O
small	JJ	O
molecule	NN	O
with	IN	O
the	DT	O
proviso	NN	O
it	PRP	O
is	VBZ	O
not	RB	O
a	DT	O
compound	NN	O
described	VBN	O
in	IN	O
US	NNP	O
2007/0037862	CD	O
.	.	O
In	IN	O
certain	JJ	O
embodiments	NNS	O
the	DT	O
therapeutic	JJ	O
agent	NN	O
is	VBZ	O
a	DT	O
small	JJ	O
molecule	NN	O
with	IN	O
the	DT	O
proviso	NN	O
it	PRP	O
is	VBZ	O
not	RB	O
a	DT	O
compound	NN	O
described	VBN	O
in	IN	O
2007/0010566	CD	O
.	.	O
In	IN	O
certain	JJ	O
embodiments	NNS	O
the	DT	O
therapeutic	JJ	O
agent	NN	O
is	VBZ	O
a	DT	O
small	JJ	O
molecule	NN	O
with	IN	O
the	DT	O
proviso	NN	O
it	PRP	O
is	VBZ	O
not	RB	O
a	DT	O
compound	NN	O
described	VBN	O
in	IN	O
2006/0079503	CD	O
.	.	O
In	IN	O
certain	JJ	O
embodiments	NNS	O
the	DT	O
therapeutic	JJ	O
agent	NN	O
is	VBZ	O
a	DT	O
small	JJ	O
molecule	NN	O
with	IN	O
the	DT	O
proviso	NN	O
it	PRP	O
is	VBZ	O
not	RB	O
a	DT	O
compound	NN	O
described	VBN	O
in	IN	O
US	NNP	O
2006/0223833	CD	O
.	.	O
Each	DT	O
of	IN	O
the	DT	O
aforelisted	JJ	O
publications	NNS	O
is	VBZ	O
incorporated	VBN	O
herein	NN	O
by	IN	O
reference	NN	O
.	.	O
VI	NNP	O
.	.	O
Methods	NNS	O
of	IN	O
Treatment	NNP	O
The	DT	O
invention	NN	O
provides	VBZ	O
several	JJ	O
methods	NNS	O
of	IN	O
preventing	VBG	O
or	CC	O
treating	VBG	O
Lewy	NNP	O
Body	NNP	O
disease	NN	O
in	IN	O
patients	NNS	O
suffering	VBG	O
from	IN	O
or	CC	O
at	IN	O
risk	NN	O
of	IN	O
such	JJ	O
disease	NN	O
.	.	O
Therapeutic	JJ	O
agents	NNS	O
include	VBP	O
any	DT	O
of	IN	O
the	DT	O
agents	NNS	O
described	VBN	O
above	IN	O
that	DT	O
inhibit	NN	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	JJ	O
and/or	NN	O
reduce	VB	O
total	JJ	O
levels	NNS	O
of	IN	O
alpha-synuclein	NN	O
.	.	O
The	DT	O
experimental	JJ	O
examples	NNS	O
below	IN	O
provide	VBP	O
strong	JJ	O
evidence	NN	O
that	IN	O
PLK2	NNP	O
is	VBZ	O
a	DT	O
synuclein	JJ	O
kinase	NN	O
.	.	O
Thus	RB	O
,	,	O
in	IN	O
a	DT	O
particular	JJ	O
aspect	NN	O
,	,	O
the	DT	O
invention	NN	O
provides	VBZ	O
a	DT	O
method	NN	O
of	IN	O
effecting	VBG	O
treatment	NN	O
or	CC	O
prophylaxis	NN	O
of	IN	O
an	DT	O
LB	NNP	O
disease	NN	O
by	IN	O
administering	VBG	O
to	TO	O
a	DT	O
patient	NN	O
suffering	VBG	O
from	IN	O
or	CC	O
at	IN	O
risk	NN	O
of	IN	O
the	DT	O
disease	NN	O
an	DT	O
effective	JJ	O
regime	NN	O
of	IN	O
an	DT	O
agent	JJ	O
effective	JJ	O
to	TO	O
suppress	VB	O
activity	NN	O
or	CC	O
expression	NN	O
of	IN	O
PLK2	NNP	O
.	.	O
It	PRP	O
is	VBZ	O
preferred	VBN	O
that	IN	O
the	DT	O
agent	NN	O
shows	VBZ	O
a	DT	O
high	JJ	O
level	NN	O
of	IN	O
specificity	NN	O
for	IN	O
PLK2	NNP	O
.	.	O
Patients	NNS	O
amenable	JJ	O
to	TO	O
treatment	NN	O
include	JJ	O
individuals	NNS	O
at	IN	O
risk	NN	O
of	IN	O
disease	NN	O
of	IN	O
a	DT	O
LBD	NNP	O
but	CC	O
not	RB	O
showing	VBG	O
symptoms	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
patients	NNS	O
presently	RB	O
showing	VBG	O
symptoms	NNS	O
.	.	O
Therefore	RB	O
,	,	O
the	DT	O
present	JJ	O
methods	NNS	O
can	MD	O
be	VB	O
administered	VBN	O
prophylactically	RB	O
to	TO	O
individuals	NNS	O
who	WP	O
have	VBP	O
a	DT	O
known	VBN	O
genetic	JJ	O
risk	NN	O
of	IN	O
a	DT	O
LBD	NNP	O
.	.	O
Such	JJ	O
individuals	NNS	O
include	VBP	O
those	DT	O
having	VBG	O
relatives	NNS	O
who	WP	O
have	VBP	O
experienced	VBN	O
this	DT	O
disease	NN	O
,	,	O
and	CC	O
those	DT	O
whose	WP$	O
risk	NN	O
is	VBZ	O
determined	VBN	O
by	IN	O
analysis	NN	O
of	IN	O
genetic	JJ	O
or	CC	O
biochemical	JJ	O
markers	NNS	O
.	.	O
Genetic	JJ	O
markers	NNS	O
of	IN	O
risk	NN	O
toward	IN	O
PD	NNP	O
include	VBP	O
mutations	NNS	O
in	IN	O
the	DT	O
alpha-synuclein	NN	O
or	CC	O
Parkin	NNP	O
,	,	O
UCHLI	NNP	O
,	,	O
LRRK2	NNP	O
,	,	O
and	CC	O
CYP2D6	NNP	O
genes	NNS	O
;	:	O
particularly	RB	O
mutations	NNS	O
at	IN	O
positions	NNS	O
30	CD	O
and	CC	O
53	CD	O
of	IN	O
the	DT	O
alpha-synuclein	JJ	O
gene	NN	O
.	.	O
Another	DT	O
genetic	JJ	O
marker	NN	O
of	IN	O
risk	NN	O
toward	IN	O
PD	NNP	O
includes	VBZ	O
measuring	VBG	O
the	DT	O
levels	NNS	O
or	CC	O
SNCA	NNP	O
dosage	NN	O
or	CC	O
transcription	NN	O
.	.	O
Individuals	NNS	O
presently	RB	O
suffering	VBG	O
from	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
can	MD	O
be	VB	O
recognized	VBN	O
from	IN	O
its	PRP$	O
clinical	JJ	O
manifestations	NNS	O
including	VBG	O
resting	VBG	O
tremor	NN	O
,	,	O
muscular	JJ	O
rigidity	NN	O
,	,	O
bradykinesia	NN	O
and	CC	O
postural	JJ	O
instability	NN	O
.	.	O
In	IN	O
some	DT	O
methods	NNS	O
,	,	O
the	DT	O
patient	NN	O
is	VBZ	O
free	JJ	O
of	IN	O
clinical	JJ	O
symptoms	NNS	O
or	CC	O
risk	NN	O
factors	NNS	O
for	IN	O
any	DT	O
amyloidogenic	JJ	O
disease	NN	O
other	JJ	O
than	IN	O
one	CD	O
characterized	VBN	O
by	IN	O
Lewy	NNP	O
bodies	NNS	O
.	.	O
In	IN	O
some	DT	O
methods	NNS	O
,	,	O
the	DT	O
patient	NN	O
is	VBZ	O
free	JJ	O
of	IN	O
clinical	JJ	O
symptoms	NNS	O
or	CC	O
risk	NN	O
factors	NNS	O
of	IN	O
any	DT	O
disease	NN	O
characterized	VBN	O
by	IN	O
extracellular	JJ	O
amyloid	NN	O
deposits	NNS	O
.	.	O
In	IN	O
some	DT	O
methods	NNS	O
the	DT	O
patient	NN	O
is	VBZ	O
not	RB	O
diagnosed	VBN	O
with	IN	O
cancer	NN	O
and/or	VBP	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
.	.	O
Treatment	NNP	O
typically	RB	O
entails	VBZ	O
multiple	JJ	O
dosages	NNS	O
over	IN	O
a	DT	O
period	NN	O
of	IN	O
time	NN	O
.	.	O
Treatment	NN	O
can	MD	O
be	VB	O
monitored	VBN	O
by	IN	O
assaying	VBG	O
signs	NNS	O
or	CC	O
symptoms	NNS	O
of	IN	O
the	DT	O
disease	NN	O
being	VBG	O
treated	VBN	O
relative	JJ	O
to	TO	O
base	VB	O
line	NN	O
measurements	NNS	O
before	IN	O
initiating	VBG	O
treatment	NN	O
.	.	O
In	IN	O
some	DT	O
methods	NNS	O
,	,	O
administration	NN	O
of	IN	O
an	DT	O
agent	JJ	O
results	NNS	O
in	IN	O
reduction	NN	O
of	IN	O
intracellular	JJ	O
levels	NNS	O
of	IN	O
aggregated	JJ	O
alpha-synuclein	NN	O
.	.	O
In	IN	O
some	DT	O
methods	NNS	O
,	,	O
administration	NN	O
of	IN	O
the	DT	O
agent	NN	O
results	NNS	O
in	IN	O
a	DT	O
reduction	NN	O
in	IN	O
levels	NNS	O
of	IN	O
phosphorylated	VBN	O
synuclein	NN	O
.	.	O
In	IN	O
some	DT	O
methods	NNS	O
,	,	O
administration	NN	O
of	IN	O
an	DT	O
agent	JJ	O
results	NNS	O
in	IN	O
improvement	NN	O
in	IN	O
a	DT	O
clinical	JJ	O
symptom	NN	O
of	IN	O
a	DT	O
LBD	NNP	O
,	,	O
such	JJ	O
as	IN	O
motor	NN	O
or	CC	O
cognitive	JJ	O
function	NN	O
in	IN	O
the	DT	O
case	NN	O
of	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
.	.	O
In	IN	O
prophylactic	JJ	O
applications	NNS	O
,	,	O
pharmaceutical	JJ	O
compositions	NNS	O
or	CC	O
medicaments	NNS	O
are	VBP	O
administered	VBN	O
to	TO	O
a	DT	O
patient	NN	O
susceptible	JJ	O
to	TO	O
,	,	O
or	CC	O
otherwise	RB	O
at	IN	O
risk	NN	O
of	IN	O
a	DT	O
LBD	NNP	O
in	IN	O
regime	NN	O
comprising	VBG	O
an	DT	O
amount	NN	O
and	CC	O
frequency	NN	O
of	IN	O
administration	NN	O
of	IN	O
the	DT	O
composition	NN	O
or	CC	O
medicament	NN	O
sufficient	NN	O
to	TO	O
eliminate	VB	O
or	CC	O
reduce	VB	O
the	DT	O
risk	NN	O
,	,	O
lessen	VBD	O
the	DT	O
severity	NN	O
,	,	O
or	CC	O
delay	VB	O
the	DT	O
outset	NN	O
of	IN	O
the	DT	O
disease	NN	O
,	,	O
including	VBG	O
physiological	JJ	O
,	,	O
biochemical	JJ	O
,	,	O
histologic	JJ	O
and/or	JJ	O
behavioral	JJ	O
symptoms	NNS	O
of	IN	O
the	DT	O
disease	NN	O
,	,	O
its	PRP$	O
complications	NNS	O
and	CC	O
intermediate	JJ	O
pathological	JJ	O
phenotypes	NNS	O
presenting	VBG	O
during	IN	O
development	NN	O
of	IN	O
the	DT	O
disease	NN	O
.	.	O
In	IN	O
therapeutic	JJ	O
applications	NNS	O
,	,	O
compositions	NNS	O
or	CC	O
medicates	NNS	O
are	VBP	O
administered	VBN	O
to	TO	O
a	DT	O
patient	NN	O
suspected	VBN	O
of	IN	O
,	,	O
or	CC	O
already	RB	O
suffering	VBG	O
from	IN	O
such	JJ	O
a	DT	O
disease	NN	O
in	IN	O
a	DT	O
regime	NN	O
comprising	VBG	O
an	DT	O
amount	NN	O
and	CC	O
frequency	NN	O
of	IN	O
administration	NN	O
of	IN	O
the	DT	O
composition	NN	O
sufficient	NN	O
to	TO	O
cure	VB	O
,	,	O
or	CC	O
at	IN	O
least	JJS	O
partially	RB	O
arrest	RB	O
,	,	O
the	DT	O
symptoms	NNS	O
of	IN	O
the	DT	O
disease	NN	O
(	(	O
physiological	JJ	O
,	,	O
biochemical	JJ	O
,	,	O
histologic	JJ	O
and/or	IN	O
behavioral	JJ	O
)	)	O
,	,	O
including	VBG	O
its	PRP$	O
complications	NNS	O
and	CC	O
intermediate	JJ	O
pathological	JJ	O
phenotypes	NNS	O
in	IN	O
development	NN	O
of	IN	O
the	DT	O
disease	NN	O
.	.	O
An	DT	O
amount	NN	O
adequate	NN	O
to	TO	O
accomplish	VB	O
therapeutic	JJ	O
or	CC	O
prophylactic	JJ	O
treatment	NN	O
is	VBZ	O
defined	VBN	O
as	IN	O
a	DT	O
therapeutically-	JJ	O
or	CC	O
prophylactically-effective	JJ	O
dose	NN	O
.	.	O
A	DT	O
combination	NN	O
of	IN	O
amount	NN	O
and	CC	O
dosage	NN	O
frequency	NN	O
adequate	NN	O
to	TO	O
accomplish	VB	O
therapeutic	JJ	O
or	CC	O
prophylactic	JJ	O
treatment	NN	O
is	VBZ	O
defined	VBN	O
as	IN	O
a	DT	O
therapeutically	RB	O
or	CC	O
prophylactically-effective	JJ	O
regime	NN	O
.	.	O
Effective	JJ	O
doses	NNS	O
of	IN	O
the	DT	O
compositions	NNS	O
of	IN	O
the	DT	O
present	JJ	O
invention	NN	O
,	,	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
the	DT	O
above	JJ	O
described	NN	O
conditions	NNS	O
vary	VBP	O
depending	VBG	O
upon	IN	O
many	JJ	O
different	JJ	O
factors	NNS	O
,	,	O
including	VBG	O
means	NNS	O
of	IN	O
administration	NN	O
,	,	O
target	VB	O
site	NN	O
,	,	O
physiological	JJ	O
state	NN	O
of	IN	O
the	DT	O
patient	NN	O
,	,	O
whether	IN	O
the	DT	O
patient	NN	O
is	VBZ	O
human	JJ	O
or	CC	O
an	DT	O
animal	NN	O
,	,	O
other	JJ	O
medications	NNS	O
administered	VBN	O
,	,	O
and	CC	O
whether	IN	O
treatment	NN	O
is	VBZ	O
prophylactic	JJ	O
or	CC	O
therapeutic	JJ	O
.	.	O
Usually	RB	O
,	,	O
the	DT	O
patient	NN	O
is	VBZ	O
a	DT	O
human	JJ	O
but	CC	O
nonhuman	JJ	O
mammals	NNS	O
including	VBG	O
transgenic	JJ	O
mammals	NNS	O
can	MD	O
also	RB	O
be	VB	O
treated	VBN	O
.	.	O
Treatment	NN	O
dosages	NNS	O
need	VBP	O
to	TO	O
be	VB	O
titrated	VBN	O
to	TO	O
optimize	VB	O
safety	NN	O
and	CC	O
efficacy	NN	O
.	.	O
The	DT	O
dosage	NN	O
and	CC	O
frequency	NN	O
of	IN	O
administration	NN	O
can	MD	O
vary	VB	O
depending	VBG	O
on	IN	O
whether	IN	O
the	DT	O
treatment	NN	O
is	VBZ	O
prophylactic	JJ	O
or	CC	O
therapeutic	JJ	O
.	.	O
Guidance	NN	O
can	MD	O
be	VB	O
obtained	VBN	O
from	IN	O
the	DT	O
dosing	VBG	O
schedules	NNS	O
of	IN	O
kinase	NN	O
inhibitors	NNS	O
currently	RB	O
approved	VBD	O
or	CC	O
in	IN	O
clinical	JJ	O
trials	NNS	O
for	IN	O
other	JJ	O
indications	NNS	O
.	.	O
Dosages	NNS	O
in	IN	O
the	DT	O
range	NN	O
of	IN	O
0.1-1000	CD	O
mg	NNS	O
,	,	O
preferably	RB	O
10-500	CD	O
mg	NNS	O
,	,	O
may	MD	O
be	VB	O
used	VBN	O
.	.	O
Frequency	NN	O
of	IN	O
dosing	VBG	O
(	(	O
e.g.	JJ	O
,	,	O
daily	JJ	O
,	,	O
weekly	JJ	O
or	CC	O
monthly	JJ	O
)	)	O
depends	VBZ	O
on	IN	O
the	DT	O
half-life	NN	O
of	IN	O
the	DT	O
drug	NN	O
.	.	O
In	IN	O
prophylactic	JJ	O
applications	NNS	O
,	,	O
a	DT	O
relatively	RB	O
low	JJ	O
dosage	NN	O
is	VBZ	O
administered	VBN	O
at	IN	O
relatively	RB	O
infrequent	JJ	O
intervals	NNS	O
over	IN	O
a	DT	O
long	JJ	O
period	NN	O
of	IN	O
time	NN	O
.	.	O
Some	DT	O
patients	NNS	O
continue	VBP	O
to	TO	O
receive	VB	O
treatment	NN	O
for	IN	O
the	DT	O
rest	NN	O
of	IN	O
their	PRP$	O
lives	NNS	O
.	.	O
In	IN	O
therapeutic	JJ	O
applications	NNS	O
,	,	O
a	DT	O
relatively	RB	O
high	JJ	O
dosage	NN	O
at	IN	O
relatively	RB	O
short	JJ	O
intervals	NNS	O
is	VBZ	O
sometimes	RB	O
required	VBN	O
until	IN	O
progression	NN	O
of	IN	O
the	DT	O
disease	NN	O
is	VBZ	O
reduced	VBN	O
or	CC	O
terminated	VBN	O
,	,	O
and	CC	O
preferably	RB	O
until	IN	O
the	DT	O
patient	NN	O
shows	VBZ	O
partial	JJ	O
or	CC	O
complete	JJ	O
amelioration	NN	O
of	IN	O
symptoms	NNS	O
of	IN	O
disease	NN	O
.	.	O
Thereafter	RB	O
,	,	O
the	DT	O
patent	NN	O
can	MD	O
be	VB	O
administered	VBN	O
a	DT	O
prophylactic	JJ	O
regime	NN	O
.	.	O
Therapeutic	JJ	O
agents	NNS	O
can	MD	O
be	VB	O
administered	VBN	O
by	IN	O
parenteral	JJ	O
,	,	O
topical	JJ	O
,	,	O
intravenous	JJ	O
,	,	O
oral	JJ	O
,	,	O
subcutaneous	JJ	O
,	,	O
intraarterial	JJ	O
,	,	O
intracranial	JJ	O
,	,	O
intrathecal	JJ	O
,	,	O
intraperitoneal	JJ	O
,	,	O
intranasal	NN	O
or	CC	O
intramuscular	JJ	O
means	NNS	O
for	IN	O
prophylactic	JJ	O
and/or	JJ	O
therapeutic	JJ	O
treatment	NN	O
.	.	O
In	IN	O
some	DT	O
methods	NNS	O
,	,	O
agents	NNS	O
are	VBP	O
injected	VBN	O
directly	RB	O
into	IN	O
a	DT	O
particular	JJ	O
tissue	NN	O
where	WRB	O
deposits	NNS	O
have	VBP	O
accumulated	VBN	O
,	,	O
for	IN	O
example	NN	O
intracranial	JJ	O
injection	NN	O
.	.	O
In	IN	O
some	DT	O
methods	NNS	O
,	,	O
agents	NNS	O
are	VBP	O
administered	VBN	O
as	IN	O
a	DT	O
sustained	JJ	O
release	NN	O
composition	NN	O
or	CC	O
device	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
Medipad™	NNP	O
device	NN	O
.	.	O
Small	JJ	O
molecules	NNS	O
that	WDT	O
pass	VBP	O
through	IN	O
the	DT	O
blood	NN	O
brain	NN	O
barrier	NN	O
sufficiently	RB	O
are	VBP	O
usually	RB	O
administered	VBN	O
orally	RB	O
,	,	O
but	CC	O
can	MD	O
also	RB	O
be	VB	O
administered	VBN	O
intravenously	RB	O
.	.	O
Agents	NNS	O
of	IN	O
the	DT	O
invention	NN	O
can	MD	O
optionally	RB	O
be	VB	O
administered	VBN	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
agents	NNS	O
that	WDT	O
are	VBP	O
at	IN	O
least	JJS	O
partly	RB	O
effective	JJ	O
in	IN	O
treatment	NN	O
of	IN	O
LBD	NNP	O
.	.	O
Agents	NNS	O
of	IN	O
the	DT	O
invention	NN	O
can	MD	O
also	RB	O
be	VB	O
administered	VBN	O
in	IN	O
conjunction	NN	O
with	IN	O
other	JJ	O
agents	NNS	O
that	IN	O
increase	JJ	O
passage	NN	O
of	IN	O
the	DT	O
agents	NNS	O
of	IN	O
the	DT	O
invention	NN	O
across	IN	O
the	DT	O
blood-brain	NN	O
barrier	NN	O
.	.	O
Agents	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
often	RB	O
administered	VBN	O
as	IN	O
pharmaceutical	JJ	O
compositions	NNS	O
comprising	VBG	O
an	DT	O
active	JJ	O
therapeutic	JJ	O
agent	NN	O
and	CC	O
a	DT	O
variety	NN	O
of	IN	O
other	JJ	O
pharmaceutically	RB	O
acceptable	JJ	O
components	NNS	O
.	.	O
See	NNP	O
Remington	NNP	B
's	POS	I
Pharmaceutical	JJ	I
Science	NNP	I
(	(	I
15th	CD	I
ed.	NN	I
,	,	I
Mack	NNP	I
Publishing	NNP	I
Company	NNP	I
,	,	I
Easton	NNP	I
,	,	I
Pa.	NNP	I
,	,	I
1980	CD	I
)	)	I
.	.	O
The	DT	O
preferred	JJ	O
form	NN	O
depends	VBZ	O
on	IN	O
the	DT	O
intended	JJ	O
mode	NN	O
of	IN	O
administration	NN	O
and	CC	O
therapeutic	JJ	O
application	NN	O
.	.	O
The	DT	O
compositions	NNS	O
can	MD	O
also	RB	O
include	VB	O
,	,	O
depending	VBG	O
on	IN	O
the	DT	O
formulation	NN	O
desired	VBD	O
,	,	O
pharmaceutically-acceptable	JJ	O
,	,	O
non-toxic	JJ	O
carriers	NNS	O
or	CC	O
diluents	NNS	O
,	,	O
which	WDT	O
are	VBP	O
defined	VBN	O
as	IN	O
vehicles	NNS	O
commonly	RB	O
used	VBD	O
to	TO	O
formulate	VB	O
pharmaceutical	JJ	O
compositions	NNS	O
for	IN	O
animal	NN	O
or	CC	O
human	JJ	O
administration	NN	O
.	.	O
The	DT	O
diluent	NN	O
is	VBZ	O
selected	VBN	O
so	RB	O
as	IN	O
not	RB	O
to	TO	O
affect	VB	O
the	DT	O
biological	JJ	O
activity	NN	O
of	IN	O
the	DT	O
combination	NN	O
.	.	O
Examples	NNS	O
of	IN	O
such	JJ	O
diluents	NNS	O
are	VBP	O
distilled	JJ	O
water	NN	O
,	,	O
physiological	JJ	O
phosphate-buffered	JJ	O
saline	NN	O
,	,	O
Ringer	NNP	O
's	POS	O
solutions	NNS	O
,	,	O
dextrose	JJ	O
solution	NN	O
,	,	O
and	CC	O
Hank	NNP	O
's	POS	O
solution	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
the	DT	O
pharmaceutical	JJ	O
composition	NN	O
or	CC	O
formulation	NN	O
may	MD	O
also	RB	O
include	VB	O
other	JJ	O
carriers	NNS	O
,	,	O
adjuvants	NNS	O
,	,	O
or	CC	O
nontoxic	RB	O
,	,	O
nontherapeutic	JJ	O
,	,	O
nonimmunogenic	JJ	O
stabilizers	NNS	O
and	CC	O
the	DT	O
like	JJ	O
.	.	O
Pharmaceutical	JJ	O
compositions	NNS	O
can	MD	O
also	RB	O
include	VB	O
large	JJ	O
,	,	O
slowly	RB	O
metabolized	VBN	O
macromolecules	NNS	O
such	JJ	O
as	IN	O
proteins	NNS	O
,	,	O
polysaccharides	NNS	O
such	JJ	O
as	IN	O
chitosan	NNS	O
,	,	O
polylactic	JJ	O
acids	NNS	O
,	,	O
polyglycolic	JJ	O
acids	NNS	O
and	CC	O
copolymers	NNS	O
(	(	O
such	JJ	O
as	IN	O
latex	JJ	O
functionalized	JJ	O
Sepharose™	NNP	O
,	,	O
agarose	RB	O
,	,	O
cellulose	NN	O
,	,	O
and	CC	O
the	DT	O
like	JJ	O
)	)	O
,	,	O
polymeric	JJ	O
amino	NN	O
acids	NNS	O
,	,	O
amino	JJ	O
acid	NN	O
copolymers	NNS	O
,	,	O
and	CC	O
lipid	JJ	O
aggregates	NNS	O
(	(	O
such	JJ	O
as	IN	O
oil	NN	O
droplets	NNS	O
or	CC	O
liposomes	NNS	O
)	)	O
.	.	O
For	IN	O
parenteral	JJ	O
administration	NN	O
,	,	O
agents	NNS	O
of	IN	O
the	DT	O
invention	NN	O
can	MD	O
be	VB	O
administered	VBN	O
as	IN	O
injectable	JJ	O
dosages	NNS	O
of	IN	O
a	DT	O
solution	NN	O
or	CC	O
suspension	NN	O
of	IN	O
the	DT	O
substance	NN	O
in	IN	O
a	DT	O
physiologically	RB	O
acceptable	JJ	O
diluent	NN	O
with	IN	O
a	DT	O
pharmaceutical	JJ	O
carrier	NN	O
that	WDT	O
can	MD	O
be	VB	O
a	DT	O
sterile	JJ	O
liquid	NN	O
such	JJ	O
as	IN	O
water	NN	O
,	,	O
oils	NNS	O
,	,	O
saline	NN	O
,	,	O
glycerol	NN	O
,	,	O
or	CC	O
ethanol	NN	O
.	.	O
Additionally	RB	O
,	,	O
auxiliary	JJ	O
substances	NNS	O
,	,	O
such	JJ	O
as	IN	O
wetting	VBG	O
or	CC	O
emulsifying	VBG	O
agents	NNS	O
,	,	O
surfactants	NNS	O
,	,	O
pH	NN	O
buffering	NN	O
substances	NNS	O
and	CC	O
the	DT	O
like	JJ	O
can	MD	O
be	VB	O
present	JJ	O
in	IN	O
compositions	NNS	O
.	.	O
Other	JJ	O
components	NNS	O
of	IN	O
pharmaceutical	JJ	O
compositions	NNS	O
are	VBP	O
those	DT	O
of	IN	O
petroleum	NN	O
,	,	O
animal	NN	O
,	,	O
vegetable	JJ	O
,	,	O
or	CC	O
synthetic	JJ	O
origin	NN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
peanut	JJ	O
oil	NN	O
,	,	O
soybean	NN	O
oil	NN	O
,	,	O
and	CC	O
mineral	JJ	O
oil	NN	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
glycols	NNS	O
such	JJ	O
as	IN	O
propylene	NN	O
glycol	NN	O
or	CC	O
polyethylene	NN	O
glycol	NNS	O
are	VBP	O
preferred	VBN	O
liquid	JJ	O
carriers	NNS	O
,	,	O
particularly	RB	O
for	IN	O
injectable	JJ	O
solutions	NNS	O
.	.	O
Antibodies	NNS	O
can	MD	O
be	VB	O
administered	VBN	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
a	DT	O
depot	NN	O
injection	NN	O
or	CC	O
implant	JJ	O
preparation	NN	O
which	WDT	O
can	MD	O
be	VB	O
formulated	VBN	O
in	IN	O
such	JJ	O
a	DT	O
manner	NN	O
as	IN	O
to	TO	O
permit	VB	O
a	DT	O
sustained	JJ	O
release	NN	O
of	IN	O
the	DT	O
active	JJ	O
ingredient	NN	O
.	.	O
An	DT	O
exemplary	JJ	O
composition	NN	O
comprises	VBZ	O
monoclonal	JJ	O
antibody	NN	O
at	IN	O
5	CD	O
mg/mL	NN	O
,	,	O
formulated	VBN	O
in	IN	O
aqueous	JJ	O
buffer	NN	O
consisting	NN	O
of	IN	O
50	CD	O
mM	JJ	O
L-histidine	NNP	O
,	,	O
150	CD	O
mM	NN	O
NaCl	NNP	O
,	,	O
adjusted	VBD	O
to	TO	O
pH	VB	O
6.0	CD	O
with	IN	O
HCl	NNP	O
.	.	O
Compositions	NNS	O
for	IN	O
parenteral	JJ	O
administration	NN	O
are	VBP	O
typically	RB	O
substantially	RB	O
sterile	JJ	O
,	,	O
substantially	RB	O
isotonic	JJ	O
and	CC	O
manufactured	VBD	O
under	IN	O
GMP	NNP	O
conditions	NNS	O
of	IN	O
the	DT	O
FDA	NNP	O
or	CC	O
similar	JJ	O
body	NN	O
.	.	O
Compositions	NNS	O
may	MD	O
be	VB	O
prepared	VBN	O
as	IN	O
injectables	NNS	O
,	,	O
either	CC	O
as	IN	O
liquid	JJ	O
solutions	NNS	O
or	CC	O
suspensions	NNS	O
;	:	O
solid	JJ	O
forms	NNS	O
suitable	JJ	O
for	IN	O
solution	NN	O
in	IN	O
,	,	O
or	CC	O
suspension	NN	O
in	IN	O
,	,	O
liquid	JJ	O
vehicles	NNS	O
prior	RB	O
to	TO	O
injection	NN	O
can	MD	O
also	RB	O
be	VB	O
prepared	VBN	O
.	.	O
The	DT	O
preparation	NN	O
also	RB	O
can	MD	O
be	VB	O
emulsified	VBN	O
or	CC	O
encapsulated	VBN	O
in	IN	O
liposomes	NNS	O
or	CC	O
micro	JJ	O
particles	NNS	O
such	JJ	O
as	IN	O
polylactide	NN	O
,	,	O
polyglycolide	NN	O
,	,	O
or	CC	O
copolymer	NN	O
for	IN	O
enhanced	JJ	O
adjuvant	JJ	O
effect	NN	O
,	,	O
as	IN	O
discussed	VBN	O
above	IN	O
(	(	O
see	VB	O
Langer	NNP	B
,	,	I
Science	NNP	I
249	CD	I
,	,	I
1527	CD	I
(	(	I
1990	CD	I
)	)	I
and	CC	O
Hanes	NNP	B
,	,	I
Advanced	NNP	I
Drug	NNP	I
Delivery	NNP	I
Reviews	NNP	I
28	CD	I
,	,	I
97-119	CD	I
(	(	I
1997	CD	I
)	)	I
.	.	O
The	DT	O
agents	NNS	O
of	IN	O
this	DT	O
invention	NN	O
can	MD	O
be	VB	O
administered	VBN	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
a	DT	O
depot	NN	O
injection	NN	O
or	CC	O
implant	JJ	O
preparation	NN	O
which	WDT	O
can	MD	O
be	VB	O
formulated	VBN	O
in	IN	O
such	JJ	O
a	DT	O
manner	NN	O
as	IN	O
to	TO	O
permit	VB	O
a	DT	O
sustained	VBN	O
or	CC	O
pulsatile	JJ	O
release	NN	O
of	IN	O
the	DT	O
active	JJ	O
ingredient	NN	O
.	.	O
Additional	JJ	O
formulations	NNS	O
suitable	JJ	O
for	IN	O
other	JJ	O
modes	NNS	O
of	IN	O
administration	NN	O
include	VBP	O
oral	JJ	O
,	,	O
intranasal	NN	O
,	,	O
and	CC	O
pulmonary	JJ	O
formulations	NNS	O
,	,	O
suppositories	NNS	O
,	,	O
and	CC	O
transdermal	JJ	O
applications	NNS	O
.	.	O
For	IN	O
suppositories	NNS	O
,	,	O
binders	NNS	O
and	CC	O
carriers	NNS	O
include	VBP	O
,	,	O
for	IN	O
example	NN	O
,	,	O
polyalkylene	NN	O
glycols	NNS	O
or	CC	O
triglycerides	NNS	O
;	:	O
such	JJ	O
suppositories	NNS	O
can	MD	O
be	VB	O
formed	VBN	O
from	IN	O
mixtures	NNS	O
containing	VBG	O
the	DT	O
active	JJ	O
ingredient	NN	O
in	IN	O
the	DT	O
range	NN	O
of	IN	O
0.5	CD	O
%	NN	O
to	TO	O
10	CD	O
%	NN	O
,	,	O
preferably	RB	O
1	CD	O
%	NN	O
-2	CD	O
%	NN	O
.	.	O
Oral	JJ	O
formulations	NNS	O
include	VBP	O
excipients	NNS	O
,	,	O
such	JJ	O
as	IN	O
pharmaceutical	JJ	O
grades	NNS	O
of	IN	O
mannitol	NN	O
,	,	O
lactose	RB	O
,	,	O
starch	NN	O
,	,	O
magnesium	NN	O
stearate	NN	O
,	,	O
sodium	NN	O
saccharine	NN	O
,	,	O
cellulose	NN	O
,	,	O
and	CC	O
magnesium	NN	O
carbonate	NN	O
.	.	O
These	DT	O
compositions	NNS	O
take	VBP	O
the	DT	O
form	NN	O
of	IN	O
solutions	NNS	O
,	,	O
suspensions	NNS	O
,	,	O
tablets	NNS	O
,	,	O
pills	NNS	O
,	,	O
capsules	NNS	O
,	,	O
sustained	VBD	O
release	NN	O
formulations	NNS	O
or	CC	O
powders	NNS	O
and	CC	O
contain	VB	O
10	CD	O
%	NN	O
-95	CD	O
%	NN	O
of	IN	O
active	JJ	O
ingredient	NN	O
,	,	O
preferably	RB	O
25	CD	O
%	NN	O
-70	CD	O
%	NN	O
.	.	O
Topical	JJ	O
application	NN	O
can	MD	O
result	VB	O
in	IN	O
transdermal	NN	O
or	CC	O
intradermal	JJ	O
delivery	NN	O
.	.	O
Topical	JJ	O
administration	NN	O
can	MD	O
be	VB	O
facilitated	VBN	O
by	IN	O
co-administration	NN	O
of	IN	O
the	DT	O
agent	NN	O
with	IN	O
cholera	NN	O
toxin	NN	O
or	CC	O
detoxified	JJ	O
derivatives	NNS	O
or	CC	O
subunits	NNS	O
thereof	VBP	O
or	CC	O
other	JJ	O
similar	JJ	O
bacterial	NN	O
toxins	NNS	O
(	(	O
See	VB	O
Glenn	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nature	NNP	I
391	CD	I
,	,	I
851	CD	I
(	(	I
1998	CD	I
)	)	I
)	)	O
.	.	O
Co-administration	NN	O
can	MD	O
be	VB	O
achieved	VBN	O
by	IN	O
using	VBG	O
the	DT	O
components	NNS	O
as	IN	O
a	DT	O
mixture	NN	O
or	CC	O
as	IN	O
linked	VBN	O
molecules	NNS	O
obtained	VBN	O
by	IN	O
chemical	NN	O
crosslinking	NN	O
or	CC	O
expression	NN	O
as	IN	O
a	DT	O
fusion	NN	O
protein	NN	O
.	.	O
Alternatively	RB	O
,	,	O
transdermal	JJ	O
delivery	NN	O
can	MD	O
be	VB	O
achieved	VBN	O
using	VBG	O
a	DT	O
skin	JJ	O
patch	NN	O
or	CC	O
using	VBG	O
transferosomes	NNS	O
(	(	O
Paul	NNP	B
et	RB	I
al.	RB	I
,	,	I
Eur	NNP	I
.	.	I
J.	NNP	I
Immunol	NNP	I
.	.	I
25	CD	I
,	,	I
3521-24	CD	I
(	(	I
1995	CD	I
)	)	I
;	:	O
Cevc	NNP	B
et	FW	I
al.	NN	I
,	,	I
Biochem	NNP	I
.	.	I
Biophys	NNP	I
.	.	I
Acta	NNP	I
1368	CD	I
,	,	I
201-15	CD	I
(	(	I
1998	CD	I
)	)	I
)	)	O
.	.	O
VII	NNP	O
.	.	O
Lewy	NNP	O
Body	NNP	O
Diseases	NNP	O
Lewy	NNP	O
Body	NNP	O
Diseases	NNP	O
(	(	O
LBD	NNP	O
)	)	O
are	VBP	O
characterized	VBN	O
by	IN	O
degeneration	NN	O
of	IN	O
the	DT	O
dopaminergic	NN	O
system	NN	O
,	,	O
motor	NN	O
alterations	NNS	O
,	,	O
cognitive	JJ	O
impairment	NN	O
,	,	O
and	CC	O
formation	NN	O
of	IN	O
Lewy	NNP	O
bodies	NNS	O
(	(	O
LBs	NNP	O
)	)	O
.	.	O
(	(	O
McKeith	NNP	B
et	FW	I
al.	NN	I
,	,	I
Clinical	NNP	I
and	CC	I
pathological	JJ	I
diagnosis	NN	I
of	IN	I
dementia	NN	I
with	IN	I
Lewy	NNP	I
bodies	NNS	I
(	(	I
DLB	NNP	I
)	)	I
:	:	I
Report	NN	I
of	IN	I
the	DT	I
CDLB	NNP	I
International	NNP	I
Workshop	NNP	I
,	,	I
Neurology	NNP	I
(	(	I
1996	CD	I
)	)	I
47:1113-24	NN	I
)	)	O
.	.	O
Lewy	NNP	O
Bodies	NNS	O
are	VBP	O
spherical	JJ	O
protein	NN	O
deposits	NNS	O
found	VBN	O
in	IN	O
nerve	NN	O
cells	NNS	O
.	.	O
Their	PRP$	O
presence	NN	O
in	IN	O
the	DT	O
brain	NN	O
may	MD	O
disrupt	VB	O
the	DT	O
brain	NN	O
's	POS	O
normal	JJ	O
function	NN	O
interrupting	VBG	O
the	DT	O
action	NN	O
of	IN	O
chemical	NN	O
messengers	NNS	O
including	VBG	O
acetylcholine	NN	O
and	CC	O
dopamine	NN	O
.	.	O
Lewy	NNP	O
Body	NNP	O
diseases	VBZ	O
include	VBP	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
(	(	O
including	VBG	O
idiopathic	JJ	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
(	(	O
PD	NNP	O
)	)	O
)	)	O
,	,	O
Diffuse	NNP	O
Lewy	NNP	O
Body	NNP	O
Disease	NNP	O
(	(	O
DLBD	NNP	O
)	)	O
also	RB	O
known	VBN	O
as	IN	O
Dementia	NNP	O
with	IN	O
Lewy	NNP	O
Bodies	NNP	O
(	(	O
DLB	NNP	O
)	)	O
,	,	O
Combined	VBN	O
Alzheimer	NNP	O
's	POS	O
and	CC	O
Parkinson	NNP	O
disease	NN	O
and	CC	O
multiple	JJ	O
system	NN	O
atrophy	NN	O
(	(	O
MSA	NNP	O
)	)	O
.	.	O
DLBD	NNP	O
shares	NNS	O
symptoms	NNS	O
of	IN	O
both	DT	O
Alzheimer	NNP	O
's	POS	O
and	CC	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
.	.	O
DLBD	NNP	O
differs	NNS	O
from	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
mainly	RB	O
in	IN	O
the	DT	O
location	NN	O
of	IN	O
Lewy	NNP	O
Bodies	NNP	O
.	.	O
In	IN	O
DLBD	NNP	O
Lewy	NNP	O
Bodies	NNP	O
form	NN	O
mainly	RB	O
in	IN	O
the	DT	O
cortex	NN	O
.	.	O
In	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
,	,	O
they	PRP	O
form	VBP	O
in	IN	O
selected	VBN	O
regions	NNS	O
throughout	IN	O
the	DT	O
brain	NN	O
stem	NN	O
,	,	O
midbrain	NN	O
,	,	O
and	CC	O
in	IN	O
advanced	JJ	O
disease	NN	O
,	,	O
cerebral	JJ	O
cortex	NN	O
.	.	O
See	VB	O
,	,	O
Braak	NNP	B
et	FW	I
al.	NN	I
,	,	I
2003	CD	I
,	,	I
“	NNP	I
Staging	NNP	I
of	IN	I
brain	NN	I
pathology	NN	I
related	VBN	I
to	TO	I
sporadic	VB	I
Parkinson	NNP	I
's	POS	I
disease	NN	I
”	NNP	I
Neurobiology	NNP	I
of	IN	I
Aging	NNP	I
24:197-211	JJ	I
.	.	O
Other	JJ	O
Lewy	NNP	O
Body	NNP	O
diseases	VBZ	O
include	VBP	O
Pure	NNP	O
Autonomic	NNP	O
Failure	NNP	O
,	,	O
Lewy	NNP	O
body	NN	O
dysphagia	NN	O
,	,	O
Incidental	NNP	O
LBD	NNP	O
,	,	O
Inherited	NNP	O
LBD	NNP	O
(	(	O
e.g.	NN	O
,	,	O
mutations	NNS	O
of	IN	O
the	DT	O
alpha-synuclein	JJ	O
gene	NN	O
,	,	O
PARK3	NNP	O
and	CC	O
PARK4	NNP	O
)	)	O
and	CC	O
Multiple	NNP	O
System	NNP	O
Atrophy	NNP	O
(	(	O
e.g.	NN	O
,	,	O
Olivopontocerebellar	NNP	O
Atrophy	NNP	O
,	,	O
Striatonigral	NNP	O
Degeneration	NNP	O
and	CC	O
Shy-Drager	NNP	O
Syndrome	NNP	O
)	)	O
.	.	O
VIII	NNP	O
.	.	O
Identification	NN	O
of	IN	O
Modulators	NNS	O
of	IN	O
Kinases	NNS	O
that	WDT	O
Directly	NNP	O
or	CC	O
Indirectly	NNP	O
Phosphorylate	NNP	O
Alpha-Synuclein	NNP	O
Agents	NNS	O
that	WDT	O
modulate	VBP	O
expression	NN	O
or	CC	O
activity	NN	O
of	IN	O
a	DT	O
kinase	NN	O
that	WDT	O
directly	RB	O
or	CC	O
indirectly	RB	O
phosphorylates	VBZ	O
alpha-synuclein	NNS	O
can	MD	O
be	VB	O
identified	VBN	O
by	IN	O
a	DT	O
variety	NN	O
of	IN	O
assays	NNS	O
.	.	O
Particularly	RB	O
preferred	VBN	O
are	VBP	O
agents	NNS	O
that	IN	O
inhibit	NN	O
kinases	NNS	O
PLK2	NNP	O
or	CC	O
GRK6	NNP	O
,	,	O
or	CC	O
APEG1	NNP	O
,	,	O
CDC7L1	NNP	O
,	,	O
MET	NNP	O
GRK1	NNP	O
,	,	O
GRK2	NNP	O
,	,	O
GRK6	NNP	O
,	,	O
IKBKB	NNP	O
,	,	O
CKII	NNP	O
and	CC	O
GRK7	NNP	O
,	,	O
or	CC	O
agents	NNS	O
that	WDT	O
activate	VBP	O
PRKG1	NNP	O
,	,	O
MAPK13	NNP	O
,	,	O
and	CC	O
GAK	NNP	O
.	.	O
Agents	NNS	O
that	WDT	O
modulate	VBP	O
expression	NN	O
can	MD	O
be	VB	O
identified	VBN	O
in	IN	O
cell-based	JJ	O
assays	NNS	O
in	IN	O
which	WDT	O
an	DT	O
agent	NN	O
under	IN	O
test	NN	O
is	VBZ	O
introduced	VBN	O
into	IN	O
a	DT	O
cell	NN	O
expressing	VBG	O
alpha-synuclein	JJ	O
and	CC	O
a	DT	O
kinase	NN	O
that	WDT	O
directly	RB	O
or	CC	O
indirectly	RB	O
effects	NNS	O
phosphorylation	NN	O
of	IN	O
the	DT	O
alpha-synuclein	JJ	O
or	CC	O
modulates	VBZ	O
levels	NNS	O
of	IN	O
total	JJ	O
alpha-synuclein	NN	O
.	.	O
Optionally	RB	O
,	,	O
particularly	RB	O
for	IN	O
PLK2	NNP	O
,	,	O
synphilin	NN	O
can	MD	O
be	VB	O
expressed	VBN	O
as	RB	O
well	RB	O
to	TO	O
augment	JJ	O
activity	NN	O
of	IN	O
the	DT	O
kinase	NN	O
.	.	O
The	DT	O
agent	NN	O
can	MD	O
be	VB	O
introduced	VBN	O
directly	RB	O
or	CC	O
in	IN	O
the	DT	O
form	NN	O
of	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
encoding	VBG	O
the	DT	O
agent	NN	O
and	CC	O
capable	JJ	O
of	IN	O
expressing	VBG	O
the	DT	O
agent	NN	O
.	.	O
The	DT	O
cell	NN	O
can	MD	O
naturally	RB	O
express	VB	O
the	DT	O
alpha-synuclein	NN	O
and	CC	O
kinase	NN	O
or	CC	O
one	CD	O
or	CC	O
both	DT	O
of	IN	O
these	DT	O
can	MD	O
be	VB	O
introduced	VBN	O
into	IN	O
the	DT	O
cell	NN	O
by	IN	O
transfection	NN	O
of	IN	O
a	DT	O
suitable	JJ	O
nucleic	JJ	O
acid	NN	O
.	.	O
The	DT	O
effect	NN	O
of	IN	O
the	DT	O
agent	NN	O
on	IN	O
expression	NN	O
of	IN	O
the	DT	O
kinase	NN	O
can	MD	O
be	VB	O
measured	VBN	O
directly	RB	O
from	IN	O
the	DT	O
level	NN	O
of	IN	O
the	DT	O
kinase	NN	O
or	CC	O
its	PRP$	O
mRNA	NN	O
,	,	O
or	CC	O
indirectly	RB	O
by	IN	O
measuring	VBG	O
the	DT	O
level	NN	O
of	IN	O
phosphorylated	JJ	O
alpha-synuclein	NN	O
or	CC	O
total	JJ	O
alpha-synuclein	JJ	O
as	IN	O
described	VBN	O
above	IN	O
.	.	O
The	DT	O
level	NN	O
of	IN	O
kinase	NN	O
mRNA	NN	O
can	MD	O
be	VB	O
assayed	VBN	O
by	IN	O
a	DT	O
hybridization	NN	O
type	NN	O
assay	NN	O
.	.	O
The	DT	O
level	NN	O
of	IN	O
the	DT	O
kinase	NN	O
can	MD	O
be	VB	O
assayed	VBN	O
by	IN	O
an	DT	O
immunoassay	NN	O
.	.	O
Optionally	RB	O
,	,	O
the	DT	O
kinase	NN	O
is	VBZ	O
tagged	VBN	O
with	IN	O
a	DT	O
peptide	JJ	O
label	NN	O
such	JJ	O
as	IN	O
Flag™	NNP	O
(	(	O
Hopp	NNP	B
et	RB	I
al.	RB	I
,	,	I
BioTechnology	NNP	I
6	CD	I
,	,	I
1204-1210	CD	I
(	(	I
1988	CD	I
)	)	I
)	)	O
to	TO	O
facilitate	VB	O
detection	NN	O
.	.	O
An	DT	O
agent	NN	O
that	WDT	O
decrease	VBZ	O
the	DT	O
level	NN	O
of	IN	O
the	DT	O
kinase	NN	O
,	,	O
decrease	VB	O
the	DT	O
level	NN	O
of	IN	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	JJ	O
and/or	NN	O
decrease	NN	O
the	DT	O
level	NN	O
of	IN	O
total	JJ	O
alpha-synuclein	JJ	O
relative	NN	O
to	TO	O
similar	JJ	O
control	NN	O
cells	NNS	O
not	RB	O
treated	VBN	O
with	IN	O
an	DT	O
agent	NN	O
have	VBP	O
a	DT	O
pharmacological	JJ	O
activity	NN	O
potentially	RB	O
useful	JJ	O
for	IN	O
treatment	NN	O
of	IN	O
Lewy	NNP	O
body	NN	O
diseases	NNS	O
.	.	O
Agents	NNS	O
are	VBP	O
also	RB	O
screened	VBN	O
for	IN	O
activity	NN	O
to	TO	O
modulate	VB	O
activity	NN	O
of	IN	O
a	DT	O
kinase	NN	O
suspected	VBN	O
of	IN	O
phosphorylating	VBG	O
alpha-synuclein	JJ	O
or	CC	O
increasing	VBG	O
total	JJ	O
levels	NNS	O
of	IN	O
alpha-synuclein	NN	O
.	.	O
An	DT	O
initial	JJ	O
screen	NN	O
can	MD	O
be	VB	O
performed	VBN	O
to	TO	O
select	VB	O
a	DT	O
subset	NN	O
of	IN	O
agents	NNS	O
capable	JJ	O
of	IN	O
specifically	RB	O
binding	VBG	O
to	TO	O
a	DT	O
kinase	NN	O
.	.	O
Such	JJ	O
an	DT	O
assay	NN	O
can	MD	O
be	VB	O
performed	VBN	O
in	IN	O
vitro	NN	O
using	VBG	O
an	DT	O
isolated	JJ	O
kinase	NN	O
or	CC	O
fragment	NN	O
thereof	NN	O
having	VBG	O
kinase	NN	O
activity	NN	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
an	DT	O
agent	NN	O
that	WDT	O
reduces	VBZ	O
alpha-synuclein	JJ	O
phosphorylation	NN	O
in	IN	O
a	DT	O
mammalian	JJ	O
cell	NN	O
expressing	VBG	O
alpha-synuclein	JJ	O
,	,	O
and	CC	O
which	WDT	O
may	MD	O
be	VB	O
used	VBN	O
as	IN	O
a	DT	O
therapeutic	JJ	O
agent	NN	O
,	,	O
is	VBZ	O
identified	VBN	O
based	VBN	O
on	IN	O
the	DT	O
following	JJ	O
criteria	NNS	O
:	:	O
a	DT	O
)	)	O
reduces	VBZ	O
activity	NN	O
of	IN	O
PLK2	NNP	O
in	IN	O
a	DT	O
cell	NN	O
expressing	VBG	O
PLK2	NNP	O
;	:	O
and	CC	O
b	NN	O
)	)	O
does	VBZ	O
not	RB	O
reduce	VB	O
activity	NN	O
of	IN	O
PLK1	NNP	O
in	IN	O
a	DT	O
cell	NN	O
expressing	VBG	O
PLK1	NNP	O
,	,	O
or	CC	O
reduces	VBZ	O
activity	NN	O
of	IN	O
PLK1	NNP	O
at	IN	O
a	DT	O
higher	JJR	O
EC50	NN	O
than	IN	O
for	IN	O
PLK2	NNP	O
;	:	O
and/or	CC	O
c	NNS	O
)	)	O
does	VBZ	O
not	RB	O
reduce	VB	O
activity	NN	O
of	IN	O
PLK3	NNP	O
in	IN	O
a	DT	O
cell	NN	O
expressing	VBG	O
PLK3	NNP	O
,	,	O
or	CC	O
reduces	VBZ	O
activity	NN	O
of	IN	O
PLK3	NNP	O
at	IN	O
a	DT	O
higher	JJR	O
EC50	NN	O
than	IN	O
for	IN	O
PLK2	NNP	O
;	:	O
and/or	CC	O
d	NN	O
)	)	O
does	VBZ	O
not	RB	O
reduce	VB	O
activity	NN	O
of	IN	O
PLK4	NNP	O
in	IN	O
a	DT	O
cell	NN	O
expressing	VBG	O
PLK4	NNP	O
,	,	O
or	CC	O
reduces	VBZ	O
activity	NN	O
of	IN	O
PLK4	NNP	O
at	IN	O
a	DT	O
higher	JJR	O
EC50	NN	O
than	IN	O
for	IN	O
PLK2	NNP	O
.	.	O
In	IN	O
one	CD	O
embodiment	NN	O
an	DT	O
agent	NN	O
is	VBZ	O
selected	VBN	O
that	IN	O
meets	VBZ	O
all	DT	O
of	IN	O
criteria	NNS	O
a-d	JJ	O
.	.	O
The	DT	O
mammalian	JJ	O
cell	NN	O
may	MD	O
be	VB	O
a	DT	O
cell	NN	O
overexpressing	VBG	O
alpha-synuclein	JJ	O
(	(	O
e.g.	JJ	O
,	,	O
transfected	VBN	O
with	IN	O
a	DT	O
vectors	NNS	O
expressing	VBG	O
exogenous	JJ	O
,	,	O
e.g.	JJ	O
,	,	O
human	JJ	O
,	,	O
alpha-synuclein	JJ	O
)	)	O
.	.	O
The	DT	O
mammalian	JJ	O
cell	NN	O
may	MD	O
be	VB	O
a	DT	O
neuronally-derived	JJ	O
cell	NN	O
such	JJ	O
as	IN	O
,	,	O
for	IN	O
example	NN	O
,	,	O
cells	NNS	O
from	IN	O
mouse	NN	O
cortical	JJ	O
cell	NN	O
cultures	NNS	O
,	,	O
rat	VB	O
ventral	JJ	O
mesencephalon	NN	O
cell	NN	O
cultures	NNS	O
,	,	O
or	CC	O
other	JJ	O
neuronal	JJ	O
cells	NNS	O
from	IN	O
humans	NNS	O
or	CC	O
non-human	JJ	O
mammals	NNS	O
.	.	O
Agents	NNS	O
identified	VBN	O
by	IN	O
such	JJ	O
a	DT	O
screen	NN	O
can	MD	O
then	RB	O
be	VB	O
assayed	VBN	O
functionally	RB	O
.	.	O
Agents	NNS	O
can	MD	O
also	RB	O
be	VB	O
directly	RB	O
assayed	VBN	O
functionally	RB	O
without	IN	O
the	DT	O
binding	NN	O
assay	NN	O
.	.	O
For	IN	O
a	DT	O
kinase	NN	O
that	WDT	O
directly	RB	O
phosphorylates	VBZ	O
alpha-synuclein	NN	O
,	,	O
modulators	NNS	O
can	MD	O
be	VB	O
screened	VBN	O
by	IN	O
an	DT	O
in	IN	O
vitro	NN	O
assay	VBP	O
combining	VBG	O
the	DT	O
kinase	NN	O
,	,	O
alpha-synuclein	JJ	O
,	,	O
ATP	NNP	O
and	CC	O
the	DT	O
modulator	NN	O
in	IN	O
comparison	NN	O
with	IN	O
a	DT	O
control	NN	O
in	IN	O
which	WDT	O
the	DT	O
modulator	NN	O
is	VBZ	O
omitted	VBN	O
.	.	O
Optionally	RB	O
,	,	O
synphilin	NN	O
can	MD	O
be	VB	O
included	VBN	O
as	RB	O
well	RB	O
to	TO	O
increase	VB	O
phosphorylation	NN	O
particularly	RB	O
if	IN	O
the	DT	O
kinase	NN	O
is	VBZ	O
PLK2	NNP	O
.	.	O
The	DT	O
modulator	NN	O
has	VBZ	O
potentially	RB	O
useful	JJ	O
pharmacological	JJ	O
activity	NN	O
if	IN	O
it	PRP	O
reduces	VBZ	O
the	DT	O
level	NN	O
of	IN	O
phosphorylation	NN	O
beyond	IN	O
the	DT	O
margin	NN	O
of	IN	O
typical	JJ	O
experimental	JJ	O
error	NN	O
relative	NN	O
to	TO	O
the	DT	O
control	NN	O
.	.	O
Agents	NNS	O
can	MD	O
also	RB	O
be	VB	O
screened	VBN	O
in	IN	O
cells	NNS	O
expressing	VBG	O
alpha-synuclein	NN	O
and	CC	O
the	DT	O
kinase	NN	O
under	IN	O
test	NN	O
,	,	O
and	CC	O
optionally	RB	O
,	,	O
particularly	RB	O
if	IN	O
the	DT	O
kinase	NN	O
is	VBZ	O
PLK2	NNP	O
,	,	O
synphilin	NN	O
.	.	O
Such	JJ	O
screens	NNS	O
are	VBP	O
effective	JJ	O
regardless	NN	O
of	IN	O
whether	IN	O
the	DT	O
kinase	NN	O
phosphorylates	VBZ	O
alpha-synuclein	JJ	O
directly	RB	O
or	CC	O
indirectly	RB	O
,	,	O
or	CC	O
otherwise	RB	O
affects	VBZ	O
levels	NNS	O
of	IN	O
alpha-synuclein	NN	O
.	.	O
Cells	NNS	O
are	VBP	O
contacted	VBN	O
with	IN	O
the	DT	O
agent	NN	O
and	CC	O
levels	NNS	O
of	IN	O
total	JJ	O
alpha-synuclein	JJ	O
and	CC	O
phosphorylated	JJ	O
alpha-synuclein	NNS	O
are	VBP	O
measured	VBN	O
,	,	O
as	IN	O
above	IN	O
,	,	O
relative	JJ	O
to	TO	O
a	DT	O
control	NN	O
cell	NN	O
not	RB	O
treated	VBN	O
with	IN	O
the	DT	O
agent	NN	O
.	.	O
A	DT	O
reduction	NN	O
in	IN	O
the	DT	O
level	NN	O
of	IN	O
phosphorylated	JJ	O
alpha-synuclein	NN	O
or	CC	O
total	JJ	O
alpha-synuclein	JJ	O
relative	NN	O
to	TO	O
the	DT	O
corresponding	JJ	O
level	NN	O
in	IN	O
a	DT	O
control	NN	O
cell	NN	O
not	RB	O
treated	VBN	O
with	IN	O
the	DT	O
agent	NN	O
,	,	O
beyond	IN	O
the	DT	O
margin	NN	O
of	IN	O
typical	JJ	O
experimental	JJ	O
error	NN	O
,	,	O
is	VBZ	O
an	DT	O
indication	NN	O
that	IN	O
the	DT	O
compound	NN	O
has	VBZ	O
pharmacological	JJ	O
activity	NN	O
potential	JJ	O
useful	JJ	O
in	IN	O
treating	VBG	O
Lewy	NNP	O
body	NN	O
diseases	NNS	O
.	.	O
Agents	NNS	O
may	MD	O
also	RB	O
be	VB	O
screened	VBN	O
in	IN	O
cells	NNS	O
for	IN	O
ability	NN	O
to	TO	O
reduce	VB	O
aggregation	NN	O
of	IN	O
alpha-synuclein	NN	O
in	IN	O
the	DT	O
cell	NN	O
.	.	O
Agents	NNS	O
can	MD	O
also	RB	O
be	VB	O
screened	VBN	O
in	IN	O
transgenic	JJ	O
animal	JJ	O
models	NNS	O
of	IN	O
Lewy	NNP	O
body	NN	O
disease	NN	O
,	,	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
the	DT	O
other	JJ	O
assays	NNS	O
described	VBN	O
above	IN	O
.	.	O
Total	JJ	O
levels	NNS	O
of	IN	O
alpha-synuclein	NN	O
,	,	O
phosphorylated	VBN	O
alpha-synuclein	NN	O
or	CC	O
Lewy-like	JJ	O
bodies	NNS	O
or	CC	O
other	JJ	O
indica	NN	O
of	IN	O
Lewy	NNP	O
Body	NNP	O
pathology	NN	O
or	CC	O
symptoms	NNS	O
are	VBP	O
measured	VBN	O
in	IN	O
a	DT	O
transgenic	JJ	O
animal	NN	O
treated	VBN	O
with	IN	O
an	DT	O
agent	NN	O
under	IN	O
test	NN	O
relative	NN	O
to	TO	O
corresponding	VBG	O
levels	NNS	O
in	IN	O
a	DT	O
similar	JJ	O
control	NN	O
animal	NN	O
not	RB	O
treated	VBN	O
with	IN	O
the	DT	O
agent	NN	O
.	.	O
A	DT	O
reduction	NN	O
in	IN	O
one	CD	O
or	CC	O
more	JJR	O
of	IN	O
these	DT	O
levels	NNS	O
is	VBZ	O
an	DT	O
indication	NN	O
,	,	O
the	DT	O
agent	NN	O
has	VBZ	O
pharmacological	JJ	O
activity	NN	O
potentially	RB	O
useful	JJ	O
in	IN	O
treating	VBG	O
Lewy	NNP	O
body	NN	O
diseases	NNS	O
.	.	O
The	DT	O
kinase	NN	O
used	VBN	O
in	IN	O
the	DT	O
above	JJ	O
assays	NNS	O
and	CC	O
cellular	JJ	O
and	CC	O
transgenic	JJ	O
models	NNS	O
is	VBZ	O
preferably	RB	O
a	DT	O
human	JJ	O
kinase	NN	O
having	VBG	O
a	DT	O
sequence	NN	O
in	IN	O
one	CD	O
of	IN	O
the	DT	O
references	NNS	O
or	CC	O
accession	NN	O
numbers	NNS	O
provided	VBN	O
in	IN	O
this	DT	O
disclosure	NN	O
.	.	O
However	RB	O
,	,	O
allelic	JJ	O
(	(	O
variants	NNS	O
within	IN	O
a	DT	O
species	NNS	O
)	)	O
and	CC	O
species	VBZ	O
variants	NNS	O
(	(	O
variants	NNS	O
between	IN	O
species	NNS	O
)	)	O
of	IN	O
such	PDT	O
a	DT	O
kinase	NN	O
can	MD	O
also	RB	O
be	VB	O
used	VBN	O
,	,	O
as	IN	O
can	MD	O
variants	NNS	O
having	VBG	O
at	IN	O
least	JJS	O
90	CD	O
%	NN	O
sequence	NN	O
identity	NN	O
to	TO	O
such	PDT	O
a	DT	O
kinase	NN	O
.	.	O
For	IN	O
subsequent	JJ	O
clinical	JJ	O
use	NN	O
,	,	O
agents	NNS	O
identified	VBN	O
by	IN	O
such	JJ	O
assays	NNS	O
are	VBP	O
capable	JJ	O
of	IN	O
modulating	VBG	O
the	DT	O
activity	NN	O
or	CC	O
expression	NN	O
of	IN	O
a	DT	O
natural	JJ	O
kinase	NN	O
,	,	O
preferably	RB	O
a	DT	O
form	NN	O
occurring	VBG	O
in	IN	O
humans	NNS	O
.	.	O
IX	NNP	O
.	.	O
Transgenic	NNP	O
Animal	NNP	O
and	CC	O
Cellular	NNP	O
Models	NNP	O
of	IN	O
Lewy	NNP	O
Body	NNP	O
Disease	NNP	O
Transgenic	NNP	O
animal	NN	O
models	NNS	O
are	VBP	O
useful	JJ	O
for	IN	O
testing	VBG	O
the	DT	O
capacity	NN	O
of	IN	O
kinases	NNS	O
to	TO	O
effect	NN	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	JJ	O
and	CC	O
formation	NN	O
of	IN	O
Lewy-like	JJ	O
bodies	NNS	O
as	IN	O
described	VBN	O
above	IN	O
.	.	O
Transgenic	JJ	O
animals	NNS	O
are	VBP	O
also	RB	O
useful	JJ	O
for	IN	O
screening	VBG	O
agents	NNS	O
for	IN	O
activity	NN	O
in	IN	O
modulating	VBG	O
phosphorylation	NN	O
or	CC	O
production	NN	O
of	IN	O
alpha-synuclein	NN	O
.	.	O
Particularly	RB	O
preferred	VBN	O
are	VBP	O
agents	NNS	O
that	WDT	O
inhibit	VBP	O
or	CC	O
are	VBP	O
suspected	VBN	O
of	IN	O
inhibiting	VBG	O
kinases	NNS	O
including	VBG	O
PLK2	NNP	O
and	CC	O
GRK6	NNP	O
,	,	O
or	CC	O
APEG1	NNP	O
,	,	O
CDC7L1	NNP	O
,	,	O
MET	NNP	O
GRK1	NNP	O
,	,	O
GRK2	NNP	O
,	,	O
GRK6	NNP	O
,	,	O
IKBKB	NNP	O
,	,	O
CKII	NNP	O
and	CC	O
GRK7	NNP	O
.	.	O
Also	RB	O
preferred	VBN	O
are	VBP	O
agents	NNS	O
that	WDT	O
activate	VBP	O
or	CC	O
are	VBP	O
suspected	VBN	O
of	IN	O
activating	VBG	O
kinases	NNS	O
PRKG1	NNP	O
,	,	O
MAPK13	NNP	O
,	,	O
and	CC	O
GAK	NNP	O
.	.	O
Further	RB	O
,	,	O
knockout	NN	O
animals	NNS	O
(	(	O
i.e.	FW	O
,	,	O
animals	NNS	O
in	IN	O
which	WDT	O
an	DT	O
endogenous	JJ	O
kinase	NN	O
is	VBZ	O
inactivated	VBN	O
either	RB	O
by	IN	O
insertional	JJ	O
inactivation	NN	O
or	CC	O
trans	NNS	O
inhibition	NN	O
by	IN	O
an	DT	O
siRNA	NN	O
,	,	O
zinc	NN	O
finger	NN	O
protein	NN	O
or	CC	O
the	DT	O
like	JJ	O
)	)	O
are	VBP	O
useful	JJ	O
for	IN	O
identifying	VBG	O
the	DT	O
effect	NN	O
of	IN	O
eliminating	VBG	O
activity	NN	O
of	IN	O
a	DT	O
kinase	NN	O
on	IN	O
an	DT	O
animal	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
analysis	NN	O
of	IN	O
a	DT	O
PLK2-knockout	JJ	O
mouse	NN	O
can	MD	O
indicate	VB	O
whether	IN	O
inhibitors	NNS	O
of	IN	O
PLK2	NNP	O
have	VBP	O
any	DT	O
side	NN	O
effects	NNS	O
.	.	O
Analogous	JJ	O
knockouts	NNS	O
can	MD	O
reveal	VB	O
similar	JJ	O
information	NN	O
for	IN	O
other	JJ	O
kinases	NNS	O
.	.	O
In	IN	O
general	JJ	O
,	,	O
transgenic	JJ	O
models	NNS	O
have	VBP	O
a	DT	O
genome	NN	O
comprising	VBG	O
an	DT	O
alpha-synuclein	JJ	O
transgene	NN	O
in	IN	O
operable	JJ	O
linkage	NN	O
with	IN	O
one	CD	O
or	CC	O
more	JJR	O
regulatory	JJ	O
sequences	NNS	O
to	TO	O
ensure	VB	O
its	PRP$	O
expression	NN	O
.	.	O
Expression	NN	O
of	IN	O
the	DT	O
transgene	NN	O
leads	VBZ	O
to	TO	O
Lewy-body	NNP	O
like	IN	O
deposits	NNS	O
of	IN	O
alpha-synuclein	NN	O
in	IN	O
the	DT	O
brain	NN	O
of	IN	O
the	DT	O
animal	NN	O
.	.	O
Several	JJ	O
such	JJ	O
transgenic	JJ	O
animals	NNS	O
have	VBP	O
been	VBN	O
described	VBN	O
in	IN	O
the	DT	O
scientific	JJ	O
and	CC	O
patent	JJ	O
literature	NN	O
(	(	O
see	VB	O
Masliah	NNP	B
et	FW	I
al.	NN	I
,	,	I
Am	NNP	I
.	.	I
J.	NNP	I
Pathol	NNP	I
.	.	I
(	(	I
1996	CD	I
)	)	I
148:201-10	CD	I
and	CC	O
Feany	NNP	B
et	VBP	I
al.	NN	I
,	,	I
Nature	NNP	I
(	(	I
2000	CD	I
)	)	I
404:394-8	CD	I
)	)	O
)	)	O
,	,	O
U.S.	NNP	O
Pat	NNP	O
.	.	O
No	DT	O
.	.	O
5,811,633	CD	O
(	(	O
for	IN	O
transgenic	NN	O
animals	NNS	O
with	IN	O
a	DT	O
mutant	JJ	O
form	NN	O
of	IN	O
APP	NNP	O
)	)	O
.	.	O
Some	DT	O
transgenic	JJ	O
animals	NNS	O
express	VBP	O
variant	JJ	O
or	CC	O
mutant	JJ	O
alpha-synuclein	JJ	O
,	,	O
such	JJ	O
as	IN	O
familial	JJ	O
mutants	NNS	O
A30P	NNP	O
,	,	O
A53T	NNP	O
,	,	O
and	CC	O
E46K	NNP	O
of	IN	O
alpha	JJ	O
synuclein	NN	O
.	.	O
Some	DT	O
transgenic	JJ	O
animals	NNS	O
have	VBP	O
an	DT	O
additional	JJ	O
transgene	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
transgene	NN	O
encoding	VBG	O
a	DT	O
kinase	NN	O
as	IN	O
described	VBN	O
above	IN	O
.	.	O
Transgenic	JJ	O
animals	NNS	O
bearing	VBG	O
a	DT	O
transgene	JJ	O
expressing	VBG	O
alpha-synuclein	JJ	O
protein	NN	O
can	MD	O
also	RB	O
be	VB	O
crossed	VBN	O
with	IN	O
other	JJ	O
transgenic	JJ	O
models	NNS	O
of	IN	O
neurogenic	JJ	O
disease	NN	O
,	,	O
such	JJ	O
as	IN	O
models	NNS	O
of	IN	O
Alzheimer	NNP	O
's	POS	O
disease	NN	O
.	.	O
For	IN	O
example	NN	O
,	,	O
transgenic	JJ	O
animals	NNS	O
bearing	VBG	O
a	DT	O
transgene	NN	O
expressing	VBG	O
a	DT	O
truncated	JJ	O
alpha-synuclein	JJ	O
protein	NN	O
can	MD	O
be	VB	O
crossed	VBN	O
with	IN	O
transgenic	JJ	O
animals	NNS	O
bearing	VBG	O
a	DT	O
transgene	NN	O
expressed	VBN	O
APP	NNP	O
with	IN	O
a	DT	O
FAD	NNP	O
mutation	NN	O
as	IN	O
described	VBN	O
by	IN	O
e.g.	NN	O
,	,	O
Games	NNP	B
et	FW	I
al.	NN	I
,	,	I
Nature	NNP	I
373	CD	I
,	,	I
523	CD	I
(	(	I
1995	CD	I
)	)	I
McConlogue	NNP	B
et	CC	I
al.	NN	I
,	,	I
U.S.	NNP	I
Pat	NNP	I
.	.	I
No	DT	I
.	.	I
5,612,486	CD	I
,	,	O
Hsiao	NNP	B
et	FW	I
al.	NN	I
,	,	I
Science	NNP	I
274	CD	I
,	,	I
99	CD	I
(	(	I
1996	CD	I
)	)	I
;	:	O
Staufenbiel	NNP	B
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
94	CD	I
,	,	I
13287-13292	CD	I
(	(	I
1997	CD	I
)	)	I
;	:	O
Sturchler-Pierrat	NNP	B
et	FW	I
al.	NN	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
94	CD	I
,	,	I
13287-13292	CD	I
(	(	I
1997	CD	I
)	)	I
;	:	O
Borchelt	NNP	B
et	FW	I
al.	NN	I
,	,	I
Neuron	NNP	I
19	CD	I
,	,	I
939-945	CD	I
(	(	I
1997	CD	I
)	)	I
)	)	O
.	.	O
The	DT	O
procedure	NN	O
for	IN	O
performing	VBG	O
such	PDT	O
a	DT	O
cross	NN	O
is	VBZ	O
described	VBN	O
by	IN	O
e.g.	NN	O
,	,	O
Masliah	NNP	B
et	FW	I
al.	NN	I
,	,	I
PNAS	NNP	I
USA	NNP	I
98:12245-12250	CD	I
(	(	I
2001	CD	I
)	)	I
,	,	O
which	WDT	O
reports	VBZ	O
a	DT	O
cross	NN	O
between	IN	O
transgenic	JJ	O
mice	NN	O
expressing	VBG	O
a	DT	O
full	JJ	O
length	NN	O
alpha-synuclein	NN	O
with	IN	O
PDAPP	NNP	O
mice	NN	O
as	IN	O
described	VBN	O
by	IN	O
Games	NNP	O
et	FW	O
al	NN	O
Transgenic	NNP	O
animals	NNS	O
of	IN	O
the	DT	O
invention	NN	O
are	VBP	O
preferably	RB	O
rodents	NNS	O
,	,	O
such	JJ	O
as	IN	O
mice	NNS	O
or	CC	O
rats	NNS	O
,	,	O
or	CC	O
insects	NNS	O
,	,	O
such	JJ	O
as	IN	O
Drosophila	NNP	O
.	.	O
Transgenic	JJ	O
animals	NNS	O
can	MD	O
be	VB	O
produced	VBN	O
by	IN	O
introduction	NN	O
of	IN	O
a	DT	O
transgene	NN	O
at	IN	O
the	DT	O
germline	NN	O
stage	NN	O
in	IN	O
which	WDT	O
case	NN	O
all	DT	O
or	CC	O
substantially	RB	O
all	DT	O
(	(	O
except	IN	O
for	IN	O
rare	JJ	O
loss	NN	O
through	IN	O
somatic	JJ	O
mutation	NN	O
)	)	O
of	IN	O
the	DT	O
cells	NNS	O
of	IN	O
the	DT	O
transgenic	JJ	O
animal	NN	O
include	VBP	O
the	DT	O
transgene	NN	O
integrated	VBN	O
into	IN	O
the	DT	O
genome	NN	O
.	.	O
Transgenes	NNS	O
can	MD	O
be	VB	O
introduced	VBN	O
by	IN	O
microinjection	NN	O
,	,	O
nuclear	JJ	O
transfer	NN	O
or	CC	O
viral	JJ	O
infection	NN	O
into	IN	O
cells	NNS	O
or	CC	O
animals	NNS	O
.	.	O
Adeno	NNP	O
Associated	NNP	O
Viruses	NNP	O
and	CC	O
Lentiviruses	NNP	O
are	VBP	O
particularly	RB	O
suitable	JJ	O
for	IN	O
the	DT	O
latter	NN	O
.	.	O
Alternatively	RB	O
,	,	O
transgenes	NNS	O
can	MD	O
be	VB	O
introduced	VBN	O
by	IN	O
viral	JJ	O
infection	NN	O
into	IN	O
the	DT	O
brain	NN	O
of	IN	O
the	DT	O
animal	NN	O
.	.	O
Such	JJ	O
transgenes	NNS	O
are	VBP	O
not	RB	O
part	NN	O
of	IN	O
the	DT	O
germline	NN	O
of	IN	O
recipient	NN	O
animals	NNS	O
but	CC	O
can	MD	O
be	VB	O
targeted	VBN	O
to	TO	O
regions	NNS	O
of	IN	O
the	DT	O
brain	NN	O
responsible	JJ	O
for	IN	O
disease	NN	O
(	(	O
e.g.	UH	O
,	,	O
the	DT	O
substantia	NN	O
nigra	NN	O
)	)	O
.	.	O
Such	JJ	O
animal	JJ	O
models	NNS	O
incorporate	VBP	O
an	DT	O
alpha-synuclein	JJ	O
into	IN	O
the	DT	O
genome	NN	O
of	IN	O
brain	NN	O
cells	NNS	O
and	CC	O
are	VBP	O
disposed	VBN	O
to	TO	O
develop	VB	O
at	IN	O
least	JJS	O
one	CD	O
characteristic	NN	O
of	IN	O
LBD	NNP	O
disease	NN	O
.	.	O
Lentiviruses	NNS	O
provide	VBP	O
a	DT	O
suitable	JJ	O
vehicle	NN	O
for	IN	O
so	RB	O
introducing	VBG	O
an	DT	O
alpha-synuclein	JJ	O
transgene	NN	O
into	IN	O
the	DT	O
brain	NN	O
(	(	O
see	VB	O
Brain	NNP	B
Pathology	NNP	I
13	CD	I
,	,	I
364-372	CD	I
(	(	I
2003	CD	I
)	)	I
;	:	O
Bjorklund	NNP	B
,	,	I
Trends	NNP	I
Neurosci	NNP	I
.	.	I
26	CD	I
,	,	I
386-92	CD	I
(	(	I
2003	CD	I
)	)	I
,	,	O
Lotharius	NNP	B
et	FW	I
al.	NN	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
277	CD	I
,	,	I
38884-94	CD	I
(	(	I
2002	CD	I
)	)	I
,	,	O
Zhou	NNP	B
et	FW	I
al.	NN	I
,	,	I
Brain	NNP	I
Research	NNP	I
866	CD	I
,	,	I
33-43	CD	I
(	(	I
2000	CD	I
)	)	I
)	)	O
.	.	O
Transgenic	JJ	O
animals	NNS	O
can	MD	O
also	RB	O
include	VB	O
a	DT	O
transgene	NN	O
capable	JJ	O
of	IN	O
expressing	VBG	O
one	CD	O
of	IN	O
the	DT	O
kinases	NNS	O
of	IN	O
the	DT	O
invention	NN	O
(	(	O
e.g.	NN	O
,	,	O
a	DT	O
nucleic	JJ	O
acid	NN	O
encoding	VBG	O
the	DT	O
kinase	NN	O
in	IN	O
operable	JJ	O
linkage	NN	O
with	IN	O
regulatory	JJ	O
elements	NNS	O
to	TO	O
ensure	VB	O
its	PRP$	O
expression	NN	O
in	IN	O
the	DT	O
brain	NN	O
of	IN	O
an	DT	O
animal	NN	O
)	)	O
,	,	O
instead	RB	O
of	IN	O
or	CC	O
as	RB	O
well	RB	O
as	IN	O
a	DT	O
transgene	NN	O
expressing	VBG	O
alpha	JJ	O
synuclein	NN	O
.	.	O
Optionally	RB	O
,	,	O
a	DT	O
transgene	NN	O
expressing	VBG	O
synphilin	NN	O
can	MD	O
be	VB	O
included	VBN	O
as	RB	O
well	RB	O
.	.	O
Some	DT	O
cellular	JJ	O
models	NNS	O
express	VBP	O
variant	JJ	O
or	CC	O
mutant	JJ	O
alpha-synuclein	JJ	O
,	,	O
such	JJ	O
as	IN	O
familial	JJ	O
mutants	NNS	O
A30P	NNP	O
,	,	O
A53T	NNP	O
,	,	O
and	CC	O
E46K	NNP	O
of	IN	O
alpha	JJ	O
synuclein	NN	O
.	.	O
Some	DT	O
cells	NNS	O
have	VBP	O
an	DT	O
additional	JJ	O
transgene	NN	O
,	,	O
such	JJ	O
as	IN	O
a	DT	O
transgene	NN	O
encoding	VBG	O
a	DT	O
kinase	NN	O
as	IN	O
described	VBN	O
above	IN	O
,	,	O
e.g.	NN	O
,	,	O
PLK2	NNP	O
.	.	O
Cellular	JJ	O
models	NNS	O
of	IN	O
Lewy	NNP	O
body	NN	O
disease	NN	O
can	MD	O
also	RB	O
be	VB	O
used	VBN	O
in	IN	O
the	DT	O
screening	NN	O
methods	NNS	O
of	IN	O
the	DT	O
invention	NN	O
.	.	O
Cells	NNS	O
transfected	VBN	O
with	IN	O
alpha-synuclein	JJ	O
form	NN	O
inclusion	NN	O
bodies	NNS	O
containing	VBG	O
aggregated	JJ	O
alpha-synuclein	NN	O
.	.	O
The	DT	O
transformed	JJ	O
cells	NNS	O
are	VBP	O
preferably	RB	O
neuronal	JJ	O
cells	NNS	O
,	,	O
such	JJ	O
as	IN	O
GT1-7	NNP	O
neuronal	JJ	O
cells	NNS	O
(	(	O
Hsue	NNP	B
et	RB	I
al	RB	I
.	.	I
Am	NNP	I
.	.	I
J.	NNP	I
Pathol	NNP	I
.	.	I
157:401-410	CD	I
(	(	I
2000	CD	I
)	)	I
)	)	O
,	,	O
PC12	NNP	O
cells	NNS	O
or	CC	O
SY5Y	NNP	O
neuroblastoma	JJ	O
cells	NNS	O
.	.	O
PEAK	NNP	O
and/or	NN	O
HCC	NNP	O
cells	NNS	O
can	MD	O
also	RB	O
be	VB	O
used	VBN	O
(	(	O
see	VB	O
Example	NNP	O
10	CD	O
)	)	O
.	.	O
The	DT	O
cells	NNS	O
are	VBP	O
preferably	RB	O
human	JJ	O
cells	NNS	O
.	.	O
A	DT	O
vector	NN	O
comprising	VBG	O
a	DT	O
segment	NN	O
encoding	VBG	O
a	DT	O
form	NN	O
of	IN	O
alpha-synuclein	JJ	O
operably	RB	O
linked	VBN	O
to	TO	O
one	CD	O
or	CC	O
more	JJR	O
regulatory	JJ	O
sequences	NNS	O
that	WDT	O
ensure	VB	O
expression	NN	O
of	IN	O
the	DT	O
expression	NN	O
is	VBZ	O
transfected	VBN	O
into	IN	O
the	DT	O
cells	NNS	O
.	.	O
Cells	NNS	O
can	MD	O
also	RB	O
be	VB	O
transfected	VBN	O
with	IN	O
a	DT	O
nucleic	JJ	O
acid	NN	O
encoding	VBG	O
a	DT	O
kinase	NN	O
of	IN	O
the	DT	O
invention	NN	O
as	IN	O
described	VBN	O
above	IN	O
.	.	O
Transfected	VBN	O
cells	NNS	O
can	MD	O
be	VB	O
used	VBN	O
to	TO	O
screen	JJ	O
agents	NNS	O
for	IN	O
activity	NN	O
in	IN	O
clearing	VBG	O
alpha-synuclein	JJ	O
inclusions	NNS	O
.	.	O
An	DT	O
exemplary	JJ	O
cellular	JJ	O
model	NN	O
is	VBZ	O
identified	VBN	O
in	IN	O
Example	NNP	O
10	CD	O
in	IN	O
which	WDT	O
HCC	NNP	O
neuronal	JJ	O
cells	NNS	O
are	VBP	O
transfected	VBN	O
with	IN	O
synuclein	NN	O
and	CC	O
PLK2	NNP	O
with	IN	O
the	DT	O
result	NN	O
that	IN	O
aggregation	NN	O
and	CC	O
phosphorylation	NN	O
of	IN	O
the	DT	O
synuclein	NN	O
matching	VBG	O
LB	NNP	O
formation	NN	O
occurs	VBZ	O
.	.	O
In	IN	O
order	NN	O
to	TO	O
identify	VB	O
inhibitors	NNS	O
of	IN	O
the	DT	O
kinase	NN	O
,	,	O
the	DT	O
cell	NN	O
is	VBZ	O
contacted	VBN	O
with	IN	O
the	DT	O
inhibitor	NN	O
and	CC	O
a	DT	O
reduction	NN	O
in	IN	O
the	DT	O
amount	NN	O
of	IN	O
phosphorylation	NN	O
and/or	NN	O
aggregation	NN	O
is	VBZ	O
identified	VBN	O
.	.	O
X.	JJ	O
Alpha-Synuclein	NNP	O
Isolation	NNP	O
and	CC	O
Phosphorylation	NNP	O
Human	NNP	O
alpha-synuclein	NN	O
is	VBZ	O
a	DT	O
polypeptide	NN	O
of	IN	O
140	CD	O
amino	NN	O
acids	NNS	O
having	VBG	O
the	DT	O
following	JJ	O
amino	NN	O
acid	JJ	O
sequence	NN	O
:	:	O
(	(	O
Ueda	NNP	B
et	RB	I
al.	RB	I
,	,	I
Proc	NNP	I
.	.	I
Natl	NNP	I
.	.	I
Acad	NNP	I
.	.	I
Sci	NNP	I
.	.	I
USA	NNP	I
(	(	I
1993	CD	I
)	)	I
90:11282-6	CD	I
)	)	O
;	:	O
GenBank	NNP	O
accession	NN	O
number	NN	O
:	:	O
P37840	NNP	O
)	)	O
.	.	O
The	DT	O
protein	NN	O
has	VBZ	O
three	CD	O
recognized	VBN	O
domains	NNS	O
,	,	O
a	DT	O
KTKE	NNP	O
repeat	NN	O
domain	NN	O
covering	VBG	O
amino	JJ	O
acids	NNS	O
1-61	JJ	O
,	,	O
a	DT	O
NAC	NNP	O
(	(	O
Non-Amyloid	NNP	O
Component	NNP	O
)	)	O
domain	VBP	O
running	VBG	O
from	IN	O
about	IN	O
amino	JJ	O
acids	NNS	O
60-95	JJ	O
,	,	O
and	CC	O
a	DT	O
C-terminal	JJ	O
acidic	JJ	O
domain	NN	O
running	VBG	O
from	IN	O
about	IN	O
amino	NN	O
acid	NN	O
98	CD	O
to	TO	O
140	CD	O
.	.	O
Unless	IN	O
otherwise	RB	O
apparent	NN	O
from	IN	O
the	DT	O
context	NN	O
,	,	O
reference	NN	O
to	TO	O
alpha-synuclein	JJ	O
includes	VBZ	O
the	DT	O
natural	JJ	O
human	JJ	O
amino	NN	O
acid	NN	O
sequence	NN	O
indicated	VBD	O
above	IN	O
as	RB	O
well	RB	O
as	IN	O
analogs	NNS	O
including	VBG	O
allelic	JJ	O
,	,	O
species	NNS	O
and	CC	O
induced	JJ	O
variants	NNS	O
(	(	O
e.g.	NN	O
,	,	O
E83Q	NNP	O
,	,	O
A90V	NNP	O
,	,	O
A76T	NNP	O
)	)	O
having	VBG	O
at	IN	O
least	JJS	O
90	CD	O
%	NN	O
sequence	NN	O
identity	NN	O
to	TO	O
natural	JJ	O
human	JJ	O
alpha-synuclein	NN	O
.	.	O
Amino	NNP	O
acids	NNS	O
of	IN	O
analogs	NNS	O
are	VBP	O
assigned	VBN	O
the	DT	O
same	JJ	O
numbers	NNS	O
as	IN	O
corresponding	VBG	O
amino	JJ	O
acids	NNS	O
in	IN	O
the	DT	O
natural	JJ	O
human	JJ	O
sequence	NN	O
when	WRB	O
the	DT	O
analog	NN	O
and	CC	O
human	JJ	O
sequence	NN	O
are	VBP	O
maximally	RB	O
aligned	VBN	O
.	.	O
Analogs	NNP	O
typically	RB	O
differ	VBP	O
from	IN	O
naturally	RB	O
occurring	VBG	O
peptides	NNS	O
at	IN	O
one	CD	O
,	,	O
two	CD	O
or	CC	O
a	DT	O
few	JJ	O
positions	NNS	O
,	,	O
often	RB	O
by	IN	O
virtue	NNS	O
of	IN	O
conservative	JJ	O
substitutions	NNS	O
.	.	O
Some	DT	O
natural	JJ	O
allelic	JJ	O
variants	NNS	O
are	VBP	O
genetically	RB	O
associated	VBN	O
with	IN	O
hereditary	JJ	O
LBD	NNP	O
.	.	O
The	DT	O
term	NN	O
“	NNP	O
allelic	JJ	O
variant	NN	O
”	NN	O
is	VBZ	O
used	VBN	O
to	TO	O
refer	VB	O
to	TO	O
variations	NNS	O
between	IN	O
genes	NNS	O
of	IN	O
different	JJ	O
individuals	NNS	O
in	IN	O
the	DT	O
same	JJ	O
species	NNS	O
and	CC	O
corresponding	VBG	O
variations	NNS	O
in	IN	O
proteins	NNS	O
encoded	VBN	O
by	IN	O
the	DT	O
genes	NNS	O
.	.	O
Allelic	JJ	O
variants	NNS	O
include	VBP	O
familial	JJ	O
mutants	NNS	O
or	CC	O
variants	NNS	O
,	,	O
such	JJ	O
as	IN	O
E46K	NNP	O
,	,	O
A30P	NNP	O
and	CC	O
A53T	NNP	O
(	(	O
the	DT	O
first	JJ	O
letter	NN	O
indicates	VBZ	O
the	DT	O
amino	NN	O
acid	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:1	NNP	O
,	,	O
the	DT	O
number	NN	O
is	VBZ	O
the	DT	O
residue	JJ	O
position	NN	O
in	IN	O
SEQ	NNP	O
ID	NNP	O
NO:1	NNP	O
,	,	O
and	CC	O
the	DT	O
second	JJ	O
letter	NN	O
is	VBZ	O
the	DT	O
amino	NN	O
acid	NN	O
in	IN	O
the	DT	O
allelic	JJ	O
variant	NN	O
)	)	O
.	.	O
Analogs	NNS	O
can	MD	O
include	VB	O
any	DT	O
combination	NN	O
of	IN	O
allelic	JJ	O
variants	NNS	O
.	.	O
The	DT	O
A53T	NNP	O
variation	NN	O
is	VBZ	O
associated	VBN	O
with	IN	O
enhanced	JJ	O
levels	NNS	O
of	IN	O
phosphorylation	NN	O
at	IN	O
position	NN	O
129	CD	O
of	IN	O
alpha-synuclein	NN	O
in	IN	O
an	DT	O
individual	JJ	O
having	VBG	O
the	DT	O
mutation	NN	O
relative	NN	O
to	TO	O
the	DT	O
norm	NN	O
of	IN	O
phosphorylation	NN	O
in	IN	O
undiseased	JJ	O
individuals	NNS	O
who	WP	O
lack	VBP	O
the	DT	O
mutation	NN	O
.	.	O
Alpha-synuclein	NNP	O
,	,	O
its	PRP$	O
fragments	NNS	O
,	,	O
and	CC	O
analogs	NNS	O
can	MD	O
be	VB	O
synthesized	VBN	O
by	IN	O
solid	JJ	O
phase	NN	O
peptide	JJ	O
synthesis	NN	O
or	CC	O
recombinant	JJ	O
expression	NN	O
,	,	O
or	CC	O
can	MD	O
be	VB	O
obtained	VBN	O
from	IN	O
natural	JJ	O
sources	NNS	O
.	.	O
Automatic	NNP	O
peptide	NN	O
synthesizers	NNS	O
are	VBP	O
commercially	RB	O
available	JJ	O
from	IN	O
numerous	JJ	O
suppliers	NNS	O
,	,	O
such	JJ	O
as	IN	O
Applied	NNP	O
Biosystems	NNP	O
,	,	O
Foster	NNP	O
City	NNP	O
,	,	O
Calif.	NNP	O
Recombinant	NNP	O
expression	NN	O
can	MD	O
be	VB	O
in	IN	O
bacteria	NNS	O
,	,	O
such	JJ	O
as	IN	O
E.	NNP	O
coli	NNS	O
,	,	O
yeast	NN	O
,	,	O
insect	JJ	O
cells	NNS	O
or	CC	O
mammalian	JJ	O
cells	NNS	O
.	.	O
Procedures	NNS	O
for	IN	O
recombinant	JJ	O
expression	NN	O
are	VBP	O
described	VBN	O
by	IN	O
Sambrook	NNP	B
et	FW	I
al.	NN	I
,	,	I
Molecular	JJ	I
Cloning	NN	I
:	:	I
A	DT	I
Laboratory	NNP	I
Manual	NNP	I
(	(	I
C.S.H.P	NNP	I
.	.	I
Press	NN	I
,	,	I
NY	NNP	I
2d	CD	I
ed.	NN	I
,	,	I
1989	CD	I
)	)	I
.	.	O
A	DT	O
method	NN	O
was	VBD	O
developed	VBN	O
herein	NN	O
to	TO	O
prepare	VB	O
large	JJ	O
amounts	NNS	O
of	IN	O
wild-type	JJ	O
phospho-S129	JJ	O
alpha-synuclein	NN	O
,	,	O
mutant	JJ	O
and/or	NN	O
familial	JJ	O
forms	NNS	O
in	IN	O
a	DT	O
bacterial	JJ	O
expression	NN	O
system	NN	O
.	.	O
When	WRB	O
recombinant	JJ	O
hPLK2	NN	O
was	VBD	O
co-expressed	JJ	O
with	IN	O
alpha-synuclein	JJ	O
in	IN	O
bacteria	NNS	O
,	,	O
the	DT	O
phospho-S129	JJ	O
alpha-synuclein	NN	O
that	WDT	O
was	VBD	O
produced	VBN	O
in	IN	O
the	DT	O
cell	NN	O
was	VBD	O
recovered	VBN	O
with	IN	O
a	DT	O
very	RB	O
high	JJ	O
yield	NN	O
and	CC	O
purity	NN	O
.	.	O
This	DT	O
is	VBZ	O
because	RB	O
,	,	O
unlike	IN	O
most	JJS	O
E.	NNP	O
coli	JJ	O
proteins	NNS	O
,	,	O
the	DT	O
alpha-synuclein	NN	O
could	MD	O
resist	VB	O
heating	NN	O
.	.	O
After	IN	O
boiling	VBG	O
of	IN	O
the	DT	O
bacterial	JJ	O
lysate	NN	O
,	,	O
alpha-synuclein	JJ	O
purity	NN	O
reached	VBD	O
about	IN	O
95	CD	O
%	NN	O
before	IN	O
chromatography	NN	O
.	.	O
To	TO	O
co-express	JJ	O
recombinant	JJ	O
protein	NN	O
in	IN	O
a	DT	O
bacterial	JJ	O
system	NN	O
,	,	O
the	DT	O
plasmids	NNS	O
harboring	VBG	O
each	DT	O
gene	NN	O
of	IN	O
interest	NN	O
were	VBD	O
chosen	VBN	O
be	VB	O
compatible	JJ	O
within	IN	O
the	DT	O
bacterial	JJ	O
cell	NN	O
by	IN	O
ensuring	VBG	O
that	IN	O
they	PRP	O
possessed	VBD	O
a	DT	O
different	JJ	O
origin	NN	O
of	IN	O
replication	NN	O
and	CC	O
a	DT	O
different	JJ	O
antibiotic	JJ	O
selection	NN	O
.	.	O
The	DT	O
alpha-synuclein	JJ	O
gene	NN	O
was	VBD	O
sub-cloned	VBN	O
into	IN	O
a	DT	O
pDEST24	NN	O
compatible	JJ	O
vector	NN	O
,	,	O
pCDF1b	NN	O
.	.	O
BL21-DE3	JJ	O
bacteria	NNS	O
were	VBD	O
then	RB	O
co-transformed	VBN	O
with	IN	O
both	DT	O
the	DT	O
pDEST24	NN	O
containing	VBG	O
wild-type	JJ	O
hPLK2	NN	O
or	CC	O
hPLK2	NN	O
constitutive	JJ	O
mutant	NN	O
constructs	NNS	O
without	IN	O
a	DT	O
GST	NNP	O
tag	NN	O
and	CC	O
the	DT	O
pCDF1b/AS	NN	O
plasmid	NN	O
.	.	O
The	DT	O
bacterial	JJ	O
lysates	NNS	O
were	VBD	O
boiled	VBN	O
and	CC	O
the	DT	O
supernatant	NN	O
,	,	O
expected	VBN	O
to	TO	O
contain	VB	O
alpha-synuclein	NN	O
was	VBD	O
analyzed	VBN	O
by	IN	O
Western	JJ	O
blot	NN	O
with	IN	O
an	DT	O
anti-phospho-S129-alpha-synuclein	JJ	O
antibody	NN	O
(	(	O
11A5	CD	O
)	)	O
,	,	O
by	IN	O
using	VBG	O
the	DT	O
SYPRO	NNP	O
Ruby™	NNP	O
and	CC	O
ProZDiamond™	NNP	O
dyes	NNS	O
(	(	O
total	JJ	O
protein	NN	O
and	CC	O
phospho-Ser/Thr	JJ	O
specific	JJ	O
dye	NN	O
respectively	RB	O
)	)	O
,	,	O
by	IN	O
SDS-PAGE	NNP	O
and	CC	O
by	IN	O
mass	NN	O
spectrometry	NN	O
,	,	O
with	IN	O
the	DT	O
results	NNS	O
that	IN	O
a	DT	O
fairly	RB	O
pure	JJ	O
phospho-S129-alpha-synuclein	JJ	O
product	NN	O
was	VBD	O
isolated	VBN	O
that	IN	O
,	,	O
upon	IN	O
analysis	NN	O
by	IN	O
mass	NN	O
spectrometry	NN	O
was	VBD	O
revealed	VBN	O
to	TO	O
be	VB	O
more	JJR	O
than	IN	O
95	CD	O
%	NN	O
phosphorylated	VBN	O
.	.	O
To	TO	O
ensure	VB	O
that	IN	O
the	DT	O
final	JJ	O
product	NN	O
was	VBD	O
100	CD	O
%	NN	O
phosphorylated	VBN	O
and	CC	O
highly	RB	O
pure	NN	O
,	,	O
the	DT	O
supernatant	NN	O
of	IN	O
the	DT	O
last	JJ	O
centrifugation	NN	O
was	VBD	O
passed	VBN	O
through	IN	O
an	DT	O
11A5-sepharose-affinity	JJ	O
purification	NN	O
column	NN	O
one	CD	O
or	CC	O
more	JJR	O
times	NNS	O
.	.	O
Any	DT	O
contamination	NN	O
was	VBD	O
removed	VBN	O
using	VBG	O
HPLC	NNP	O
.	.	O
XI	NN	O
.	.	O
Examples	NNS	O
EXAMPLE	NNP	O
1	CD	O
Screen	NNP	O
for	IN	O
Kinases	NNP	O
that	WDT	O
Modulate	NNP	O
Alpha-Synuclein	NNP	O
Phosphorylation	NNP	O
To	TO	O
identify	VB	O
the	DT	O
kinase	NN	O
or	CC	O
kinases	VBZ	O
that	DT	O
phosphorylates	VBZ	O
α-synuclein	JJ	O
at	IN	O
serine-129	JJ	O
an	DT	O
siRNA	JJ	O
kinase	NN	O
library	NN	O
(	(	O
Ambion	NNP	O
)	)	O
was	VBD	O
screened	VBN	O
on	IN	O
cells	NNS	O
containing	VBG	O
a	DT	O
quantifiable	JJ	O
amount	NN	O
of	IN	O
phosphorylated	JJ	O
α-synuclein	NN	O
.	.	O
Human	NNP	O
embryonic	JJ	O
kidney	NN	O
cell	NN	O
line	NN	O
HEK293	NNP	O
cells	NNS	O
(	(	O
PEAK	NNP	O
cells	NNS	O
)	)	O
stably	RB	O
transfected	VBN	O
with	IN	O
human	JJ	O
wild-type	JJ	O
α-synuclein	JJ	O
under	IN	O
control	NN	O
of	IN	O
a	DT	O
CMV	NNP	O
promoter	NN	O
(	(	O
PEAK-Syn	NNP	O
cells	NNS	O
)	)	O
were	VBD	O
transfected	VBN	O
with	IN	O
100	CD	O
nM	NNS	O
siRNAs	VBD	O
targeting	VBG	O
597	CD	O
human	JJ	O
kinases	NNS	O
and	CC	O
were	VBD	O
assayed	VBN	O
by	IN	O
ELISA	NNP	O
assays	NNS	O
to	TO	O
quantitate	VB	O
total	JJ	O
and	CC	O
phospho-synuclein	JJ	O
levels	NNS	O
.	.	O
Ninety-five	JJ	O
kinases	NNS	O
with	IN	O
siRNAs	NN	O
that	WDT	O
altered	VBD	O
the	DT	O
percentage	NN	O
of	IN	O
phosphorylated	JJ	O
alpha-synuclein	NNS	O
were	VBD	O
identified	VBN	O
(	(	O
see	VB	O
Tables	NNP	O
1-2	CD	O
)	)	O
.	.	O
Of	IN	O
those	DT	O
,	,	O
28	CD	O
belonged	VBD	O
to	TO	O
the	DT	O
class	NN	O
of	IN	O
kinases	NNS	O
that	WDT	O
phosphorylate	VBP	O
serine	NN	O
residues	NNS	O
and	CC	O
hence	NN	O
were	VBD	O
capable	JJ	O
of	IN	O
directly	RB	O
phosphorylating	VBG	O
α-synuclein	NN	O
at	IN	O
serine-129	NN	O
.	.	O
Others	NNS	O
were	VBD	O
tyrosine	JJ	O
kinases	NNS	O
.	.	O
Although	IN	O
tyrosine	NN	O
kinases	NNS	O
do	VBP	O
not	RB	O
phosphorylate	VB	O
α-synuclein	NNS	O
at	IN	O
ser-129	JJ	O
directly	RB	O
,	,	O
they	PRP	O
can	MD	O
act	VB	O
as	IN	O
upstream	JJ	O
regulators	NNS	O
of	IN	O
the	DT	O
alpha-synuclein	JJ	O
kinase	NN	O
.	.	O
Two	CD	O
of	IN	O
these	DT	O
ser/thr	JJ	O
kinases	NNS	O
,	,	O
casein	JJ	O
kinase	NN	O
2	CD	O
and	CC	O
calcium/calmodulin	JJ	O
dependent	NN	O
protein	NN	O
kinase	NN	O
II	NNP	O
,	,	O
have	VBP	O
been	VBN	O
reported	VBN	O
to	TO	O
phosphorylate	VB	O
α-synuclein	NNS	O
in	IN	O
vitro	NN	O
(	(	O
Pronin	NNP	B
et	RB	I
al	RB	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
275	CD	I
:	:	I
26515-26522	CD	I
(	(	I
2000	CD	I
)	)	I
,	,	O
Okochoa	NNP	B
et	FW	I
al	NN	I
,	,	I
J.	NNP	I
Biol	NNP	I
.	.	I
Chem	NNP	I
.	.	I
275	CD	I
:	:	I
390-397	CD	I
(	(	I
2000	CD	I
)	)	I
;	:	O
Nakajo	NNP	B
et	FW	I
al	NN	I
,	,	I
Eur	NNP	I
.	.	I
J.	NNP	I
Biochem	NNP	I
.	.	I
217	CD	I
:	:	I
1057-1063	CD	I
(	(	I
1993	CD	I
)	)	I
and	CC	O
a	DT	O
casein	JJ	O
kinase	NN	O
2	CD	O
inhibitor	NN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
decrease	VB	O
phospho-synuclein	JJ	O
levels	NNS	O
in	IN	O
cells	NNS	O
(	(	O
Okochoa	NNP	B
et	RB	I
al	RB	I
,	,	I
2000	CD	I
)	)	O
.	.	O
Several	JJ	O
of	IN	O
the	DT	O
GRK	NNP	O
family	NN	O
members	NNS	O
(	(	O
although	IN	O
not	RB	O
GRK6	NNP	O
)	)	O
have	VBP	O
been	VBN	O
reported	VBN	O
to	TO	O
phosphorylate	VB	O
alpha-synuclein	NNS	O
in	IN	O
vitro	NN	O
(	(	O
Pronin	NNP	B
et	RB	I
al	RB	I
,	,	I
2000	CD	I
)	)	O
.	.	O
GRK2	NNP	O
expression	NN	O
in	IN	O
flies	NNS	O
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
increase	VB	O
phospho-synuclein	JJ	O
levels	NNS	O
(	(	O
Chen	NNP	B
and	CC	I
Feany	NNP	I
,	,	I
Nature	NNP	I
Neurosci	NNP	I
.	.	I
8	CD	I
:	:	I
657-663	JJ	I
(	(	I
2005	CD	I
)	)	I
)	)	O
.	.	O
In	IN	O
addition	NN	O
to	TO	O
kinases	VB	O
that	DT	O
lower	JJR	O
phospho-synuclein	NN	O
levels	NNS	O
,	,	O
99	CD	O
kinases	NNS	O
whose	WP$	O
siRNAs	NN	O
altered	VBD	O
total	JJ	O
α-synuclein	JJ	O
levels	NNS	O
in	IN	O
the	DT	O
PEAK-Syn	NNP	O
cells	NNS	O
were	VBD	O
identified	VBN	O
in	IN	O
Table	JJ	O
2	CD	O
and	CC	O
included	VBD	O
fucokinase	NN	O
(	(	O
FUK	NNP	O
)	)	O
,	,	O
Genbank	NNP	O
number	NN	O
NM—145059	NNP	O
;	:	O
Protein	NNP	O
Kinase	NNP	O
N1	NNP	O
(	(	O
PRKCL1	NNP	O
,	,	O
PKN1	NNP	O
)	)	O
,	,	O
Genbank	NNP	O
number	NN	O
NM—002741	NNP	O
;	:	O
Doublecortin	NNP	O
and	CC	O
CaM	NNP	O
kinase-like	JJ	O
1	CD	O
(	(	O
DCAMKL1	NNP	O
)	)	O
NM—004734	NNP	O
;	:	O
Branched	NNP	O
chain	NN	O
Ketoacid	NNP	O
dehydrogenase	NN	O
kinase	NN	O
(	(	O
BCKDK	NNP	O
)	)	O
NM—005881	NNP	O
;	:	O
Aurora	NNP	O
Kinase	NNP	O
C	NNP	O
(	(	O
AURKC	NNP	O
,	,	O
STK13	NNP	O
)	)	O
;	:	O
NM—003160	NNP	O
,	,	O
Kinase	NNP	O
suppressor	NN	O
of	IN	O
ras	NNS	O
2	CD	O
(	(	O
FLJ25965	NNP	O
)	)	O
,	,	O
NM—173598	NNP	O
;	:	O
FLJ32704	NNP	O
;	:	O
MAP2K6	NNP	O
;	:	O
and	CC	O
Tousled-like	NNP	O
kinase	NN	O
2	CD	O
(	(	O
TLK2	NNP	O
)	)	O
NM—006842	NNP	O
.	.	O
The	DT	O
mechanism	NN	O
of	IN	O
action	NN	O
may	MD	O
involve	VB	O
either	DT	O
regulation	NN	O
of	IN	O
alpha-synuclein	JJ	O
turnover	NN	O
or	CC	O
synthesis	NN	O
(	(	O
See	NNP	O
Table	NNP	O
2	CD	O
)	)	O
.	.	O
Tables	NNS	O
1A	CD	O
,	,	O
1B	CD	O
and	CC	O
1C	CD	O
show	NN	O
kinases	NNS	O
whose	WP$	O
inhibition	NN	O
modulates	VBZ	O
the	DT	O
phosphorylation	NN	O
at	IN	O
position	NN	O
ser-129	NN	O
.	.	O
Table	JJ	O
1A	CD	O
,	,	O
B	NNP	O
,	,	O
and	CC	O
C	NNP	O
differ	VBP	O
in	IN	O
the	DT	O
type	NN	O
of	IN	O
kinase	NN	O
.	.	O
Table	JJ	O
1A	CD	O
shows	NNS	O
kinases	NNS	O
that	WDT	O
can	MD	O
phosphorylate	VB	O
serine	NN	O
residues	NNS	O
and	CC	O
often	RB	O
tyrosine	JJ	O
and/or	JJ	O
threonine	NN	O
as	IN	O
well	RB	O
.	.	O
Table	JJ	O
1B	CD	O
shows	NNS	O
tyrosine	VBP	O
kinases	NNS	O
that	WDT	O
can	MD	O
not	RB	O
(	(	O
so	RB	O
far	RB	O
as	IN	O
is	VBZ	O
known	VBN	O
)	)	O
modify	FW	O
serine	NN	O
residues	NNS	O
.	.	O
Table	JJ	O
1C	CD	O
shows	NNS	O
kinases	VBZ	O
not	RB	O
known	VBN	O
to	TO	O
have	VB	O
phosphorylate	JJ	O
proteins	NNS	O
.	.	O
Kinases	NNS	O
from	IN	O
the	DT	O
upper	JJ	O
portion	NN	O
of	IN	O
Table	JJ	O
1A	CD	O
are	VBP	O
candidates	NNS	O
for	IN	O
direct	JJ	O
phosphorylation	NN	O
of	IN	O
ser-129	NN	O
of	IN	O
alpha-synuclein	NN	O
.	.	O
Kinases	NNS	O
from	IN	O
the	DT	O
upper	JJ	O
part	NN	O
of	IN	O
Table	JJ	O
1B	CD	O
are	VBP	O
also	RB	O
useful	JJ	O
therapeutic	JJ	O
targets	NNS	O
via	IN	O
roles	NNS	O
indirectly	RB	O
phosphorylating	VBG	O
alpha-synuclein	NN	O
.	.	O
Proteins	NNS	O
in	IN	O
the	DT	O
upper	JJ	O
part	NN	O
of	IN	O
Table	JJ	O
1C	CD	O
are	VBP	O
also	RB	O
useful	JJ	O
therapeutic	JJ	O
targets	NNS	O
for	IN	O
the	DT	O
same	JJ	O
reason	NN	O
.	.	O
Cols	NNP	O
.	.	O
1	CD	O
,	,	O
2	CD	O
and	CC	O
3	CD	O
of	IN	O
each	DT	O
table	NN	O
indicate	VBP	O
the	DT	O
gene	NN	O
name	NN	O
,	,	O
kinase	NN	O
name	NN	O
and	CC	O
Genbank	NNP	O
accession	NN	O
number	NN	O
of	IN	O
kinases	NNS	O
.	.	O
The	DT	O
next	JJ	O
column	NN	O
indicates	VBZ	O
whether	IN	O
inhibiting	VBG	O
expression	NN	O
of	IN	O
the	DT	O
kinase	NN	O
decreased	VBD	O
(	(	O
“	VB	O
down	RP	O
”	NNP	O
)	)	O
or	CC	O
increased	VBN	O
(	(	O
“	VB	O
up	RP	O
”	NNP	O
)	)	O
phosphorylation	NN	O
.	.	O
The	DT	O
next	JJ	O
three	CD	O
columns	NN	O
indicate	VBP	O
the	DT	O
number	NN	O
of	IN	O
standard	JJ	O
deviations	NNS	O
the	DT	O
measured	JJ	O
level	NN	O
of	IN	O
phosphorylation	NN	O
departs	NNS	O
from	IN	O
the	DT	O
mean	NN	O
in	IN	O
three	CD	O
independent	JJ	O
experiments	NNS	O
.	.	O
The	DT	O
final	JJ	O
two	CD	O
columns	NN	O
indicate	VBP	O
the	DT	O
kinase	NN	O
family	NN	O
(	(	O
i.e.	FW	O
,	,	O
amino	JJ	O
acid	VBP	O
specificity	NN	O
)	)	O
and	CC	O
group	NN	O
.	.	O
Tables	NNS	O
2	CD	O
and	CC	O
3	CD	O
show	NN	O
kinases	NNS	O
whose	WP$	O
inhibition	NN	O
modulates	VBZ	O
the	DT	O
overall	JJ	O
levels	NNS	O
of	IN	O
human	JJ	O
alpha-synuclein	NN	O
without	IN	O
changing	VBG	O
the	DT	O
percentage	NN	O
of	IN	O
phosphorylation	NN	O
.	.	O
Table	JJ	O
2	CD	O
shows	VBZ	O
all	DT	O
of	IN	O
the	DT	O
kinases	NNS	O
with	IN	O
the	DT	O
strongest	JJS	O
reduction	NN	O
in	IN	O
levels	NNS	O
of	IN	O
human	JJ	O
alpha-synuclein	NN	O
.	.	O
The	DT	O
columns	NN	O
are	VBP	O
labeled	VBN	O
similarly	RB	O
to	TO	O
Tables	NNP	O
1A	CD	O
,	,	O
1B	CD	O
and	CC	O
1C	CD	O
.	.	O
Tables	NNS	O
1A-C	NNS	O
:	:	O
Complete	JJ	O
list	NN	O
of	IN	O
Kinase	NNP	O
candidates	NNS	O
that	IN	O
reduce	VB	O
phosphorylation	NN	O
EXAMPLE	NNP	O
2	CD	O
Verification	NNP	O
of	IN	O
Alpha-Synuclein	NNP	O
Phosphorylation	NNP	O
Modulation	NNP	O
by	IN	O
Re-Screening	NNP	O
and	CC	O
by	IN	O
qRT-PCR	JJ	O
The	DT	O
kinases	NNS	O
that	WDT	O
showed	VBD	O
either	DT	O
an	DT	O
increase	NN	O
or	CC	O
decrease	NN	O
in	IN	O
alpha-synuclein	JJ	O
phosphorylation	NN	O
from	IN	O
Example	JJ	O
1	CD	O
were	VBD	O
retested	VBN	O
to	TO	O
verify	VB	O
the	DT	O
effect	NN	O
on	IN	O
alpha-synuclein	NN	O
.	.	O
The	DT	O
confirmation	NN	O
screen	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
10	CD	O
nM	JJ	O
siRNA	NN	O
on	IN	O
the	DT	O
targets	NNS	O
identified	VBN	O
in	IN	O
Example	NNP	O
1	CD	O
along	IN	O
with	IN	O
several	JJ	O
additional	JJ	O
kinases	NNS	O
of	IN	O
interest	NN	O
.	.	O
The	DT	O
higher	JJR	O
concentration	NN	O
of	IN	O
siRNA	NN	O
in	IN	O
Example	NNP	O
1	CD	O
was	VBD	O
used	VBN	O
to	TO	O
ensure	VB	O
that	IN	O
marginal	JJ	O
knockdown	NNS	O
caused	VBN	O
by	IN	O
poorly	RB	O
designed	VBN	O
siRNAs	NN	O
could	MD	O
be	VB	O
observed	VBN	O
.	.	O
By	IN	O
using	VBG	O
a	DT	O
much	RB	O
lower	JJR	O
siRNA	JJ	O
concentration	NN	O
in	IN	O
the	DT	O
confirmation	NN	O
screens	NNS	O
,	,	O
the	DT	O
chance	NN	O
of	IN	O
effects	NNS	O
due	JJ	O
to	TO	O
a	DT	O
general	JJ	O
response	NN	O
to	TO	O
the	DT	O
siRNA	NN	O
itself	PRP	O
could	MD	O
be	VB	O
much	RB	O
reduced	VBN	O
.	.	O
Some	DT	O
siRNAs	NN	O
that	WDT	O
were	VBD	O
later	RB	O
reported	VBN	O
by	IN	O
Ambion	NNP	O
to	TO	O
be	VB	O
ineffective	JJ	O
were	VBD	O
also	RB	O
re-screened	JJ	O
(	(	O
see	VB	O
replacement	NN	O
library	JJ	O
screen	NN	O
below	IN	O
)	)	O
.	.	O
Finally	RB	O
,	,	O
some	DT	O
newly	RB	O
identified	VBN	O
kinases	NNS	O
were	VBD	O
screened	VBN	O
and	CC	O
those	DT	O
results	NNS	O
were	VBD	O
added	VBN	O
to	TO	O
the	DT	O
pool	NN	O
of	IN	O
results	NNS	O
.	.	O
The	DT	O
kinases	NNS	O
that	WDT	O
were	VBD	O
identified	VBN	O
as	IN	O
candidates	NNS	O
were	VBD	O
tested	VBN	O
by	IN	O
quantitative	JJ	O
RT-PCR	NNP	O
(	(	O
qRT-PCR	NN	O
)	)	O
to	TO	O
confirm	VB	O
that	IN	O
they	PRP	O
were	VBD	O
actually	RB	O
present	JJ	O
in	IN	O
the	DT	O
PEAK-Syn	NNP	O
cells	NNS	O
(	(	O
see	VB	O
Example	NNP	O
6	CD	O
)	)	O
.	.	O
The	DT	O
experimental	JJ	O
procedures	NNS	O
and	CC	O
results	NNS	O
for	IN	O
the	DT	O
confirmation	NN	O
and	CC	O
rescreening	VBG	O
were	VBD	O
as	IN	O
follows	VBZ	O
:	:	O
Confirmation	NN	O
Screen	NNP	O
The	DT	O
results	NNS	O
for	IN	O
the	DT	O
confirmation	NN	O
screen	NN	O
were	VBD	O
grouped	VBN	O
into	IN	O
four	CD	O
categories	NNS	O
shown	VBN	O
below	IN	O
:	:	O
Completely	RB	O
Confirmed	VBN	O
:	:	O
This	DT	O
category	NN	O
included	VBD	O
the	DT	O
kinases	NNS	O
for	IN	O
which	WDT	O
all	DT	O
three	CD	O
siRNAs	NNS	O
produced	VBD	O
identical	JJ	O
phenotypes	NNS	O
in	IN	O
the	DT	O
10	CD	O
nM	NN	O
screen	NN	O
and	CC	O
in	IN	O
the	DT	O
100	CD	O
nM	JJ	O
screen	NN	O
.	.	O
Mostly	RB	O
Confirmed	VBN	O
:	:	O
This	DT	O
category	NN	O
included	VBD	O
the	DT	O
kinases	NNS	O
for	IN	O
which	WDT	O
⅔	NN	O
of	IN	O
the	DT	O
siRNAs	NN	O
produced	VBD	O
identical	JJ	O
phenotypes	NNS	O
in	IN	O
the	DT	O
10	CD	O
nM	NN	O
and	CC	O
in	IN	O
the	DT	O
100	CD	O
nM	NN	O
screen	NN	O
,	,	O
but	CC	O
one	CD	O
third	NN	O
did	VBD	O
not	RB	O
;	:	O
or	CC	O
,	,	O
alternatively	RB	O
one	CD	O
siRNA	NN	O
result	NN	O
was	VBD	O
replicated	VBN	O
,	,	O
but	CC	O
for	IN	O
a	DT	O
second	JJ	O
siRNA	NN	O
there	EX	O
was	VBD	O
a	DT	O
trend	NN	O
for	IN	O
the	DT	O
same	JJ	O
phenotype	NN	O
but	CC	O
with	IN	O
a	DT	O
different	JJ	O
siRNA	NN	O
from	IN	O
that	DT	O
used	VBN	O
in	IN	O
the	DT	O
original	JJ	O
screen	NN	O
.	.	O
Partly	RB	O
Confirmed	VBN	O
:	:	O
This	DT	O
category	NN	O
included	VBD	O
the	DT	O
kinases	NNS	O
for	IN	O
which	WDT	O
⅓	NN	O
of	IN	O
the	DT	O
siRNAs	NN	O
produced	VBD	O
the	DT	O
same	JJ	O
phenotype	NN	O
in	IN	O
the	DT	O
10	CD	O
nM	NN	O
screen	NN	O
and	CC	O
in	IN	O
the	DT	O
100	CD	O
nM	JJ	O
screen	NN	O
.	.	O
Not	RB	O
Confirmed	VBN	O
:	:	O
This	DT	O
category	NN	O
included	VBD	O
the	DT	O
kinases	NNS	O
for	IN	O
which	WDT	O
either	DT	O
or	CC	O
both	DT	O
of	IN	O
the	DT	O
following	JJ	O
occurred	VBD	O
:	:	O
The	DT	O
number	NN	O
of	IN	O
kinases	NNS	O
that	WDT	O
fell	VBD	O
into	IN	O
each	DT	O
category	NN	O
was	VBD	O
tabulated	VBN	O
and	CC	O
the	DT	O
results	NNS	O
are	VBP	O
shown	VBN	O
in	IN	O
Table	JJ	O
3	CD	O
.	.	O
Seven	JJ	O
kinases	NNS	O
were	VBD	O
completely	RB	O
confirmed	VBN	O
,	,	O
and	CC	O
they	PRP	O
are	VBP	O
listed	VBN	O
in	IN	O
Table	JJ	O
4	CD	O
.	.	O
Of	IN	O
these	DT	O
seven	CD	O
,	,	O
only	RB	O
three	CD	O
were	VBD	O
identified	VBN	O
as	IN	O
possessing	VBG	O
the	DT	O
qualities	NNS	O
to	TO	O
be	VB	O
good	JJ	O
candidates	NNS	O
for	IN	O
a	DT	O
kinase	NN	O
that	WDT	O
directly	RB	O
phosphorylates	VBZ	O
alpha-synuclein	NN	O
at	IN	O
ser-129	NN	O
.	.	O
This	DT	O
is	VBZ	O
because	IN	O
only	RB	O
three	CD	O
were	VBD	O
both	DT	O
ser/thr	JJ	O
kinases	NNS	O
and	CC	O
decreased	JJ	O
phospho	NN	O
alpha-synuclein	NN	O
levels	NNS	O
when	WRB	O
the	DT	O
kinase	NN	O
levels	NNS	O
were	VBD	O
reduced	VBN	O
by	IN	O
the	DT	O
specific	JJ	O
siRNA	NN	O
.	.	O
These	DT	O
included	VBD	O
:	:	O
APEG1	NNP	O
,	,	O
which	WDT	O
is	VBZ	O
believed	VBN	O
to	TO	O
play	VB	O
a	DT	O
role	NN	O
in	IN	O
growth	NN	O
and	CC	O
differentiation	NN	O
of	IN	O
smooth	JJ	O
muscle	NN	O
,	,	O
PLK2	NNP	O
(	(	O
SNK	NNP	O
)	)	O
,	,	O
which	WDT	O
is	VBZ	O
expressed	VBN	O
in	IN	O
brain	NN	O
and	CC	O
is	VBZ	O
believed	VBN	O
to	TO	O
play	VB	O
a	DT	O
role	NN	O
in	IN	O
normal	JJ	O
cell	NN	O
division	NN	O
,	,	O
and	CC	O
CDC7L1	NNP	O
,	,	O
a	DT	O
cell	NN	O
division	NN	O
cycle	NN	O
protein	NN	O
with	IN	O
kinase	NN	O
activity	NN	O
.	.	O
Of	IN	O
the	DT	O
three	CD	O
,	,	O
PLK2	NNP	O
was	VBD	O
of	IN	O
the	DT	O
most	RBS	O
interest	NN	O
due	JJ	O
to	TO	O
its	PRP$	O
role	NN	O
and	CC	O
localization	NN	O
in	IN	O
cells	NNS	O
,	,	O
such	JJ	O
as	IN	O
activated	JJ	O
neurons	NNS	O
.	.	O
Alpha-synuclein	NNP	O
is	VBZ	O
a	DT	O
synaptic-associated	JJ	O
protein	NN	O
thought	VBD	O
to	TO	O
be	VB	O
involved	VBN	O
in	IN	O
synaptic	JJ	O
plasticity	NN	O
and	CC	O
vesicular	JJ	O
transport	NN	O
.	.	O
Thus	RB	O
,	,	O
PLK2	NNP	O
was	VBD	O
identified	VBN	O
as	IN	O
a	DT	O
very	RB	O
good	JJ	O
candidate	NN	O
for	IN	O
a	DT	O
kinase	NN	O
that	WDT	O
directly	RB	O
phosphorylates	VBZ	O
α-synuclein	NN	O
.	.	O
Key	NNP	O
to	TO	O
shading	VBG	O
:	:	O
Table	NN	O
4	CD	O
shows	VBZ	O
the	DT	O
seven	CD	O
candidates	NNS	O
whose	WP$	O
results	NNS	O
were	VBD	O
completely	RB	O
replicated	VBN	O
at	IN	O
10	CD	O
nM	NNS	O
.	.	O
Only	RB	O
the	DT	O
first	JJ	O
three	CD	O
were	VBD	O
identified	VBN	O
as	IN	O
having	VBG	O
strong	JJ	O
potential	NN	O
to	TO	O
be	VB	O
a	DT	O
direct	JJ	O
kinase	NN	O
,	,	O
because	IN	O
they	PRP	O
are	VBP	O
ser/thr	JJ	O
kinases	NNS	O
that	WDT	O
reduce	VB	O
phospho-synuclein	NN	O
levels	NNS	O
when	WRB	O
the	DT	O
kinase	NN	O
level	NN	O
is	VBZ	O
reduced	VBN	O
.	.	O
There	EX	O
were	VBD	O
29	CD	O
kinases	NNS	O
that	WDT	O
fell	VBD	O
into	IN	O
the	DT	O
mostly	RB	O
confirmed	VBN	O
category	NN	O
,	,	O
12	CD	O
of	IN	O
which	WDT	O
were	VBD	O
candidates	NNS	O
for	IN	O
a	DT	O
direct	JJ	O
kinase	NN	O
.	.	O
These	DT	O
are	VBP	O
listed	VBN	O
in	IN	O
Table	JJ	O
5	CD	O
.	.	O
There	EX	O
were	VBD	O
17	CD	O
additional	JJ	O
kinases	NNS	O
that	WDT	O
were	VBD	O
mostly	RB	O
confirmed	VBN	O
at	IN	O
10	CD	O
nM	NNS	O
.	.	O
Although	IN	O
not	RB	O
likely	JJ	O
to	TO	O
be	VB	O
a	DT	O
direct	JJ	O
kinase	NN	O
,	,	O
these	DT	O
could	MD	O
play	VB	O
a	DT	O
role	NN	O
in	IN	O
the	DT	O
regulation	NN	O
of	IN	O
a	DT	O
direct	JJ	O
kinase	NN	O
and	CC	O
are	VBP	O
listed	VBN	O
in	IN	O
Table	JJ	O
6	CD	O
.	.	O
Twenty-two	JJ	O
kinases	NNS	O
fell	VBD	O
into	IN	O
the	DT	O
partly	RB	O
confirmed	VBN	O
category	NN	O
.	.	O
The	DT	O
ser/thr	NN	O
kinases	VBZ	O
that	IN	O
decreased	VBD	O
phospho	JJ	O
alpha-synuclein	JJ	O
(	(	O
i.e	NN	O
.	.	O
potentially	RB	O
a	DT	O
direct	JJ	O
kinase	NN	O
for	IN	O
alpha-synuclein	NN	O
)	)	O
are	VBP	O
listed	VBN	O
in	IN	O
Table	JJ	O
8	CD	O
,	,	O
and	CC	O
the	DT	O
remaining	VBG	O
potentially	RB	O
regulatory	JJ	O
kinases	NNS	O
are	VBP	O
listed	VBN	O
in	IN	O
Table	JJ	O
8	CD	O
.	.	O
The	DT	O
ser/thr	NN	O
kinases	VBZ	O
shown	VBN	O
in	IN	O
Table	JJ	O
5	CD	O
were	VBD	O
identified	VBN	O
as	IN	O
having	VBG	O
potential	JJ	O
to	TO	O
be	VB	O
a	DT	O
direct	JJ	O
kinase	NN	O
that	WDT	O
phosphorylates	VBZ	O
alpha-synuclein	RB	O
because	IN	O
they	PRP	O
significantly	RB	O
reduced	VBD	O
phospho-synuclein	JJ	O
levels	NNS	O
when	WRB	O
the	DT	O
kinase	NN	O
level	NN	O
was	VBD	O
reduced	VBN	O
.	.	O
⅔	NN	O
of	IN	O
the	DT	O
siRNAs	NN	O
produced	VBD	O
identical	JJ	O
results	NNS	O
at	IN	O
10	CD	O
nM	NNS	O
as	IN	O
they	PRP	O
did	VBD	O
at	IN	O
100	CD	O
nM	NN	O
,	,	O
and	CC	O
as	IN	O
such	JJ	O
,	,	O
were	VBD	O
designated	VBN	O
as	IN	O
Mostly	NNP	O
Confirmed	NNP	O
hits	NNS	O
.	.	O
The	DT	O
kinases	NNS	O
in	IN	O
Table	JJ	O
6	CD	O
were	VBD	O
designated	VBN	O
as	IN	O
Mostly	NNP	O
Confirmed	NNP	O
,	,	O
because	IN	O
⅔	NN	O
of	IN	O
the	DT	O
siRNAs	NN	O
produced	VBD	O
identical	JJ	O
results	NNS	O
at	IN	O
10	CD	O
nM	NNS	O
and	CC	O
100	CD	O
nM	JJ	O
concentration	NN	O
of	IN	O
siRNA	NN	O
.	.	O
However	RB	O
,	,	O
because	IN	O
they	PRP	O
did	VBD	O
not	RB	O
produce	VB	O
the	DT	O
appropriate	JJ	O
phenotype	NN	O
or	CC	O
were	VBD	O
the	DT	O
wrong	JJ	O
class	NN	O
of	IN	O
kinase	NN	O
(	(	O
i.e	NN	O
.	.	O
tyr	NN	O
or	CC	O
non-protein	JJ	O
kinase	NN	O
as	IN	O
opposed	VBN	O
to	TO	O
a	DT	O
ser/thr	JJ	O
kinase	NN	O
)	)	O
,	,	O
they	PRP	O
were	VBD	O
identified	VBN	O
as	IN	O
not	RB	O
likely	JJ	O
to	TO	O
be	VB	O
a	DT	O
direct	JJ	O
kinase	NN	O
that	WDT	O
phosphorylates	VBZ	O
ser-129	JJ	O
on	IN	O
alpha-synuclein	NN	O
.	.	O
Instead	RB	O
,	,	O
they	PRP	O
may	MD	O
be	VB	O
upstream	JJ	O
modulators	NNS	O
of	IN	O
alpha-synuclein	JJ	O
phosphorylation	NN	O
.	.	O
The	DT	O
ser/thr	NN	O
kinases	VBZ	O
in	IN	O
Table	JJ	O
7	CD	O
were	VBD	O
identified	VBN	O
as	IN	O
having	VBG	O
potential	JJ	O
to	TO	O
be	VB	O
a	DT	O
direct	JJ	O
kinase	NN	O
that	WDT	O
phosphorylates	VBZ	O
alpha-synuclein	RB	O
because	IN	O
they	PRP	O
significantly	RB	O
reduced	VBD	O
phospho-synuclein	JJ	O
levels	NNS	O
when	WRB	O
the	DT	O
kinase	NN	O
levels	NNS	O
were	VBD	O
reduced	VBN	O
.	.	O
Only	RB	O
⅓	NN	O
of	IN	O
the	DT	O
siRNAs	NN	O
produced	VBD	O
identical	JJ	O
results	NNS	O
at	IN	O
10	CD	O
nM	NNS	O
as	IN	O
they	PRP	O
did	VBD	O
at	IN	O
100	CD	O
nM	NN	O
,	,	O
and	CC	O
as	IN	O
such	JJ	O
,	,	O
were	VBD	O
designated	VBN	O
as	IN	O
Partly	NNP	O
Confirmed	NNP	O
hits	NNS	O
.	.	O
Several	JJ	O
candidates	NNS	O
had	VBD	O
contradictory	JJ	O
results	NNS	O
and	CC	O
,	,	O
thus	RB	O
,	,	O
were	VBD	O
identified	VBN	O
as	IN	O
having	VBG	O
less	JJR	O
potential	JJ	O
to	TO	O
be	VB	O
a	DT	O
direct	JJ	O
kinase	NN	O
for	IN	O
alpha-synuclein	NN	O
.	.	O
The	DT	O
kinases	NNS	O
in	IN	O
Table	JJ	O
8	CD	O
were	VBD	O
identified	VBN	O
as	IN	O
having	VBG	O
less	JJR	O
potential	JJ	O
to	TO	O
be	VB	O
direct	JJ	O
kinases	NNS	O
in	IN	O
the	DT	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	NN	O
at	IN	O
ser-129	JJ	O
but	CC	O
could	MD	O
be	VB	O
upstream	JJ	O
modulators	NNS	O
of	IN	O
alpha-synuclein	JJ	O
phosphorylation	NN	O
.	.	O
⅓	NN	O
of	IN	O
the	DT	O
siRNAs	NN	O
produced	VBD	O
identical	JJ	O
results	NNS	O
at	IN	O
10	CD	O
nM	NNS	O
as	IN	O
they	PRP	O
did	VBD	O
at	IN	O
100	CD	O
nM	NN	O
,	,	O
and	CC	O
as	IN	O
such	JJ	O
,	,	O
were	VBD	O
designated	VBN	O
as	IN	O
Partly	NNP	O
Confirmed	NNP	O
hits	NNS	O
.	.	O
However	RB	O
,	,	O
several	JJ	O
had	VBD	O
contradictory	JJ	O
results	NNS	O
and	CC	O
,	,	O
thus	RB	O
,	,	O
were	VBD	O
designated	VBN	O
as	IN	O
having	VBG	O
less	JJR	O
potential	JJ	O
to	TO	O
be	VB	O
direct	JJ	O
kinases	NNS	O
of	IN	O
alpha-synuclein	NN	O
.	.	O
Forty-two	JJ	O
kinases	NNS	O
did	VBD	O
not	RB	O
have	VB	O
their	PRP$	O
initial	JJ	O
results	NNS	O
confirmed	VBD	O
at	IN	O
10	CD	O
nM	NNS	O
.	.	O
Of	IN	O
these	DT	O
,	,	O
19	CD	O
fell	VBD	O
into	IN	O
category	NN	O
(	(	O
a	DT	O
)	)	O
listed	VBN	O
above	IN	O
,	,	O
and	CC	O
are	VBP	O
listed	VBN	O
in	IN	O
Table	JJ	O
9	CD	O
.	.	O
At	IN	O
10	CD	O
nM	NNS	O
,	,	O
none	NN	O
of	IN	O
the	DT	O
three	CD	O
siRNAs	NN	O
at	IN	O
10	CD	O
nM	NNS	O
produced	VBD	O
any	DT	O
change	NN	O
in	IN	O
the	DT	O
phospho-alpha-synuclein	JJ	O
phenotype	NN	O
,	,	O
indicating	VBG	O
that	IN	O
the	DT	O
results	NNS	O
for	IN	O
these	DT	O
kinases	NNS	O
from	IN	O
the	DT	O
100	CD	O
nM	NNS	O
screen	NN	O
were	VBD	O
possibly	RB	O
due	JJ	O
to	TO	O
off-target	JJ	O
effects	NNS	O
.	.	O
Twenty-three	JJ	O
kinases	NNS	O
(	(	O
Table	JJ	O
10	CD	O
)	)	O
produced	VBD	O
the	DT	O
opposite	JJ	O
effect	NN	O
on	IN	O
phospho-alpha-synuclein	NN	O
levels	NNS	O
at	IN	O
10	CD	O
nM	NNS	O
than	IN	O
at	IN	O
100	CD	O
nM	JJ	O
siRNA	NN	O
.	.	O
There	EX	O
is	VBZ	O
a	DT	O
possibility	NN	O
that	IN	O
the	DT	O
results	NNS	O
at	IN	O
10	CD	O
nM	NNS	O
were	VBD	O
the	DT	O
true	JJ	O
effects	NNS	O
due	JJ	O
to	TO	O
the	DT	O
fact	NN	O
that	IN	O
at	IN	O
100	CD	O
nM	JJ	O
results	NNS	O
are	VBP	O
sometimes	RB	O
masked	VBN	O
by	IN	O
off-target	JJ	O
effects	NNS	O
.	.	O
This	DT	O
can	MD	O
happen	VB	O
at	IN	O
the	DT	O
much	RB	O
higher	JJR	O
siRNA	JJ	O
concentration	NN	O
.	.	O
Alternatively	RB	O
,	,	O
the	DT	O
true	JJ	O
effect	NN	O
may	MD	O
have	VB	O
been	VBN	O
seen	VBN	O
at	IN	O
the	DT	O
higher	JJR	O
concentration	NN	O
.	.	O
In	IN	O
any	DT	O
case	NN	O
,	,	O
these	DT	O
kinases	NNS	O
were	VBD	O
designated	VBN	O
as	IN	O
less	RBR	O
likely	JJ	O
to	TO	O
be	VB	O
direct	JJ	O
kinases	NNS	O
of	IN	O
alpha-synuclein	NN	O
.	.	O
The	DT	O
nineteen	JJ	O
kinases	NNS	O
shown	VBN	O
in	IN	O
Table	JJ	O
9	CD	O
had	VBD	O
no	DT	O
significant	JJ	O
reactivity	NN	O
at	IN	O
10	CD	O
nM	NNS	O
compared	VBN	O
to	TO	O
controls	NNS	O
.	.	O
Thus	RB	O
,	,	O
it	PRP	O
is	VBZ	O
possible	JJ	O
that	IN	O
the	DT	O
change	NN	O
in	IN	O
phospho-synuclein	JJ	O
levels	NNS	O
observed	VBN	O
at	IN	O
100	CD	O
nM	NN	O
was	VBD	O
due	JJ	O
to	TO	O
off-target	JJ	O
effects	NNS	O
caused	VBN	O
by	IN	O
high	JJ	O
concentrations	NNS	O
of	IN	O
siRNA	NN	O
.	.	O
GPRK5	NNP	O
and	CC	O
GPRK7	NNP	O
were	VBD	O
not	RB	O
candidates	NNS	O
in	IN	O
the	DT	O
original	JJ	O
100	CD	O
nM	JJ	O
screen	NN	O
,	,	O
but	CC	O
were	VBD	O
analyzed	VBN	O
at	IN	O
10	CD	O
nM	JJ	O
siRNA	NN	O
because	IN	O
of	IN	O
additional	JJ	O
interest	NN	O
in	IN	O
their	PRP$	O
role	NN	O
in	IN	O
alpha-synuclein	JJ	O
phosphorylation	NN	O
.	.	O
The	DT	O
results	NNS	O
for	IN	O
the	DT	O
kinases	NNS	O
in	IN	O
Table	JJ	O
10	CD	O
were	VBD	O
not	RB	O
confirmed	VBN	O
at	IN	O
10	CD	O
nM	NNS	O
because	IN	O
they	PRP	O
had	VBD	O
the	DT	O
opposite	JJ	O
effect	NN	O
on	IN	O
phospho-synuclein	NN	O
levels	NNS	O
from	IN	O
that	DT	O
seen	VBN	O
at	IN	O
100	CD	O
nM	NNS	O
.	.	O
However	RB	O
,	,	O
it	PRP	O
is	VBZ	O
possible	JJ	O
that	IN	O
the	DT	O
results	NNS	O
at	IN	O
10	CD	O
nM	JJ	O
siRNA	NN	O
were	VBD	O
the	DT	O
true	JJ	O
results	NNS	O
,	,	O
and	CC	O
that	IN	O
the	DT	O
high	JJ	O
concentration	NN	O
(	(	O
100	CD	O
nM	RB	O
)	)	O
of	IN	O
siRNA	NN	O
was	VBD	O
masking	VBG	O
the	DT	O
true	JJ	O
effects	NNS	O
.	.	O
It	PRP	O
is	VBZ	O
also	RB	O
possible	JJ	O
that	IN	O
the	DT	O
initial	JJ	O
effects	NNS	O
observed	VBD	O
at	IN	O
100	CD	O
nM	NNS	O
were	VBD	O
the	DT	O
true	JJ	O
effects	NNS	O
.	.	O
These	DT	O
were	VBD	O
designated	VBN	O
as	IN	O
likely	JJ	O
to	TO	O
be	VB	O
direct	JJ	O
kinases	NNS	O
of	IN	O
alpha-synuclein	JJ	O
and	CC	O
set	VBD	O
aside	RB	O
to	TO	O
be	VB	O
tested	VBN	O
further	RB	O
at	IN	O
a	DT	O
later	JJ	O
date	NN	O
.	.	O
Replacement	NN	O
and	CC	O
Up-Dated	JJ	O
Library	NNP	O
Screens	NNP	O
Because	IN	O
some	DT	O
siRNAs	NNS	O
used	VBN	O
in	IN	O
the	DT	O
initial	JJ	O
screen	NN	O
were	VBD	O
later	RB	O
identified	VBN	O
as	IN	O
being	VBG	O
of	IN	O
poor	JJ	O
quality	NN	O
,	,	O
screens	NNS	O
were	VBD	O
performed	VBN	O
at	IN	O
both	DT	O
concentrations	NNS	O
with	IN	O
replacement	NN	O
siRNAs	NN	O
.	.	O
The	DT	O
data	NN	O
for	IN	O
the	DT	O
replacement	NN	O
siRNAs	NN	O
was	VBD	O
used	VBN	O
to	TO	O
replace	VB	O
the	DT	O
data	NN	O
for	IN	O
that	DT	O
specific	JJ	O
siRNA	NN	O
result	NN	O
from	IN	O
the	DT	O
original	JJ	O
screen	NN	O
.	.	O
Statistical	NNP	O
data	NN	O
was	VBD	O
tabulated	VBN	O
for	IN	O
the	DT	O
three	CD	O
siRNAs	NN	O
for	IN	O
each	DT	O
kinase	NN	O
,	,	O
and	CC	O
using	VBG	O
this	DT	O
,	,	O
nine	CD	O
additional	JJ	O
kinases	NNS	O
were	VBD	O
identified	VBN	O
as	IN	O
candidates	NNS	O
from	IN	O
the	DT	O
original	JJ	O
screen	NN	O
that	WDT	O
were	VBD	O
missed	VBN	O
in	IN	O
the	DT	O
primary	JJ	O
screen	NN	O
.	.	O
These	DT	O
were	VBD	O
retested	VBN	O
,	,	O
and	CC	O
two	CD	O
of	IN	O
the	DT	O
kinases	NNS	O
were	VBD	O
partially	RB	O
confirmed	VBN	O
at	IN	O
10	CD	O
nM	JJ	O
siRNA	NN	O
.	.	O
These	DT	O
were	VBD	O
BCKDK	NNP	O
and	CC	O
FLJ25965	NNP	O
(	(	O
KSR2	NNP	O
)	)	O
.	.	O
During	IN	O
the	DT	O
process	NN	O
,	,	O
a	DT	O
number	NN	O
of	IN	O
new	JJ	O
kinases	NNS	O
were	VBD	O
identified	VBN	O
and	CC	O
siRNAs	JJ	O
became	VBD	O
available	JJ	O
.	.	O
These	DT	O
were	VBD	O
tested	VBN	O
as	IN	O
in	IN	O
Example	NNP	O
1	CD	O
as	IN	O
an	DT	O
AMBION	NNP	O
Up-Dates	NNP	O
library	NN	O
and	CC	O
new	JJ	O
kinase	NN	O
candidates	NNS	O
were	VBD	O
identified	VBN	O
.	.	O
Many	JJ	O
of	IN	O
the	DT	O
newly	RB	O
identified	VBN	O
kinases	NNS	O
fell	VBD	O
under	IN	O
the	DT	O
GO	NNP	O
(	(	O
Gene	NNP	O
Ontology	NNP	O
Consortium	NNP	O
)	)	O
classification	NN	O
.	.	O
As	IN	O
such	JJ	O
,	,	O
it	PRP	O
was	VBD	O
difficult	JJ	O
to	TO	O
find	VB	O
detailed	JJ	O
information	NN	O
on	IN	O
some	DT	O
of	IN	O
these	DT	O
kinases	NNS	O
.	.	O
Several	JJ	O
of	IN	O
the	DT	O
genes	NNS	O
included	VBD	O
in	IN	O
this	DT	O
category	NN	O
were	VBD	O
not	RB	O
true	JJ	O
kinases	NNS	O
,	,	O
but	CC	O
were	VBD	O
kinase	VBN	O
binding	VBG	O
proteins	NNS	O
or	CC	O
adaptor	NN	O
proteins	NNS	O
.	.	O
At	IN	O
10	CD	O
nM	JJ	O
siRNA	NN	O
,	,	O
thirteen	JJ	O
kinases	NNS	O
were	VBD	O
confirmed	VBN	O
to	TO	O
be	VB	O
candidates	NNS	O
for	IN	O
directly	RB	O
acting	VBG	O
on	IN	O
alpha-synuclein	NN	O
.	.	O
Two	CD	O
of	IN	O
these	DT	O
were	VBD	O
likely	JJ	O
candidates	NNS	O
for	IN	O
being	VBG	O
a	DT	O
direct	JJ	O
kinase	NN	O
,	,	O
see	VBP	O
Table	JJ	O
11	CD	O
.	.	O
The	DT	O
remaining	VBG	O
eleven	NN	O
were	VBD	O
designated	VBN	O
as	IN	O
possible	JJ	O
indirect	JJ	O
regulators	NNS	O
of	IN	O
phospho-synuclein	NN	O
levels	NNS	O
,	,	O
see	VBP	O
Table	JJ	O
11	CD	O
.	.	O
Table	JJ	O
11	CD	O
provides	VBZ	O
Genbank	NNP	O
accession	NN	O
numbers	NNS	O
for	IN	O
the	DT	O
kinase	NN	O
sequences	VBZ	O
as	RB	O
deposited	VBN	O
in	IN	O
Genbank	NNP	O
as	IN	O
of	IN	O
Nov.	NNP	O
1	CD	O
,	,	O
2005	CD	O
.	.	O
A	DT	O
summary	NN	O
of	IN	O
the	DT	O
results	NNS	O
showing	VBG	O
the	DT	O
kinase	NN	O
siRNAs	NN	O
that	WDT	O
were	VBD	O
identified	VBN	O
and	CC	O
verified	VBN	O
in	IN	O
Examples	NNP	O
1	CD	O
and	CC	O
2	CD	O
are	VBP	O
shown	VBN	O
in	IN	O
Tables	NNP	O
12	CD	O
and	CC	O
13	CD	O
.	.	O
From	IN	O
these	DT	O
results	NNS	O
,	,	O
PLK2	NNP	O
,	,	O
APEG1	NNP	O
,	,	O
CDC7L1	NNP	O
,	,	O
MET	NNP	O
,	,	O
IKBKB	NNP	O
,	,	O
CKII	NNP	O
,	,	O
GRK1	NNP	O
,	,	O
2	CD	O
,	,	O
6	CD	O
and	CC	O
7	CD	O
were	VBD	O
identified	VBN	O
as	IN	O
kinases	NNS	O
that	WDT	O
are	VBP	O
very	RB	O
likely	JJ	O
to	TO	O
phosphorylate	VB	O
alpha-synuclein	JJ	O
directly	RB	O
or	CC	O
indirectly	RB	O
.	.	O
The	DT	O
kinases	NNS	O
that	WDT	O
were	VBD	O
identified	VBN	O
as	IN	O
having	VBG	O
siRNAs	NN	O
that	WDT	O
increased	VBD	O
alpha-synuclein	JJ	O
phosphorylation	NN	O
(	(	O
PRKG1	NNP	O
,	,	O
MAPK13	NNP	O
,	,	O
and	CC	O
GAK	NNP	O
)	)	O
could	MD	O
very	RB	O
well	RB	O
be	VB	O
negative	JJ	O
regulators	NNS	O
of	IN	O
alpha-synuclein	JJ	O
phosphorylation	NN	O
.	.	O
Tables	NNS	O
12	CD	O
and	CC	O
13	CD	O
:	:	O
Summary	NN	O
of	IN	O
Confirmation	NNP	O
Studies	NNPS	O
In	IN	O
the	DT	O
following	JJ	O
examples	NNS	O
,	,	O
in	IN	O
vitro	JJ	O
kinase	NN	O
assays	NNS	O
were	VBD	O
performed	VBN	O
on	IN	O
a	DT	O
number	NN	O
of	IN	O
the	DT	O
potential	JJ	O
targets	NNS	O
identified	VBN	O
in	IN	O
Examples	NNP	O
1	CD	O
and	CC	O
2	CD	O
.	.	O
EXAMPLE	RB	O
3	CD	O
Identification	NNP	O
of	IN	O
Direct	NNP	O
Phosphorylation	NNP	O
of	IN	O
Alpha-Synuclein	NNP	O
In	IN	O
Vitro	NNP	O
To	TO	O
determine	VB	O
which	WDT	O
of	IN	O
the	DT	O
kinase	NN	O
(	(	O
s	PRP	O
)	)	O
from	IN	O
the	DT	O
siRNA	NN	O
screen	NN	O
directly	RB	O
phosphorylated	VBD	O
alpha-synuclein	NN	O
,	,	O
purified	JJ	O
kinases	NNS	O
were	VBD	O
incubated	VBN	O
with	IN	O
alpha-synuclein	NN	O
in	IN	O
in	IN	O
vitro	JJ	O
kinase	NN	O
reactions	NNS	O
.	.	O
These	DT	O
results	NNS	O
showed	VBD	O
that	IN	O
PLK2	NNP	O
,	,	O
GRK2	NNP	O
,	,	O
5	CD	O
,	,	O
6.	CD	O
and	CC	O
7	CD	O
(	(	O
GPRK2	NNP	O
,	,	O
5	CD	O
,	,	O
6	CD	O
and	CC	O
7	CD	O
)	)	O
were	VBD	O
all	DT	O
capable	JJ	O
of	IN	O
phosphorylating	VBG	O
alpha-synuclein	JJ	O
specifically	RB	O
at	IN	O
serine	JJ	O
129	CD	O
and	CC	O
did	VBD	O
not	RB	O
phosphorylate	VB	O
serine	NN	O
87	CD	O
in	IN	O
vitro	NN	O
,	,	O
showing	VBG	O
that	IN	O
they	PRP	O
could	MD	O
directly	RB	O
phosphorylate	VB	O
alpha-synuclein	NN	O
.	.	O
MET	NNP	O
,	,	O
CDC7L1	NNP	O
,	,	O
and	CC	O
IKBKB	NNP	O
were	VBD	O
shown	VBN	O
to	TO	O
be	VB	O
incapable	JJ	O
of	IN	O
directly	RB	O
phosphorylating	VBG	O
alpha-synuclein	NN	O
(	(	O
FIGS	NNP	O
.	.	O
1A-C	JJ	O
)	)	O
.	.	O
Assay	NNP	O
conditions	NNS	O
for	IN	O
testing	VBG	O
recombinant	JJ	O
kinase	NN	O
activities	NNS	O
toward	IN	O
recombinant	JJ	O
alpha-synuclein	NN	O
at	IN	O
serine	JJ	O
129	CD	O
were	VBD	O
established	VBN	O
and	CC	O
found	VBN	O
to	TO	O
be	VB	O
reproducible	JJ	O
by	IN	O
immunoblot	NN	O
and	CC	O
ELISA	NNP	O
analyses	NNS	O
.	.	O
Commercially	RB	O
available	JJ	O
recombinant	JJ	O
kinases	NNS	O
were	VBD	O
used	VBN	O
when	WRB	O
possible	JJ	O
.	.	O
Those	DT	O
that	WDT	O
were	VBD	O
not	RB	O
available	JJ	O
were	VBD	O
produced	VBN	O
as	IN	O
indicated	VBN	O
by	IN	O
recombinant	NN	O
means	NNS	O
.	.	O
In	IN	O
FIGS	NNP	O
.	.	O
1A-C	JJ	O
,	,	O
recombinant	JJ	O
kinases	NNS	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
in	IN	O
vitro	JJ	O
alpha-synuclein	JJ	O
(	(	O
AS	IN	O
)	)	O
assay	VBP	O
by	IN	O
standardizing	VBG	O
kinase	NN	O
to	TO	O
alpha-synuclein	JJ	O
substrate	NN	O
at	IN	O
a	DT	O
constant	JJ	O
molar	NN	O
ratio	NN	O
(	(	O
derived	VBN	O
from	IN	O
MW	NNP	O
of	IN	O
predicted	JJ	O
mature	NN	O
protein	NN	O
)	)	O
in	IN	O
each	DT	O
reaction	NN	O
(	(	O
1:200	CD	O
;	:	O
kinase	NN	O
:	:	O
recombinant	JJ	O
alpha-synuclein	JJ	O
kinase—rAS	NN	O
)	)	O
.	.	O
−control	NN	O
,	,	O
+kinase	NN	O
;	:	O
In	IN	O
FIG	NNP	O
.	.	O
1A	CD	O
,	,	O
a	DT	O
probe	NN	O
for	IN	O
total	JJ	O
alpha-synuclein	JJ	O
(	(	O
AS	IN	O
)	)	O
(	(	O
mAb	JJ	O
Syn-1	NNP	O
;	:	O
0.1	CD	O
μg/mL	NN	O
)	)	O
was	VBD	O
used	VBN	O
indicating	VBG	O
equivalent	JJ	O
substrate	NN	O
in	IN	O
each	DT	O
reaction	NN	O
;	:	O
In	IN	O
FIG	NNP	O
.	.	O
1B	CD	O
,	,	O
a	DT	O
parallel	JJ	O
blot	NN	O
was	VBD	O
probed	VBN	O
for	IN	O
5129	CD	O
phosphorylation	NN	O
(	(	O
mAb	JJ	O
11A5	CD	O
1	CD	O
μg/mL	NN	O
)	)	O
.	.	O
Prominent	JJ	O
signals	NNS	O
came	VBD	O
from	IN	O
GRK6	NNP	O
,	,	O
CKI	NNP	O
,	,	O
CKII	NNP	O
and	CC	O
PLK2	NNP	O
(	(	O
not	RB	O
previously	RB	O
tested	VBN	O
by	IN	O
activity	NN	O
normalization	NN	O
)	)	O
.	.	O
In	IN	O
FIG	NNP	O
.	.	O
1C	CD	O
,	,	O
a	DT	O
parallel	JJ	O
blot	NN	O
probed	VBD	O
for	IN	O
S87	NNP	O
phosphorylation	NN	O
(	(	O
pAb	JJ	O
,	,	O
ELADW-110	JJ	O
5	CD	O
μg/mL	NN	O
)	)	O
.	.	O
A	DT	O
signal	NN	O
was	VBD	O
detected	VBN	O
only	RB	O
with	IN	O
CKI	NNP	O
phosphorylation	NN	O
.	.	O
In	IN	O
FIGS	NNP	O
.	.	O
1D-F	JJ	O
,	,	O
a	DT	O
more	RBR	O
focused	JJ	O
study	NN	O
was	VBD	O
performed	VBN	O
with	IN	O
recombinant	JJ	O
kinases	NNS	O
from	IN	O
the	DT	O
GPCR-receptor	NNP	O
kinase	NN	O
(	(	O
GRK	NNP	O
)	)	O
family	NN	O
and	CC	O
PLK2	NNP	O
were	VBD	O
included	VBN	O
in	IN	O
the	DT	O
in	IN	O
vitro	JJ	O
alpha-synuclein	JJ	O
(	(	O
AS	IN	O
)	)	O
assay	VBP	O
by	IN	O
standardizing	VBG	O
kinase	NN	O
to	TO	O
AS	NNP	O
substrate	NN	O
at	IN	O
a	DT	O
constant	JJ	O
molar	NN	O
ratio	NN	O
(	(	O
derived	VBN	O
from	IN	O
MW	NNP	O
of	IN	O
predicted	JJ	O
mature	NN	O
protein	NN	O
)	)	O
in	IN	O
each	DT	O
reaction	NN	O
(	(	O
1:200	CD	O
;	:	O
kinase	NN	O
:	:	O
rAS	NN	O
)	)	O
.	.	O
−control	NN	O
,	,	O
+kinase	NN	O
;	:	O
CAM	NNP	O
kinases	VBZ	O
served	VBD	O
as	IN	O
negative	JJ	O
controls	NNS	O
while	IN	O
CKI	NNP	O
and	CC	O
II	NNP	O
served	VBD	O
as	IN	O
positive	JJ	O
controls	NNS	O
.	.	O
In	IN	O
FIG	NNP	O
.	.	O
1D	CD	O
,	,	O
a	DT	O
probe	NN	O
for	IN	O
total	JJ	O
AS	NNP	O
(	(	O
mAb	IN	O
Syn-1	NNP	O
;	:	O
0.1	CD	O
μg/mL	NN	O
)	)	O
was	VBD	O
used	VBN	O
indicating	VBG	O
equivalent	JJ	O
substrate	NN	O
in	IN	O
each	DT	O
reaction	NN	O
;	:	O
In	IN	O
FIG	NNP	O
.	.	O
1E	CD	O
,	,	O
a	DT	O
parallel	JJ	O
blot	NN	O
probed	VBN	O
for	IN	O
5129	CD	O
phosphorylation	NN	O
(	(	O
mAb	JJ	O
11	CD	O
A5	NNP	O
1	CD	O
μg/mL	NN	O
)	)	O
.	.	O
Prominent	JJ	O
signals	NNS	O
came	VBD	O
from	IN	O
all	DT	O
GRKs	NNP	O
except	IN	O
for	IN	O
GRK7	NNP	O
.	.	O
A	DT	O
specificity	NN	O
between	IN	O
GRK	NNP	O
members	NNS	O
could	MD	O
be	VB	O
seen	VBN	O
with	IN	O
signal	JJ	O
and	CC	O
can	MD	O
be	VB	O
represented	VBN	O
as	IN	O
:	:	O
CKI	NNP	O
>	NNP	O
GRK6	NNP	O
>	NNP	O
PLK2	NNP	O
>	NNP	O
GRK4	NNP	O
>	NNP	O
GRK5	NNP	O
>	NNP	O
GRK2	NNP	O
.	.	O
In	IN	O
FIG	NNP	O
.	.	O
1F	CD	O
,	,	O
a	DT	O
parallel	JJ	O
blot	NN	O
probed	VBD	O
for	IN	O
S87	NNP	O
phosphorylation	NN	O
(	(	O
pAb	JJ	O
,	,	O
ELADW-110	JJ	O
5	CD	O
μg/mL	NN	O
)	)	O
.	.	O
Signal	NNP	O
was	VBD	O
detected	VBN	O
only	RB	O
with	IN	O
CKI	NNP	O
phosphorylation	NN	O
.	.	O
The	DT	O
assay	JJ	O
conditions	NNS	O
are	VBP	O
defined	VBN	O
in	IN	O
Table	JJ	O
14	CD	O
and	CC	O
were	VBD	O
held	VBN	O
constant	JJ	O
for	IN	O
all	DT	O
kinases	NNS	O
tested	VBN	O
.	.	O
All	DT	O
of	IN	O
the	DT	O
kinases	NNS	O
listed	VBN	O
were	VBD	O
available	JJ	O
as	IN	O
tagged/recombinant	JJ	O
protein	NN	O
with	IN	O
the	DT	O
exception	NN	O
of	IN	O
CDC7L1	NNP	O
,	,	O
PRKG1	NNP	O
and	CC	O
APEG	NNP	O
.	.	O
Those	DT	O
putative	JJ	O
targets	NNS	O
were	VBD	O
expressed	VBN	O
in	IN	O
an	DT	O
in	IN	O
vitro	NN	O
translation	NN	O
system	NN	O
and	CC	O
tested	VBN	O
in	IN	O
the	DT	O
in	IN	O
vitro	NN	O
AS	IN	O
assay	NN	O
without	IN	O
protein	JJ	O
concentration	NN	O
or	CC	O
activity	NN	O
measurements	NNS	O
.	.	O
The	DT	O
Standard	NNP	O
Conditions	NNPS	O
were	VBD	O
:	:	O
40	CD	O
mM	JJ	O
MOPS-NaOH	NNP	O
;	:	O
1	CD	O
mM	NN	O
EDTA	NNP	O
MgCl	NNP	O
10	CD	O
mM	NN	O
pH	NN	O
8.0	CD	O
,	,	O
0.1	CD	O
%	NN	O
BME	NNP	O
;	:	O
0.01	CD	O
%	NN	O
Brij-35	NNP	O
;	:	O
5	CD	O
ug	JJ	O
BSA	NNP	O
,	,	O
100	CD	O
uM	JJ	O
ATP	NNP	O
(	(	O
5×	CD	O
[	NN	O
substrate	NN	O
]	NN	O
)	)	O
,	,	O
100	CD	O
uL	JJ	O
volume	NN	O
;	:	O
300	CD	O
ng	IN	O
r-wt-AS	NN	O
(	(	O
208	CD	O
nM	NN	O
)	)	O
,	,	O
(	(	O
1:200	CD	O
kinase	NN	O
:	:	O
AS	IN	O
or	CC	O
activity	NN	O
normalized	VBN	O
0.03	CD	O
U/rxn	NNP	O
,	,	O
34	CD	O
C	NNP	O
;	:	O
17	CD	O
hrs	NN	O
.	.	O
Further	RB	O
,	,	O
those	DT	O
kinases	NNS	O
with	IN	O
varying	VBG	O
levels	NNS	O
of	IN	O
significance/confirmation	NN	O
from	IN	O
combined	VBN	O
screening	VBG	O
data	NNS	O
were	VBD	O
purchased	VBN	O
as	IN	O
recombinant	NN	O
,	,	O
tagged	VBD	O
protein	NN	O
,	,	O
annotated	VBN	O
and	CC	O
incorporated	VBN	O
into	IN	O
a	DT	O
table	JJ	O
format	NN	O
for	IN	O
the	DT	O
purposes	NNS	O
of	IN	O
establishing	VBG	O
in	IN	O
vitro	NN	O
assays	NNS	O
that	WDT	O
were	VBD	O
comparable	JJ	O
based	VBN	O
upon	IN	O
normalization	NN	O
to	TO	O
activity	NN	O
units	NNS	O
(	(	O
determined	VBN	O
by	IN	O
the	DT	O
manufacturer	NN	O
from	IN	O
synthetic	JJ	O
substrates	NNS	O
)	)	O
or	CC	O
substrate	NN	O
:	:	O
enzyme	NN	O
molar	JJ	O
ratios	NNS	O
determined	VBN	O
from	IN	O
MW	NNP	O
and	CC	O
reaction	NN	O
volume	NN	O
.	.	O
The	DT	O
details	NNS	O
of	IN	O
reaction	NN	O
conditions	NNS	O
are	VBP	O
stipulated	VBN	O
in	IN	O
Table	JJ	O
14	CD	O
.	.	O
Kin.=kinase	NNP	O
.	.	O
For	IN	O
Confirmation	NN	O
:	:	O
Most=mostly	RB	O
,	,	O
Part=partially	NNP	O
,	,	O
del=deleted	VBD	O
,	,	O
conf=confirmed	VBD	O
.	.	O
Kinase	NNP	O
activity	NN	O
was	VBD	O
initially	RB	O
tested	VBN	O
against	IN	O
AS	NNP	O
by	IN	O
activity	NN	O
units	NNS	O
as	IN	O
determined	VBN	O
from	IN	O
non-native	JJ	O
substrates	NNS	O
(	(	O
peptides	NNS	O
or	CC	O
casein	NN	O
)	)	O
.	.	O
This	DT	O
method	NN	O
was	VBD	O
used	VBN	O
to	TO	O
get	VB	O
a	DT	O
rough	JJ	O
estimate	NN	O
as	IN	O
to	TO	O
specificity	NN	O
between	IN	O
kinases	NNS	O
and	CC	O
whether	IN	O
AS	NNP	O
was	VBD	O
an	DT	O
in	IN	O
vitro	NN	O
substrate	NN	O
for	IN	O
the	DT	O
kinase	NN	O
panel	NN	O
.	.	O
The	DT	O
results	NNS	O
of	IN	O
this	DT	O
study	NN	O
are	VBP	O
found	VBN	O
in	IN	O
FIGS	NNP	O
.	.	O
2	CD	O
and	CC	O
3	CD	O
.	.	O
At	IN	O
the	DT	O
time	NN	O
of	IN	O
this	DT	O
experiment	NN	O
,	,	O
only	RB	O
a	DT	O
portion	NN	O
of	IN	O
available	JJ	O
kinases	NNS	O
were	VBD	O
obtained	VBN	O
and	CC	O
⅔	JJ	O
kinases	NNS	O
from	IN	O
the	DT	O
“	NNP	O
most	RBS	O
probable	JJ	O
7	CD	O
confirmed	VBN	O
”	NNS	O
were	VBD	O
included	VBN	O
(	(	O
PLK2	NNP	O
was	VBD	O
not	RB	O
tested	VBN	O
)	)	O
.	.	O
The	DT	O
most	RBS	O
prominent	JJ	O
result	NN	O
came	VBD	O
from	IN	O
GRK6	NNP	O
(	(	O
G-protein	NNP	O
coupled	VBD	O
receptor	NN	O
kinase	NN	O
6	CD	O
)	)	O
.	.	O
CKI	NNP	O
gave	VBD	O
a	DT	O
modest	JJ	O
signal	NN	O
and	CC	O
CKII	NNP	O
was	VBD	O
not	RB	O
detectable	JJ	O
.	.	O
Because	IN	O
both	DT	O
CK	NNP	O
kinases	NNS	O
are	VBP	O
known	VBN	O
to	TO	O
phosphorylate	VB	O
5129	CD	O
AS	NNP	O
,	,	O
normalization	NN	O
by	IN	O
activity	NN	O
units	NNS	O
was	VBD	O
biased	VBN	O
against	IN	O
those	DT	O
kinases	NNS	O
which	WDT	O
had	VBD	O
higher	RBR	O
specific	JJ	O
activity	NN	O
for	IN	O
tested	VBN	O
substrates	NNS	O
vs	RB	O
AS	NNP	O
.	.	O
This	DT	O
was	VBD	O
likely	JJ	O
the	DT	O
situation	NN	O
for	IN	O
GRK6	NNP	O
which	WDT	O
might	MD	O
have	VB	O
preferred	VBN	O
AS	NNP	O
as	IN	O
a	DT	O
substrate	NN	O
rather	RB	O
than	IN	O
the	DT	O
peptide	NN	O
substrate	NN	O
which	WDT	O
defined	VBD	O
its	PRP$	O
activity	NN	O
units	NNS	O
.	.	O
In	IN	O
the	DT	O
following	JJ	O
examples	NNS	O
,	,	O
in	IN	O
vitro	JJ	O
kinase	NN	O
assays	NNS	O
were	VBD	O
performed	VBN	O
on	IN	O
a	DT	O
number	NN	O
of	IN	O
the	DT	O
potential	JJ	O
targets	NNS	O
identified	VBN	O
in	IN	O
Examples	NNP	O
1	CD	O
and	CC	O
2	CD	O
.	.	O
To	TO	O
correct	VB	O
for	IN	O
the	DT	O
activity	NN	O
bias	NN	O
,	,	O
kinases	NNS	O
were	VBD	O
retested	VBN	O
and	CC	O
newly	RB	O
procured	VBN	O
kinases	NNS	O
were	VBD	O
put	VBN	O
into	IN	O
an	DT	O
assay	NN	O
that	WDT	O
normalized	VBD	O
for	IN	O
molarity	NN	O
.	.	O
This	DT	O
gave	VBD	O
a	DT	O
better	RBR	O
measurement	NN	O
of	IN	O
stoichiometric	JJ	O
ratios	NNS	O
between	IN	O
enzyme	NN	O
and	CC	O
substrate	NN	O
,	,	O
thus	RB	O
reporting	VBG	O
the	DT	O
phosphorylation	NN	O
event	NN	O
as	IN	O
a	DT	O
function	NN	O
of	IN	O
AS/kinase	NNP	O
interaction	NN	O
.	.	O
This	DT	O
was	VBD	O
in	IN	O
contrast	NN	O
to	TO	O
the	DT	O
event	NN	O
in	IN	O
which	WDT	O
unrelated	JJ	O
substrate/kinase	NN	O
phosphorylation	NN	O
was	VBD	O
measured	VBN	O
.	.	O
FIGS	NNP	O
.	.	O
3A-C	JJ	O
illustrate	NN	O
a	DT	O
more	RBR	O
realistic	JJ	O
view	NN	O
of	IN	O
AS	NNP	O
phosphorylation	NN	O
with	IN	O
roughly	RB	O
equivalent	JJ	O
levels	NNS	O
of	IN	O
phospho	JJ	O
ser-129	NN	O
between	IN	O
CKI	NNP	O
,	,	O
GRK6	NNP	O
and	CC	O
PLK2	NNP	O
(	(	O
one	CD	O
of	IN	O
7	CD	O
highly	RB	O
confirmed	VBN	O
)	)	O
.	.	O
With	IN	O
the	DT	O
exception	NN	O
of	IN	O
CKI	NNP	O
,	,	O
none	NN	O
of	IN	O
the	DT	O
tested	JJ	O
kinases	NNS	O
were	VBD	O
capable	JJ	O
of	IN	O
phosphorylating	VBG	O
AS	NNP	O
at	IN	O
the	DT	O
ser-87	JJ	O
residue	NN	O
.	.	O
This	DT	O
observation	NN	O
confirmed	VBD	O
the	DT	O
specificity/preference	NN	O
of	IN	O
these	DT	O
kinases	NNS	O
for	IN	O
the	DT	O
ser-129	JJ	O
site	NN	O
and/or	IN	O
the	DT	O
low	JJ	O
preference/inaccessibility	NN	O
for	IN	O
the	DT	O
ser-87	JJ	O
site	NN	O
.	.	O
However	RB	O
,	,	O
CKI	NNP	O
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
phosphorylate	VB	O
at	IN	O
both	DT	O
sites	NNS	O
.	.	O
Effect	NN	O
of	IN	O
Acidic	NNP	O
Phospholipid	NNP	O
on	IN	O
the	DT	O
Assay	NNP	O
Results	NNP	O
The	DT	O
significant	JJ	O
levels	NNS	O
of	IN	O
activity	NN	O
by	IN	O
GRK6	NNP	O
and	CC	O
PLK2	NNP	O
(	(	O
polo-like	JJ	O
kinase	NN	O
phylogenetically	RB	O
related	VBN	O
to	TO	O
the	DT	O
GRK	NNP	O
family	NN	O
)	)	O
in	IN	O
the	DT	O
in	IN	O
vitro	JJ	O
assay	NN	O
combined	VBN	O
with	IN	O
the	DT	O
identification	NN	O
of	IN	O
PLK2	NNP	O
,	,	O
GRK2	NNP	O
and	CC	O
GRK1	NNP	O
as	IN	O
decreasers	NNS	O
of	IN	O
phosphorylation	NN	O
in	IN	O
the	DT	O
RNAi	NNP	O
screen	NN	O
,	,	O
prompted	VBD	O
a	DT	O
more	RBR	O
comprehensive	JJ	O
survey	NN	O
of	IN	O
other	JJ	O
GRK	NNP	O
members	NNS	O
.	.	O
FIGS	NNP	O
.	.	O
4A	CD	O
and	CC	O
B	NNP	O
indicate	VBP	O
the	DT	O
results	NNS	O
of	IN	O
GRK	NNP	O
2	CD	O
,	,	O
4	CD	O
,	,	O
5	CD	O
,	,	O
6	CD	O
,	,	O
7	CD	O
and	CC	O
PLK2	NNP	O
compared	VBN	O
in	IN	O
the	DT	O
in	IN	O
vitro	JJ	O
assay	NN	O
.	.	O
This	DT	O
preference	NN	O
could	MD	O
be	VB	O
represented	VBN	O
as	IN	O
CKI	NNP	O
>	NNP	O
GRK6	NNP	O
>	NNP	O
PLK2	NNP	O
>	NNP	O
GRK4	NNP	O
>	NNP	O
GRK5	NNP	O
>	NNP	O
GRK2	NNP	O
.	.	O
GRK	NNP	O
7	CD	O
was	VBD	O
not	RB	O
able	JJ	O
to	TO	O
phosphorylate	VB	O
at	IN	O
appreciable	JJ	O
levels	NNS	O
.	.	O
All	DT	O
GRKs	NNP	O
were	VBD	O
unable	JJ	O
to	TO	O
phosphorylate	VB	O
at	IN	O
ser-87	JJ	O
pointing	VBG	O
to	TO	O
a	DT	O
specificity	NN	O
for	IN	O
the	DT	O
acidic	JJ	O
sequence	NN	O
flanking	VBG	O
amino	JJ	O
acid	JJ	O
129	CD	O
.	.	O
These	DT	O
reactions	NNS	O
were	VBD	O
quantitated	VBN	O
and	CC	O
confirmed	VBN	O
by	IN	O
ELISA	NNP	O
measurements	NNS	O
.	.	O
These	DT	O
values	NNS	O
more	RBR	O
or	CC	O
less	JJR	O
agreed	VBN	O
with	IN	O
the	DT	O
immunoblot	NN	O
data	NNS	O
with	IN	O
an	DT	O
apparent	JJ	O
decrease	NN	O
in	IN	O
PLK2	NNP	O
level	NN	O
vs	NN	O
GRKs	NNP	O
.	.	O
It	PRP	O
is	VBZ	O
likely	JJ	O
that	IN	O
most	JJS	O
of	IN	O
the	DT	O
AS	NNP	O
substrate	NN	O
was	VBD	O
depleted	VBN	O
(	(	O
phosphorylated	VBN	O
)	)	O
based	VBN	O
on	IN	O
the	DT	O
assay	NN	O
design	NN	O
(	(	O
300	CD	O
ng	RB	O
AS	NNP	O
,	,	O
210	CD	O
nM	NN	O
for	IN	O
17	CD	O
hr	NN	O
)	)	O
.	.	O
The	DT	O
positive	JJ	O
effect	NN	O
of	IN	O
acidic	JJ	O
phospholipids	NNS	O
on	IN	O
the	DT	O
phosphorylation	NN	O
of	IN	O
AS	NNP	O
has	VBZ	O
been	VBN	O
previously	RB	O
reported	VBN	O
Pronin	NNP	B
et	NN	I
.	.	I
al	NN	I
.	.	I
JBC	RB	I
275	CD	I
(	(	I
34	CD	I
)	)	I
:	:	I
26515-26522	JJ	I
(	(	I
2000	CD	I
)	)	I
and	CC	O
a	DT	O
pronounced	JJ	O
effect	NN	O
on	IN	O
GRK	NNP	O
2	CD	O
and	CC	O
5	CD	O
was	VBD	O
observed	VBN	O
.	.	O
Because	IN	O
of	IN	O
this	DT	O
report	NN	O
and	CC	O
the	DT	O
many	JJ	O
studies	NNS	O
indicating	VBG	O
that	IN	O
acidic	JJ	O
phospholipids	NNS	O
modulate	NN	O
AS	IN	O
conformation	NN	O
,	,	O
a	DT	O
mixture	NN	O
of	IN	O
phosphatidylcholine	NN	O
(	(	O
PC	NN	O
)	)	O
:	:	O
phosphatidylserine	NN	O
(	(	O
PS	NNP	O
)	)	O
:	:	O
phosphatidyl-inositol-phosphate-3	NN	O
(	(	O
PIP3	NNP	O
)	)	O
was	VBD	O
generated	VBN	O
and	CC	O
incorporated	VBN	O
into	IN	O
the	DT	O
established	VBN	O
in	IN	O
vitro	JJ	O
assay	NN	O
.	.	O
The	DT	O
lipid	JJ	O
mixture	NN	O
was	VBD	O
shown	VBN	O
to	TO	O
increase	VB	O
signal	NN	O
for	IN	O
almost	RB	O
all	DT	O
of	IN	O
the	DT	O
kinases	NNS	O
tested	VBN	O
.	.	O
The	DT	O
addition	NN	O
of	IN	O
a	DT	O
lipid	JJ	O
environment	NN	O
is	VBZ	O
likely	JJ	O
to	TO	O
imitate	VB	O
the	DT	O
membrane	NN	O
surface	NN	O
in	IN	O
a	DT	O
cell	NN	O
where	WRB	O
AS	NNP	O
and	CC	O
GRKs	NNP	O
are	VBP	O
likely	JJ	O
to	TO	O
associate	VB	O
.	.	O
Without	IN	O
being	VBG	O
bound	VBN	O
by	IN	O
the	DT	O
following	JJ	O
theory	NN	O
,	,	O
it	PRP	O
is	VBZ	O
probably	RB	O
due	JJ	O
to	TO	O
a	DT	O
favorable	JJ	O
exposure	NN	O
of	IN	O
the	DT	O
C-term	NNP	O
of	IN	O
AS	NNP	O
upon	IN	O
lipid	JJ	O
binding	NN	O
of	IN	O
the	DT	O
N-term	NNP	O
helices	NNS	O
of	IN	O
AS	NNP	O
.	.	O
Interestingly	RB	O
,	,	O
the	DT	O
lipid	JJ	O
effect	NN	O
of	IN	O
ser-87	JJ	O
phosphorylation	NN	O
(	(	O
as	IN	O
see	NN	O
by	IN	O
the	DT	O
CKI	NNP	O
reaction	NN	O
)	)	O
led	VBD	O
to	TO	O
a	DT	O
decrease	NN	O
in	IN	O
the	DT	O
level	NN	O
of	IN	O
phosphorylation	NN	O
.	.	O
This	DT	O
may	MD	O
be	VB	O
the	DT	O
result	NN	O
of	IN	O
epitope	NN	O
masking	NN	O
by	IN	O
lipid	JJ	O
interaction	NN	O
if	IN	O
ser-87	JJ	O
is	VBZ	O
buried	VBN	O
upon	IN	O
helix	NN	O
interaction	NN	O
.	.	O
EXAMPLE	RB	O
4	CD	O
Identification	NNP	O
of	IN	O
Direct	NNP	O
Phosphorylation	NNP	O
of	IN	O
Alpha-Synuclein	NNP	O
in	IN	O
Cell	NNP	O
Lines	NNP	O
Because	IN	O
kinases	NNS	O
can	MD	O
be	VB	O
more	RBR	O
promiscuous	JJ	O
in	IN	O
vitro	NN	O
than	IN	O
they	PRP	O
are	VBP	O
in	IN	O
cells	NNS	O
,	,	O
an	DT	O
assay	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
cell	NN	O
lines	NNS	O
to	TO	O
confirm	VB	O
the	DT	O
direct	JJ	O
interaction	NN	O
with	IN	O
alpha-synuclein	NN	O
.	.	O
cDNAs	NN	O
for	IN	O
the	DT	O
kinases	NNS	O
that	WDT	O
phosphorylated	VBD	O
alpha-synuclein	RB	O
in	IN	O
vitro	NN	O
from	IN	O
Example	JJ	O
3	CD	O
were	VBD	O
transfected	VBN	O
into	IN	O
the	DT	O
PEAK-Syn	NNP	O
cell	NN	O
line	NN	O
to	TO	O
see	VB	O
which	WDT	O
was	VBD	O
capable	JJ	O
of	IN	O
phosphorylating	VBG	O
alpha-synuclein	JJ	O
ser-129	NN	O
in	IN	O
cells	NNS	O
.	.	O
The	DT	O
results	NNS	O
showed	VBD	O
that	IN	O
GRK6	NNP	O
and	CC	O
,	,	O
to	TO	O
an	DT	O
even	RB	O
greater	JJR	O
extent	NN	O
,	,	O
PLK2	NNP	O
were	VBD	O
able	JJ	O
to	TO	O
mediate	VB	O
alpha-synuclein	JJ	O
phosphorylation	NN	O
in	IN	O
cells	NNS	O
(	(	O
FIG	NNP	O
.	.	O
6	CD	O
)	)	O
.	.	O
cDNA	NN	O
clones	NNS	O
for	IN	O
PLK2	NNP	O
,	,	O
GPRK6	NNP	O
,	,	O
APEG1	NNP	O
,	,	O
CDC7	NNP	O
and	CC	O
PRKG1	NNP	O
were	VBD	O
obtained	VBN	O
from	IN	O
Origene	NNP	O
.	.	O
The	DT	O
cDNA	NN	O
was	VBD	O
transcribed	VBN	O
and	CC	O
transfected	VBN	O
into	IN	O
PEAK-Syn	NNP	O
cells	NNS	O
using	VBG	O
Lipofectamine	NNP	O
2000™	CD	O
(	(	O
Invitrogen	NNP	O
)	)	O
.	.	O
For	IN	O
each	DT	O
cDNA	NN	O
analyzed	VBD	O
,	,	O
12	CD	O
wells	NNS	O
of	IN	O
a	DT	O
96-well	JJ	O
plate	NN	O
were	VBD	O
transfected	VBN	O
,	,	O
along	IN	O
with	IN	O
12	CD	O
control	NN	O
wells	NNS	O
of	IN	O
untransfected	JJ	O
cells	NNS	O
.	.	O
Cells	NNS	O
were	VBD	O
harvested	VBN	O
at	IN	O
48	CD	O
hrs	JJ	O
post-transfection	NN	O
as	IN	O
per	IN	O
the	DT	O
ELISA	NNP	O
screening	NN	O
protocol	NN	O
,	,	O
and	CC	O
analyzed	VBN	O
by	IN	O
ELISA	NNP	O
for	IN	O
total	JJ	O
and	CC	O
phospho-synuclein	JJ	O
,	,	O
and	CC	O
values	NNS	O
were	VBD	O
normalized	VBN	O
for	IN	O
total	JJ	O
protein	NN	O
.	.	O
For	IN	O
those	DT	O
kinase	NNP	O
targets	NNS	O
not	RB	O
commercially	RB	O
available	JJ	O
as	IN	O
recombinant	JJ	O
proteins	NNS	O
(	(	O
namely	RB	O
APEG	NNP	O
,	,	O
PRKGI	NNP	O
and	CC	O
CDC7LI	NNP	O
)	)	O
,	,	O
an	DT	O
in	IN	O
vitro	JJ	O
cell-free	JJ	O
reticulocyte	NN	O
system	NN	O
(	(	O
Promega	NNP	O
)	)	O
was	VBD	O
employed	VBN	O
to	TO	O
express	VB	O
protein	NN	O
from	IN	O
human	JJ	O
full-length	JJ	O
cDNA	NN	O
clones	NNS	O
(	(	O
Origene	NNP	O
)	)	O
.	.	O
Proper	NNP	O
sequence	NN	O
was	VBD	O
determined	VBN	O
and	CC	O
DNA	NNP	O
prepared	VBD	O
.	.	O
PLK2	NNP	O
and	CC	O
GRK6	NNP	O
cDNA	NN	O
was	VBD	O
also	RB	O
included	VBN	O
in	IN	O
the	DT	O
study	NN	O
as	IN	O
positive	JJ	O
controls	NNS	O
.	.	O
The	DT	O
percentage	NN	O
of	IN	O
phospho-synuclein	NN	O
in	IN	O
untransfected	JJ	O
cells	NNS	O
was	VBD	O
calculated	VBN	O
to	TO	O
be	VB	O
7.8	CD	O
%	NN	O
.	.	O
The	DT	O
percentage	NN	O
of	IN	O
phospho-synuclein	NN	O
for	IN	O
the	DT	O
cells	NNS	O
transfected	VBN	O
with	IN	O
APEG1	NNP	O
,	,	O
CDC7	NNP	O
and	CC	O
PRKG1	NNP	O
cDNA	NN	O
was	VBD	O
only	RB	O
marginally	RB	O
higher	JJR	O
than	IN	O
untransfected	JJ	O
cells	NNS	O
at	IN	O
8.9	CD	O
%	NN	O
.	.	O
These	DT	O
kinases	NNS	O
were	VBD	O
considered	VBN	O
to	TO	O
have	VB	O
produced	VBN	O
a	DT	O
negative	JJ	O
result	NN	O
in	IN	O
altering	VBG	O
phospho-synuclein	JJ	O
levels	NNS	O
,	,	O
and	CC	O
were	VBD	O
considered	VBN	O
negative	JJ	O
controls	NNS	O
for	IN	O
experimental	JJ	O
purposes	NNS	O
,	,	O
as	IN	O
they	PRP	O
were	VBD	O
subjected	VBN	O
to	TO	O
the	DT	O
same	JJ	O
rigors	NNS	O
of	IN	O
transfection	NN	O
that	IN	O
the	DT	O
other	JJ	O
kinases	NNS	O
were	VBD	O
exposed	VBN	O
to	TO	O
cDNA	VB	O
to	TO	O
PLK2	NNP	O
was	VBD	O
transfected	VBN	O
into	IN	O
293-synuclein	JJ	O
cells	NNS	O
.	.	O
Cells	NNS	O
were	VBD	O
harvested	VBN	O
48	CD	O
hrs	NN	O
following	VBG	O
transfection	NN	O
and	CC	O
analyzed	VBN	O
by	IN	O
ELISA	NNP	O
for	IN	O
total	JJ	O
and	CC	O
phospho-synuclein	JJ	O
levels	NNS	O
.	.	O
ELISA	NN	O
values	NNS	O
were	VBD	O
corrected	VBN	O
for	IN	O
total	JJ	O
protein	NN	O
levels	NNS	O
.	.	O
Overexpression	NN	O
of	IN	O
PLK2	NNP	O
resulted	VBD	O
in	IN	O
a	DT	O
dramatic	JJ	O
increase	NN	O
in	IN	O
phospho-synuclein	JJ	O
levels	NNS	O
,	,	O
increasing	VBG	O
phospho-synuclein	JJ	O
expression	NN	O
by	IN	O
4.3-fold	JJ	O
above	IN	O
expression	NN	O
in	IN	O
untransfected	JJ	O
cells	NNS	O
.	.	O
It	PRP	O
is	VBZ	O
likely	JJ	O
that	IN	O
when	WRB	O
a	DT	O
direct	JJ	O
kinase	NN	O
that	WDT	O
phosphorylates	VBZ	O
α-synuclein	NN	O
is	VBZ	O
introduced	VBN	O
into	IN	O
the	DT	O
cell	NN	O
an	DT	O
increase	NN	O
in	IN	O
phospho-synuclein	JJ	O
levels	NNS	O
would	MD	O
be	VB	O
observed	VBN	O
.	.	O
This	DT	O
was	VBD	O
the	DT	O
case	NN	O
for	IN	O
both	DT	O
GPRK6	NNP	O
and	CC	O
PLK2	NNP	O
(	(	O
FIG	NNP	O
.	.	O
6	CD	O
)	)	O
.	.	O
The	DT	O
percent	NN	O
phospho-synuclein	NN	O
in	IN	O
cells	NNS	O
transfected	VBN	O
with	IN	O
GPRK6	NNP	O
cDNA	NN	O
increased	VBD	O
dramatically	RB	O
,	,	O
from	IN	O
8.9	CD	O
%	NN	O
to	TO	O
18.9	CD	O
%	NN	O
.	.	O
This	DT	O
increase	NN	O
is	VBZ	O
significant	JJ	O
to	TO	O
9.25	CD	O
standard	JJ	O
deviations	NNS	O
above	IN	O
the	DT	O
percent	NN	O
phospho-synuclein	NN	O
observed	VBD	O
for	IN	O
the	DT	O
negative	JJ	O
kinases	NNS	O
.	.	O
The	DT	O
increase	NN	O
in	IN	O
phospho-synuclein	JJ	O
levels	NNS	O
for	IN	O
the	DT	O
PLK2-transfected	JJ	O
cells	NNS	O
was	VBD	O
even	RB	O
more	RBR	O
dramatic	JJ	O
,	,	O
increasing	VBG	O
the	DT	O
percent	NN	O
phospho-synuclein	JJ	O
almost	RB	O
four-fold	JJ	O
to	TO	O
33.2	CD	O
%	NN	O
.	.	O
This	DT	O
represents	VBZ	O
an	DT	O
extremely	RB	O
significant	JJ	O
change	NN	O
,	,	O
an	DT	O
increase	NN	O
of	IN	O
22.75	CD	O
standard	JJ	O
deviations	NNS	O
above	IN	O
the	DT	O
phospho-synuclein	JJ	O
levels	NNS	O
observed	VBN	O
for	IN	O
the	DT	O
negative	JJ	O
kinases	NNS	O
.	.	O
This	DT	O
dramatic	JJ	O
increase	NN	O
was	VBD	O
by	IN	O
far	RB	O
the	DT	O
largest	JJS	O
change	NN	O
observed	VBD	O
previously	RB	O
in	IN	O
using	VBG	O
this	DT	O
assay	NN	O
.	.	O
This	DT	O
data	NN	O
strongly	RB	O
indicates	VBZ	O
GPRK6	NNP	O
,	,	O
and	CC	O
especially	RB	O
PLK2	NNP	O
as	IN	O
very	RB	O
solid	JJ	O
contenders	NNS	O
as	IN	O
direct	JJ	O
kinases	VBZ	O
responsible	JJ	O
for	IN	O
phosphorylating	VBG	O
α-synuclein	NN	O
.	.	O
Thus	RB	O
,	,	O
as	IN	O
shown	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
6	CD	O
,	,	O
when	WRB	O
GPRK6	NNP	O
cDNA	NN	O
is	VBZ	O
transfected	VBN	O
into	IN	O
HEK-synuclein	NNP	O
cells	NNS	O
,	,	O
the	DT	O
expression	NN	O
of	IN	O
phospho-synuclein	JJ	O
increases	NNS	O
2-fold	JJ	O
.	.	O
Introduction	NN	O
of	IN	O
PLK2	NNP	O
cDNA	NN	O
into	IN	O
cells	NNS	O
results	NNS	O
in	IN	O
an	DT	O
even	RB	O
more	RBR	O
dramatic	JJ	O
increase	NN	O
in	IN	O
phospho-synuclein	JJ	O
expression	NN	O
,	,	O
a	DT	O
change	NN	O
of	IN	O
almost	RB	O
four-fold	JJ	O
above	IN	O
control	NN	O
values	NNS	O
.	.	O
EXAMPLE	RB	O
5	CD	O
Phosphorylation	NN	O
by	IN	O
PLK2	NNP	O
(	(	O
SNK	NNP	O
)	)	O
GRK6	NNP	O
,	,	O
CKII	NNP	O
and	CC	O
IKBKB	NNP	O
The	DT	O
data	NN	O
in	IN	O
Example	NNP	O
4	CD	O
was	VBD	O
further	RB	O
substantiated	VBN	O
for	IN	O
PLK2	NNP	O
by	IN	O
showing	VBG	O
that	IN	O
PLK2	NNP	O
siRNAs	VBD	O
reduced	VBN	O
alpha-synuclein	JJ	O
phosphorylation	NN	O
.	.	O
This	DT	O
strengthened	VBD	O
the	DT	O
data	NNS	O
showing	VBG	O
that	IN	O
PLK2	NNP	O
is	VBZ	O
a	DT	O
likely	JJ	O
candidate	NN	O
as	IN	O
a	DT	O
cellular	JJ	O
kinase	NN	O
that	WDT	O
directly	RB	O
phosphorylates	VBZ	O
alpha-synuclein	NN	O
at	IN	O
Serine	NNP	O
129	CD	O
(	(	O
Tables	NNP	O
2	CD	O
and	CC	O
12	CD	O
)	)	O
.	.	O
HEK	$	O
293	CD	O
cells	NNS	O
stably	RB	O
transfected	VBD	O
with	IN	O
alpha-synuclein	JJ	O
were	VBD	O
transfected	VBN	O
with	IN	O
10	CD	O
nM	NNS	O
and	CC	O
100	CD	O
nM	NN	O
of	IN	O
SmartPool	NNP	O
siRNAs	NN	O
(	(	O
Dharmacon	NNP	O
)	)	O
.	.	O
SmartPool	NNP	O
siRNAs	VBD	O
include	VBP	O
4	CD	O
individual	JJ	O
siRNAs	NN	O
to	TO	O
a	DT	O
specific	JJ	O
target	NN	O
.	.	O
Thus	RB	O
,	,	O
the	DT	O
actual	JJ	O
concentration	NN	O
of	IN	O
each	DT	O
of	IN	O
the	DT	O
four	CD	O
siRNAs	NN	O
transfected	VBD	O
into	IN	O
cells	NNS	O
was	VBD	O
2.5	CD	O
nM	NN	O
and	CC	O
25	CD	O
nM	NN	O
respectively	RB	O
.	.	O
The	DT	O
results	NNS	O
in	IN	O
FIG	NNP	O
.	.	O
7	CD	O
show	NN	O
that	WDT	O
PLK2	NNP	O
significantly	RB	O
decreased	VBD	O
phospho-synuclein	JJ	O
levels	NNS	O
,	,	O
a	DT	O
change	NN	O
of	IN	O
approximately	RB	O
25	CD	O
%	NN	O
.	.	O
At	IN	O
10	CD	O
nM	NN	O
,	,	O
but	CC	O
not	RB	O
at	IN	O
100	CD	O
nM	NN	O
of	IN	O
siRNA	NN	O
,	,	O
GPRK6	NNP	O
significantly	RB	O
increased	VBD	O
the	DT	O
percentage	NN	O
of	IN	O
phospho-synuclein	NN	O
by	IN	O
one	CD	O
standard	JJ	O
deviation	NN	O
above	IN	O
the	DT	O
mean	NN	O
of	IN	O
the	DT	O
control	NN	O
negative	JJ	O
kinases	NNS	O
(	(	O
FIG	NNP	O
.	.	O
7	CD	O
)	)	O
.	.	O
This	DT	O
is	VBZ	O
the	DT	O
opposite	JJ	O
effect	NN	O
to	TO	O
what	WP	O
was	VBD	O
previously	RB	O
observed	VBN	O
in	IN	O
the	DT	O
primary	JJ	O
siRNA	NN	O
screen	NN	O
and	CC	O
may	MD	O
be	VB	O
due	JJ	O
to	TO	O
the	DT	O
quality	NN	O
of	IN	O
the	DT	O
siRNA	NN	O
used	VBN	O
in	IN	O
the	DT	O
first	JJ	O
or	CC	O
second	JJ	O
assays	NNS	O
.	.	O
These	DT	O
results	NNS	O
were	VBD	O
confirmed	VBN	O
by	IN	O
immunohistochemistry	NN	O
.	.	O
The	DT	O
significant	JJ	O
knockdown	NN	O
of	IN	O
phospho-synuclein	JJ	O
levels	NNS	O
by	IN	O
different	JJ	O
siRNAs	NN	O
from	IN	O
a	DT	O
different	JJ	O
source	NN	O
,	,	O
independently	RB	O
confirms	VBZ	O
and	CC	O
solidifies	VBZ	O
the	DT	O
data	NN	O
,	,	O
and	CC	O
substantiates	VBZ	O
the	DT	O
role	NN	O
of	IN	O
PLK2	NNP	O
as	IN	O
a	DT	O
direct	JJ	O
kinase	NN	O
that	WDT	O
phosphorylates	VBZ	O
α-synuclein	NNS	O
.	.	O
These	DT	O
experiments	NNS	O
were	VBD	O
then	RB	O
performed	VBN	O
on	IN	O
two	CD	O
other	JJ	O
kinases	NNS	O
identified	VBN	O
in	IN	O
the	DT	O
screens	NNS	O
to	TO	O
be	VB	O
of	IN	O
interest	NN	O
,	,	O
casein	JJ	O
kinase	NN	O
two	CD	O
(	(	O
CKII	NNP	O
)	)	O
and	CC	O
IKBKB	NNP	O
.	.	O
The	DT	O
individual	JJ	O
CKII	NNP	O
catalytic	JJ	O
subunits	NNS	O
were	VBD	O
hits	NNS	O
in	IN	O
the	DT	O
primary	JJ	O
siRNA	NN	O
screen	NN	O
(	(	O
see	VB	O
Example	NNP	O
1	CD	O
and	CC	O
Table	NNP	O
1B	CD	O
)	)	O
and	CC	O
confirmed	VBN	O
at	IN	O
the	DT	O
10	CD	O
mM	NN	O
siRNA	NN	O
screen	NN	O
.	.	O
It	PRP	O
was	VBD	O
of	IN	O
interest	NN	O
to	TO	O
determine	VB	O
if	IN	O
the	DT	O
individual	JJ	O
CKII	NNP	O
subunits	NNS	O
α1	NNP	O
and	CC	O
α′	NNP	O
,	,	O
when	WRB	O
cotransfected	VBN	O
with	IN	O
PLK2	NNP	O
or	CC	O
each	DT	O
other	JJ	O
,	,	O
had	VBD	O
additive	JJ	O
effects	NNS	O
on	IN	O
alpha-synuclein	JJ	O
phosphorylation	NN	O
.	.	O
Transfections	NNS	O
were	VBD	O
performed	VBN	O
using	VBG	O
the	DT	O
individual	JJ	O
CKII	NNP	O
subunits	VBZ	O
A	NNP	O
(	(	O
α1	NNP	O
)	)	O
and	CC	O
B	NNP	O
(	(	O
α′	NNP	O
)	)	O
,	,	O
cotransfected	VBN	O
with	IN	O
PLK2	NNP	O
or	CC	O
each	DT	O
other	JJ	O
.	.	O
Overexpression	NN	O
of	IN	O
these	DT	O
catalytic	JJ	O
subunits	NNS	O
increased	VBD	O
phospho-synuclein	NN	O
levels	NNS	O
by	IN	O
1.75	CD	O
and	CC	O
1	CD	O
standard	JJ	O
deviations	NNS	O
respectively	RB	O
(	(	O
the	DT	O
effect	NN	O
was	VBD	O
not	RB	O
additive	JJ	O
)	)	O
.	.	O
When	WRB	O
each	DT	O
of	IN	O
the	DT	O
individual	JJ	O
subunits	NNS	O
was	VBD	O
co-transfected	JJ	O
with	IN	O
PLK2	NNP	O
,	,	O
the	DT	O
levels	NNS	O
of	IN	O
phospho-synuclein	NN	O
increased	VBN	O
over	IN	O
that	DT	O
of	IN	O
PLK2	NNP	O
alone	RB	O
(	(	O
18.6	CD	O
%	NN	O
phospho-synuclein	NN	O
)	)	O
by	IN	O
1.25	CD	O
standard	JJ	O
deviations	NNS	O
each	DT	O
to	TO	O
22.8	CD	O
%	NN	O
phospho-synuclein	NN	O
.	.	O
However	RB	O
when	WRB	O
both	DT	O
subunits	NNS	O
were	VBD	O
co-transfected	JJ	O
with	IN	O
PLK2	NNP	O
phospho-synuclein	NN	O
levels	NNS	O
were	VBD	O
not	RB	O
significantly	RB	O
increased	VBN	O
above	IN	O
that	DT	O
for	IN	O
PLK2	NNP	O
alone	RB	O
(	(	O
21.4	CD	O
%	NN	O
phospho-synuclein	NN	O
)	)	O
.	.	O
IKBKB	NNP	O
siRNA	VBD	O
knockdown	RP	O
resulted	VBN	O
in	IN	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
alpha-synuclein	JJ	O
phosphorylation	NN	O
so	IN	O
this	DT	O
gene	NN	O
was	VBD	O
tested	VBN	O
for	IN	O
capacity	NN	O
to	TO	O
phosphorylate	VB	O
alpha	JJ	O
synuclein	NN	O
.	.	O
Transfections	NNS	O
and	CC	O
ELISA	NNP	O
analysis	NN	O
were	VBD	O
performed	VBN	O
as	IN	O
per	IN	O
standard	JJ	O
procedure	NN	O
.	.	O
Previous	JJ	O
in	IN	O
vitro	JJ	O
experiments	NNS	O
demonstrated	VBD	O
that	IN	O
IKBKB	NNP	O
was	VBD	O
not	RB	O
a	DT	O
direct	JJ	O
synuclein	NN	O
kinase	NN	O
as	IN	O
it	PRP	O
did	VBD	O
not	RB	O
phosphorylate	VB	O
synuclein	NN	O
in	IN	O
a	DT	O
direct	JJ	O
kinase	NN	O
assay	NN	O
(	(	O
see	VB	O
Example	NNP	O
3	CD	O
)	)	O
,	,	O
but	CC	O
may	MD	O
be	VB	O
an	DT	O
upstream	JJ	O
regulator	NN	O
of	IN	O
synuclein	JJ	O
phosphorylation	NN	O
.	.	O
Thus	RB	O
,	,	O
IKBKB	NNP	O
was	VBD	O
over-expressed	JJ	O
in	IN	O
HEK-syn	NNP	O
cells	NNS	O
to	TO	O
identify	VB	O
the	DT	O
effect	NN	O
on	IN	O
phosphorylation	NN	O
of	IN	O
synuclein	NN	O
.	.	O
Following	VBG	O
introduction	NN	O
of	IN	O
IKBKB	NNP	O
cDNA	NN	O
into	IN	O
cells	NNS	O
,	,	O
synuclein	JJ	O
phosphorylation	NN	O
increased	VBD	O
from	IN	O
8.3	CD	O
%	NN	O
in	IN	O
the	DT	O
negative	JJ	O
(	(	O
empty	JJ	O
vector	NN	O
)	)	O
control	NN	O
to	TO	O
21.5	CD	O
%	NN	O
,	,	O
a	DT	O
2.6-fold	JJ	O
increase	NN	O
.	.	O
This	DT	O
represented	VBD	O
an	DT	O
increase	NN	O
in	IN	O
synuclein	JJ	O
phosphorylation	NN	O
that	WDT	O
was	VBD	O
significant	JJ	O
to	TO	O
almost	RB	O
53	CD	O
standard	JJ	O
deviations	NNS	O
.	.	O
The	DT	O
PLK2	NNP	O
positive	JJ	O
control	NN	O
increased	VBD	O
synuclein	JJ	O
phosphorylation	NN	O
to	TO	O
65.8	CD	O
%	NN	O
,	,	O
an	DT	O
almost	RB	O
8-fold	JJ	O
increase	NN	O
in	IN	O
phosphorylation	NN	O
(	(	O
significant	JJ	O
to	TO	O
230	CD	O
standard	JJ	O
deviations	NNS	O
)	)	O
.	.	O
Although	IN	O
the	DT	O
effect	NN	O
on	IN	O
synuclein	NN	O
phosphorylation	NN	O
was	VBD	O
much	RB	O
more	JJR	O
modest	JJ	O
for	IN	O
IKBKA	NNP	O
,	,	O
a	DT	O
related	JJ	O
kinase	NN	O
,	,	O
(	(	O
1.2	CD	O
fold	NN	O
)	)	O
than	IN	O
for	IN	O
IKBKB	NNP	O
,	,	O
it	PRP	O
was	VBD	O
still	RB	O
significant	JJ	O
to	TO	O
1.4	CD	O
standard	JJ	O
deviations	NNS	O
.	.	O
EXAMPLE	RB	O
6	CD	O
Synphilin	NNP	O
as	IN	O
an	DT	O
Alternative	NNP	O
Therapeutic	NNP	O
Target	NNP	O
Synphilin	NNP	O
is	VBZ	O
a	DT	O
synuclein-associated	JJ	O
protein	NN	O
that	WDT	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
bind	VB	O
alpha-synuclein	JJ	O
.	.	O
To	TO	O
determine	VB	O
if	IN	O
the	DT	O
presence	NN	O
of	IN	O
synphilin	NN	O
can	MD	O
enhance	VB	O
the	DT	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	NN	O
,	,	O
it	PRP	O
was	VBD	O
over-expressed	JJ	O
in	IN	O
HEK	NNP	O
cells	NNS	O
with	IN	O
and	CC	O
without	IN	O
alpha-synuclein	JJ	O
and	CC	O
PLK2	NNP	O
.	.	O
Transfections	NNS	O
were	VBD	O
performed	VBN	O
according	VBG	O
to	TO	O
standard	JJ	O
protocol	NN	O
,	,	O
followed	VBN	O
by	IN	O
alpha-synuclein	JJ	O
ELISA	NNP	O
and	CC	O
analysis	NN	O
.	.	O
Cells	NNS	O
were	VBD	O
also	RB	O
harvested	VBN	O
for	IN	O
Western	JJ	O
blot	NN	O
analysis	NN	O
.	.	O
Transfected	VBN	O
cell	NN	O
lysates	NNS	O
were	VBD	O
analyzed	VBN	O
for	IN	O
total	JJ	O
synuclein	NN	O
using	VBG	O
1H7	CD	O
antibody	NN	O
and	CC	O
phospho-serine	JJ	O
129	CD	O
synuclein	NN	O
using	VBG	O
11A5	CD	O
antibody	NN	O
(	(	O
See	NNP	O
WO	NNP	O
05047860	CD	O
)	)	O
.	.	O
The	DT	O
total	JJ	O
amount	NN	O
of	IN	O
DNA	NNP	O
transfected	VBD	O
into	IN	O
cells	NNS	O
remained	VBN	O
constant	JJ	O
at	IN	O
0.16	CD	O
μg/well	NN	O
of	IN	O
a	DT	O
96-well	JJ	O
plate	NN	O
.	.	O
The	DT	O
type	NN	O
of	IN	O
DNA	NN	O
introduced	VBN	O
into	IN	O
cells	NNS	O
varied	VBN	O
,	,	O
with	IN	O
empty	JJ	O
vector	NN	O
being	VBG	O
used	VBN	O
to	TO	O
make	VB	O
up	RP	O
the	DT	O
full	JJ	O
quota	NN	O
of	IN	O
DNA	NNP	O
.	.	O
Varying	VBG	O
concentrations	NNS	O
of	IN	O
alpha-synuclein	NN	O
,	,	O
PLK2	NNP	O
,	,	O
and	CC	O
synphilin	NN	O
cDNA	NN	O
were	VBD	O
introduced	VBN	O
into	IN	O
naïve	JJ	O
HEK	NNP	O
cells	NNS	O
.	.	O
Cells	NNS	O
transfected	VBN	O
with	IN	O
all	DT	O
three	CD	O
showed	VBD	O
a	DT	O
slight	JJ	O
increase	NN	O
in	IN	O
total	JJ	O
synuclein	NN	O
.	.	O
For	IN	O
phospho-synuclein	NN	O
,	,	O
the	DT	O
levels	NNS	O
in	IN	O
untransfected	JJ	O
cells	NNS	O
were	VBD	O
below	IN	O
the	DT	O
limit	NN	O
of	IN	O
quantitation	NN	O
.	.	O
Introducing	VBG	O
alpha-synuclein	JJ	O
alone	RB	O
yielded	VBD	O
5.2	CD	O
%	NN	O
phospho-synuclein	NN	O
,	,	O
which	WDT	O
was	VBD	O
marginally	RB	O
less	JJR	O
than	IN	O
co-transfection	NN	O
of	IN	O
synuclein	NN	O
with	IN	O
synphilin	NN	O
(	(	O
5.4	CD	O
%	NN	O
phospho-synuclein	NN	O
)	)	O
.	.	O
Co-transfection	NN	O
of	IN	O
PLK2	NNP	O
and	CC	O
synuclein	RB	O
yielded	VBN	O
levels	NNS	O
similar	JJ	O
those	DT	O
observed	VBN	O
for	IN	O
transfecting	VBG	O
PLK2	NNP	O
into	IN	O
HEK-syn	NNP	O
stable	JJ	O
cells	NNS	O
,	,	O
60	CD	O
%	NN	O
phospho-synuclein	NN	O
.	.	O
Strikingly	RB	O
,	,	O
concurrent	JJ	O
over-expression	NN	O
of	IN	O
all	DT	O
three	CD	O
cDNA	NN	O
's	POS	O
(	(	O
PLK2	NNP	O
,	,	O
synuclein	NN	O
and	CC	O
synphilin	NN	O
)	)	O
resulted	VBD	O
in	IN	O
83.3	CD	O
%	NN	O
phospho-synuclein	NN	O
in	IN	O
the	DT	O
HEK	NNP	O
cells	NNS	O
.	.	O
Thus	RB	O
,	,	O
synphilin	NN	O
increased	VBD	O
synuclein	JJ	O
phosphorylation	NN	O
in	IN	O
PLK2	NNP	O
,	,	O
alpha-synuclein	JJ	O
over-expressed	JJ	O
HEK	NNP	O
cells	NNS	O
.	.	O
Increased	VBN	O
phosphorylation	NN	O
of	IN	O
alpha	JJ	O
synuclein	NN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
synphilin	NN	O
can	MD	O
be	VB	O
explained	VBN	O
by	IN	O
synphilin	NN	O
binding	NN	O
to	TO	O
the	DT	O
PLK2	NNP	O
polo-box	JJ	O
thereby	NN	O
facilitating	VBG	O
phosphorylation	NN	O
of	IN	O
synuclein	NN	O
by	IN	O
PLK2	NNP	O
.	.	O
Synuclein	NNP	O
itself	PRP	O
is	VBZ	O
unlikely	JJ	O
to	TO	O
bind	VB	O
the	DT	O
polo-box	JJ	O
domain	NN	O
.	.	O
EXAMPLE	RB	O
7	CD	O
PLK2	NNP	O
Activity	NN	O
:	:	O
Phosphorylation	NN	O
of	IN	O
Alpha	NNP	O
Synuclein	NNP	O
and	CC	O
Familial	NNP	O
Mutants	NNP	O
of	IN	O
Alpha	NNP	O
Synuclein	NNP	O
To	TO	O
analyze	VB	O
PLK2	NNP	O
phosphorylation	NN	O
of	IN	O
a	DT	O
number	NN	O
of	IN	O
known	VBN	O
familial	JJ	O
mutants	NNS	O
of	IN	O
alpha	NN	O
synuclein	NN	O
,	,	O
in	IN	O
vitro	JJ	O
studies	NNS	O
were	VBD	O
performed	VBN	O
and	CC	O
the	DT	O
phosphorylation	NN	O
of	IN	O
the	DT	O
alpha	NN	O
synuclein	NN	O
and	CC	O
mutants	NNS	O
analyzed	VBN	O
.	.	O
The	DT	O
familial	JJ	O
mutants	NNS	O
(	(	O
FPD	NNP	O
)	)	O
were	VBD	O
A30P	NNP	O
,	,	O
A53T	NNP	O
,	,	O
and	CC	O
E46K	NNP	O
.	.	O
All	DT	O
in	IN	O
vitro	JJ	O
reactions	NNS	O
were	VBD	O
performed	VBN	O
using	VBG	O
the	DT	O
following	JJ	O
conditions	NNS	O
,	,	O
10	CD	O
mM	NN	O
MgCl2	NNP	O
,	,	O
100	CD	O
μM	NN	O
ATP	NNP	O
,	,	O
27	CD	O
mM	NN	O
HEPES	NNP	O
,	,	O
250	CD	O
ng/ml	NN	O
PLK2	NNP	O
,	,	O
1/50	CD	O
dilution	NN	O
of	IN	O
Protease	NNP	O
Inhibitor	NNP	O
solution	NN	O
(	(	O
1	CD	O
tablet	NN	O
in	IN	O
1	CD	O
ml	NN	O
of	IN	O
reaction	NN	O
buffer	NN	O
)	)	O
,	,	O
40	CD	O
mM	NN	O
Nitrophenylphosphate	NNP	O
,	,	O
1	CD	O
mg/ml	NN	O
of	IN	O
95	CD	O
%	NN	O
Type	NNP	O
II-S	NNP	O
Phosphatidylcholine	NNP	O
from	IN	O
soybean	NN	O
,	,	O
and	CC	O
10	CD	O
,	,	O
100	CD	O
,	,	O
or	CC	O
1000	CD	O
nM	JJ	O
alpha	NN	O
synuclein	NN	O
(	(	O
AS	IN	O
)	)	O
.	.	O
The	DT	O
reaction	NN	O
was	VBD	O
incubated	VBN	O
at	IN	O
37°	CD	O
C.	NNP	O
The	DT	O
activity	NN	O
was	VBD	O
analyzed	VBN	O
by	IN	O
autoradiography	NN	O
.	.	O
PLK2	NNP	O
was	VBD	O
found	VBN	O
to	TO	O
be	VB	O
more	RBR	O
active	JJ	O
against	IN	O
wild-type	JJ	O
alpha	NN	O
synuclein	NN	O
than	IN	O
beta	NN	O
synuclein	NN	O
.	.	O
Further	RB	O
,	,	O
the	DT	O
mutant	JJ	O
alpha-synucleins	NNS	O
were	VBD	O
phosphorylated	VBN	O
more	JJR	O
at	IN	O
a	DT	O
given	VBN	O
concentration	NN	O
(	(	O
especially	RB	O
at	IN	O
lower	JJR	O
concentrations	NNS	O
)	)	O
than	IN	O
WT	NNP	O
.	.	O
A	DT	O
trend	NN	O
of	IN	O
PLK2	NNP	O
activity	NN	O
was	VBD	O
identified	VBN	O
with	IN	O
PLK2	NNP	O
activity	NN	O
being	VBG	O
highest	JJS	O
with	IN	O
FPD	NNP	O
mutants	NNS	O
,	,	O
followed	VBN	O
by	IN	O
wild-type	JJ	O
alpha	NN	O
synuclein	NN	O
,	,	O
and	CC	O
minimally	RB	O
against	IN	O
beta	NN	O
synuclein	NN	O
.	.	O
This	DT	O
order	NN	O
is	VBZ	O
consistent	JJ	O
with	IN	O
a	DT	O
mechanism	NN	O
by	IN	O
which	WDT	O
phosphorylation	NN	O
of	IN	O
alpha	JJ	O
synuclein	NN	O
drives	NNS	O
Lewy	NNP	O
body	NN	O
formation	NN	O
and	CC	O
subsequent	JJ	O
pathology	NN	O
.	.	O
EXAMPLE	RB	O
8	CD	O
Confirmation	NN	O
of	IN	O
the	DT	O
Presence	NNP	O
of	IN	O
Kinases	NNP	O
in	IN	O
HEK-Synuclein	NNP	O
and	CC	O
SY5Y-Synuclein	NNP	O
Cells	NNP	O
qRT-PCR	NN	O
was	VBD	O
performed	VBN	O
to	TO	O
determine	VB	O
if	IN	O
the	DT	O
kinases	NNS	O
of	IN	O
interest	NN	O
were	VBD	O
expressed	VBN	O
in	IN	O
HEK-synuclein	NNP	O
and	CC	O
SY5Y-synuclein	NNP	O
cells	NNS	O
.	.	O
In	IN	O
Table	JJ	O
15	CD	O
all	DT	O
samples	NNS	O
were	VBD	O
normalized	VBN	O
to	TO	O
GAPDH	NNP	O
expression	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
two	CD	O
of	IN	O
the	DT	O
negative	JJ	O
kinases	NNS	O
were	VBD	O
analyzed	VBN	O
in	IN	O
each	DT	O
experiment	NN	O
as	IN	O
a	DT	O
reference	NN	O
.	.	O
Of	IN	O
the	DT	O
24	CD	O
potential	JJ	O
direct	JJ	O
kinase	NN	O
candidates	NNS	O
tested	VBD	O
,	,	O
20	CD	O
were	VBD	O
detected	VBN	O
in	IN	O
the	DT	O
HEK293-synuclein	NNP	O
cells	NNS	O
,	,	O
including	VBG	O
PLK2	NNP	O
.	.	O
Thus	RB	O
,	,	O
the	DT	O
remaining	VBG	O
completely	RB	O
confirmed	VBN	O
kinases	NNS	O
were	VBD	O
detected	VBN	O
in	IN	O
the	DT	O
cells	NNS	O
(	(	O
FIG	NNP	O
.	.	O
9	CD	O
)	)	O
.	.	O
Four	CD	O
of	IN	O
the	DT	O
potential	JJ	O
direct	JJ	O
kinases	NNS	O
tested	VBN	O
,	,	O
GPRK1	NNP	O
,	,	O
GPRK7	NNP	O
,	,	O
ERK8	NNP	O
and	CC	O
RIPK3	NNP	O
,	,	O
were	VBD	O
not	RB	O
detected	VBN	O
.	.	O
GPRK6	NNP	O
was	VBD	O
barely	RB	O
detectable	JJ	O
.	.	O
The	DT	O
qRT-PCR	NN	O
was	VBD	O
performed	VBN	O
as	IN	O
follows	VBZ	O
:	:	O
the	DT	O
mRNA	NN	O
levels	NNS	O
were	VBD	O
normalized	VBN	O
to	TO	O
GAPDH	NNP	O
mRNA	NNP	O
expression	NN	O
levels	NNS	O
.	.	O
Total	JJ	O
RNA	NNP	O
was	VBD	O
purified	VBN	O
from	IN	O
a	DT	O
cell	NN	O
pellet	NN	O
using	VBG	O
the	DT	O
QIAGEN	NNP	O
RNeasy	NNP	O
Kit	NNP	O
and	CC	O
protocol	NN	O
.	.	O
Primer-probe	NNP	O
sets	NNS	O
for	IN	O
24	CD	O
of	IN	O
the	DT	O
potential	JJ	O
direct	JJ	O
kinases	NNS	O
and	CC	O
the	DT	O
four	CD	O
indirect	NN	O
completely	RB	O
confirmed	VBN	O
kinases	NNS	O
were	VBD	O
ordered	VBN	O
from	IN	O
Applied	NNP	O
Biosystems	NNP	O
(	(	O
TaqMan	NNP	O
Gene	NNP	O
Expression	NNP	O
Assays	NNP	O
)	)	O
,	,	O
along	IN	O
with	IN	O
reverse	JJ	O
transcriptase	NN	O
,	,	O
RNase	NNP	O
inhibitors	NNS	O
and	CC	O
standard	JJ	O
PCR	NNP	O
reagents	NNS	O
.	.	O
A	DT	O
one-step	JJ	O
RT-PCR/qRT-PCR	JJ	O
reaction	NN	O
as	IN	O
performed	VBN	O
an	DT	O
ABI7500	NNP	O
Real-Time	JJ	O
PCR	NNP	O
machine	NN	O
for	IN	O
each	DT	O
primer-probe	NN	O
set	VBN	O
using	VBG	O
20	CD	O
ng	NN	O
or	CC	O
200	CD	O
ng	JJ	O
total	JJ	O
RNA	NNP	O
using	VBG	O
the	DT	O
following	VBG	O
cycling	NN	O
conditions	NNS	O
:	:	O
48°	CD	O
C./30	NNP	O
mins	NNS	O
(	(	O
RT-PCR	NNP	O
step	NN	O
)	)	O
,	,	O
95°	CD	O
C./10	NNP	O
mins	NNS	O
(	(	O
denature	NN	O
)	)	O
,	,	O
then	RB	O
40	CD	O
cycles	NNS	O
of	IN	O
95°	CD	O
C./15	NNP	O
secs	NN	O
,	,	O
60°	CD	O
C./1	NNP	O
min	NN	O
.	.	O
For	IN	O
each	DT	O
primer-probe	NN	O
set	NN	O
,	,	O
an	DT	O
RT-negative	JJ	O
reaction	NN	O
and	CC	O
PCR-negative	JJ	O
reaction	NN	O
was	VBD	O
performed	VBN	O
.	.	O
The	DT	O
RT-negative	JJ	O
controls	NNS	O
for	IN	O
background	NN	O
amplification	NN	O
of	IN	O
DNA	NNP	O
(	(	O
not	RB	O
RNA	NNP	O
)	)	O
that	WDT	O
is	VBZ	O
contaminating	VBG	O
the	DT	O
purified	JJ	O
RNA	NNP	O
.	.	O
The	DT	O
PCR-negative	JJ	O
control	NN	O
was	VBD	O
to	TO	O
ensure	VB	O
all	DT	O
of	IN	O
the	DT	O
PCR	NNP	O
reagents	NNS	O
were	VBD	O
free	JJ	O
of	IN	O
contaminating	VBG	O
RNA	NNP	O
and	CC	O
DNA	NNP	O
,	,	O
and	CC	O
should	MD	O
have	VB	O
had	VBD	O
no	DT	O
signal	NN	O
.	.	O
All	DT	O
three	CD	O
of	IN	O
the	DT	O
completely	RB	O
confirmed	VBN	O
potential	JJ	O
direct	JJ	O
kinases	NNS	O
,	,	O
along	IN	O
with	IN	O
the	DT	O
four	CD	O
indirect	NN	O
completely	RB	O
confirmed	VBN	O
kinases	NNS	O
were	VBD	O
easily	RB	O
detected	VBN	O
in	IN	O
SY5Y-synuclein	NNP	O
cells	NNS	O
,	,	O
indicating	VBG	O
this	DT	O
cell	NN	O
line	NN	O
may	MD	O
be	VB	O
a	DT	O
viable	JJ	O
option	NN	O
for	IN	O
a	DT	O
neuronally-derived	JJ	O
cell	NN	O
line	NN	O
for	IN	O
further	JJ	O
experimental	JJ	O
analysis	NN	O
of	IN	O
kinases	NNS	O
.	.	O
EXAMPLE	RB	O
9	CD	O
Identification	NNP	O
of	IN	O
Increased	VBN	O
Phosphorylation	NN	O
of	IN	O
Alpha-Synuclein	NNP	O
in	IN	O
293	CD	O
Cells	NNS	O
and	CC	O
Neuronally-Derived	NNP	O
Cell	NNP	O
Lines	NNP	O
PLK2	NNP	O
and	CC	O
GRK	NNP	O
were	VBD	O
overexpressed	VBN	O
in	IN	O
293	CD	O
cells	NNS	O
stably	RB	O
transfected	VBD	O
with	IN	O
alpha	JJ	O
synuclein	NN	O
.	.	O
ELISA	NNP	O
and	CC	O
Western	JJ	O
blot	NN	O
were	VBD	O
performed	VBN	O
to	TO	O
identify	VB	O
increase	NN	O
in	IN	O
phospho-synuclein	JJ	O
with	IN	O
PLK	NNP	O
and	CC	O
GRK	NNP	O
kinases	NNS	O
and	CC	O
an	DT	O
increase	NN	O
in	IN	O
phosphorylation	NN	O
was	VBD	O
demonstrated	VBN	O
.	.	O
A	DT	O
second	JJ	O
method	NN	O
was	VBD	O
used	VBN	O
to	TO	O
confirm	VB	O
the	DT	O
increase	NN	O
using	VBG	O
the	DT	O
same	JJ	O
biotinylated	JJ	O
antibodies	NNS	O
used	VBN	O
in	IN	O
the	DT	O
ELISA	NNP	O
for	IN	O
immunostaining	VBG	O
(	(	O
11A5	CD	O
)	)	O
in	IN	O
293	CD	O
cells	NNS	O
.	.	O
This	DT	O
method	NN	O
also	RB	O
demonstrated	VBD	O
an	DT	O
increase	NN	O
in	IN	O
phospho-synuclein	JJ	O
in	IN	O
cells	NNS	O
transfected	VBN	O
with	IN	O
PLK2	NNP	O
and	CC	O
to	TO	O
a	DT	O
lesser	JJR	O
extent	NN	O
GRK	NNP	O
.	.	O
The	DT	O
increase	NN	O
was	VBD	O
detected	VBN	O
in	IN	O
a	DT	O
small	JJ	O
population	NN	O
of	IN	O
cells	NNS	O
that	WDT	O
brightly	RB	O
stain	VBP	O
for	IN	O
11A5	CD	O
,	,	O
not	RB	O
a	DT	O
general	JJ	O
increase	NN	O
in	IN	O
all	DT	O
cells	NNS	O
.	.	O
The	DT	O
amount	NN	O
of	IN	O
total	JJ	O
synuclein	NN	O
(	(	O
measured	VBN	O
using	VBG	O
the	DT	O
5C12	CD	O
antibody	NN	O
)	)	O
did	VBD	O
not	RB	O
appear	VB	O
to	TO	O
change	VB	O
.	.	O
This	DT	O
was	VBD	O
a	DT	O
significant	JJ	O
increase	NN	O
in	IN	O
phosphorylation	NN	O
in	IN	O
the	DT	O
293	CD	O
cells	NNS	O
.	.	O
Thus	RB	O
,	,	O
it	PRP	O
was	VBD	O
of	IN	O
interest	NN	O
to	TO	O
see	VB	O
if	IN	O
the	DT	O
results	NNS	O
could	MD	O
be	VB	O
repeated	VBN	O
in	IN	O
neuroblastoma	JJ	O
cells	NNS	O
.	.	O
To	TO	O
identify	VB	O
that	IN	O
the	DT	O
dramatic	JJ	O
upregulation	NN	O
of	IN	O
phospho-synuclein	JJ	O
observed	VBN	O
with	IN	O
PLK2	NNP	O
and	CC	O
GPRK6	NNP	O
occurs	VBZ	O
in	IN	O
neuronally-derived	JJ	O
cells	NNS	O
,	,	O
the	DT	O
same	JJ	O
experiment	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
human	JJ	O
neuroblastoma	NN	O
cells	NNS	O
(	(	O
SY5Y	NNP	O
cells	NNS	O
)	)	O
.	.	O
Immunostaining	VBG	O
results	NNS	O
showed	VBD	O
that	IN	O
PLK2	NNP	O
caused	VBD	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
phospho-synuclein	NN	O
in	IN	O
a	DT	O
small	JJ	O
population	NN	O
of	IN	O
cells	NNS	O
,	,	O
in	IN	O
a	DT	O
very	RB	O
similar	JJ	O
pattern	NN	O
to	TO	O
the	DT	O
293	CD	O
cell	NN	O
experiments	NNS	O
.	.	O
Quantitation	NN	O
was	VBD	O
performed	VBN	O
by	IN	O
immunohistochemistry	NN	O
using	VBG	O
the	DT	O
ArrayScan™	NNP	O
in	IN	O
two	CD	O
ways	NNS	O
.	.	O
First	RB	O
all	DT	O
cells	NNS	O
were	VBD	O
counted	VBN	O
and	CC	O
did	VBD	O
not	RB	O
show	VB	O
any	DT	O
difference	NN	O
.	.	O
Then	RB	O
just	RB	O
the	DT	O
bright	JJ	O
cells	NNS	O
were	VBD	O
counted	VBN	O
and	CC	O
this	DT	O
analysis	NN	O
showed	VBD	O
about	IN	O
a	DT	O
5-10	JJ	O
fold	JJ	O
increase	NN	O
in	IN	O
the	DT	O
number	NN	O
of	IN	O
11A5	CD	O
positive	JJ	O
cells	NNS	O
that	WDT	O
were	VBD	O
PLK	NNP	O
transfected	VBD	O
,	,	O
with	IN	O
a	DT	O
slight	JJ	O
increase	NN	O
with	IN	O
GRK6	NNP	O
as	RB	O
well	RB	O
.	.	O
The	DT	O
cDNA	NN	O
transfection	NN	O
experiment	NN	O
is	VBZ	O
repeated	VBN	O
in	IN	O
HCC	NNP	O
cells	NNS	O
and	CC	O
immunohistochemistry	NN	O
is	VBZ	O
performed	VBN	O
with	IN	O
a	DT	O
variety	NN	O
of	IN	O
alpha-synuclein	JJ	O
antibodies	NNS	O
on	IN	O
the	DT	O
cells	NNS	O
that	WDT	O
have	VBP	O
been	VBN	O
transfected	VBN	O
with	IN	O
PLK2	NNP	O
and	CC	O
GPRK6	NNP	O
.	.	O
Cells	NNS	O
may	MD	O
be	VB	O
treated	VBN	O
with	IN	O
additional	JJ	O
reagents	NNS	O
to	TO	O
mimic	VB	O
the	DT	O
pathology	NN	O
of	IN	O
Parkinson	NNP	O
's	POS	O
disease	NN	O
;	:	O
such	JJ	O
reagents	NNS	O
could	MD	O
include	VB	O
,	,	O
for	IN	O
example	NN	O
,	,	O
rotenone	NN	O
,	,	O
paraquat	NN	O
,	,	O
hydrogen	NN	O
peroxide	NN	O
,	,	O
or	CC	O
ferric	JJ	O
chloride	NN	O
.	.	O
In	IN	O
this	DT	O
way	NN	O
,	,	O
inclusion	NN	O
formation	NN	O
and/or	IN	O
alpha-synuclein	JJ	O
aggregation	NN	O
is	VBZ	O
observed	VBN	O
in	IN	O
these	DT	O
cells	NNS	O
.	.	O
Antibodies	NNS	O
used	VBN	O
to	TO	O
look	VB	O
for	IN	O
inclusions/aggregation	NN	O
include	VBP	O
LB509	NNP	O
,	,	O
SYN-1	NNP	O
,	,	O
11A5	CD	O
and	CC	O
ELADW-110	NNP	O
.	.	O
Next	JJ	O
,	,	O
cDNA	NN	O
for	IN	O
PLK2	NNP	O
and	CC	O
GPRK6	NNP	O
siRNA	NN	O
is	VBZ	O
transfected	VBN	O
in	IN	O
primary	JJ	O
neuronal	JJ	O
cultures	NNS	O
in	IN	O
preparation	NN	O
for	IN	O
introducing	VBG	O
targets	NNS	O
into	IN	O
a	DT	O
mouse	NN	O
model	NN	O
.	.	O
The	DT	O
method	NN	O
is	VBZ	O
performed	VBN	O
as	IN	O
in	IN	O
Example	NNP	O
4.	CD	O
qRT-PCR	NN	O
is	VBZ	O
performed	VBN	O
(	(	O
as	IN	O
in	IN	O
Example	NNP	O
2	CD	O
)	)	O
using	VBG	O
SY5Y-synuclein	NNP	O
RNA	NNP	O
.	.	O
SY5Y-synuclein	JJ	O
cells	NNS	O
are	VBP	O
derived	VBN	O
from	IN	O
neuroblastoma	JJ	O
cells	NNS	O
and	CC	O
have	VBP	O
been	VBN	O
stably	RB	O
transfected	VBN	O
with	IN	O
a	DT	O
WT-synuclein	JJ	O
vector	NN	O
.	.	O
EXAMPLE	RB	O
10	CD	O
Distribution	NNP	O
of	IN	O
Lentivirus-Expressed	JJ	O
Alpha-Synuclein	NNP	O
in	IN	O
Human	NNP	O
Cortical	NNP	O
Culture	NNP	O
(	(	O
HCC	NNP	O
)	)	O
—a	VBP	O
Cellular	JJ	O
Model	NNP	O
for	IN	O
Lewy	NNP	O
Body	NNP	O
Disease	NNP	O
Of	IN	O
interest	NN	O
was	VBD	O
the	DT	O
identification	NN	O
of	IN	O
a	DT	O
cellular	JJ	O
model	NN	O
for	IN	O
Lewy	NNP	O
body	NN	O
disease	NN	O
and/or	NN	O
for	IN	O
PD	NNP	O
pathology	NN	O
.	.	O
Thus	RB	O
,	,	O
lentivirus-mediated	JJ	O
expression	NN	O
of	IN	O
alpha-synuclein	NN	O
in	IN	O
human	JJ	O
cortical	JJ	O
cultures	NNS	O
was	VBD	O
used	VBN	O
to	TO	O
establish	VB	O
a	DT	O
model	NN	O
of	IN	O
alpha-synuclein	JJ	O
deposition	NN	O
in	IN	O
vivo	NN	O
.	.	O
Experiments	NNS	O
were	VBD	O
performed	VBN	O
on	IN	O
donors	NNS	O
,	,	O
and	CC	O
HCC	NNP	O
cells	NNS	O
overexpressing	VBG	O
wild-type	JJ	O
and	CC	O
variant	JJ	O
alpha-synuclein	NN	O
to	TO	O
fractionate	VB	O
the	DT	O
cells	NNS	O
and	CC	O
localize	VB	O
wild-type	JJ	O
alpha-synuclein	JJ	O
and	CC	O
variant	JJ	O
alpha-synuclein	NN	O
within	IN	O
the	DT	O
cells	NNS	O
.	.	O
In	IN	O
one	CD	O
experiment	JJ	O
aggregation	NN	O
of	IN	O
alpha	JJ	O
synuclein	NN	O
in	IN	O
a	DT	O
manner	NN	O
matching	VBG	O
LB	NNP	O
disease	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
the	DT	O
HCC	NNP	O
cells	NNS	O
.	.	O
Further	RB	O
,	,	O
in	IN	O
one	CD	O
experiment	NN	O
when	WRB	O
PLK2	NNP	O
was	VBD	O
expressed	VBN	O
,	,	O
the	DT	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	NN	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
aggregation	NN	O
increased	VBD	O
.	.	O
In	IN	O
other	JJ	O
experiments	NNS	O
this	DT	O
was	VBD	O
not	RB	O
observed	VBN	O
.	.	O
Further	JJ	O
experiments	NNS	O
were	VBD	O
performed	VBN	O
to	TO	O
determine	VB	O
whether	IN	O
extending	VBG	O
culture	NN	O
might	MD	O
increase	VB	O
the	DT	O
accumulation	NN	O
of	IN	O
overexpressed	JJ	O
synuclein	NN	O
,	,	O
and	CC	O
would	MD	O
stress	VB	O
the	DT	O
cells	NNS	O
,	,	O
which	WDT	O
also	RB	O
might	MD	O
favor	VB	O
synuclein	JJ	O
deposition	NN	O
or	CC	O
toxicity	NN	O
.	.	O
Accordingly	RB	O
,	,	O
HCC	NNP	O
were	VBD	O
transduced	VBN	O
with	IN	O
viral	JJ	O
vectors	NNS	O
expressing	VBG	O
WT	NNP	O
,	,	O
A53T	NNP	O
,	,	O
S129A	NNP	O
or	CC	O
both	DT	O
A53T/S129A	NNP	O
alpha-synuclein	NN	O
mutants	NNS	O
.	.	O
Following	VBG	O
transfection	NN	O
cells	NNS	O
were	VBD	O
grown	VBN	O
in	IN	O
vitro	NN	O
for	IN	O
9	CD	O
,	,	O
16	CD	O
or	CC	O
23	CD	O
days	NNS	O
before	IN	O
collecting	VBG	O
and	CC	O
fractionating	NN	O
.	.	O
ELISA	JJ	O
results	NNS	O
were	VBD	O
normalized	VBN	O
to	TO	O
protein	VB	O
concentration	NN	O
and	CC	O
showed	VBD	O
an	DT	O
accumulation	NN	O
of	IN	O
synuclein	NN	O
in	IN	O
the	DT	O
soluble	JJ	O
fraction	NN	O
with	IN	O
increasing	VBG	O
time	NN	O
.	.	O
Somewhat	RB	O
greater	JJR	O
accumulation	NN	O
was	VBD	O
observed	VBN	O
with	IN	O
the	DT	O
S129A	NNP	O
mutant	NN	O
.	.	O
When	WRB	O
further	JJ	O
experiments	NNS	O
were	VBD	O
performed	VBN	O
with	IN	O
WT	NNP	O
,	,	O
119-truncated	JJ	O
,	,	O
and	CC	O
E46K	NNP	O
AS	NNP	O
,	,	O
the	DT	O
results	NNS	O
were	VBD	O
as	IN	O
follows	VBZ	O
.	.	O
The	DT	O
higher	JJR	O
the	DT	O
expression	NN	O
of	IN	O
wild-type	JJ	O
the	DT	O
larger	JJR	O
the	DT	O
portion	NN	O
of	IN	O
alpha	NN	O
synuclein	NN	O
recovered	VBD	O
in	IN	O
the	DT	O
soluble	JJ	O
fraction	NN	O
.	.	O
E46K	NNP	O
synuclein	NN	O
showed	VBD	O
a	DT	O
50-100	JJ	O
%	NN	O
increase	NN	O
in	IN	O
the	DT	O
amount	NN	O
of	IN	O
phosphorylated	JJ	O
alpha-synuclein	NN	O
.	.	O
However	RB	O
,	,	O
the	DT	O
E46K	NNP	O
mutation	NN	O
did	VBD	O
not	RB	O
markedly	RB	O
affect	JJ	O
relative	JJ	O
amounts	NNS	O
of	IN	O
synuclein	NN	O
recovered	VBN	O
in	IN	O
the	DT	O
membrane-bound	NN	O
or	CC	O
insoluble	JJ	O
fractions	NNS	O
.	.	O
Expression	NN	O
of	IN	O
119-truncated	JJ	O
alpha	NN	O
synuclein	NN	O
led	VBD	O
to	TO	O
a	DT	O
slight	JJ	O
increase	NN	O
in	IN	O
the	DT	O
relative	JJ	O
amount	NN	O
accumulating	VBG	O
in	IN	O
the	DT	O
insoluble	JJ	O
fraction	NN	O
(	(	O
about	IN	O
3	CD	O
fold	NN	O
higher	JJR	O
relative	JJ	O
to	TO	O
WT	NNP	O
)	)	O
.	.	O
The	DT	O
increase	NN	O
is	VBZ	O
expected	VBN	O
in	IN	O
view	NN	O
of	IN	O
the	DT	O
published	VBN	O
results	NNS	O
suggesting	VBG	O
that	IN	O
truncated	VBD	O
synuclein	NN	O
forms	NNS	O
fibrils	VBP	O
much	RB	O
more	JJR	O
readily	RB	O
in	IN	O
vitro	NN	O
than	IN	O
does	VBZ	O
full-length	JJ	O
(	(	O
Murray	NNP	B
et	RB	I
al	RB	I
.	.	I
2003	CD	I
Biochemistry	NNP	I
42:8530	CD	I
)	)	O
.	.	O
The	DT	O
119	CD	O
truncation	NN	O
resulted	VBD	O
in	IN	O
an	DT	O
increased	VBN	O
association	NN	O
with	IN	O
membranes	NNS	O
consistent	JJ	O
with	IN	O
the	DT	O
N-terminal	JJ	O
domain	NN	O
being	VBG	O
responsible	JJ	O
for	IN	O
association	NN	O
with	IN	O
lipid	JJ	O
bilayers	NNS	O
.	.	O
The	DT	O
increased	VBN	O
association	NN	O
with	IN	O
membranes	NNS	O
may	MD	O
mitigate	VB	O
the	DT	O
increased	JJ	O
tendency	NN	O
of	IN	O
the	DT	O
soluble	JJ	O
protein	NN	O
to	TO	O
aggregate	VB	O
.	.	O
The	DT	O
response	NN	O
of	IN	O
the	DT	O
insoluble	JJ	O
fraction	NN	O
to	TO	O
increases	NNS	O
in	IN	O
levels	NNS	O
of	IN	O
soluble	JJ	O
synuclein	NN	O
on	IN	O
overexpression	NN	O
and	CC	O
to	TO	O
truncation	NN	O
,	,	O
a	DT	O
change	NN	O
favoring	VBG	O
aggregation	NN	O
,	,	O
suggest	VBP	O
that	IN	O
it	PRP	O
provides	VBZ	O
a	DT	O
way	NN	O
to	TO	O
identify	VB	O
factors	NNS	O
affecting	VBG	O
aggregation	NN	O
in	IN	O
the	DT	O
intraneuronal	JJ	O
milieu	NN	O
.	.	O
The	DT	O
increased	VBN	O
alpha-synuclein	NN	O
in	IN	O
the	DT	O
soluble	JJ	O
compartment	NN	O
might	MD	O
be	VB	O
shifting	VBG	O
the	DT	O
alpha-synuclein	JJ	O
to	TO	O
a	DT	O
potentially	RB	O
more	RBR	O
vulnerable	JJ	O
compartment	NN	O
,	,	O
leading	VBG	O
to	TO	O
changes	NNS	O
which	WDT	O
could	MD	O
result	VB	O
in	IN	O
increased	JJ	O
deposition	NN	O
.	.	O
Since	IN	O
the	DT	O
kinases	NNS	O
proposed	VBN	O
to	TO	O
phosphorylate	VB	O
alpha-synuclein	NN	O
at	IN	O
Ser129	NNP	O
are	VBP	O
soluble	JJ	O
,	,	O
it	PRP	O
seems	VBZ	O
likely	JJ	O
that	IN	O
the	DT	O
soluble	JJ	O
alpha-synuclein	NN	O
is	VBZ	O
more	RBR	O
accessible	JJ	O
to	TO	O
phosphorylation	NN	O
as	RB	O
well	RB	O
.	.	O
Additional	JJ	O
experiments	NNS	O
are	VBP	O
performed	VBN	O
to	TO	O
identify	VB	O
inhibitors	NNS	O
of	IN	O
the	DT	O
phosphorylation	NN	O
and/or	NN	O
aggregation	NN	O
in	IN	O
this	DT	O
cellular	JJ	O
model	NN	O
by	IN	O
expressing	VBG	O
the	DT	O
inhibitors	NNS	O
in	IN	O
the	DT	O
cells	NNS	O
and	CC	O
identifying	VBG	O
a	DT	O
reduction	NN	O
in	IN	O
the	DT	O
phosphorylation	NN	O
and/or	NN	O
aggregation	NN	O
.	.	O
EXAMPLE	RB	O
11	CD	O
Analysis	NN	O
of	IN	O
Endogenous	JJ	O
Kinase	NNP	O
Activity	NNP	O
in	IN	O
Alpha-Synuclein	NNP	O
Knock-Out	NNP	O
Mice	NNP	O
The	DT	O
utilization	NN	O
of	IN	O
an	DT	O
alpha-synuclein	JJ	O
knockout	NN	O
(	(	O
alpha-synuclein	JJ	O
KO	NNP	O
)	)	O
mouse	NN	O
brain	NN	O
for	IN	O
the	DT	O
identification	NN	O
of	IN	O
a	DT	O
putative	JJ	O
alpha-synuclein	JJ	O
kinase	NN	O
has	VBZ	O
the	DT	O
advantage	NN	O
over	IN	O
the	DT	O
siRNA	NN	O
screen	NN	O
in	IN	O
the	DT	O
following	JJ	O
ways	NNS	O
:	:	O
1	CD	O
)	)	O
the	DT	O
use	NN	O
of	IN	O
brain	NN	O
material	NN	O
provides	VBZ	O
relevant	JJ	O
and	CC	O
possibly	RB	O
higher	JJR	O
levels	NNS	O
of	IN	O
brain-specific	JJ	O
kinase	NN	O
activity	NN	O
which	WDT	O
the	DT	O
HEK	NNP	O
cell	NN	O
line	NN	O
may	MD	O
not	RB	O
provide	VB	O
;	:	O
2	CD	O
)	)	O
cofactors	NNS	O
may	MD	O
be	VB	O
present	JJ	O
in	IN	O
brain	NN	O
(	(	O
lipid	JJ	O
,	,	O
protein	NN	O
,	,	O
etc	FW	O
.	.	O
)	)	O
which	WDT	O
may	MD	O
not	RB	O
be	VB	O
present	JJ	O
in	IN	O
cells	NNS	O
and	CC	O
3	CD	O
)	)	O
absence	NN	O
of	IN	O
any	DT	O
endogenous	JJ	O
alpha-synuclein	NN	O
which	WDT	O
could	MD	O
be	VB	O
detected	VBN	O
as	IN	O
a	DT	O
phosphorylated	VBN	O
AS	IN	O
.	.	O
The	DT	O
inclusion	NN	O
of	IN	O
25-50	JJ	O
μg	NN	O
of	IN	O
extracts	NNS	O
(	(	O
soluble	JJ	O
and	CC	O
detergent	JJ	O
soluble	NN	O
)	)	O
with	IN	O
recombinant	JJ	O
alpha-synuclein	NN	O
(	(	O
rAS	NN	O
)	)	O
was	VBD	O
assessed	VBN	O
with	IN	O
250	CD	O
μM	NNS	O
ATP	NNP	O
to	TO	O
determine	VB	O
if	IN	O
appreciable	JJ	O
kinase	NN	O
activity	NN	O
was	VBD	O
present	JJ	O
in	IN	O
crude	JJ	O
material	NN	O
.	.	O
FIG	NNP	O
.	.	O
8A	CD	O
shows	NNS	O
total	JJ	O
alpha-synuclein	JJ	O
in	IN	O
each	DT	O
reaction	NN	O
indicating	VBG	O
equivalent	JJ	O
loadings	NNS	O
of	IN	O
rAS	NN	O
.	.	O
In	IN	O
FIG	NNP	O
.	.	O
8B	CD	O
,	,	O
the	DT	O
levels	NNS	O
of	IN	O
phospho-ser-129	JJ	O
alpha-synuclein	NNS	O
were	VBD	O
investigated	VBN	O
.	.	O
The	DT	O
rAS	NN	O
in	IN	O
both	DT	O
TBS	NNP	O
(	(	O
sucrose	JJ	O
soluble	NN	O
)	)	O
and	CC	O
TX	NNP	O
(	(	O
Triton-S	NNP	O
100	CD	O
soluble	NN	O
)	)	O
extracts	VBZ	O
was	VBD	O
phosphorylated	VBN	O
,	,	O
with	IN	O
roughly	RB	O
twice	RB	O
the	DT	O
level	NN	O
of	IN	O
signal	NN	O
from	IN	O
the	DT	O
TBS	NNP	O
material	NN	O
than	IN	O
the	DT	O
TX	NNP	O
(	(	O
although	IN	O
reactions	NNS	O
were	VBD	O
not	RB	O
normalized	VBN	O
for	IN	O
protein	NN	O
)	)	O
.	.	O
Phosphorylation	NN	O
levels	NNS	O
were	VBD	O
increased	VBN	O
by	IN	O
addition	NN	O
of	IN	O
CKI	NNP	O
but	CC	O
were	VBD	O
not	RB	O
significantly	RB	O
affected	VBN	O
by	IN	O
the	DT	O
addition	NN	O
of	IN	O
phospholipids	NNS	O
from	IN	O
soybean	NN	O
.	.	O
An	DT	O
identical	JJ	O
blot	NN	O
was	VBD	O
probed	VBN	O
for	IN	O
ser-87	JJ	O
phosphorylation	NN	O
in	IN	O
FIG	NNP	O
.	.	O
9B	CD	O
.	.	O
This	DT	O
pAb	JJ	O
presents	VBZ	O
cross-reactivity	NN	O
with	IN	O
rAS	NN	O
at	IN	O
100	CD	O
ng	NNS	O
,	,	O
thus	RB	O
levels	NNS	O
above	IN	O
background	NN	O
indicate	VBP	O
true	JJ	O
phosphorylation	NN	O
at	IN	O
the	DT	O
ser-87	JJ	O
site	NN	O
.	.	O
In	IN	O
both	DT	O
TBS	NNP	O
and	CC	O
TX	NNP	O
reactions	NNS	O
there	EX	O
is	VBZ	O
no	DT	O
significant	JJ	O
phosphorylation	NN	O
at	IN	O
this	DT	O
site	NN	O
whereas	VBZ	O
the	DT	O
CKI	NNP	O
spike	NN	O
achieved	VBD	O
phosphorylation	NN	O
at	IN	O
appreciable	JJ	O
levels	NNS	O
.	.	O
These	DT	O
experiments	NNS	O
suggest	VBP	O
that	IN	O
measurable	JJ	O
and	CC	O
real	JJ	O
kinase	NN	O
activit	NN	O
(	(	O
ies	NNS	O
)	)	O
are	VBP	O
present	JJ	O
in	IN	O
the	DT	O
soluble	JJ	O
and	CC	O
membrane	JJ	O
fractions	NNS	O
of	IN	O
KO	NNP	O
mouse	NN	O
brain	NN	O
and	CC	O
are	VBP	O
specific	JJ	O
to	TO	O
the	DT	O
ser-129	JJ	O
site	NN	O
compared	VBN	O
to	TO	O
ser-87	NN	O
.	.	O
The	DT	O
potential	JJ	O
exists	NNS	O
for	IN	O
phosphorylation	NN	O
at	IN	O
other	JJ	O
serine	NN	O
or	CC	O
threonine	VB	O
sites	NNS	O
in	IN	O
alpha-synuclein	JJ	O
but	CC	O
antibodies	NNS	O
are	VBP	O
not	RB	O
yet	RB	O
available	JJ	O
to	TO	O
detect	VB	O
such	JJ	O
modifications	NNS	O
.	.	O
Thus	RB	O
,	,	O
measurable	JJ	O
levels	NNS	O
of	IN	O
ser-129	JJ	O
specific	JJ	O
kinase	NN	O
activity/activities	NNS	O
are	VBP	O
present	JJ	O
in	IN	O
alpha-synuclein	JJ	O
KO	NNP	O
mouse	NN	O
brain	NN	O
extracts	NNS	O
and	CC	O
could	MD	O
serve	VB	O
as	IN	O
starting	VBG	O
material	NN	O
for	IN	O
purification	NN	O
of	IN	O
a	DT	O
kinase	NN	O
from	IN	O
the	DT	O
brain	NN	O
.	.	O
In	IN	O
FIGS	NNP	O
.	.	O
8A	CD	O
,	,	O
8B	CD	O
,	,	O
9A	CD	O
and	CC	O
9B	CD	O
,	,	O
cortices	NNS	O
of	IN	O
alpha-synuclein	JJ	O
KO	NNP	O
mouse	NN	O
brain	NN	O
were	VBD	O
Dounce	NNP	O
homogenized	VBN	O
to	TO	O
obtain	VB	O
200	CD	O
mM	NNS	O
sucrose	JJ	O
soluble	JJ	O
and	CC	O
0.1	CD	O
%	NN	O
Triton	NNP	O
X-100	NNP	O
soluble	JJ	O
extracts	NNS	O
with	IN	O
protease	NN	O
and	CC	O
phosphatase	NN	O
inhibitors	NNS	O
present	VBP	O
.	.	O
20	CD	O
μl	NN	O
of	IN	O
sample	NN	O
(	(	O
100	CD	O
μl	NNP	O
total	JJ	O
volume	NN	O
of	IN	O
reaction	NN	O
)	)	O
was	VBD	O
incubated	VBN	O
with	IN	O
2.4	CD	O
μg	NNS	O
of	IN	O
wt-rAS	NN	O
in	IN	O
the	DT	O
presence	NN	O
or	CC	O
absence	NN	O
of	IN	O
1000	CD	O
units	NNS	O
of	IN	O
casein	JJ	O
kinase	NN	O
I	PRP	O
(	(	O
CKI	NNP	O
)	)	O
as	IN	O
a	DT	O
positive	JJ	O
control	NN	O
,	,	O
and/or	RB	O
200	CD	O
μg	NN	O
of	IN	O
phosphatidycholine	NN	O
(	(	O
PC	NN	O
;	:	O
soybean	CC	O
lecithin	NN	O
)	)	O
to	TO	O
increase	VB	O
kinase	NN	O
activiti	NN	O
(	(	O
es	NN	O
)	)	O
.	.	O
Reactions	NNS	O
were	VBD	O
loaded	VBN	O
on	IN	O
SDS-PAGE	NNP	O
(	(	O
130	CD	O
ng	RB	O
total	JJ	O
AS	NNP	O
)	)	O
and	CC	O
immunoblotted	VBN	O
with	IN	O
Syn-1	NNP	O
(	(	O
total	JJ	O
Syn	NNP	O
;	:	O
0.1	CD	O
ug/ml	NN	O
)	)	O
,	,	O
11A5	CD	O
(	(	O
phospho	JJ	O
ser-129	NN	O
;	:	O
1	CD	O
μg/ml	NN	O
)	)	O
or	CC	O
ELADW110	NNP	O
(	(	O
phospho	JJ	O
ser-87	NN	O
;	:	O
2	CD	O
μg/mL	NN	O
)	)	O
.	.	O
The	DT	O
above	NN	O
data	NN	O
shows	NNS	O
that	IN	O
PLK2	NNP	O
other	JJ	O
direct	JJ	O
and/or	NN	O
indirect	NN	O
kinases	NNS	O
(	(	O
such	JJ	O
as	IN	O
GRK6	NNP	O
)	)	O
,	,	O
and	CC	O
modulators	NNS	O
such	JJ	O
as	IN	O
synphilin	NN	O
are	VBP	O
novel	JJ	O
targets	NNS	O
for	IN	O
therapeutic	JJ	O
intervention	NN	O
in	IN	O
DLB	NNP	O
and	CC	O
PD	NNP	O
.	.	O
PLK2	NNP	O
is	VBZ	O
a	DT	O
preferred	JJ	O
target	NN	O
because	IN	O
it	PRP	O
can	MD	O
directly	RB	O
phosphorylate	VB	O
alpha-synuclein	JJ	O
specifically	RB	O
at	IN	O
ser-129	NN	O
.	.	O
EXAMPLE	RB	O
12	CD	O
Effect	NNP	O
of	IN	O
Overexpression	NNP	O
of	IN	O
PLK	NNP	O
Family	NNP	O
Members	NNP	O
on	IN	O
Synuclein	NNP	O
Phosphorylation	NNP	O
Overexpression	NNP	O
of	IN	O
PLK	NNP	O
family	NN	O
members	NNS	O
PLK1	NNP	O
,	,	O
2	CD	O
and	CC	O
3	CD	O
,	,	O
but	CC	O
not	RB	O
PLK4	NNP	O
,	,	O
increased	VBD	O
synuclein	JJ	O
phosphorylation	NN	O
above	IN	O
the	DT	O
level	NN	O
of	IN	O
the	DT	O
endogenous	JJ	O
kinase	NN	O
in	IN	O
HEK-293	NNP	O
cells	NNS	O
.	.	O
Methods	NNS	O
HEK-293	NNP	O
naïve	NN	O
cells	NNS	O
were	VBD	O
transfected	VBN	O
with	IN	O
an	DT	O
expression	NN	O
vector	NN	O
encoding	VBG	O
PLK1	NNP	O
,	,	O
PLK2	NNP	O
,	,	O
PLK3	NNP	O
,	,	O
or	CC	O
PLK4	NNP	O
under	IN	O
the	DT	O
control	NN	O
of	IN	O
a	DT	O
CMV	NNP	O
promoter	NN	O
,	,	O
or	CC	O
empty	JJ	O
vector	NN	O
,	,	O
together	RB	O
with	IN	O
an	DT	O
expression	NN	O
vector	NN	O
encoding	VBG	O
WT-synuclein	NNP	O
.	.	O
All	DT	O
vectors	NNS	O
had	VBD	O
the	DT	O
sequence	NN	O
coding	NN	O
for	IN	O
the	DT	O
protein	NN	O
of	IN	O
interest	NN	O
.	.	O
Transfection	NN	O
was	VBD	O
accomplished	VBN	O
using	VBG	O
Lipofectamine	JJ	O
2000	CD	O
(	(	O
Invitrogen	NNP	O
,	,	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
with	IN	O
0.08	CD	O
μg	NNS	O
vector	NN	O
.	.	O
Cells	NNS	O
were	VBD	O
washed	VBN	O
and	CC	O
harvested	VBN	O
48	CD	O
hours	NNS	O
post-transfection	NN	O
.	.	O
A	DT	O
Micro	NNP	O
BCA	NNP	O
(	(	O
Pierce	NNP	O
)	)	O
total	VBP	O
protein	JJ	O
assay	NN	O
and	CC	O
total	JJ	O
synuclein	NN	O
and	CC	O
phospho-synuclein	JJ	O
ELISAs	NNP	O
were	VBD	O
performed	VBN	O
on	IN	O
each	DT	O
plate	NN	O
of	IN	O
treated	JJ	O
cells	NNS	O
.	.	O
Results	NNS	O
Results	NNS	O
are	VBP	O
summarized	VBN	O
in	IN	O
Table	JJ	O
16	CD	O
.	.	O
PLK2	NNP	O
Over-expression	NNP	O
of	IN	O
PLK2	NNP	O
in	IN	O
the	DT	O
293	CD	O
cells	NNS	O
yielded	VBD	O
similar	JJ	O
results	NNS	O
to	TO	O
those	DT	O
observed	VBN	O
in	IN	O
previous	JJ	O
experiments	NNS	O
,	,	O
resulting	VBG	O
in	IN	O
a	DT	O
21-fold	JJ	O
increase	NN	O
in	IN	O
synuclein	JJ	O
phosphorylation	NN	O
,	,	O
from	IN	O
2	CD	O
%	NN	O
to	TO	O
42.3	CD	O
%	NN	O
.	.	O
PLK3	VB	O
The	DT	O
over-expression	NN	O
of	IN	O
PLK3	NNP	O
generated	VBD	O
an	DT	O
even	RB	O
more	RBR	O
striking	JJ	O
39-fold	JJ	O
increase	NN	O
in	IN	O
synuclein	JJ	O
phosphorylation	NN	O
,	,	O
from	IN	O
2	CD	O
%	NN	O
to	TO	O
79.2	CD	O
%	NN	O
phospho-synuclein	NN	O
.	.	O
However	RB	O
,	,	O
knockdown	NN	O
of	IN	O
PLK3	NNP	O
does	VBZ	O
not	RB	O
decrease	VB	O
the	DT	O
percentage	NN	O
of	IN	O
phosphorylated	JJ	O
synuclein	NN	O
in	IN	O
the	DT	O
293	CD	O
cells	NNS	O
(	(	O
see	VB	O
Example	NNP	O
13	CD	O
,	,	O
infra	NN	O
)	)	O
.	.	O
PLK3	NNP	O
is	VBZ	O
structurally	RB	O
most	RBS	O
similar	JJ	O
to	TO	O
PLK2	NNP	O
of	IN	O
all	PDT	O
the	DT	O
PLK	NNP	O
family	NN	O
members	NNS	O
,	,	O
so	RB	O
even	RB	O
if	IN	O
PLK3	NNP	O
is	VBZ	O
not	RB	O
the	DT	O
synuclein	NN	O
kinase	NN	O
,	,	O
it	PRP	O
may	MD	O
be	VB	O
able	JJ	O
to	TO	O
perform	VB	O
the	DT	O
same	JJ	O
physiological	JJ	O
tasks	NNS	O
as	IN	O
PLK2	NNP	O
.	.	O
It	PRP	O
has	VBZ	O
been	VBN	O
proposed	VBN	O
that	IN	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
PLK2	NNP	O
expression	NN	O
,	,	O
PLK3	NNP	O
can	MD	O
functionally	RB	O
compensate	VB	O
for	IN	O
the	DT	O
absent	NN	O
PLK2	NNP	O
(	(	O
Smith	NNP	B
et	FW	I
al.	NN	I
,	,	I
2006	CD	I
,	,	I
“	NNP	I
Epigenetic	NNP	I
inactivation	NN	I
implies	VBZ	I
a	DT	I
tumor	NN	I
suppressor	NN	I
function	NN	I
in	IN	I
hematologic	JJ	I
malignancies	NNS	I
for	IN	I
Polo-like	NNP	I
kinase	NN	I
2	CD	I
but	CC	I
not	RB	I
Polo-like	NNP	I
kinase	NN	I
3.Cell	CD	I
Cycle.	NNP	I
”	NNP	I
Cell	NNP	I
Cycle	NNP	I
5:1262-4	JJ	I
)	)	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
over-expression	JJ	O
experiments	NNS	O
can	MD	O
yield	VB	O
off-target	JJ	O
and	CC	O
non-physiological	JJ	O
effects	NNS	O
and	CC	O
results	NNS	O
should	MD	O
be	VB	O
substantiated	VBN	O
through	IN	O
additional	JJ	O
experimentation	NN	O
such	JJ	O
as	IN	O
siRNA	JJ	O
knockdown	NN	O
or	CC	O
in	IN	O
vitro	JJ	O
transcription/translation	NN	O
experiments	NNS	O
.	.	O
PLK1	NNP	O
Over-expression	NNP	O
of	IN	O
PLK1	NNP	O
resulted	VBD	O
in	IN	O
a	DT	O
two-fold	JJ	O
increase	NN	O
in	IN	O
the	DT	O
percent	NN	O
of	IN	O
synuclein	JJ	O
phosphorylation	NN	O
(	(	O
from	IN	O
2	CD	O
%	NN	O
to	TO	O
4.1	CD	O
%	NN	O
)	)	O
.	.	O
While	IN	O
not	RB	O
as	IN	O
robust	NN	O
an	DT	O
increase	NN	O
in	IN	O
synuclein	JJ	O
phosphorylation	NN	O
as	IN	O
the	DT	O
21-fold	JJ	O
increase	NN	O
with	IN	O
PLK2	NNP	O
or	CC	O
39-fold	JJ	O
increase	NN	O
with	IN	O
PLK3	NNP	O
over-expression	NN	O
,	,	O
it	PRP	O
is	VBZ	O
still	RB	O
significant	JJ	O
.	.	O
However	RB	O
,	,	O
as	IN	O
noted	VBN	O
above	IN	O
,	,	O
overexpression	NN	O
of	IN	O
proteins	NNS	O
can	MD	O
yield	VB	O
results	NNS	O
that	WDT	O
do	VBP	O
not	RB	O
accurately	RB	O
represent	VBP	O
the	DT	O
physiological	JJ	O
state	NN	O
within	IN	O
cells	NNS	O
and	CC	O
tissues	NNS	O
.	.	O
Over-expression	NN	O
of	IN	O
genes	NNS	O
can	MD	O
produce	VB	O
off-target	JJ	O
effects	NNS	O
and	CC	O
can	MD	O
result	VB	O
in	IN	O
erroneous	JJ	O
localizations	NNS	O
within	IN	O
cells	NNS	O
that	WDT	O
do	VBP	O
not	RB	O
characterize	VB	O
the	DT	O
true	JJ	O
physiological	JJ	O
state	NN	O
,	,	O
and	CC	O
results	NNS	O
of	IN	O
over-expression	JJ	O
experiments	NNS	O
should	MD	O
be	VB	O
substantiated	VBN	O
with	IN	O
additional	JJ	O
experimentation	NN	O
such	JJ	O
as	IN	O
siRNA	JJ	O
knockdown	NN	O
or	CC	O
in	IN	O
vitro	JJ	O
transcription/translation	NN	O
experiments	NNS	O
.	.	O
PLK4	NNP	O
Over-expression	NNP	O
of	IN	O
PLK4	NNP	O
did	VBD	O
not	RB	O
change	VB	O
the	DT	O
percentage	NN	O
of	IN	O
synuclein	JJ	O
phosphorylation	NN	O
in	IN	O
293	CD	O
cells	NNS	O
.	.	O
The	DT	O
structure	NN	O
of	IN	O
PLK4	NNP	O
is	VBZ	O
much	JJ	O
different	JJ	O
from	IN	O
those	DT	O
of	IN	O
the	DT	O
other	JJ	O
PLKs	NNP	O
,	,	O
and	CC	O
has	VBZ	O
only	RB	O
a	DT	O
single	JJ	O
polo	NN	O
box	NN	O
domain	NN	O
rather	RB	O
than	IN	O
the	DT	O
two	CD	O
that	IN	O
the	DT	O
other	JJ	O
three	CD	O
family	NN	O
members	NNS	O
have	VBP	O
.	.	O
The	DT	O
results	NNS	O
do	VBP	O
not	RB	O
exclude	VB	O
the	DT	O
possibility	NN	O
that	IN	O
in	IN	O
other	JJ	O
tissue	NN	O
types	NNS	O
,	,	O
PLK4	NNP	O
may	MD	O
be	VB	O
able	JJ	O
to	TO	O
phosphorylate	VB	O
synuclein	NN	O
.	.	O
In	IN	O
Vitro	NNP	O
Biochemical	NNP	O
Assays	NNP	O
In	IN	O
vitro	NNP	O
biochemical	JJ	O
assays	NNS	O
using	VBG	O
each	DT	O
of	IN	O
the	DT	O
four	CD	O
PLK	NNP	O
family	NN	O
members	NNS	O
as	IN	O
the	DT	O
kinase	NN	O
to	TO	O
phosphorylate	VB	O
synuclein	NNS	O
were	VBD	O
conducted	VBN	O
.	.	O
The	DT	O
results	NNS	O
(	(	O
not	RB	O
shown	VBN	O
)	)	O
mirror	VBP	O
the	DT	O
cell-based	JJ	O
ovewrexpression	NN	O
assays	NNS	O
described	VBN	O
above	IN	O
,	,	O
with	IN	O
PLK1	NNP	O
being	VBG	O
able	JJ	O
to	TO	O
phosphorylate	VB	O
synuclein	NN	O
moderately	RB	O
,	,	O
PLK2	NNP	O
and	CC	O
PLK3	NNP	O
having	VBG	O
extremely	RB	O
robust	JJ	O
phosphorylation	NN	O
of	IN	O
synuclein	NN	O
,	,	O
and	CC	O
PLK4	NNP	O
exhibiting	VBG	O
no	DT	O
ability	NN	O
to	TO	O
phosphorylate	VB	O
synuclein	NN	O
.	.	O
EXAMPLE	RB	O
13	CD	O
siRNA	JJ	O
Knockdown	NNP	O
of	IN	O
PLK	NNP	O
Family	NNP	O
Members	NNP	O
HEK-293	NNP	O
naïve	JJ	O
cells	NNS	O
were	VBD	O
transfected	VBN	O
with	IN	O
40	CD	O
nM	NNS	O
,	,	O
100	CD	O
nM	NN	O
and	CC	O
200	CD	O
nM	NN	O
of	IN	O
Dharmacon	NNP	O
On	IN	O
Target	NNP	O
Plus	NNP	O
Smart	NNP	O
Pool	NNP	O
siRNAs	NN	O
(	(	O
Darmacon	NNP	O
,	,	O
Lafayette	NNP	O
,	,	O
Colo.	NNP	O
)	)	O
designed	VBN	O
to	TO	O
knock	VB	O
down	RP	O
the	DT	O
expression	NN	O
of	IN	O
each	DT	O
of	IN	O
the	DT	O
four	CD	O
PLK	NNP	O
family	NN	O
members	NNS	O
.	.	O
The	DT	O
transfection	NN	O
was	VBD	O
performed	VBN	O
using	VBG	O
Lipofectamine	JJ	O
2000	CD	O
(	(	O
Invitrogen	NNP	O
Carlsbad	NNP	O
,	,	O
Calif.	NNP	O
)	)	O
.	.	O
Cells	NNS	O
were	VBD	O
washed	VBN	O
and	CC	O
harvested	VBN	O
48	CD	O
hours	NNS	O
post-transfection	NN	O
.	.	O
A	DT	O
Micro	NNP	O
BCA	NNP	O
(	(	O
Pierce	NNP	O
)	)	O
total	VBP	O
protein	JJ	O
assay	NN	O
and	CC	O
total	JJ	O
synuclein	NN	O
and	CC	O
phospho-synuclein	JJ	O
ELISAs	NNP	O
were	VBD	O
performed	VBN	O
on	IN	O
each	DT	O
plate	NN	O
of	IN	O
treated	JJ	O
cells	NNS	O
.	.	O
PLK2	VB	O
The	DT	O
results	NNS	O
of	IN	O
the	DT	O
siRNA	NN	O
knockdown	JJ	O
experiment	NN	O
are	VBP	O
summarized	VBN	O
in	IN	O
FIG	NNP	O
.	.	O
10	CD	O
.	.	O
In	IN	O
agreement	NN	O
with	IN	O
what	WP	O
we	PRP	O
have	VBP	O
observed	VBN	O
previously	RB	O
for	IN	O
PLK2	NNP	O
siRNA	NN	O
inhibition	NN	O
(	(	O
see	VB	O
Example	NNP	O
5	CD	O
)	)	O
knockdown	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
25	CD	O
%	NN	O
decrease	NN	O
in	IN	O
the	DT	O
percentage	NN	O
of	IN	O
phosphorylated	JJ	O
synuclein	NN	O
in	IN	O
the	DT	O
293	CD	O
cells	NNS	O
.	.	O
PLK3	VB	O
The	DT	O
knockdown	NN	O
of	IN	O
PLK3	NNP	O
also	RB	O
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
synuclein	NN	O
phosphorylation	NN	O
,	,	O
which	WDT	O
is	VBZ	O
not	RB	O
in	IN	O
agreement	NN	O
with	IN	O
the	DT	O
PLK3	NNP	O
overexpression	NN	O
data	NNS	O
.	.	O
This	DT	O
may	MD	O
be	VB	O
due	JJ	O
to	TO	O
the	DT	O
fact	NN	O
that	IN	O
overexpression	NN	O
can	MD	O
be	VB	O
somewhat	RB	O
promiscuous	JJ	O
,	,	O
and	CC	O
not	RB	O
indicative	JJ	O
of	IN	O
the	DT	O
true	JJ	O
physiological	JJ	O
state	NN	O
within	IN	O
cells	NNS	O
.	.	O
It	PRP	O
may	MD	O
also	RB	O
be	VB	O
that	IN	O
PLK3	NNP	O
is	VBZ	O
not	RB	O
the	DT	O
synuclein	NN	O
kinase	NN	O
in	IN	O
293	CD	O
cells	NNS	O
,	,	O
but	CC	O
it	PRP	O
could	MD	O
still	RB	O
be	VB	O
the	DT	O
synuclein	JJ	O
kinase	NN	O
in	IN	O
neurons	NNS	O
or	CC	O
other	JJ	O
cells	NNS	O
due	JJ	O
to	TO	O
the	DT	O
potential	NN	O
for	IN	O
isoform	NN	O
switching	NN	O
between	IN	O
cell	NN	O
types	NNS	O
.	.	O
Thus	RB	O
,	,	O
although	IN	O
PLK3	NNP	O
knockdown	NN	O
does	VBZ	O
not	RB	O
reduce	VB	O
synuclein	JJR	O
phosphorylation	NN	O
as	IN	O
we	PRP	O
would	MD	O
expect	VB	O
from	IN	O
inhibition	NN	O
of	IN	O
the	DT	O
synuclein	NN	O
kinase	NN	O
,	,	O
it	PRP	O
does	VBZ	O
not	RB	O
completely	RB	O
eliminate	VB	O
PLK3	NNP	O
as	IN	O
being	VBG	O
the	DT	O
correct	NN	O
PLK	NNP	O
family	NN	O
member	NN	O
as	IN	O
the	DT	O
synuclein	NN	O
kinase	NN	O
in	IN	O
neurons	NNS	O
.	.	O
PLK1	NNP	O
Cells	NNP	O
treated	VBD	O
with	IN	O
PLK1	NNP	O
siRNA	NN	O
showed	VBD	O
a	DT	O
40	CD	O
%	NN	O
decrease	NN	O
in	IN	O
the	DT	O
total	JJ	O
protein	NN	O
levels	NNS	O
compared	VBN	O
to	TO	O
the	DT	O
negative	JJ	O
siRNA	NN	O
control	NN	O
,	,	O
indicating	VBG	O
that	IN	O
treatment	NN	O
of	IN	O
cells	NNS	O
with	IN	O
PLK1	NNP	O
siRNA	VBP	O
inhibits	NNS	O
proliferation	NN	O
of	IN	O
cells	NNS	O
.	.	O
This	DT	O
has	VBZ	O
been	VBN	O
noted	VBN	O
in	IN	O
the	DT	O
literature	NN	O
,	,	O
and	CC	O
confirms	VBZ	O
the	DT	O
role	NN	O
of	IN	O
PLK1	NNP	O
in	IN	O
mitosis	NN	O
.	.	O
Taking	VBG	O
into	IN	O
account	NN	O
this	DT	O
change	NN	O
in	IN	O
total	JJ	O
protein	NN	O
levels	NNS	O
,	,	O
knockdown	NN	O
of	IN	O
PLK1	NNP	O
transcript	NN	O
results	NNS	O
in	IN	O
a	DT	O
60-90	JJ	O
%	NN	O
increase	NN	O
in	IN	O
the	DT	O
percentage	NN	O
of	IN	O
phospho-synuclein	NN	O
.	.	O
This	DT	O
indicates	VBZ	O
that	IN	O
PLK1	NNP	O
is	VBZ	O
negative	JJ	O
regulator	NN	O
of	IN	O
synuclein	JJ	O
phosphorylation	NN	O
.	.	O
It	PRP	O
appears	VBZ	O
that	IN	O
when	WRB	O
PLK1	NNP	O
is	VBZ	O
present	JJ	O
in	IN	O
cell	NN	O
,	,	O
it	PRP	O
regulates	VBZ	O
PLK2	NNP	O
or	CC	O
it	PRP	O
's	VBZ	O
upstream	JJ	O
pathway	NN	O
and	CC	O
accordingly	RB	O
the	DT	O
level	NN	O
of	IN	O
PLK2-mediated	JJ	O
phosphorylation	NN	O
of	IN	O
synuclein	NN	O
.	.	O
This	DT	O
increase	NN	O
in	IN	O
phospho-synuclein	JJ	O
with	IN	O
PLK1	NNP	O
knockdown	NN	O
has	VBZ	O
been	VBN	O
observed	VBN	O
in	IN	O
two	CD	O
independent	JJ	O
experiments	NNS	O
,	,	O
and	CC	O
is	VBZ	O
intriguing	VBG	O
as	IN	O
a	DT	O
potential	JJ	O
regulator	NN	O
of	IN	O
PLK2-driven	NNP	O
synuclein	NN	O
phosphorylation	NN	O
.	.	O
PLK4	NNP	O
Knockdown	NNP	O
of	IN	O
PLK4	NNP	O
with	IN	O
siRNA	NN	O
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
synuclein	NN	O
phosphorylation	NN	O
,	,	O
in	IN	O
accord	NN	O
with	IN	O
the	DT	O
PLK4	NNP	O
overexpression	NN	O
data	NNS	O
above	IN	O
(	(	O
Example	NNP	O
11	CD	O
)	)	O
.	.	O
EXAMPLE	NNP	O
14	CD	O
Treatment	NNP	O
of	IN	O
Primary	NNP	O
Neuronal	NNP	O
Cultures	NNP	O
with	IN	O
Kinase	NNP	O
Inhibitors	NNPS	O
The	DT	O
effect	NN	O
on	IN	O
levels	NNS	O
of	IN	O
serine-129	JJ	O
synuclein	NN	O
was	VBD	O
tested	VBN	O
for	IN	O
kinase	NN	O
inhibitors	NNS	O
with	IN	O
various	JJ	O
specificities	NNS	O
in	IN	O
rat	NN	O
and	CC	O
mouse	NN	O
primary	JJ	O
cortical	JJ	O
cell	NN	O
culture	NN	O
was	VBD	O
tested	VBN	O
.	.	O
Table	JJ	O
17	CD	O
shows	VBZ	O
the	DT	O
inhibitors	NNS	O
used	VBN	O
in	IN	O
the	DT	O
experiment	NN	O
:	:	O
Preparation	NN	O
of	IN	O
Mouse	NNP	O
Neuronal	NNP	O
Cell	NNP	O
Cultures	NNP	O
Mouse	NNP	O
cortical	JJ	O
cultures	NNS	O
from	IN	O
fetal	JJ	O
(	(	O
i	JJ	O
)	)	O
Swiss-Webster	NN	O
,	,	O
(	(	O
ii	NN	O
)	)	O
C56BL/6	NNP	O
WT	NNP	O
and	CC	O
(	(	O
iii	NN	O
)	)	O
C56BL/6	NNP	O
E46K-Synuclein	NNP	O
Trangenic	NNP	O
mice	NN	O
were	VBD	O
prepared	JJ	O
and	CC	O
maintained	VBN	O
in	IN	O
B27/DMEM/1	NNP	O
%	NN	O
Penicillin-Streptomycin	NNP	O
at	IN	O
37°	CD	O
C./10	NNP	O
%	NN	O
CO2	NNP	O
for	IN	O
three	CD	O
to	TO	O
fourteen	VB	O
days	NNS	O
and	CC	O
then	RB	O
treated	VBD	O
with	IN	O
kinase	NN	O
inhibitors	NNS	O
.	.	O
Cultures	NNS	O
were	VBD	O
exposed	VBN	O
to	TO	O
inhibitors	NNS	O
for	IN	O
two	CD	O
hours	NNS	O
in	IN	O
B27/DMEM/1	NNP	O
%	NN	O
Penicillin-Streptomycin	NNP	O
.	.	O
Cells	NNS	O
were	VBD	O
immediately	RB	O
washed	VBN	O
in	IN	O
100	CD	O
μL	NN	O
of	IN	O
PBS	NNP	O
plus	CC	O
Mg2+	NNP	O
and	CC	O
Ca2+	NNP	O
,	,	O
and	CC	O
harvested	VBD	O
in	IN	O
ice-cold	JJ	O
CEB	NNP	O
minus	NN	O
EGTA	NNP	O
plus	CC	O
protease	JJ	O
inhibitors	NNS	O
,	,	O
frozen	VBP	O
on	IN	O
dry	JJ	O
ice	NN	O
and	CC	O
stored	VBN	O
at	IN	O
−80°	NNP	O
C.	NNP	O
until	IN	O
processed	VBN	O
.	.	O
A	DT	O
Micro	NNP	O
BCA	NNP	O
(	(	O
Pierce	NNP	O
)	)	O
total	VBP	O
protein	JJ	O
assay	NN	O
,	,	O
and	CC	O
total	JJ	O
synuclein	NN	O
and	CC	O
phospho-synuclein	JJ	O
ELISAs	NNP	O
were	VBD	O
performed	VBN	O
on	IN	O
each	DT	O
plate	NN	O
of	IN	O
treated	JJ	O
cells	NNS	O
using	VBG	O
standard	JJ	O
methods	NNS	O
.	.	O
Preparation	NN	O
of	IN	O
Rat	NNP	O
Neuronal	NNP	O
Cell	NNP	O
Cultures	NNP	O
Rat	NNP	O
Ventral	NNP	O
Mesencephalon	NNP	O
(	(	O
RVM	NNP	O
)	)	O
cultures	NNS	O
were	VBD	O
prepared	VBN	O
from	IN	O
E15	NNP	O
Wistar	NNP	O
rats	NNS	O
.	.	O
The	DT	O
RVM	NNP	O
cultures	NNS	O
were	VBD	O
cultured	VBN	O
for	IN	O
2	CD	O
days	NNS	O
and	CC	O
transduced	VBD	O
with	IN	O
0.75	CD	O
MOI	NNP	O
E46K-Synuclein	NNP	O
lentivirus	NN	O
alone	RB	O
,	,	O
or	CC	O
0.75	CD	O
MOI	NNP	O
E46K-Synuclein	NNP	O
lentivirus	NN	O
plus	CC	O
0.75	CD	O
MOI	NNP	O
ca-PLK2	JJ	O
lentivirus	NN	O
.	.	O
The	DT	O
mid-brain	JJ	O
region	NN	O
,	,	O
ventral	JJ	O
mesencephalon	NN	O
,	,	O
from	IN	O
embryonic	JJ	O
day	NN	O
15	CD	O
Wistar	NNP	O
rats	NNS	O
were	VBD	O
dissected	VBN	O
and	CC	O
pooled	VBN	O
for	IN	O
processing	VBG	O
for	IN	O
culture	NN	O
as	IN	O
described	NN	O
previously	RB	O
in	IN	O
Steven	NNP	B
et	CC	I
al.	NN	I
,	,	I
2001	CD	I
,	,	I
Genetics	NNP	I
10:1317-24	JJ	I
with	IN	O
the	DT	O
medium	NN	O
supplement	NN	O
replaced	VBD	O
with	IN	O
B27	NNP	O
(	(	O
Invitrogen	NNP	O
)	)	O
and	CC	O
1	CD	O
%	NN	O
FBS	NNP	O
(	(	O
HyClone	NNP	O
)	)	O
.	.	O
Transduced	VBN	O
cultures	NNS	O
were	VBD	O
maintained	VBN	O
in	IN	O
neuronal	JJ	O
media	NNS	O
with	IN	O
B27/1	NNP	O
%	NN	O
FBS	NNP	O
and	CC	O
37°	CD	O
C./5	NNP	O
%	NN	O
CO2	NNP	O
until	IN	O
treated	VBN	O
with	IN	O
inhibitors	NNS	O
.	.	O
On	IN	O
DIV	NNP	O
17	CD	O
(	(	O
which	WDT	O
corresponds	VBZ	O
to	TO	O
15	CD	O
days	NNS	O
after	IN	O
viral	JJ	O
transduction	NN	O
of	IN	O
the	DT	O
cultures	NNS	O
)	)	O
cells	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
inhibitors	NNS	O
for	IN	O
two	CD	O
hours	NNS	O
.	.	O
Cells	NNS	O
were	VBD	O
then	RB	O
harvested	VBN	O
as	IN	O
detailed	VBN	O
above	IN	O
in	IN	O
neuronal	JJ	O
media	NNS	O
with	IN	O
B27/1	NNP	O
%	NN	O
FBS	NNP	O
.	.	O
A	DT	O
Micro	NNP	O
BCA	NNP	O
(	(	O
Pierce	NNP	O
)	)	O
total	VBP	O
protein	JJ	O
assay	NN	O
,	,	O
and	CC	O
total	JJ	O
synuclein	NN	O
and	CC	O
phospho-synuclein	JJ	O
ELISAs	NNP	O
were	VBD	O
performed	VBN	O
on	IN	O
each	DT	O
plate	NN	O
of	IN	O
treated	JJ	O
cells	NNS	O
using	VBG	O
standard	JJ	O
methods	NNS	O
.	.	O
Results	NNS	O
The	DT	O
effects	NNS	O
of	IN	O
inhibitors	NNS	O
on	IN	O
phosphorylation	NN	O
of	IN	O
alpha-synuclein	NN	O
are	VBP	O
summarized	VBN	O
in	IN	O
Tables	NNP	O
18	CD	O
and	CC	O
19	CD	O
.	.	O
Table	JJ	O
18	CD	O
shows	NNS	O
that	IN	O
the	DT	O
extent	NN	O
of	IN	O
inhibition	NN	O
of	IN	O
synuclein	JJ	O
phosphorylation	NN	O
by	IN	O
selected	VBN	O
inhibitors	NNS	O
is	VBZ	O
similar	JJ	O
for	IN	O
the	DT	O
endogenous	JJ	O
kinase	NN	O
in	IN	O
mouse	NN	O
and	CC	O
rat	NN	O
primary	JJ	O
cultures	NNS	O
,	,	O
as	RB	O
well	RB	O
as	IN	O
a	DT	O
constitutively	RB	O
active	JJ	O
PLK2	NNP	O
variant	NN	O
(	(	O
caPLK2	NN	O
)	)	O
.	.	O
In	IN	O
caPLK2	PDT	O
the	DT	O
polo-box	NN	O
has	VBZ	O
been	VBN	O
deleted	VBN	O
,	,	O
activating	VBG	O
the	DT	O
Thr	NNP	O
to	TO	O
Asp	NNP	O
mutation	NN	O
in	IN	O
the	DT	O
kinase	NN	O
activation	NN	O
loop	NN	O
.	.	O
Table	JJ	O
19	CD	O
shows	VBZ	O
the	DT	O
rank	NN	O
order	NN	O
of	IN	O
potency	NN	O
for	IN	O
selected	VBN	O
inhibitors	NNS	O
is	VBZ	O
similar	JJ	O
between	IN	O
cell	NN	O
types	NNS	O
and	CC	O
across	IN	O
species	NNS	O
(	(	O
mouse	NN	O
,	,	O
rat	NN	O
and	CC	O
human	NN	O
)	)	O
The	DT	O
results	NNS	O
of	IN	O
treatment	NN	O
of	IN	O
several	JJ	O
primary	JJ	O
neuronal	JJ	O
cultures	NNS	O
with	IN	O
PLK	NNP	O
and	CC	O
other	JJ	O
inhibitors	NNS	O
were	VBD	O
very	RB	O
similar	JJ	O
to	TO	O
those	DT	O
observed	VBN	O
in	IN	O
293	CD	O
cells	NNS	O
in	IN	O
both	DT	O
the	DT	O
EC50	NNP	O
values	NNS	O
(	(	O
Table	JJ	O
18	CD	O
)	)	O
and	CC	O
the	DT	O
rank	NN	O
order	NN	O
of	IN	O
potency	NN	O
(	(	O
Table	JJ	O
19	CD	O
)	)	O
.	.	O
The	DT	O
EC50	NNP	O
values	NNS	O
for	IN	O
the	DT	O
potent	NN	O
PLK	NNP	O
inhibitor	NN	O
BI	NNP	O
2536	CD	O
(	(	O
ELN-481574-2	NNP	O
)	)	O
in	IN	O
all	DT	O
cellular	JJ	O
paradigms	NNS	O
were	VBD	O
in	IN	O
the	DT	O
nanomolar	JJ	O
range	NN	O
,	,	O
with	IN	O
most	JJS	O
EC50	NNP	O
values	NNS	O
being	VBG	O
100	CD	O
nM	NN	O
or	CC	O
less	JJR	O
,	,	O
and	CC	O
has	VBZ	O
an	DT	O
IC50	NNP	O
of	IN	O
27	CD	O
nM	NNS	O
in	IN	O
the	DT	O
in	IN	O
vitro	JJ	O
biochemical	JJ	O
assay	NN	O
.	.	O
This	DT	O
PLK	NNP	O
inhibitor	NN	O
is	VBZ	O
a	DT	O
very	RB	O
potent	JJ	O
inhibitor	NN	O
of	IN	O
synuclein	JJ	O
phosphorylation	NN	O
in	IN	O
primary	JJ	O
neuronal	JJ	O
cultures	NNS	O
in	IN	O
mouse	NN	O
and	CC	O
rat	NN	O
,	,	O
substantiating	VBG	O
the	DT	O
role	NN	O
of	IN	O
a	DT	O
PLK	NNP	O
family	NN	O
member	NN	O
as	IN	O
the	DT	O
synuclein	NN	O
kinase	NN	O
.	.	O
The	DT	O
second	JJ	O
most	RBS	O
potent	JJ	O
inhibitor	NN	O
in	IN	O
most	JJS	O
of	IN	O
the	DT	O
cellular	JJ	O
paradigms	NN	O
tested	VBN	O
was	VBD	O
the	DT	O
generic	JJ	O
kinase	NN	O
inhibitor	NN	O
K252A	NNP	O
(	(	O
EC50	NNP	O
values	NNS	O
of	IN	O
3-7	JJ	O
μM	NN	O
)	)	O
.	.	O
In	IN	O
the	DT	O
in	IN	O
vitro	JJ	O
biochemical	JJ	O
reaction	NN	O
,	,	O
K252A	NNP	O
does	VBZ	O
not	RB	O
inhibit	VB	O
PLK2-driven	JJ	O
synuclein	NN	O
phosphorylation	NN	O
(	(	O
IC50	NNP	O
>	VBZ	O
10	CD	O
μM	NN	O
)	)	O
,	,	O
indicating	VBG	O
that	IN	O
its	PRP$	O
inhibition	NN	O
of	IN	O
synuclein	JJ	O
phosphorylation	NN	O
is	VBZ	O
through	IN	O
an	DT	O
upstream	NN	O
or	CC	O
downstream	NN	O
regulator	NN	O
of	IN	O
PLK2	NNP	O
.	.	O
The	DT	O
third	JJ	O
most	RBS	O
potent	JJ	O
inhibitor	NN	O
of	IN	O
synuclein	JJ	O
phosphorylation	NN	O
in	IN	O
primary	JJ	O
neuronal	JJ	O
cells	NNS	O
is	VBZ	O
ELN-481080	NNP	O
,	,	O
a	DT	O
PLK1	NNP	O
inhibitor	NN	O
that	WDT	O
also	RB	O
has	VBZ	O
inhibitory	JJ	O
activity	NN	O
on	IN	O
PLK2	NNP	O
,	,	O
and	CC	O
to	TO	O
a	DT	O
lesser	JJR	O
degree	NN	O
,	,	O
PLK3	NNP	O
and	CC	O
PLK4	NNP	O
(	(	O
see	VB	O
Table	NNP	O
21	CD	O
)	)	O
.	.	O
The	DT	O
IC50	NNP	O
of	IN	O
ELN-481080	NNP	O
was	VBD	O
7.7	CD	O
μM	NN	O
,	,	O
and	CC	O
the	DT	O
EC50	NNP	O
values	NNS	O
in	IN	O
most	JJS	O
cellular	JJ	O
paradigms	NN	O
was	VBD	O
12-38	JJ	O
μM	NN	O
.	.	O
The	DT	O
fourth	JJ	O
most	RBS	O
potent	JJ	O
inhibitor	NN	O
of	IN	O
synuclein	JJ	O
phosphorylation	NN	O
in	IN	O
primary	JJ	O
neuronal	JJ	O
cells	NNS	O
is	VBZ	O
the	DT	O
casein	JJ	O
kinase	NN	O
2	CD	O
inhibitor	NN	O
DMAT	NNP	O
(	(	O
2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole	JJ	O
)	)	O
.	.	O
The	DT	O
EC50	NNP	O
values	NNS	O
for	IN	O
inhibition	NN	O
of	IN	O
synuclein	JJ	O
phosphorylation	NN	O
in	IN	O
each	DT	O
of	IN	O
the	DT	O
cell	NN	O
types	NNS	O
were	VBD	O
16-33	JJ	O
μM	NN	O
.	.	O
In	IN	O
the	DT	O
biochemical	JJ	O
assay	NN	O
DMAT	NNP	O
was	VBD	O
the	DT	O
second	JJ	O
most	RBS	O
potent	JJ	O
inhibitor	NN	O
of	IN	O
synuclein	JJ	O
phosphorylation	NN	O
with	IN	O
an	DT	O
IC50	NNP	O
of	IN	O
2.07	CD	O
μM	NNS	O
.	.	O
That	DT	O
DMAT	NNP	O
can	MD	O
directly	RB	O
act	VB	O
on	IN	O
PLK2	NNP	O
to	TO	O
inhibit	VB	O
synuclein	JJ	O
phosphorylation	NN	O
suggests	VBZ	O
that	IN	O
reports	NNS	O
by	IN	O
others	NNS	O
using	VBG	O
to	TO	O
DMAT	NNP	O
to	TO	O
show	VB	O
that	IN	O
the	DT	O
CKII	NNP	O
is	VBZ	O
the	DT	O
synuclein	JJ	O
kinase	NN	O
may	MD	O
be	VB	O
due	JJ	O
to	TO	O
the	DT	O
inhibitory	NN	O
effect	NN	O
the	DT	O
DMAT	NNP	O
has	VBZ	O
on	IN	O
PLK2	NNP	O
and	CC	O
not	RB	O
on	IN	O
casein	NNS	O
kinase	VBD	O
2	CD	O
.	.	O
To	TO	O
confirm	VB	O
that	IN	O
the	DT	O
inhibitory	JJ	O
effect	NN	O
DMAT	NNP	O
is	VBZ	O
due	JJ	O
to	TO	O
inhibition	NN	O
of	IN	O
PLK2	NNP	O
,	,	O
MCC	NNP	O
were	VBD	O
treated	VBN	O
with	IN	O
TBB	NNP	O
,	,	O
a	DT	O
very	RB	O
specific	JJ	O
CKII	NNP	O
inhibitor	NN	O
.	.	O
TBB	NNP	O
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
synuclein	NN	O
phosphorylation	NN	O
,	,	O
even	RB	O
at	IN	O
concentrations	NNS	O
of	IN	O
100	CD	O
μM	NNS	O
(	(	O
data	NNS	O
not	RB	O
shown	VBN	O
)	)	O
.	.	O
Thus	RB	O
,	,	O
we	PRP	O
are	VBP	O
confident	JJ	O
that	IN	O
the	DT	O
inhibitory	JJ	O
effect	NN	O
of	IN	O
DMAT	NNP	O
on	IN	O
synuclein	JJ	O
phosphorylation	NN	O
is	VBZ	O
due	JJ	O
to	TO	O
its	PRP$	O
direct	JJ	O
activity	NN	O
on	IN	O
PLK2	NNP	O
and	CC	O
not	RB	O
CKII	NNP	O
.	.	O
The	DT	O
other	JJ	O
four	CD	O
inhibitors	NNS	O
tested	VBD	O
,	,	O
Scytonemin	NNP	O
,	,	O
Wortmannin	NNP	O
and	CC	O
N-benzoyl	NNP	O
staurosporine	NN	O
did	VBD	O
not	RB	O
inhibit	VB	O
50	CD	O
%	NN	O
of	IN	O
synuclein	JJ	O
phosphorylation	NN	O
in	IN	O
any	DT	O
of	IN	O
the	DT	O
cells	NNS	O
or	CC	O
in	IN	O
the	DT	O
in	IN	O
vitro	JJ	O
assay	NN	O
.	.	O
ELN-481530	NNP	O
,	,	O
the	DT	O
JNK3	NNP	O
inhibitor	NN	O
,	,	O
also	RB	O
did	VBD	O
not	RB	O
inhibit	VB	O
PLK2-driven	JJ	O
phosphorylation	NN	O
in	IN	O
vitro	NN	O
,	,	O
or	CC	O
in	IN	O
most	JJS	O
cell	NN	O
types	NNS	O
tested	VBN	O
.	.	O
However	RB	O
,	,	O
in	IN	O
RVM	NNP	O
stably	RB	O
transduced	VBD	O
with	IN	O
E46K-synuclein	NNP	O
(	(	O
but	CC	O
not	RB	O
in	IN	O
conjunction	NN	O
with	IN	O
caPLK2	NN	O
)	)	O
,	,	O
concentrations	NNS	O
of	IN	O
1	CD	O
μM	NNS	O
or	CC	O
greater	JJR	O
of	IN	O
ELN-481530	NNP	O
and	CC	O
above	IN	O
inhibited	VBN	O
50	CD	O
%	NN	O
of	IN	O
synuclein	JJ	O
phosphorylation	NN	O
,	,	O
with	IN	O
the	DT	O
inhibition	NN	O
reaching	VBG	O
a	DT	O
plateau	NN	O
of	IN	O
50	CD	O
%	NN	O
.	.	O
In	IN	O
addition	NN	O
,	,	O
293	CD	O
cells	NNS	O
over-expressing	JJ	O
human	JJ	O
WT-synuclein	NNP	O
and	CC	O
WT-PLK2	NNP	O
reached	VBD	O
the	DT	O
same	JJ	O
plateau	NN	O
of	IN	O
50	CD	O
%	NN	O
inhibition	NN	O
at	IN	O
10	CD	O
μM	JJ	O
ELN-481530	NNP	O
.	.	O
While	IN	O
further	JJ	O
work	NN	O
needs	NNS	O
to	TO	O
be	VB	O
done	VBN	O
to	TO	O
elucidate	VB	O
the	DT	O
role	NN	O
that	IN	O
JNK	NNP	O
may	MD	O
play	VB	O
in	IN	O
synuclein	JJ	O
phosphorylation	NN	O
,	,	O
it	PRP	O
seems	VBZ	O
reasonable	JJ	O
to	TO	O
suggest	VB	O
the	DT	O
JNK	NNP	O
may	MD	O
be	VB	O
a	DT	O
regulator	NN	O
of	IN	O
PLK2	NNP	O
and	CC	O
synuclein	JJ	O
phosphorylation	NN	O
in	IN	O
certain	JJ	O
cell	NN	O
types	NNS	O
.	.	O
EXAMPLE	RB	O
15	CD	O
Specificity	NNP	O
of	IN	O
ELN-481574	NNP	O
PLK	NNP	O
inhibitor	NN	O
ELN-481574-2	NNP	O
(	(	O
BI	NNP	O
2536	CD	O
)	)	O
exhibited	VBN	O
high	JJ	O
potency	NN	O
for	IN	O
reducing	VBG	O
alpha-synuclein	JJ	O
phosphorylation	NN	O
in	IN	O
a	DT	O
variety	NN	O
of	IN	O
cells	NNS	O
,	,	O
including	VBG	O
primary	JJ	O
neuronal	JJ	O
cells	NNS	O
(	(	O
see	VB	O
Example	NNP	O
14	CD	O
)	)	O
.	.	O
The	DT	O
inhibitor	NN	O
was	VBD	O
screened	VBN	O
against	IN	O
a	DT	O
panel	NN	O
of	IN	O
260	CD	O
kinases	NNS	O
(	(	O
almost	RB	O
half	PDT	O
the	DT	O
kinome	NN	O
)	)	O
and	CC	O
found	VBD	O
that	IN	O
at	IN	O
10	CD	O
uM	JJ	O
,	,	O
ELN-481574	NNP	O
was	VBD	O
very	RB	O
potent	JJ	O
in	IN	O
inhibiting	VBG	O
PLK2	NNP	O
and	CC	O
PLK3	NNP	O
,	,	O
although	IN	O
the	DT	O
compound	NN	O
also	RB	O
inhibited	VBD	O
several	JJ	O
CaMKs	NNP	O
and	CC	O
casein	NN	O
kinases	NNS	O
.	.	O
The	DT	O
ten	NN	O
kinases	VBZ	O
that	WDT	O
were	VBD	O
inhibited	VBN	O
the	DT	O
most	RBS	O
by	IN	O
ELN-481574	NNP	O
were	VBD	O
subjected	VBN	O
to	TO	O
a	DT	O
nine-point	JJ	O
dose-response	NN	O
(	(	O
0.003	CD	O
uM	NN	O
to	TO	O
3	CD	O
uM	NN	O
)	)	O
of	IN	O
the	DT	O
compound	NN	O
to	TO	O
determine	VB	O
the	DT	O
IC50	NNP	O
.	.	O
The	DT	O
ELN-481574	NNP	O
compound	NN	O
has	VBZ	O
16-fold	JJ	O
selectivity	NN	O
for	IN	O
PLK2	NNP	O
(	(	O
IC50	NNP	O
11	CD	O
nM	NN	O
)	)	O
and	CC	O
13-fold	JJ	O
selectivity	NN	O
for	IN	O
PLK3	NNP	O
(	(	O
IC50	NNP	O
14	CD	O
nM	NN	O
)	)	O
over	IN	O
the	DT	O
next	JJ	O
closest	NN	O
kinase	NN	O
IC50	NNP	O
(	(	O
CaMKIIδ	NNP	O
182	CD	O
nM	NN	O
)	)	O
.	.	O
See	VB	O
Table	JJ	O
20	CD	O
for	IN	O
a	DT	O
summary	NN	O
.	.	O
This	DT	O
confirms	VBZ	O
that	IN	O
this	DT	O
inhibitor	NN	O
is	VBZ	O
indeed	RB	O
potent	JJ	O
and	CC	O
highly	RB	O
selective	JJ	O
for	IN	O
at	IN	O
least	JJS	O
two	CD	O
members	NNS	O
of	IN	O
the	DT	O
PLK	NNP	O
family	NN	O
.	.	O
EXAMPLE	RB	O
16	CD	O
Effect	NNP	O
of	IN	O
Kinase	NNP	O
Inhibitors	NNP	O
in	IN	O
HEK-293	NNP	O
Cells	NNP	O
Overexpressing	NNP	O
PLK	NNP	O
Family	NNP	O
Members	NNP	O
HEK-293	NNP	O
cells	NNS	O
as	IN	O
described	VBN	O
in	IN	O
Example	NNP	O
12	CD	O
,	,	O
which	WDT	O
overexpress	VBP	O
synuclein	NN	O
in	IN	O
conjunction	NN	O
with	IN	O
empty	JJ	O
vector	NN	O
or	CC	O
one	CD	O
of	IN	O
the	DT	O
PLK	NNP	O
family	NN	O
members	NNS	O
,	,	O
were	VBD	O
exposed	VBN	O
to	TO	O
inhibitors	NNS	O
.	.	O
EC50	NN	O
values	NNS	O
(	(	O
Table	JJ	O
21	CD	O
)	)	O
and	CC	O
a	DT	O
rank	JJ	O
order	NN	O
of	IN	O
potency	NN	O
(	(	O
Table	JJ	O
22	CD	O
)	)	O
was	VBD	O
similar	JJ	O
to	TO	O
that	DT	O
seen	VBN	O
in	IN	O
primary	JJ	O
neuronal	JJ	O
cells	NNS	O
(	(	O
see	VB	O
Example	NNP	O
13	CD	O
)	)	O
.	.	O
The	DT	O
PLK	NNP	O
inhibitor	NN	O
ELN-481574-2	NNP	O
was	VBD	O
the	DT	O
most	RBS	O
potent	JJ	O
inhibitor	NN	O
of	IN	O
synuclein	JJ	O
phosphorylation	NN	O
by	IN	O
the	DT	O
endogenous	JJ	O
kinase	NN	O
and	CC	O
by	IN	O
each	DT	O
of	IN	O
the	DT	O
over-expressed	JJ	O
PLKs	NNP	O
.	.	O
The	DT	O
EC50	NNP	O
for	IN	O
the	DT	O
endogenous	JJ	O
kinase	NN	O
was	VBD	O
99	CD	O
nM	NN	O
,	,	O
and	CC	O
was	VBD	O
36	CD	O
nM	NN	O
,	,	O
80	CD	O
nM	NN	O
,	,	O
438	CD	O
nM	NN	O
and	CC	O
192	CD	O
nM	NN	O
for	IN	O
each	DT	O
of	IN	O
the	DT	O
PLK1	NNP	O
,	,	O
2	CD	O
,	,	O
3	CD	O
and	CC	O
4	CD	O
.	.	O
The	DT	O
EC50	NNP	O
for	IN	O
PLK3	NNP	O
is	VBZ	O
somewhat	RB	O
higher	JJR	O
than	IN	O
it	PRP	O
is	VBZ	O
for	IN	O
the	DT	O
endogenous	JJ	O
kinase	NN	O
or	CC	O
the	DT	O
other	JJ	O
PLKs	NNP	O
.	.	O
The	DT	O
second	JJ	O
most	RBS	O
potent	JJ	O
inhibitor	NN	O
of	IN	O
synuclein	JJ	O
phosphorylation	NN	O
was	VBD	O
DMAT	NNP	O
,	,	O
with	IN	O
EC50	NNP	O
values	NNS	O
of	IN	O
˜14-74	JJ	O
μM	NN	O
for	IN	O
the	DT	O
over-expressed	JJ	O
PLKs	NNP	O
and	CC	O
56	CD	O
μM	NN	O
for	IN	O
the	DT	O
endogenous	JJ	O
kinase	NN	O
.	.	O
The	DT	O
PLK1	NNP	O
inhibitor	NN	O
ELN-481080	NNP	O
shows	VBZ	O
selectivity	NN	O
for	IN	O
PLK1	NNP	O
(	(	O
16.7	CD	O
μM	NN	O
)	)	O
over	IN	O
PLK2	NNP	O
(	(	O
47.8	CD	O
μM	NN	O
)	)	O
,	,	O
and	CC	O
while	IN	O
an	DT	O
EC50	NNP	O
was	VBD	O
not	RB	O
reached	VBN	O
for	IN	O
inhibition	NN	O
of	IN	O
synuclein	JJ	O
phosphorylation	NN	O
by	IN	O
over-expressed	JJ	O
PLK3	NNP	O
or	CC	O
PLK4	NNP	O
,	,	O
ELN-481080	NNP	O
did	VBD	O
inhibit	VB	O
30-40	JJ	O
%	NN	O
of	IN	O
synuclein	JJ	O
phosphorylation	NN	O
at	IN	O
concentrations	NNS	O
of	IN	O
30-100	JJ	O
μM	NN	O
.	.	O
It	PRP	O
should	MD	O
be	VB	O
noted	VBN	O
that	IN	O
while	IN	O
the	DT	O
EC50	NNP	O
for	IN	O
ELN-481080	NNP	O
activity	NN	O
on	IN	O
the	DT	O
endogenous	JJ	O
kinase	NN	O
was	VBD	O
>	JJ	O
100	CD	O
μM	NN	O
in	IN	O
this	DT	O
experiment	NN	O
,	,	O
in	IN	O
previous	JJ	O
experiments	NNS	O
,	,	O
the	DT	O
EC50	NNP	O
has	VBZ	O
been	VBN	O
˜100	VBN	O
μM	NNP	O
(	(	O
Table	NNP	O
18	CD	O
)	)	O
,	,	O
which	WDT	O
is	VBZ	O
still	RB	O
within	IN	O
the	DT	O
three-fold	JJ	O
range	NN	O
of	IN	O
variation	NN	O
of	IN	O
the	DT	O
EC50	NNP	O
of	IN	O
PLK2	NNP	O
.	.	O
In	IN	O
this	DT	O
experiment	NN	O
,	,	O
treatment	NN	O
of	IN	O
overexpressed	JJ	O
PLK	NNP	O
family	NN	O
members	NNS	O
with	IN	O
the	DT	O
JNK3	NNP	O
inhibitor	NN	O
ELN-481530	NNP	O
did	VBD	O
not	RB	O
inhibit	VB	O
synuclein	JJ	O
phosphorylation	NN	O
by	IN	O
50	CD	O
%	NN	O
.	.	O
However	RB	O
,	,	O
it	PRP	O
did	VBD	O
inhibit	VB	O
30-45	JJ	O
%	NN	O
of	IN	O
synuclein	JJ	O
phosphorylation	NN	O
by	IN	O
cells	NNS	O
overexpressing	VBG	O
PLK2	NNP	O
or	CC	O
PLK3	NNP	O
at	IN	O
concentrations	NNS	O
of	IN	O
1	CD	O
μM	NNS	O
and	CC	O
above	NN	O
.	.	O
In	IN	O
the	DT	O
presence	NN	O
of	IN	O
endogenous	JJ	O
kinase	NN	O
or	CC	O
over-expressed	JJ	O
PLK1	NNP	O
or	CC	O
PLK4	NNP	O
,	,	O
inhibition	NN	O
was	VBD	O
lower	JJR	O
,	,	O
reaching	VBG	O
a	DT	O
maximum	NN	O
of	IN	O
15-20	JJ	O
%	NN	O
.	.	O
EXAMPLE	RB	O
17	CD	O
Effect	NNP	O
of	IN	O
Staurosporin	NNP	O
in	IN	O
HEK-293	NNP	O
Cells	NNP	O
Overexpressing	NNP	O
PLK2	NNP	O
HEK-293	NNP	O
cells	NNS	O
as	IN	O
described	VBN	O
in	IN	O
Example	NNP	O
12	CD	O
,	,	O
which	WDT	O
overexpress	VBP	O
synuclein	NN	O
or	CC	O
synuclein	NN	O
and	CC	O
PLK2	NNP	O
.	.	O
The	DT	O
EC50	NNP	O
value	NN	O
for	IN	O
the	DT	O
endogenous	JJ	O
kinase	NN	O
(	(	O
synuclein	FW	O
only	RB	O
)	)	O
was	VBD	O
4.35	CD	O
μM	NN	O
,	,	O
and	CC	O
11.16	CD	O
μM	NN	O
for	IN	O
PLK2	NNP	O
over-expressing	JJ	O
cells	NNS	O
.	.	O
The	DT	O
above	JJ	O
examples	NNS	O
are	VBP	O
illustrative	JJ	O
only	RB	O
and	CC	O
do	VB	O
not	RB	O
define	VB	O
the	DT	O
invention	NN	O
;	:	O
other	JJ	O
variants	NNS	O
will	MD	O
be	VB	O
readily	RB	O
apparent	JJ	O
to	TO	O
those	DT	O
of	IN	O
ordinary	JJ	O
skill	NN	O
in	IN	O
the	DT	O
art	NN	O
.	.	O
The	DT	O
scope	NN	O
of	IN	O
the	DT	O
invention	NN	O
is	VBZ	O
encompassed	VBN	O
by	IN	O
the	DT	O
claims	NNS	O
of	IN	O
any	DT	O
patent	NN	O
(	(	O
s	PRP	O
)	)	O
issuing	VBG	O
herefrom	NN	O
.	.	O
The	DT	O
scope	NN	O
of	IN	O
the	DT	O
invention	NN	O
should	MD	O
,	,	O
therefore	VB	O
,	,	O
be	VB	O
determined	VBN	O
not	RB	O
with	IN	O
reference	NN	O
to	TO	O
the	DT	O
above	JJ	O
description	NN	O
,	,	O
but	CC	O
instead	RB	O
should	MD	O
be	VB	O
determined	VBN	O
with	IN	O
reference	NN	O
to	TO	O
the	DT	O
issued	VBN	O
claims	NNS	O
along	IN	O
with	IN	O
their	PRP$	O
full	JJ	O
scope	NN	O
of	IN	O
equivalents	NNS	O
.	.	O
All	DT	O
publications	NNS	O
,	,	O
references	NNS	O
(	(	O
including	VBG	O
accession	NN	O
numbers	NNS	O
)	)	O
,	,	O
and	CC	O
patent	NN	O
documents	NNS	O
cited	VBN	O
in	IN	O
this	DT	O
application	NN	O
are	VBP	O
incorporated	VBN	O
by	IN	O
reference	NN	O
in	IN	O
their	PRP$	O
entirety	NN	O
for	IN	O
all	DT	O
purposes	NNS	O
to	TO	O
the	DT	O
same	JJ	O
extent	NN	O
as	IN	O
if	IN	O
each	DT	O
individual	JJ	O
publication	NN	O
or	CC	O
patent	NN	O
document	NN	O
were	VBD	O
so	RB	O
individually	RB	O
denoted	VBN	O
.	.	O
Claims	NNS	O
(	(	O
12	CD	O
)	)	O
Priority	NN	O
Applications	NNP	O
(	(	O
4	CD	O
)	)	O
Applications	NNPS	O
Claiming	NNP	O
Priority	NNP	O
(	(	O
1	CD	O
)	)	O
Related	VBN	O
Parent	NN	O
Applications	NNP	O
(	(	O
1	CD	O
)	)	O
Publications	NNPS	O
(	(	O
2	CD	O
)	)	O
Family	RB	O
ID=38328036	NNP	O
Family	NNP	O
Applications	NNP	O
(	(	O
3	CD	O
)	)	O
Family	NNP	O
Applications	NNP	O
Before	NNP	O
(	(	O
2	CD	O
)	)	O
Country	NN	O
Status	NNP	O
(	(	O
5	CD	O
)	)	O
Families	NNPS	O
Citing	VBG	O
this	DT	O
family	NN	O
(	(	O
8	CD	O
)	)	O
Citations	NNPS	O
(	(	O
19	CD	O
)	)	O
Patent	NN	O
Citations	NNP	O
(	(	O
26	CD	O
)	)	O
Non-Patent	JJ	O
Citations	NNP	O
(	(	O
27	CD	O
)	)	O
Also	RB	O
Published	VBN	O
As	IN	O
Similar	JJ	O
Documents	NNP	O
Legal	NNP	O
Events	NNP	O
Effective	JJ	O
date	NN	O
:	:	O
20160403	CD	O
